Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Open in Screener

MDGL

Madrigal Pharmaceuticals Inc

Jun 20 • 04:00PM ET

267.79

Dollar change -8.22
Percentage change -2.98	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM XBI VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-23.08	Insider Own	17.75%	Shs Outstand	19.88M	Perf Week	-6.31%
Market Cap	5.71B	Forward P/E	-	EPS next Y	-17.94	Insider Trans	-6.89%	Shs Float	17.53M	Perf Month	15.38%
Income	-444.27M	PEG	-	EPS next Q	-7.51	Inst Own	96.79%	Short Float	29.83%	Perf Quarter	3.40%
Sales	0.00M	P/S	-	EPS this Y	-42.98%	Inst Trans	-1.64%	Short Ratio	10.81	Perf Half Y	16.43%
Book/sh	42.80	P/B	6.26	EPS next Y	37.25%	ROA	-62.81%	Short Interest	5.23M	Perf Year	9.09%
Cash/sh	49.70	P/C	5.39	EPS next 5Y	0.00%	ROE	-88.78%	52W Range	119.76 - 299.98	Perf YTD	15.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.24%	ROI	-45.90%	52W High	-10.73%	Beta	-0.43
Dividend TTM	-	Quick Ratio	9.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	123.60%	ATR (14)	14.69
Dividend Ex-Date	-	Current Ratio	9.39	EPS Y/Y TTM	-27.58%	Oper. Margin	0.00%	RSI (14)	59.78	Volatility	4.04% 6.19%
Employees	376	Debt/Eq	0.14	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.44	Target Price	365.07
Option/Short	Yes / Yes	LT Debt/Eq	0.14	EPS Q/Q	-74.47%	Payout	-	Rel Volume	0.83	Prev Close	276.01
Sales Surprise	-	EPS Surprise	-17.42%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	483.86K	Price	267.79
SMA20	7.10%	SMA50	15.76%	SMA200	27.99%	Trades		Volume	403,547	Change	-2.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135
May-05-20	Initiated	Chardan Capital Markets	Buy	$205
Jan-30-20	Initiated	Canaccord Genuity	Buy	$198
Jan-09-20	Upgrade	UBS	Neutral → Buy	$125 → $127

Show Previous Ratings

Jun-16-24 12:05PM	Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. (Motley Fool)
Jun-15-24 09:45AM	Where Will Madrigal Pharmaceuticals Be in 3 Years? (Motley Fool)
Jun-12-24 03:56PM	Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Jun-10-24 09:45AM	Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
Jun-06-24 08:00AM	Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress (GlobeNewswire)
04:10PM	Loading…
Jun-05-24 04:10PM	Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
03:17PM	What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? (Benzinga)
10:56AM	Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
08:00AM	Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-29-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress (GlobeNewswire)
May-24-24 03:17AM	Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ... (GuruFocus.com)
May-21-24 09:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
May-17-24 03:08AM	Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:19PM	John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role (GuruFocus.com)
May-10-24 08:51AM	B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating (MT Newswires)
10:53AM	Loading…
May-09-24 10:53AM	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating (MT Newswires)
May-08-24 01:23PM	Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires) -7.48%
08:34AM	Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch (GuruFocus.com)
08:08AM	Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell (MT Newswires)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-24-24 04:00PM	Madrigal Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire) -6.29% -5.02%
Apr-23-24 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Apr-16-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:28PM	Latest Insider Selling in April 2024: 10 Stocks to Watch (Insider Monkey)
Apr-09-24 08:00AM	Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Apr-05-24 07:15AM	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics (Motley Fool)
01:55AM	Loading…
Apr-04-24 01:55AM	Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares (GuruFocus.com)
Apr-03-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:45AM	1 No-Brainer Growth Stock to Buy Now (Motley Fool)
Apr-01-24 09:09PM	The 3 Best Biotech Stocks to Buy in April 2024 (InvestorPlace)
09:59AM	ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:00AM	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
04:43AM	Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? (Motley Fool)
Mar-26-24 09:53AM	Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock (Motley Fool)
Mar-22-24 06:15AM	This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? (Motley Fool)
Mar-19-24 05:50AM	Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? (Motley Fool) -6.20%
Mar-18-24 11:58PM	Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering (GlobeNewswire)
08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
04:47PM	UPDATE 1-Madrigal plans $500 million fund raising to prepare for NASH drug launch (Reuters)
04:12PM	Madrigal commences $500 million public offering of common stock (Reuters)
04:04PM	Madrigal Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
03:15PM	Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark (Investor's Business Daily)
07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
05:50AM	Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? (Motley Fool)
Mar-15-24 04:35PM	Wegovy and Zepbound Cast Shadow Over Madrigals Liver Drug (Barrons.com) +11.00%
04:14PM	Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment (Investor's Business Daily)
03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video)
02:34PM	Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment (The Wall Street Journal)
01:45PM	Madrigal Pharmaceuticals Soars After Getting FDA Approval for Liver-Scarring Treatment (Investopedia)
12:56PM	Top Stock Movers Now: Adobe, Ulta Beauty, Jabil, and More (Investopedia)
12:09PM	US STOCKS-Wall St slides as inflation woes dampen rate-cut bets (Reuters)
10:17AM	MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today (InvestorPlace)
10:01AM	Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars. (Barrons.com)
09:30AM	Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH (Zacks)
07:45AM	Madrigal Stock Soars More Than 25% After FDA Approved First In MASH Treatment (Investor's Business Daily)
05:35AM	Madrigal, FDA approval in hand, outlines plan to sell MASH drug (BioPharma Dive)
Mar-14-24 04:25PM	Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH (Investor's Business Daily) -10.77%
04:15PM	Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
12:11PM	Madrigal wins FDA approval of first drug for MASH (BioPharma Dive)
Mar-09-24 05:52AM	Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Mar-06-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 08:00AM	Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis (GlobeNewswire)
06:03AM	1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? (Motley Fool)
Feb-28-24 07:01AM	Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer (GlobeNewswire) +6.02%
07:00AM	Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:45AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
Feb-26-24 04:04PM	Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study (Investor's Business Daily)
10:52AM	Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena (Investor's Business Daily)
Feb-23-24 05:43AM	1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street (Motley Fool)
Feb-21-24 08:00AM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.33%
Feb-08-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine (GlobeNewswire) -9.11%
Feb-06-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.28% -6.40%
11:29AM	Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent Seven (The Wall Street Journal)
11:28AM	Madrigal Pharmaceuticals Stock Shows Rising Relative Strength (Investor's Business Daily)
Jan-29-24 08:00AM	Madrigal Pharmaceuticals Announces Additions to Its Leadership Team (GlobeNewswire)
02:59AM	2 Rising Biotechs That Could Become the Next Novo Nordisk (Motley Fool)
Jan-22-24 08:00AM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:29AM	2 Stocks That Could Soar This Year: Are They Buys? (Motley Fool)
Jan-04-24 08:00AM	Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference (GlobeNewswire)
01:21AM	5 FDA decisions to watch in the first quarter (BioPharma Dive)
Jan-03-24 04:30PM	Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.58%
Dec-30-23 06:50AM	3 Stocks That Could Be Monster Winners in 2024 (Motley Fool)
Dec-22-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.74%
Dec-19-23 01:02PM	Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL) (GuruFocus.com)
10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-15-23 11:01PM	Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals Inc (GuruFocus.com)
Dec-07-23 08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Nov-27-23 04:30PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:00AM	Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-21-23 08:00AM	Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer (GlobeNewswire)
Nov-17-23 10:46AM	Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating (Investor's Business Daily)

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Option Exercise	87.09	1,900	165,471	7,400	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Sale	280.00	1,900	532,000	5,500	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Option Exercise	87.92	2,000	175,840	7,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Sale	285.00	2,000	570,000	5,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	May 21 '24	Sale	231.34	1,036	239,668	5,500	May 23 09:36 PM
CRAVES FRED B	Director	May 14 '24	Option Exercise	103.02	22,489	2,316,844	435,851	May 16 09:53 PM
CRAVES FRED B	Director	May 14 '24	Sale	212.88	22,489	4,787,404	413,362	May 16 09:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Option Exercise	9.45	26,270	248,251	212,005	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Option Exercise	9.45	2,676	25,288	461,675	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Sale	246.19	26,270	6,467,491	185,735	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Sale	245.99	2,676	658,258	458,999	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Option Exercise	9.45	27,613	260,943	213,348	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Option Exercise	9.45	27,506	259,932	486,505	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Sale	243.40	27,613	6,721,081	185,735	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Sale	243.36	27,506	6,693,790	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Option Exercise	9.45	18,710	176,810	204,445	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Option Exercise	9.45	18,537	175,175	477,536	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Sale	242.96	18,710	4,545,721	185,735	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Sale	242.91	18,537	4,502,823	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Option Exercise	9.45	27,845	263,135	486,844	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Option Exercise	9.45	27,407	258,996	213,142	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Sale	245.14	27,845	6,825,976	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Sale	245.12	27,407	6,718,002	185,735	Apr 05 08:50 PM
BATE KENNETH	Director	Apr 02 '24	Option Exercise	105.08	11,212	1,178,157	12,410	Apr 03 08:44 PM
Daly James M	Director	Apr 02 '24	Option Exercise	105.08	10,912	1,146,633	12,110	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 02 '24	Sale	244.49	11,212	2,741,219	1,198	Apr 03 08:44 PM
Daly James M	Director	Apr 02 '24	Sale	244.51	10,912	2,668,087	1,198	Apr 03 08:41 PM
Daly James M	Director	Apr 01 '24	Option Exercise	100.79	21,577	2,174,711	22,775	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 01 '24	Option Exercise	57.96	21,277	1,233,187	22,475	Apr 03 08:44 PM
Levy Richard S	Director	Apr 01 '24	Option Exercise	63.92	11,000	703,160	21,298	Apr 03 08:47 PM
Daly James M	Director	Apr 01 '24	Sale	257.24	21,577	5,550,544	1,198	Apr 03 08:41 PM
BATE KENNETH	Director	Apr 01 '24	Sale	257.26	21,277	5,473,779	1,198	Apr 03 08:44 PM
Levy Richard S	Director	Apr 01 '24	Sale	257.48	11,000	2,832,335	10,298	Apr 03 08:47 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Sale	238.50	2,000	477,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 14 '23	Buy	228.32	20,633	4,710,893	1,793,403	Dec 14 06:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Sale	232.50	2,000	465,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Option Exercise	87.92	2,500	219,800	8,167	Dec 14 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '23	Buy	219.39	81,159	17,805,684	1,774,294	Dec 14 06:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Sale	225.40	2,500	563,500	5,667	Dec 14 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Option Exercise	87.92	1,300	114,296	6,967	Dec 14 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 12 '23	Buy	218.31	34,578	7,548,616	1,699,129	Dec 14 06:09 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Sale	217.85	1,300	283,200	5,667	Dec 14 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Option Exercise	87.09	1,000	87,090	16,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Sale	227.33	1,000	227,330	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Option Exercise	81.16	1,800	146,090	16,801	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Sale	218.87	1,800	393,964	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Option Exercise	73.75	3,000	221,250	18,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Sale	204.58	3,000	613,730	15,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Option Exercise	73.75	4,000	295,000	19,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Sale	199.19	4,000	796,750	15,001	Dec 01 04:30 PM
BAKER BROS. ADVISORS LP	Director	Nov 21 '23	Buy	188.47	64,350	12,128,340	1,667,104	Nov 21 06:15 PM
BAKER BROS. ADVISORS LP	Director	Nov 20 '23	Buy	185.74	20,709	3,846,575	1,607,668	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 17 '23	Buy	174.70	46,370	8,100,704	1,588,541	Nov 21 06:14 PM
BAKER BROS. ADVISORS LP	Director	Nov 15 '23	Buy	161.97	15,199	2,461,721	1,545,775	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 14 '23	Buy	154.00	37,660	5,799,653	1,500,227	Nov 15 05:12 PM
BAKER BROS. ADVISORS LP	Director	Nov 14 '23	Buy	156.42	34,188	5,347,837	1,531,757	Nov 15 05:13 PM
BAKER BROS. ADVISORS LP	Director	Nov 13 '23	Buy	143.21	69,839	10,001,368	1,465,494	Nov 15 05:12 PM

Open in Screener

RNA

Avidity Biosciences Inc

Jun 20 • 04:00PM ET

37.61

Dollar change -0.72
Percentage change -1.88	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

RNA Avidity Biosciences Inc daily Stock Chart

Held by: IWM XBI VTI VXF IWN IBB SCHA VTWO LABU DWAS

Index	RUT	P/E	-	EPS (ttm)	-2.95	Insider Own	9.29%	Shs Outstand	95.64M	Perf Week	-1.96%
Market Cap	3.60B	Forward P/E	-	EPS next Y	-3.36	Insider Trans	-10.48%	Shs Float	86.75M	Perf Month	28.63%
Income	-228.68M	PEG	-	EPS next Q	-0.84	Inst Own	91.78%	Short Float	12.48%	Perf Quarter	55.16%
Sales	10.87M	P/S	330.91	EPS this Y	-6.95%	Inst Trans	-0.74%	Short Ratio	8.49	Perf Half Y	329.34%
Book/sh	8.69	P/B	4.33	EPS next Y	-8.03%	ROA	-29.22%	Short Interest	10.82M	Perf Year	223.94%
Cash/sh	9.58	P/C	3.93	EPS next 5Y	-	ROE	-32.91%	52W Range	4.82 - 42.00	Perf YTD	315.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.60%	ROI	-27.34%	52W High	-10.45%	Beta	0.90
Dividend TTM	-	Quick Ratio	12.47	Sales past 5Y	148.90%	Gross Margin	64.89%	52W Low	679.48%	ATR (14)	2.36
Dividend Ex-Date	-	Current Ratio	12.47	EPS Y/Y TTM	12.25%	Oper. Margin	-2347.64%	RSI (14)	70.36	Volatility	6.55% 6.92%
Employees	253	Debt/Eq	0.01	Sales Y/Y TTM	12.50%	Profit Margin	-2103.78%	Recom	1.00	Target Price	62.25
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-6.13%	Payout	-	Rel Volume	2.23	Prev Close	38.33
Sales Surprise	36.18%	EPS Surprise	0.77%	Sales Q/Q	58.67%	Earnings	May 09 AMC	Avg Volume	1.27M	Price	37.61
SMA20	23.72%	SMA50	36.46%	SMA200	146.93%	Trades		Volume	2,844,796	Change	-1.88%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37
Jul-07-20	Initiated	Wells Fargo	Overweight	$60
Jul-07-20	Initiated	Wells Fargo	Overweight
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform	$34
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-20-24 09:00AM	Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day (PR Newswire)
Jun-17-24 04:05PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-14-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Jun-13-24 08:00PM	Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire)
10:39AM	Avidity (RNA) Up 33% on Rare Muscle Disease Study Results (Zacks)
04:04PM	Loading…
Jun-12-24 04:04PM	The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record (Investor's Business Daily) +32.64%
04:01PM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
07:45AM	Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss (BioPharma Dive)
07:00AM	Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy (PR Newswire)
May-29-24 04:05PM	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress (PR Newswire)
08:45AM	2 Potentially High-Reward Growth Stocks to Buy Right Now (Motley Fool)
May-23-24 06:00AM	Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound (InvestorPlace) -7.26%
May-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
May-17-24 03:24AM	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing (MT Newswires)
09:00AM	Loading…
May-15-24 09:00AM	Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors (PR Newswire)
May-09-24 11:55PM	RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
May-08-24 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
12:27PM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 (MT Newswires)
06:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Apr-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.29%
Apr-04-24 01:30AM	Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares (GuruFocus.com) -11.07%
Mar-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-15-24 07:01PM	Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA) (GuruFocus.com)
Mar-04-24 04:02PM	Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy (Investor's Business Daily) -6.22%
07:00AM	Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR Trial (PR Newswire)
Feb-29-24 12:00PM	Avidity Biosciences Honors Rare Disease Day (PR Newswire) +19.92%
07:00AM	Avidity Biosciences Announces Oversubscribed $400 Million Private Placement (PR Newswire)
05:20PM	Loading…
Feb-28-24 05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:40PM	Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress (GuruFocus.com)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights (PR Newswire)
Feb-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +5.51%
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-20-24 09:00AM	Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Feb-15-24 05:00PM	Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Jan-29-24 08:54AM	Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jan-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-05-24 08:30AM	Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth (PR Newswire)
Dec-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.10%
Dec-13-23 08:30AM	Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44 Trial for Duchenne Muscular Dystrophy (PR Newswire) +10.28%
Nov-29-23 09:03AM	Avidity (RNA) Expands Collaboration With BMY, Shares Rise (Zacks) +10.31%
Nov-28-23 10:09AM	Why Is Avidity Biosciences (RNA) Stock Up 15% Today? (InvestorPlace) +14.94%
10:02AM	Avidity Stock Soars on Collaboration Deal With Bristol Myers (Barrons.com)
07:01AM	Bristol Myers pours $100M into RNA drugs for cardiovascular diseases (BioPharma Dive)
06:30AM	Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology (PR Newswire)
Nov-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.63%
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-08-23 06:12PM	Avidity Biosciences Inc (RNA) Reports Third Quarter 2023 Financial Results and Recent Highlights (GuruFocus.com) -7.03%
04:05PM	Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Oct-23-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.49%
Oct-07-23 07:30AM	Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 (PR Newswire)
Sep-26-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society (PR Newswire)
Sep-25-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Sep-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -7.33%
Sep-11-23 07:28PM	Down More Than 50%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks) +9.74%
Sep-07-23 09:00AM	Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs (PR Newswire)
Aug-31-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference (PR Newswire) -5.14%
Aug-30-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-15-23 09:00AM	Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Aug-08-23 07:15PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Jul-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-12-23 07:24AM	Avidity Biosciences (NASDAQ:RNA) shareholders have endured a 59% loss from investing in the stock three years ago (Simply Wall St.)
Jun-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-23 09:00AM	Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day (PR Newswire)
Jun-08-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress (PR Newswire)
May-22-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +11.65%
May-17-23 12:38PM	FDA Eases Partial Hold On Avidity Biosciences' Investigational Drug Study In Type Of Dystrophy (Benzinga)
07:00AM	Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1 (PR Newswire)
May-09-23 06:15PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
May-04-23 09:00PM	Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar? (Zacks)
Apr-28-23 10:08AM	Avidity Biosciences Touts Encouraging Data From Myotonic Dystrophy Type 1 Study (Benzinga) -14.78%
Apr-27-23 03:40PM	Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1 (PR Newswire) -16.09%
Apr-24-23 09:00AM	Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping (PR Newswire)
Apr-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-17-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting (PR Newswire) +8.08%
Apr-13-23 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 (PR Newswire) +9.08%
Apr-11-23 11:23AM	After Falling 18% in 1 Day, Is This Growth Stock Done For? (Motley Fool)
Apr-05-23 10:14AM	Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates (Zacks)
Mar-31-23 11:44AM	Avidity (RNA) Down on Update From Neuromuscular Disease Study (Zacks) -8.63%
Mar-30-23 04:16PM	Avidity Bio Crashes 17% After 'Rarer Than Rare' Event Sidelines Key Study (Investor's Business Daily) -16.83%
03:25PM	Why Avidity Biosciences Shares Are Sliding Today (Benzinga)
07:00AM	Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA Trial at AAN Annual Meeting (PR Newswire)
Mar-25-23 10:17AM	Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.28%
Mar-13-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference (PR Newswire)
Mar-01-23 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Feb-28-23 07:45PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights (PR Newswire)
09:00AM	Avidity Biosciences Honors Rare Disease Day® (PR Newswire)
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga)
08:00AM	Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC Platform (PR Newswire)
Feb-23-23 08:00AM	Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader (PR Newswire)
Feb-21-23 08:29PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -9.59%
Feb-14-23 09:00AM	Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (PR Newswire)

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyce Sarah	President and CEO	Jun 18 '24	Sale	39.13	32,074	1,255,040	142,543	Jun 20 06:47 PM
MacLean Michael F	Chief Financial Officer	Jun 18 '24	Sale	39.13	11,228	439,345	57,865	Jun 20 06:48 PM
Flanagan W. Michael	CSTO	Jun 18 '24	Sale	39.13	10,106	395,445	50,765	Jun 20 06:47 PM
McCarthy Teresa	Chief Human Resources Officer	Jun 18 '24	Sale	39.13	9,864	385,972	32,171	Jun 20 06:49 PM
Boyce Sarah	President and CEO	Jun 14 '24	Option Exercise	1.24	35,767	44,351	147,884	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 14 '24	Sale	40.08	35,767	1,433,484	112,117	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 13 '24	Option Exercise	1.24	164,233	203,649	276,350	Jun 14 06:58 PM
Boyce Sarah	President and CEO	Jun 13 '24	Sale	40.08	164,233	6,581,802	112,117	Jun 14 06:58 PM
LEVIN ARTHUR A	Director	Jun 13 '24	Sale	40.08	60,000	2,404,782	153,872	Jun 14 07:03 PM
MacLean Michael F	Chief Financial Officer	Jun 12 '24	Option Exercise	8.82	104,245	919,441	148,338	Jun 14 07:07 PM
Boyce Sarah	President and CEO	Jun 12 '24	Option Exercise	1.24	100,000	124,000	212,117	Jun 14 06:58 PM
MacLean Michael F	Chief Financial Officer	Jun 12 '24	Sale	35.72	104,245	3,723,141	44,093	Jun 14 07:07 PM
Boyce Sarah	President and CEO	Jun 12 '24	Sale	35.73	100,000	3,573,020	112,117	Jun 14 06:58 PM
LEVIN ARTHUR A	Director	Jun 12 '24	Sale	35.07	40,000	1,402,628	213,872	Jun 14 07:03 PM
Boyce Sarah	President and CEO	Jun 04 '24	Option Exercise	1.24	28,000	34,720	140,117	Jun 05 05:46 PM
Boyce Sarah	President and CEO	Jun 04 '24	Sale	27.42	28,000	767,780	112,117	Jun 05 05:46 PM
LEVIN ARTHUR A	Director	May 20 '24	Option Exercise	1.24	5,000	6,200	19,830	May 21 05:05 PM
LEVIN ARTHUR A	Director	May 20 '24	Sale	29.90	5,000	149,481	14,830	May 21 05:05 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Option Exercise	8.82	75,000	661,500	119,093	May 16 06:25 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Sale	28.28	75,000	2,121,045	44,093	May 16 06:25 PM
Boyce Sarah	President and CEO	May 07 '24	Option Exercise	1.24	28,000	34,720	140,117	May 07 09:52 PM
Boyce Sarah	President and CEO	May 07 '24	Sale	25.54	28,000	715,050	112,117	May 07 09:52 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Sale	22.82	5,000	114,123	14,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 03 '24	Sale	27.11	20,000	542,214	253,872	Apr 03 08:26 PM
Boyce Sarah	President and CEO	Apr 02 '24	Option Exercise	1.24	28,000	34,720	140,117	Apr 03 06:16 PM
Boyce Sarah	President and CEO	Apr 02 '24	Sale	26.25	28,000	734,919	112,117	Apr 03 06:16 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Mar 21 04:10 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Sale	23.97	5,000	119,848	14,830	Mar 21 04:10 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Option Exercise	8.82	40,000	352,800	84,093	Mar 15 04:12 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Sale	24.52	40,000	980,760	44,093	Mar 15 04:12 PM
Boyce Sarah	President and CEO	Mar 12 '24	Option Exercise	1.24	28,000	34,720	140,117	Mar 12 05:29 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Option Exercise	1.24	25,000	31,000	42,471	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 12 '24	Sale	22.63	28,000	633,682	112,117	Mar 12 05:29 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Sale	22.03	27,641	609,017	14,830	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 08 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 08 '24	Sale	21.39	84,000	1,796,710	112,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 01 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Mar 01 '24	Sale	20.13	84,000	1,691,306	112,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Jan 22 '24	Sale	10.13	5,092	51,582	44,008	Jan 23 03:13 PM
Flanagan W. Michael	CSTO	Jan 22 '24	Sale	10.13	4,129	41,827	35,871	Jan 23 03:12 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 22 '24	Sale	10.13	2,065	20,918	17,035	Jan 23 03:11 PM
LEVIN ARTHUR A	Director	Jan 22 '24	Sale	10.13	1,859	18,832	17,471	Jan 23 03:14 PM
MacLean Michael F	Chief Financial Officer	Jan 22 '24	Sale	10.13	1,616	16,370	16,884	Jan 23 03:11 PM

Open in Screener

MLYS

Mineralys Therapeutics Inc

Jun 20 • 04:00PM ET

11.71

Dollar change -0.08
Percentage change -0.68	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

MLYS Mineralys Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWN VTWO HRTS SCHA IWO IWC

Index	RUT	P/E	-	EPS (ttm)	-2.16	Insider Own	57.77%	Shs Outstand	41.13M	Perf Week	-7.06%
Market Cap	581.40M	Forward P/E	-	EPS next Y	-3.10	Insider Trans	1.19%	Shs Float	20.97M	Perf Month	-8.59%
Income	-90.80M	PEG	-	EPS next Q	-0.70	Inst Own	39.57%	Short Float	4.39%	Perf Quarter	-12.55%
Sales	0.00M	P/S	-	EPS this Y	-47.15%	Inst Trans	-	Short Ratio	6.75	Perf Half Y	48.98%
Book/sh	6.61	P/B	1.77	EPS next Y	-5.79%	ROA	-27.78%	Short Interest	0.92M	Perf Year	-26.81%
Cash/sh	6.82	P/C	1.72	EPS next 5Y	-	ROE	-29.11%	52W Range	5.85 - 17.44	Perf YTD	36.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-27.68%	52W High	-32.86%	Beta	1.95
Dividend TTM	-	Quick Ratio	18.06	Sales past 5Y	0.00%	Gross Margin	-	52W Low	100.17%	ATR (14)	0.59
Dividend Ex-Date	-	Current Ratio	18.06	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	36.18	Volatility	3.73% 4.28%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	33.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-127.38%	Payout	-	Rel Volume	0.83	Prev Close	11.79
Sales Surprise	-	EPS Surprise	-4.79%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	136.43K	Price	11.71
SMA20	-7.81%	SMA50	-7.54%	SMA200	7.37%	Trades		Volume	113,304	Change	-0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:56AM	Loading…
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire) +6.18%
May-02-24 08:00AM	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 (GlobeNewswire)
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
08:00AM	Loading…
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-04-24 04:05PM	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer (GlobeNewswire)
Dec-21-23 04:05PM	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire) +8.30%
Nov-12-23 09:22AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-11-23 11:30AM	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 (GlobeNewswire)
Nov-09-23 04:05PM	Mineralys Therapeutics to Participate in Three Upcoming Conferences (GlobeNewswire) -9.31% -12.84%
Nov-07-23 05:12PM	Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ... (GuruFocus.com) +8.02% -6.74%
04:05PM	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 10:00AM	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting (GlobeNewswire)
Oct-31-23 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-13-23 04:10PM	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 (GlobeNewswire) +5.59% +5.19%
Sep-19-23 04:00PM	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy (GlobeNewswire)
Sep-14-23 04:05PM	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas (GlobeNewswire)
04:05PM	Loading…
Sep-11-23 04:05PM	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 (GlobeNewswire)
Sep-10-23 07:47AM	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension (GlobeNewswire)
07:45AM	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire)
Sep-09-23 05:00AM	CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Sep-05-23 04:05PM	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire) -5.57%
09:55AM	Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High? (Zacks)
Aug-29-23 04:05PM	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 (GlobeNewswire)
Aug-22-23 05:45PM	Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.84%
Aug-07-23 04:05PM	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.02% +6.96%
Jul-31-23 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 (GlobeNewswire)
Jul-17-23 04:01PM	Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) (GlobeNewswire)
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-31-23 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-15-23 04:01PM	Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 08:39AM	We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth (Simply Wall St.)
May-02-23 08:00AM	Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension (GlobeNewswire)
May-01-23 08:00AM	Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023 (GlobeNewswire)
Apr-27-23 04:47PM	Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023 (GlobeNewswire)
Mar-15-23 04:01PM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Mar-04-23 04:30PM	Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC (GlobeNewswire)
Mar-01-23 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023 (GlobeNewswire)
Feb-17-23 12:08PM	Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO (American City Business Journals)
Feb-14-23 04:01PM	Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-23 05:16PM	Mineralys, Enlight Trading Debuts Add to Big Week for US IPOs (Bloomberg)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Congleton Jon	Chief Executive Officer	Jun 20 '24	Sale	11.73	14,940	175,237	926,958	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 18 '24	Sale	11.99	16,607	199,073	941,898	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 17 '24	Sale	12.25	17,766	217,712	958,505	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 14 '24	Sale	12.52	16,229	203,163	976,271	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 13 '24	Sale	12.74	39,961	509,027	992,500	Jun 14 06:15 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '24	Option Exercise	1.08	6,349	6,857	89,729	Jun 13 05:32 PM
Congleton Jon	Chief Executive Officer	Jun 12 '24	Sale	12.77	16,607	212,013	1,032,461	Jun 14 06:15 PM
Rodman David Malcom	Chief Medical Officer	Jun 11 '24	Option Exercise	0.54	5,017	2,709	83,380	Jun 13 05:32 PM
Levy Adam Scott	CFO and Secretary	Jun 11 '24	Sale	12.94	96,815	1,252,718	255,462	Jun 13 05:33 PM
Rodman David Malcom	Chief Medical Officer	May 13 '24	Option Exercise	0.84	11,366	9,566	78,363	May 15 04:43 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Option Exercise	1.08	100	108	67,097	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Sale	15.00	100	1,500	66,997	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 12 '24	Option Exercise	1.08	6,349	6,857	66,997	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '24	Option Exercise	1.08	6,348	6,856	55,631	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Mar 11 '24	Option Exercise	0.54	5,017	2,709	49,283	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '24	Option Exercise	0.84	11,366	9,566	44,266	Feb 13 04:08 PM
Samsara BioCapital GP, LLC	10% Owner	Feb 12 '24	Buy	13.50	555,555	7,499,992	5,074,916	Feb 14 09:06 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '24	Option Exercise	1.08	6,348	6,856	32,900	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Jan 11 '24	Option Exercise	0.54	5,017	2,709	26,552	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Dec 11 '23	Option Exercise	0.54	5,018	2,710	20,069	Dec 12 05:08 PM
Congleton Jon	Chief Executive Officer	Nov 22 '23	Buy	5.97	4,250	25,356	1,049,068	Nov 27 04:01 PM
Rodman David Malcom	Chief Medical Officer	Nov 13 '23	Option Exercise	0.54	5,017	2,709	15,051	Nov 14 06:18 PM
Rodman David Malcom	Chief Medical Officer	Nov 03 '23	Option Exercise	0.54	10,034	5,418	10,034	Nov 07 05:15 PM
Congleton Jon	Chief Executive Officer	Sep 06 '23	Buy	12.08	2,250	27,180	1,044,818	Sep 08 08:49 AM
Congleton Jon	Chief Executive Officer	Aug 17 '23	Buy	12.10	2,250	27,225	1,042,568	Aug 21 04:03 PM
Rodman David Malcom	Chief Medical Officer	Aug 11 '23	Option Exercise	0.80	157,091	125,967	80,909	Aug 11 07:11 PM
Congleton Jon	Chief Executive Officer	Aug 11 '23	Buy	12.89	2,000	25,780	1,040,318	Aug 11 07:11 PM
Rodman David Malcom	Chief Medical Officer	Aug 11 '23	Sale	12.81	157,091	2,012,336	0	Aug 11 07:11 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '23	Option Exercise	0.54	74,625	40,298	74,625	Aug 11 07:11 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '23	Sale	13.16	74,625	982,065	0	Aug 11 07:11 PM

Open in Screener

NKTR

Nektar Therapeutics

Jun 20 • 04:00PM ET

1.09

Dollar change -0.05
Percentage change -4.39	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

NKTR Nektar Therapeutics daily Stock Chart

Held by: VTI VXF SCHA VHT PRFZ SCHB NANC AVUS

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	2.88%	Shs Outstand	191.38M	Perf Week	-15.50%
Market Cap	200.58M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-2.62%	Shs Float	178.72M	Perf Month	-37.71%
Income	-175.84M	PEG	-	EPS next Q	-0.20	Inst Own	59.55%	Short Float	1.53%	Perf Quarter	21.11%
Sales	90.17M	P/S	2.22	EPS this Y	44.14%	Inst Trans	-4.28%	Short Ratio	1.25	Perf Half Y	122.90%
Book/sh	0.69	P/B	1.58	EPS next Y	14.32%	ROA	-36.72%	Short Interest	2.74M	Perf Year	99.05%
Cash/sh	1.57	P/C	0.69	EPS next 5Y	-7.30%	ROE	-95.68%	52W Range	0.41 - 1.93	Perf YTD	92.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-51.83%	52W High	-43.46%	Beta	0.65
Dividend TTM	-	Quick Ratio	5.79	Sales past 5Y	-20.42%	Gross Margin	60.91%	52W Low	164.18%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	58.37%	Oper. Margin	-147.13%	RSI (14)	32.49	Volatility	7.17% 9.66%
Employees	137	Debt/Eq	1.83	Sales Y/Y TTM	1.51%	Profit Margin	-195.02%	Recom	3.50	Target Price	1.60
Option/Short	Yes / Yes	LT Debt/Eq	1.68	EPS Q/Q	73.95%	Payout	-	Rel Volume	0.58	Prev Close	1.14
Sales Surprise	41.05%	EPS Surprise	0.00%	Sales Q/Q	0.21%	Earnings	May 09 AMC	Avg Volume	2.20M	Price	1.09
SMA20	-20.80%	SMA50	-26.05%	SMA200	30.07%	Trades		Volume	1,269,892	Change	-4.39%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform	$18 → $6
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform	$21
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy	$20
Sep-10-21	Initiated	BofA Securities	Neutral	$18
Jun-28-21	Upgrade	Stifel	Hold → Buy	$22 → $24
May-18-21	Resumed	Goldman	Neutral	$24
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold	$18

Show Previous Ratings

Jun-12-24 09:30AM	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 (PR Newswire)
May-30-24 06:00PM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire) -8.70%
May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Loading…
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire) -5.99%
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)
09:13AM	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Loading…
09:00AM	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata (PR Newswire)
07:19AM	Q4 2023 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 05:30PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.38%
04:51PM	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results (GuruFocus.com)
04:42PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
08:30AM	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX (PR Newswire)
Feb-27-24 06:00PM	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference (PR Newswire) +11.94%
Feb-26-24 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-20-24 10:00AM	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know (Zacks) -6.78%
Jan-03-24 06:00PM	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) -6.36%
Dec-11-23 06:00PM	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire) -5.94%
Dec-07-23 11:31AM	Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
05:28PM	Loading…
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-26-23 10:02AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -7.11%
Oct-13-23 08:30AM	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
Oct-02-23 09:00AM	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
Sep-27-23 09:00AM	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Sep-14-23 07:54AM	Nektar (NKTR) Up on Positive New Data From Eczema Study (Zacks)
Sep-13-23 09:00AM	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Sep-07-23 11:31AM	Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report? (Zacks)
Sep-06-23 06:00PM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
Aug-17-23 07:02PM	RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics (GuruFocus.com) -6.26%
Aug-09-23 09:25AM	Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss (Zacks) -8.94%
Aug-08-23 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Nektar: Q2 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
11:08AM	Nektar Therapeutics sues Lilly for breach of contract around skin drug (American City Business Journals)
Aug-07-23 10:23AM	Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment (Reuters) +91.51%
06:30AM	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
Aug-01-23 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-23 03:48AM	Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last? (Zacks) -5.69%
Jul-16-23 08:49AM	Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company (Simply Wall St.)
Jun-12-23 06:00PM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
Jun-08-23 12:55PM	Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel (Simply Wall St.)
11:31AM	Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report? (Zacks)
May-10-23 11:28AM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
May-09-23 06:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Nektar: Q1 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
May-08-23 09:29AM	Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More (Zacks) -5.94%
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-02-23 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 08:30AM	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 05:00PM	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire) +6.26% -5.67%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-13-23 10:59AM	Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio (Zacks) +10.16%
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks) +10.53%
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks) +6.57%
Apr-02-23 08:27AM	We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? (Zacks) -12.42%
Mar-29-23 05:44PM	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
Mar-24-23 12:00PM	Nektar (NKTR) Upgraded to Buy: Here's Why (Zacks)
Mar-22-23 09:35AM	Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR) (Zacks) -9.73%
Mar-14-23 03:43AM	Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Feb-28-23 05:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire) +9.42%
Feb-24-23 10:23AM	Why Nektar Therapeutics Stock Is Plunging Today (Benzinga) -49.66%
07:29AM	Boeing stock slips after deliveries of 787s halted; Beyond Meat shares rally after plant-food makers results (MarketWatch)
Feb-23-23 06:20PM	UPDATE 1-Nektar Therapeutics' autoimmune disease drug fails mid-stage study (Reuters)
05:24PM	Nektar stock drops more than 30% after study involving lupus treatment will not go forward (MarketWatch)
04:30PM	Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus (PR Newswire)
Jan-09-23 09:04AM	Concert (CNCE) Moves 19.3% Higher: Will This Strength Last? (Zacks)
Jan-04-23 09:00AM	Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) +6.85%
Dec-12-22 10:05AM	Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Dec-05-22 08:00AM	Nektar Therapeutics to Host Investor & Analyst Event on December 12th (PR Newswire)
Nov-10-22 09:05AM	Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire) +8.66%
07:58AM	Nektar Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-09-22 09:00AM	Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy (PR Newswire) -5.54%
Nov-04-22 12:35PM	Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates (Zacks) +5.90%
Nov-03-22 06:35PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-28-22 10:00AM	ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-22 10:02AM	Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-25-22 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-24-22 07:55AM	Here's Why We're Watching Nektar Therapeutics' (NASDAQ:NKTR) Cash Burn Situation (Simply Wall St.)
Oct-11-22 05:13PM	Why a S.F. biotech and its potential merger partner pulled the plug on talks (American City Business Journals)
Oct-07-22 03:42PM	Longtime S.F. biotech in talks with London company on 'combination' (American City Business Journals)
11:21AM	PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics (Benzinga)
Sep-07-22 01:15AM	Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress (PR Newswire)

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHESS ROBERT	Director	Jun 14 '24	Sale	1.20	19,500	23,400	255,273	Jun 14 06:02 PM
ROBIN HOWARD W	President & CEO	May 17 '24	Sale	1.75	16,650	29,138	863,239	May 20 09:14 PM
Zalevsky Jonathan	Chief R&D Officer	May 17 '24	Sale	1.75	7,355	12,871	257,670	May 20 09:13 PM
Wilson Mark Andrew	Chief Legal Officer	May 17 '24	Sale	1.75	6,260	10,955	230,414	May 20 09:12 PM
Deep Track Capital, LP	10% Owner	May 10 '24	Sale	1.78	56,000	99,630	18,344,000	May 13 04:36 PM
ROBIN HOWARD W	President & CEO	Feb 20 '24	Sale	0.68	20,033	13,622	879,889	Feb 22 08:16 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 20 '24	Sale	0.68	9,014	6,130	265,025	Feb 22 08:19 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 20 '24	Sale	0.68	7,606	5,172	236,674	Feb 22 08:17 PM
ROBIN HOWARD W	President & CEO	Nov 17 '23	Sale	0.49	19,877	9,740	899,922	Nov 20 08:58 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 17 '23	Sale	0.49	9,646	4,727	274,039	Nov 20 09:02 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 17 '23	Sale	0.49	7,179	3,518	243,780	Nov 20 09:00 PM
Curet Myriam	Director	Sep 18 '23	Sale	0.69	4,359	3,008	27,418	Sep 20 08:09 PM
Ajer Jeffrey Robert	Director	Sep 18 '23	Sale	0.69	4,359	3,008	34,153	Sep 20 08:06 PM
ROBIN HOWARD W	President & CEO	Aug 16 '23	Sale	0.78	19,998	15,598	919,799	Aug 17 08:06 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 16 '23	Sale	0.78	9,703	7,568	283,685	Aug 17 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 16 '23	Sale	0.78	7,221	5,632	250,959	Aug 17 08:07 PM

Open in Screener

AVTE

Aerovate Therapeutics Inc

Jun 20 • 04:00PM ET

1.46

Dollar change +0.05
Percentage change 3.55	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

AVTE Aerovate Therapeutics Inc daily Stock Chart

Held by: VTI VXF VTWO VHT IWM VTWG IWO IWC SBIO VTHR

Index	RUT	P/E	-	EPS (ttm)	-3.03	Insider Own	33.30%	Shs Outstand	27.76M	Perf Week	-93.66%
Market Cap	42.08M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	7.47%	Shs Float	19.22M	Perf Month	-92.76%
Income	-82.19M	PEG	-	EPS next Q	-0.83	Inst Own	64.74%	Short Float	11.50%	Perf Quarter	-94.36%
Sales	0.00M	P/S	-	EPS this Y	-2.29%	Inst Trans	4.19%	Short Ratio	3.23	Perf Half Y	-91.41%
Book/sh	3.26	P/B	0.45	EPS next Y	40.44%	ROA	-71.09%	Short Interest	2.21M	Perf Year	-91.10%
Cash/sh	3.45	P/C	0.42	EPS next 5Y	-	ROE	-80.58%	52W Range	1.40 - 32.42	Perf YTD	-93.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-114.14%	ROI	-90.08%	52W High	-95.50%	Beta	0.96
Dividend TTM	-	Quick Ratio	6.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	4.29%	ATR (14)	2.89
Dividend Ex-Date	-	Current Ratio	6.65	EPS Y/Y TTM	-30.59%	Oper. Margin	0.00%	RSI (14)	21.98	Volatility	23.39% 13.20%
Employees	51	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	2.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-25.12%	Payout	-	Rel Volume	5.75	Prev Close	1.41
Sales Surprise	-	EPS Surprise	-8.65%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	683.93K	Price	1.46
SMA20	-91.72%	SMA50	-92.79%	SMA200	-92.12%	Trades		Volume	3,930,744	Change	3.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$35 → $2
Jun-18-24	Downgrade	TD Cowen	Buy → Hold
Jun-18-24	Downgrade	Evercore ISI	Outperform → In-line	$27 → $2
Jun-17-24	Downgrade	Wedbush	Outperform → Neutral	$41 → $3
Jun-17-24	Downgrade	Guggenheim	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Mar-25-24	Resumed	Jefferies	Buy	$21 → $65
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$35
Mar-01-23	Initiated	Guggenheim	Buy	$36
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy	$27
Sep-19-22	Resumed	Wedbush	Outperform	$27
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral
Feb-11-22	Initiated	BTIG Research	Buy	$24
Jul-26-21	Initiated	Wedbush	Outperform	$23
Jul-26-21	Initiated	Jefferies	Buy	$21
Jul-26-21	Initiated	Evercore ISI	Outperform	$30
Jul-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-18-24 09:21AM	Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals (Zacks) -14.55%
Jun-17-24 04:11PM	Aerovate Therapeutics Stock Dropped Over 90%. Heres Why. (Barrons.com) -93.30%
04:04PM	Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke (Investor's Business Daily)
08:32AM	Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
May-21-24 04:15PM	Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) -9.04%
09:54PM	Loading…
May-13-24 09:54PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire)
Apr-04-24 01:31AM	Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares (GuruFocus.com)
Mar-27-24 09:20AM	Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) +11.11%
Mar-26-24 09:01PM	Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023 (GuruFocus.com)
Mar-25-24 09:53PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-21-24 02:32AM	Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE) (GuruFocus.com)
02:32AM	Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ... (GuruFocus.com)
Mar-06-24 08:00AM	Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair (GlobeNewswire)
11:01AM	Loading…
Dec-16-23 11:01AM	Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ... (GuruFocus.com)
Nov-20-23 04:45PM	Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
Nov-13-23 11:09AM	Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3 (GuruFocus.com) +8.45%
08:00AM	Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-14-23 08:00AM	Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights (GlobeNewswire)
Jul-22-23 09:29AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-11-23 05:00PM	Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors (GlobeNewswire)
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
Jun-01-23 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-23 01:15PM	Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference (GlobeNewswire)
May-15-23 04:05PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire) -7.45%
Mar-29-23 04:50PM	Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Loading…
Mar-02-23 08:00AM	Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-12-23 08:07AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-23-23 08:00AM	Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors (GlobeNewswire)
Dec-31-22 08:22AM	Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) (Simply Wall St.)
Dec-28-22 10:15PM	12 Best Performing Biotech Stocks in 2022 (Insider Monkey)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga)
Nov-17-22 07:45AM	Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research (GlobeNewswire)
Nov-14-22 07:45AM	Aerovate Therapeutics Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-18-22 08:00AM	Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022 (GlobeNewswire) +5.28%
Sep-05-22 07:17AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 07:50AM	Aerovate Therapeutics Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-02-22 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-22 05:15PM	Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -11.25% +5.60%
08:00AM	Aerovate Therapeutics Announces First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 04:45PM	Aerovate Therapeutics Announces Full-Year 2021 Financial Results (GlobeNewswire) +5.72%
Mar-29-22 11:42AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.) +11.35%
Mar-02-22 08:00AM	Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference (GlobeNewswire) +7.32%
Dec-15-21 08:00AM	Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension (GlobeNewswire) +16.31%
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-15-21 08:00AM	Aerovate Therapeutics Announces Third Quarter 2021 Financial Results (GlobeNewswire) -18.94%
Sep-30-21 06:40AM	Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation (Simply Wall St.)
Sep-21-21 05:05AM	48 Biggest Movers From Yesterday (Benzinga)
Sep-17-21 08:00AM	Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index (GlobeNewswire)
Aug-16-21 08:00AM	Aerovate Therapeutics Announces Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-19-21 08:00AM	Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors (GlobeNewswire)
Jul-02-21 04:01PM	Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.37%
Jun-29-21 10:59PM	Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 17 '24	Buy	1.67	928,110	1,549,944	7,893,678	Jun 20 05:56 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Jun 14 '24	Option Exercise	14.59	10,600	154,654	10,600	Jun 14 06:00 PM
Eldridge George A	SEE REMARKS	Jun 14 '24	Option Exercise	2.14	15,000	32,100	20,022	Jun 14 06:00 PM
Eldridge George A	SEE REMARKS	Jun 14 '24	Sale	25.03	15,000	375,450	5,022	Jun 14 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Jun 14 '24	Sale	25.00	10,600	265,000	0	Jun 14 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jun 13 '24	Option Exercise	2.14	6,000	12,840	11,602	Jun 14 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jun 13 '24	Sale	24.50	6,000	147,000	5,602	Jun 14 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	May 17 '24	Option Exercise	2.14	4,000	8,560	9,602	May 17 07:10 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	May 17 '24	Sale	21.08	4,000	84,332	5,602	May 17 07:10 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 16 '24	Option Exercise	2.14	10,000	21,400	10,000	May 17 07:10 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 16 '24	Sale	21.58	10,000	215,755	0	May 17 07:10 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	May 02 '24	Sale	21.02	1,981	41,631	0	May 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 01 '24	Option Exercise	2.14	10,000	21,400	10,000	May 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	20.34	11,357	230,946	0	May 03 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 17 '24	Option Exercise	2.14	6,853	14,665	8,144	Apr 19 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Apr 17 '24	Option Exercise	1.74	4,000	6,960	7,251	Apr 19 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 17 '24	Sale	22.37	6,853	153,327	1,291	Apr 19 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Apr 17 '24	Sale	22.38	4,000	89,522	3,251	Apr 19 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 16 '24	Option Exercise	2.14	10,000	21,400	10,000	Apr 18 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 16 '24	Sale	24.70	10,000	246,971	0	Apr 18 06:00 PM
Eldridge George A	SEE REMARKS	Apr 10 '24	Option Exercise	2.14	7,500	16,050	9,460	Apr 12 06:00 PM
Eldridge George A	SEE REMARKS	Apr 10 '24	Sale	26.85	7,500	201,392	1,960	Apr 12 06:00 PM
GRAYZEL DAVID S.	Director	Apr 09 '24	Sale	28.15	11,882	334,478	14,502	Apr 11 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Apr 01 '24	Option Exercise	14.59	5,300	77,327	5,300	Apr 03 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 01 '24	Option Exercise	10.61	3,325	35,278	4,616	Apr 03 06:00 PM
Eldridge George A	SEE REMARKS	Apr 01 '24	Option Exercise	2.14	12,495	26,739	14,455	Apr 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Option Exercise	2.14	10,000	21,400	10,000	Apr 03 06:00 PM
Eldridge George A	SEE REMARKS	Apr 01 '24	Sale	31.23	12,495	390,208	1,960	Apr 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Sale	30.00	10,000	300,033	0	Apr 03 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Apr 01 '24	Sale	29.19	5,300	154,697	0	Apr 03 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 01 '24	Sale	31.97	3,325	106,317	1,291	Apr 03 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 28 '24	Option Exercise	2.14	9,000	19,260	12,251	Apr 01 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 28 '24	Sale	29.50	9,000	265,500	3,251	Apr 01 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 27 '24	Option Exercise	10.61	11,068	117,431	12,359	Mar 28 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 27 '24	Sale	27.97	11,068	309,519	1,291	Mar 28 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 25 '24	Option Exercise	10.61	3,432	36,414	4,723	Mar 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 25 '24	Sale	28.01	3,432	96,119	1,291	Mar 27 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Mar 19 '24	Option Exercise	14.59	5,300	77,327	5,300	Mar 20 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Mar 19 '24	Sale	26.08	5,300	138,243	0	Mar 20 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 18 '24	Option Exercise	5.64	35,057	197,837	36,348	Mar 20 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 18 '24	Option Exercise	1.91	7,000	13,380	10,251	Mar 20 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 18 '24	Sale	25.90	35,057	908,046	1,291	Mar 20 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 18 '24	Sale	25.87	7,000	181,057	3,251	Mar 20 06:00 PM
Eldridge George A	SEE REMARKS	Mar 13 '24	Option Exercise	2.14	2,016	4,314	3,976	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 13 '24	Sale	25.02	2,016	50,445	1,960	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 12 '24	Option Exercise	2.14	2,051	4,389	4,011	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 12 '24	Sale	25.05	2,051	51,370	1,960	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 11 '24	Option Exercise	2.14	3,433	7,347	5,393	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 11 '24	Sale	25.25	3,433	86,667	1,960	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 08 '24	Option Exercise	2.14	114	244	2,074	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 08 '24	Sale	25.00	114	2,850	1,960	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 07 '24	Option Exercise	2.14	22,386	47,906	24,346	Mar 11 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 07 '24	Option Exercise	2.14	8,975	19,206	12,226	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 07 '24	Sale	25.00	22,386	559,688	1,960	Mar 11 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 07 '24	Sale	24.50	8,975	219,888	3,251	Mar 11 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 23 '24	Option Exercise	1.74	511	889	3,762	Feb 27 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 23 '24	Sale	19.50	511	9,964	3,251	Feb 27 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 20 '24	Option Exercise	1.74	3,489	6,071	6,740	Feb 22 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 20 '24	Sale	20.23	3,489	70,575	3,251	Feb 22 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Feb 05 '24	Option Exercise	2.02	4,600	9,284	6,209	Feb 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Feb 05 '24	Sale	17.45	4,600	80,249	1,609	Feb 07 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jan 17 '24	Option Exercise	1.74	4,000	6,960	7,251	Jan 19 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jan 17 '24	Sale	19.50	4,000	78,000	3,251	Jan 19 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jan 05 '24	Option Exercise	2.02	4,600	9,284	6,209	Jan 08 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jan 05 '24	Sale	19.16	4,600	88,116	1,609	Jan 08 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 27 '23	Option Exercise	2.14	125	268	3,376	Dec 29 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 27 '23	Sale	24.50	125	3,062	3,251	Dec 29 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	19.50	4,000	78,000	3,251	Dec 22 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 14 '23	Option Exercise	1.74	9,897	17,221	13,148	Dec 15 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 14 '23	Sale	19.50	9,897	192,992	3,251	Dec 15 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 13 '23	Option Exercise	1.74	4,000	6,960	7,251	Dec 22 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 13 '23	Option Exercise	1.74	2,103	3,659	5,354	Dec 15 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 13 '23	Sale	19.50	2,103	41,008	3,251	Dec 15 06:00 PM
Dake Benjamin T	SEE REMARKS	Dec 06 '23	Option Exercise	2.05	10,283	21,041	11,574	Dec 07 06:00 PM
Dake Benjamin T	SEE REMARKS	Dec 06 '23	Sale	16.11	10,283	165,628	1,291	Dec 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Dec 05 '23	Option Exercise	2.02	4,600	9,284	6,209	Dec 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Dec 05 '23	Sale	16.30	4,600	74,996	1,609	Dec 07 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 27 '23	Option Exercise	2.06	12,517	25,821	13,808	Nov 29 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 27 '23	Sale	16.24	12,517	203,237	1,291	Nov 29 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 24 '23	Option Exercise	2.14	4,990	10,679	6,281	Nov 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 24 '23	Sale	15.74	4,990	78,548	1,291	Nov 27 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Nov 22 '23	Option Exercise	2.02	13,800	27,852	15,409	Nov 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 22 '23	Option Exercise	2.04	9,382	19,113	10,673	Nov 27 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Nov 22 '23	Sale	15.00	13,800	207,000	1,609	Nov 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 22 '23	Sale	15.17	9,382	142,359	1,291	Nov 27 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Nov 01 '23	Sale	10.42	1,092	11,379	0	Nov 03 05:00 PM
Verwijs Marinus	CHIEF TECHNOLOGY OFFICER	Nov 01 '23	Sale	10.46	970	10,149	0	Nov 03 05:00 PM
Dake Benjamin T	SEE REMARKS	Sep 07 '23	Option Exercise	2.14	30	64	1,321	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Sep 07 '23	Sale	15.01	30	450	1,291	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Sep 06 '23	Option Exercise	1.89	3,931	7,447	5,222	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Sep 06 '23	Sale	15.06	3,931	59,187	1,291	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Aug 07 '23	Option Exercise	2.05	10,283	21,041	11,574	Aug 09 06:00 PM
Dake Benjamin T	SEE REMARKS	Aug 07 '23	Sale	15.52	10,283	159,580	1,291	Aug 09 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 28 '23	Option Exercise	2.14	5,478	11,723	5,478	Aug 01 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 28 '23	Sale	18.00	5,478	98,604	0	Aug 01 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 17 '23	Option Exercise	2.14	4,522	9,677	4,522	Jul 19 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 17 '23	Sale	18.11	4,522	81,896	0	Jul 19 06:00 PM
Dake Benjamin T	SEE REMARKS	Jul 06 '23	Option Exercise	2.05	10,283	21,041	11,574	Jul 07 06:00 PM
Dake Benjamin T	SEE REMARKS	Jul 06 '23	Sale	16.66	10,283	171,284	1,291	Jul 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jul 05 '23	Option Exercise	2.02	2,250	4,555	3,859	Jul 07 06:00 PM

Open in Screener

ANIP

ANI Pharmaceuticals Inc

Jun 20 • 04:00PM ET

59.39

Dollar change -1.35
Percentage change -2.22	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ANIP ANI Pharmaceuticals Inc daily Stock Chart

Held by: IJR VTI IWM VXF PJP IJT SPSM IWO SLYG SCHA

Index	RUT	P/E	35.15	EPS (ttm)	1.69	Insider Own	17.94%	Shs Outstand	20.47M	Perf Week	-7.51%
Market Cap	1.25B	Forward P/E	11.91	EPS next Y	4.99	Insider Trans	-10.25%	Shs Float	17.21M	Perf Month	-3.79%
Income	32.12M	PEG	15.98	EPS next Q	0.96	Inst Own	70.41%	Short Float	1.97%	Perf Quarter	-12.87%
Sales	517.46M	P/S	2.41	EPS this Y	-4.76%	Inst Trans	2.76%	Short Ratio	2.34	Perf Half Y	13.23%
Book/sh	21.53	P/B	2.76	EPS next Y	11.19%	ROA	4.02%	Short Interest	0.34M	Perf Year	12.76%
Cash/sh	11.36	P/C	5.23	EPS next 5Y	2.20%	ROE	8.53%	52W Range	48.20 - 70.81	Perf YTD	7.71%
Dividend Est.	-	P/FCF	11.90	EPS past 5Y	-6.27%	ROI	4.22%	52W High	-16.13%	Beta	0.75
Dividend TTM	-	Quick Ratio	3.12	Sales past 5Y	21.46%	Gross Margin	51.16%	52W Low	23.22%	ATR (14)	1.99
Dividend Ex-Date	-	Current Ratio	3.95	EPS Y/Y TTM	199.74%	Oper. Margin	10.16%	RSI (14)	33.82	Volatility	2.79% 3.13%
Employees	642	Debt/Eq	0.69	Sales Y/Y TTM	44.26%	Profit Margin	6.21%	Recom	1.40	Target Price	81.60
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	1220.00%	Payout	0.00%	Rel Volume	1.16	Prev Close	60.74
Sales Surprise	9.05%	EPS Surprise	21.49%	Sales Q/Q	28.70%	Earnings	May 10 BMO	Avg Volume	145.05K	Price	59.39
SMA20	-6.69%	SMA50	-8.57%	SMA200	-1.23%	Trades		Volume	168,857	Change	-2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60
Aug-05-15	Reiterated	Oppenheimer	Outperform	$74 → $65
Aug-04-15	Reiterated	ROTH Capital	Neutral	$70 → $67
Jul-31-15	Reiterated	Oppenheimer	Outperform	$72 → $74
Jul-15-15	Reiterated	ROTH Capital	Neutral	$60 → $70
Jun-23-15	Reiterated	Oppenheimer	Outperform	$61 → $67

Show Previous Ratings

Jun-13-24 08:53AM	Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options (Zacks)
Jun-06-24 01:00PM	Insider Sale: SVP & CFO Stephen Carey Sells 5,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-29-24 04:30PM	ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-24 10:52AM	ANI Pharmaceuticals Launches Kionex Suspension (MT Newswires)
09:35AM	Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround (Zacks)
06:50AM	Loading…
06:50AM	ANI Pharmaceuticals Announces the Launch of Kionex Suspension (GlobeNewswire)
May-18-24 02:33AM	Director Renee Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-16-24 07:00PM	Insider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
05:08PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing (MT Newswires)
May-13-24 03:03AM	ANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 01:48PM	ANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue Expectations (GuruFocus.com)
11:54AM	ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:26AM	ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance (MT Newswires)
06:58AM	Loading…
06:58AM	ANI: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
May-09-24 08:46AM	Why Earnings Season Could Be Great for ANI Pharmaceuticals (ANIP) (Zacks)
May-06-24 11:26AM	ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store? (Zacks)
May-03-24 05:51PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing (MT Newswires)
10:00AM	ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
May-01-24 04:30PM	ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences (GlobeNewswire)
Apr-18-24 04:05PM	ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET (GlobeNewswire)
Apr-15-24 12:10PM	Why ANI (ANIP) is Poised to Beat Earnings Estimates Again (Zacks)
Apr-10-24 06:15PM	ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know (Zacks)
Apr-09-24 06:50AM	ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension (GlobeNewswire)
Apr-05-24 09:30AM	Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It? (Zacks)
Apr-04-24 06:50AM	ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis (GlobeNewswire)
Apr-03-24 06:50AM	ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Apr-02-24 06:15PM	ANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should Know (Zacks)
06:15PM	Loading…
Mar-27-24 06:15PM	ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
06:50AM	ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP (GlobeNewswire)
Mar-26-24 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run? (Zacks)
Mar-22-24 09:54PM	NYCB, Vista Outdoor, Cardlytics, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-21-24 06:00PM	ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-20-24 09:30AM	ANI (ANIP) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-19-24 06:15PM	ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know (Zacks)
Mar-14-24 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-08-24 11:54PM	ANI Pharmaceuticals Inc CEO Nikhil Lalwani Sells 45,257 Shares (GuruFocus.com)
Mar-06-24 11:29PM	Director Antonio Pera Sells 7,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
12:00PM	What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 09:30AM	Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest? (Zacks)
09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
08:35AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:27AM	Q4 2023 ANI Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-29-24 09:30AM	Compared to Estimates, ANI (ANIP) Q4 Earnings: A Look at Key Metrics (Zacks) +12.26%
07:56AM	ANI Pharmaceuticals Q4 Profit Tops Estimates; Revenues Up 39.7% (RTT News)
07:15AM	ANI: Q4 Earnings Snapshot (Associated Press Finance)
07:11AM	ANI Pharmaceuticals Inc (ANIP) Reports Strong Growth in Q4 and Full-Year 2023, Sets Positive ... (GuruFocus.com)
06:50AM	ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance (GlobeNewswire)
Feb-28-24 10:30AM	13 Stocks That Will Double in 2024 (Insider Monkey)
Feb-26-24 09:15AM	Unveiling ANI (ANIP) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-22-24 10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-21-24 06:00PM	ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know (Zacks)
Feb-20-24 06:50AM	ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-12-24 06:00PM	ANI Pharmaceuticals (ANIP) Advances While Market Declines: Some Information for Investors (Zacks)
Feb-07-24 06:50AM	ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET (GlobeNewswire)
Feb-05-24 06:00PM	ANI Pharmaceuticals (ANIP) Ascends While Market Falls: Some Facts to Note (Zacks)
Jan-29-24 06:00PM	ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
06:50AM	ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-23-24 06:50AM	ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP (GlobeNewswire)
Jan-22-24 06:00PM	ANI Pharmaceuticals (ANIP) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Jan-19-24 06:59PM	Freshpet, Tillys, and More Stocks See Action From Activist Investors (Barrons.com)
06:15PM	ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-16-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP (GlobeNewswire)
Nov-22-23 09:26AM	ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-19-23 07:00AM	A Boring Biopharma Can Be a Good Bet (TheStreet.com)
Nov-17-23 05:11AM	Insider Sell Alert: SVP, CHIEF HR OFFICER Krista Davis Sells Shares of ANI Pharmaceuticals Inc (GuruFocus.com)
Nov-09-23 09:42AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 03:11PM	ANI Pharmaceuticals Inc (ANIP) Reports Record Q3 2023 Results; Raises Full-Year Guidance (GuruFocus.com) -14.64%
09:30AM	Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics (Zacks)
07:08AM	ANI: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance (GlobeNewswire)
Nov-02-23 10:00AM	Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-01-23 06:00PM	ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
10:01AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-30-23 06:50AM	ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences (GlobeNewswire)
Oct-25-23 06:50AM	ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET (GlobeNewswire)
Oct-20-23 06:00PM	ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Oct-19-23 06:15PM	ANI Pharmaceuticals (ANIP) Stock Moves -0.14%: What You Should Know (Zacks)
Oct-13-23 06:00PM	ANI Pharmaceuticals (ANIP) Stock Moves -0.48%: What You Should Know (Zacks)
Oct-06-23 06:00PM	ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why (Zacks)
Oct-05-23 06:15PM	(ANIP) Advances While Market Declines: Some Information for Investors (Zacks)
Oct-02-23 06:50AM	ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares (GlobeNewswire)
Sep-29-23 06:00PM	ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know (Zacks)
Sep-22-23 04:19AM	Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-21-23 06:00PM	ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know (Zacks)
Sep-20-23 06:15PM	ANI Pharmaceuticals (ANIP) Stock Moves -0.9%: What You Should Know (Zacks)
Sep-18-23 04:05PM	ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023 (GlobeNewswire)
Sep-14-23 06:00PM	ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know (Zacks)
Sep-12-23 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP (GlobeNewswire)
Sep-11-23 02:43PM	Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio (Zacks)
Sep-08-23 08:50AM	ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-29-23 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-28-23 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1% (GlobeNewswire)
Aug-25-23 12:00PM	What Makes ANI (ANIP) a New Strong Buy Stock (Zacks)
10:00AM	Best Momentum Stocks to Buy for August 25th (Zacks)
06:39AM	New Strong Buy Stocks for August 25th (Zacks)
Aug-24-23 06:50AM	ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 20 '24	Sale	59.86	11,447	685,217	702,620	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 18 '24	Sale	60.76	10,607	644,481	714,067	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 17 '24	Sale	61.41	7,946	487,964	724,674	Jun 20 07:11 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '24	Sale	63.80	250	15,950	59,231	Jun 14 05:23 PM
Marken James G.	SVP OPS & PROD DEV	Jun 07 '24	Option Exercise	52.70	12,550	661,366	128,916	Jun 11 04:51 PM
Gutwerg Ori	SVP, GENERICS	Jun 05 '24	Sale	67.00	2,985	199,995	77,227	Jun 06 06:21 PM
CAREY STEPHEN P.	SVP & CFO	Jun 04 '24	Sale	63.58	5,000	317,900	161,968	Jun 06 07:34 AM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jun 03 '24	Sale	64.41	20,000	1,288,200	213,226	Jun 04 06:08 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 21 '24	Sale	61.61	2,000	123,220	83,277	May 22 06:14 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 20 '24	Sale	61.81	12,855	794,568	732,620	May 21 05:21 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 17 '24	Sale	62.09	5,836	362,357	745,475	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 16 '24	Sale	63.84	16,459	1,050,743	751,311	May 17 06:05 PM
TANNENBAUM RENEE P	Director	May 16 '24	Sale	63.87	2,000	127,740	18,211	May 17 06:01 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 15 '24	Sale	65.86	14,850	978,021	767,770	May 17 06:05 PM
Lalwani Nikhil	PRESIDENT & CEO	May 14 '24	Sale	66.10	16,669	1,101,821	377,505	May 16 05:02 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '24	Sale	67.69	250	16,922	59,481	May 13 05:25 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	May 01 '24	Sale	66.62	20,000	1,332,400	233,226	May 03 05:48 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 19 '24	Sale	65.17	16,809	1,095,443	782,620	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 18 '24	Sale	64.98	10,423	677,287	799,429	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 17 '24	Sale	65.40	9,520	622,608	809,852	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 16 '24	Sale	66.20	5,834	386,211	819,372	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 15 '24	Sale	66.33	7,414	491,771	825,206	Apr 17 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 12 '24	Sale	67.79	250	16,948	59,731	Apr 15 06:28 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Apr 01 '24	Sale	67.25	20,000	1,345,000	253,226	Apr 02 06:59 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '24	Sale	66.54	250	16,635	59,981	Mar 13 04:48 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Mar 11 '24	Sale	65.81	20,000	1,316,200	273,226	Mar 13 04:44 PM
CAREY STEPHEN P.	SVP & CFO	Mar 11 '24	Sale	65.55	7,787	510,438	177,712	Mar 11 06:39 PM
Lalwani Nikhil	PRESIDENT & CEO	Mar 08 '24	Sale	67.13	16,292	1,093,682	411,629	Mar 08 07:25 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 08 '24	Sale	67.17	10,000	671,700	832,620	Mar 11 06:43 PM
Marken James G.	SVP OPS & PROD DEV	Mar 07 '24	Sale	66.37	24,338	1,615,313	124,492	Mar 07 09:42 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 07 '24	Sale	66.35	15,085	1,000,890	842,620	Mar 07 09:11 PM
Lalwani Nikhil	PRESIDENT & CEO	Mar 06 '24	Sale	65.52	28,965	1,897,787	444,981	Mar 08 07:25 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 06 '24	Sale	65.47	14,822	970,396	857,705	Mar 07 09:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 05 '24	Sale	65.35	10,093	659,578	872,527	Mar 07 09:11 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 05 '24	Sale	66.00	5,000	330,000	87,387	Mar 06 04:24 PM
Pera Antonio R	Director	Mar 04 '24	Sale	65.20	7,000	456,400	26,627	Mar 06 04:20 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '24	Sale	56.04	250	14,010	36,799	Feb 13 08:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 23 '24	Sale	56.44	15,000	846,600	882,620	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 22 '24	Sale	55.95	5,692	318,467	897,620	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 19 '24	Sale	55.57	4,524	251,399	903,312	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 18 '24	Sale	55.30	9,784	541,055	907,836	Jan 18 06:20 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 17 '24	Sale	55.11	10,000	551,100	917,620	Jan 18 06:20 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 16 '24	Sale	55.63	5,000	278,150	927,620	Jan 18 06:20 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 12 '24	Sale	56.43	250	14,108	37,049	Jan 16 09:09 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Dec 19 '23	Sale	52.65	25,000	1,316,250	932,620	Dec 19 05:44 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Dec 18 '23	Sale	52.44	13,026	683,083	957,620	Dec 19 05:44 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Dec 15 '23	Sale	52.44	11,974	627,917	970,646	Dec 19 05:44 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 11 '23	Sale	49.21	250	12,302	37,299	Dec 11 05:49 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Nov 17 '23	Sale	51.00	13,000	663,000	982,620	Nov 20 09:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Nov 16 '23	Sale	51.66	6,448	333,104	996,430	Nov 16 06:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Nov 15 '23	Sale	53.64	7,647	410,185	1,002,878	Nov 16 06:11 PM
Davis Krista	SVP, CHIEF HR OFFICER	Nov 15 '23	Sale	53.81	2,622	141,090	32,587	Nov 16 06:13 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Nov 14 '23	Sale	53.17	22,095	1,174,791	1,010,525	Nov 16 06:11 PM
Mutz Christopher	HEAD OF RARE DISEASE	Nov 10 '23	Sale	52.47	3,000	157,410	63,607	Nov 13 04:02 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Oct 19 '23	Sale	57.06	10,000	570,600	1,032,620	Oct 19 04:28 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Oct 18 '23	Sale	57.78	6,242	360,663	1,042,620	Oct 19 04:28 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Oct 17 '23	Sale	58.53	8,758	512,606	1,048,862	Oct 19 04:28 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Oct 16 '23	Sale	58.31	13,063	761,704	1,057,620	Oct 17 04:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Oct 13 '23	Sale	57.58	11,937	687,332	1,070,683	Oct 17 04:32 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Oct 02 '23	Sale	56.48	20,000	1,129,600	293,226	Oct 03 08:00 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Sep 19 '23	Sale	61.23	25,333	1,551,140	1,082,620	Sep 19 05:14 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Sep 18 '23	Sale	61.64	8,425	519,317	1,107,953	Sep 19 05:14 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Sep 15 '23	Sale	62.81	16,242	1,020,160	1,116,378	Sep 19 05:14 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Sep 01 '23	Sale	64.70	20,000	1,294,000	313,226	Sep 05 05:06 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 29 '23	Sale	63.37	25,000	1,584,250	1,132,620	Aug 30 04:29 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 28 '23	Sale	63.06	25,000	1,576,500	1,157,620	Aug 30 04:29 PM
Gutwerg Ori	SVP, GENERICS	Aug 23 '23	Option Exercise	31.49	13,502	425,178	76,476	Aug 25 04:22 PM
Marken James G.	SVP OPS & PROD DEV	Aug 23 '23	Option Exercise	38.25	5,417	207,224	137,044	Aug 25 04:17 PM
Gutwerg Ori	SVP, GENERICS	Aug 23 '23	Sale	62.39	15,561	970,851	60,915	Aug 25 04:22 PM
Marken James G.	SVP OPS & PROD DEV	Aug 23 '23	Sale	63.00	3,932	247,716	133,112	Aug 25 04:17 PM
MERIDIAN VENTURE PARTNERS II L	10% Owner	Aug 16 '23	Sale	58.50	200,000	11,700,000	1,819,259	Aug 16 08:00 PM
Lalwani Nikhil	PRESIDENT & CEO	Aug 15 '23	Option Exercise	29.00	11,616	336,864	365,006	Aug 15 08:39 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 15 '23	Sale	61.60	22,110	1,361,976	1,182,620	Aug 16 07:07 PM
Lalwani Nikhil	PRESIDENT & CEO	Aug 15 '23	Sale	61.13	11,616	710,086	353,390	Aug 15 08:39 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 14 '23	Sale	61.15	27,890	1,705,474	1,204,730	Aug 16 07:07 PM
CAREY STEPHEN P.	SVP & CFO	Aug 14 '23	Sale	61.37	17,639	1,082,505	155,839	Aug 16 04:24 PM
Pera Antonio R	Director	Aug 14 '23	Sale	60.37	3,000	181,110	33,627	Aug 15 08:45 PM
Lalwani Nikhil	PRESIDENT & CEO	Aug 11 '23	Sale	57.75	56,666	3,272,462	353,390	Aug 15 08:39 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Aug 01 '23	Sale	51.06	20,000	1,021,200	333,226	Aug 03 06:03 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 21 '23	Sale	52.56	11,500	604,440	1,232,620	Jul 21 07:15 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 20 '23	Sale	51.52	6,000	309,120	1,244,120	Jul 21 07:15 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 19 '23	Sale	51.48	5,969	307,284	1,250,120	Jul 21 07:15 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 18 '23	Sale	51.84	6,700	347,328	1,256,089	Jul 18 08:06 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 17 '23	Sale	51.06	9,831	501,971	1,262,789	Jul 18 08:06 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 14 '23	Sale	50.43	10,000	504,300	1,272,620	Jul 18 08:06 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jul 03 '23	Sale	53.43	20,000	1,068,600	353,226	Jul 06 04:15 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jun 22 '23	Sale	51.32	20,000	1,026,400	373,226	Jun 23 08:00 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 22 '23	Sale	51.38	13,500	693,630	7,407	Jun 22 08:00 PM

Open in Screener

TLPH

Talphera Inc.

Jun 20 • 04:00PM ET

0.8270

Dollar change +0.0459
Percentage change 5.88	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	1.69%	Shs Outstand	16.95M	Perf Week	-15.87%
Market Cap	14.05M	Forward P/E	-	EPS next Y	-0.84	Insider Trans	3.61%	Shs Float	16.71M	Perf Month	-23.43%
Income	-14.20M	PEG	-	EPS next Q	-0.21	Inst Own	31.29%	Short Float	1.01%	Perf Quarter	-24.13%
Sales	0.65M	P/S	21.62	EPS this Y	37.47%	Inst Trans	2.83%	Short Ratio	2.43	Perf Half Y	8.82%
Book/sh	0.96	P/B	0.86	EPS next Y	-3.72%	ROA	-51.96%	Short Interest	0.17M	Perf Year	-27.46%
Cash/sh	1.09	P/C	0.76	EPS next 5Y	-	ROE	-93.57%	52W Range	0.43 - 1.61	Perf YTD	12.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.67%	ROI	-62.69%	52W High	-48.63%	Beta	0.31
Dividend TTM	-	Quick Ratio	5.97	Sales past 5Y	-0.99%	Gross Margin	-22.73%	52W Low	94.59%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	5.97	EPS Y/Y TTM	-112.83%	Oper. Margin	-2426.73%	RSI (14)	35.40	Volatility	14.32% 7.74%
Employees	15	Debt/Eq	0.39	Sales Y/Y TTM	-51.02%	Profit Margin	-2181.11%	Recom	1.00	Target Price	4.42
Option/Short	Yes / Yes	LT Debt/Eq	0.39	EPS Q/Q	78.63%	Payout	-	Rel Volume	1.48	Prev Close	0.78
Sales Surprise	-	EPS Surprise	36.00%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	69.13K	Price	0.83
SMA20	-17.48%	SMA50	-19.74%	SMA200	-7.54%	Trades		Volume	102,498	Change	5.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral	$7 → $2
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy	$6.50
Feb-15-19	Initiated	Credit Suisse	Outperform	$7
Oct-23-18	Initiated	B. Riley FBR	Buy	$9
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform	$6 → $5
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Jul-14-17	Resumed	Jefferies	Buy	$7
Sep-15-16	Reiterated	ROTH Capital	Buy	$11.25 → $15
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy	$8.50 → $10.50
Sep-02-15	Initiated	H.C. Wainwright	Buy	$8.50
Jul-10-15	Resumed	ROTH Capital	Buy	$7.50
May-06-15	Reiterated	Mizuho	Neutral	$5.50 → $3
May-05-15	Reiterated	RBC Capital Mkts	Outperform	$8 → $7
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform	$12 → $8
Mar-09-15	Downgrade	Mizuho	Buy → Neutral	$14 → $5.59

Show Previous Ratings

Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +5.88%
May-20-24 05:25PM	Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-16-24 05:45PM	Talphera to Participate at A.G.P. Virtual Healthcare Conference (PR Newswire) -5.35% -6.09%
May-14-24 08:56PM	TLPH Stock Earnings: Talphera Beats EPS for Q1 2024 (InvestorPlace) +19.12%
04:05PM	Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
04:15PM	Loading…
May-02-24 04:15PM	Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 (PR Newswire)
Mar-06-24 09:53PM	TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.63%
04:05PM	Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-24 07:30AM	Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members (PR Newswire)
Feb-26-24 04:15PM	Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 (PR Newswire)
Jan-18-24 08:30AM	Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering (PR Newswire) +26.01%
Jan-09-24 09:05AM	AcelRx Announces Rebranding With Name Change to Talphera, Inc. (PR Newswire) +7.50%
Dec-12-23 08:30AM	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States (PR Newswire) -9.01%
Nov-09-23 11:06AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.34%
Nov-08-23 05:22PM	AcelRx Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 04:05PM	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study (PR Newswire)
Oct-26-23 04:30PM	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 (PR Newswire)
Oct-03-23 08:30AM	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study (PR Newswire)
Sep-12-23 01:02PM	Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc (GuruFocus.com) +12.80%
Sep-06-23 08:30AM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire)
Aug-22-23 05:30PM	What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks)
Aug-13-23 05:33AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:07AM	Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.46%
04:20PM	AcelRx Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-23 04:05PM	AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 (PR Newswire)
Jul-21-23 08:00AM	AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jul-18-23 08:00AM	AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (PR Newswire)
06:25PM	Loading…
May-10-23 06:25PM	AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1 (Zacks) +10.88%
05:18PM	AcelRx Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:05PM	AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-04-23 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-27-23 04:05PM	AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 (PR Newswire)
Apr-05-23 08:30AM	AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire)
Apr-04-23 12:30PM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.00%
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 (PR Newswire) +18.10% +5.68%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire) -21.05%
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures (PR Newswire) -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside (Insider Monkey) -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine (PR Newswire)
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +17.96%
04:01PM	AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 08:30AM	AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 (PR Newswire)
Oct-31-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 (PR Newswire)
Oct-27-22 08:30AM	AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant (PR Newswire) -12.47%
Oct-26-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 (PR Newswire) -12.81%
Oct-25-22 04:42PM	AcelRx Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences (PR Newswire)
Sep-06-22 04:30PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire) -7.32% +5.74%
Aug-25-22 08:30AM	AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Aug-11-22 05:35PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +33.02% -13.63%
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 (PR Newswire)
Aug-10-22 08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Jul-28-22 04:50PM	AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 (PR Newswire)
Jul-08-22 06:28AM	AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years (Simply Wall St.) -13.71%
May-20-22 12:49PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference (PR Newswire) -11.83%
May-19-22 11:56AM	Why AcelRx Pharma Shares Are Trading Higher Today? (Benzinga) +27.63%
08:30AM	AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® (PR Newswire)
May-16-22 08:45AM	AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-12-22 05:35PM	Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +17.66%
May-10-22 05:35PM	Organogenesis (ORGO) Q1 Earnings Lag Estimates (Zacks) -10.10%
08:30AM	AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia (PR Newswire)
May-09-22 07:30PM	AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 (PR Newswire) -13.47%
Apr-27-22 08:00AM	AcelRx Hosting Key Opinion Leader Webinar on Niyad Nafamostat Program (GlobeNewswire)
Apr-25-22 08:30AM	Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 (PR Newswire)
Apr-21-22 08:30AM	AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 (PR Newswire) -8.00%
Mar-31-22 04:10PM	AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures (PR Newswire)
Mar-29-22 01:08PM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit (PR Newswire) -6.87%
Mar-10-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -20.63%
04:01PM	AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Mar-03-22 04:05PM	AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 (PR Newswire) -7.14%
Feb-01-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures (PR Newswire)
Jan-31-22 04:24AM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? (Simply Wall St.) +11.77%
Jan-27-22 01:38PM	Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... (GuruFocus.com) -8.64%
08:30AM	AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures (PR Newswire)
Jan-12-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery (PR Newswire) -5.53%
Jan-10-22 08:30AM	AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics (PR Newswire)
Dec-23-21 08:05AM	Femasys Inc. to Participate in Upcoming January Investor Conferences (GlobeNewswire)
Dec-15-21 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery (PR Newswire)
Dec-01-21 07:12PM	Penny Stocks to Buy Using Technical Analysis for December 2021 (Investopedia)
Nov-23-21 05:09PM	AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors (PR Newswire) -5.22%
Nov-15-21 06:45AM	AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering (PR Newswire) -6.08%
06:00AM	AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-10-21 08:30AM	AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021 (PR Newswire)
Nov-02-21 06:22AM	Investors in AcelRx Pharmaceuticals (NASDAQ:ACRX) have unfortunately lost 80% over the last three years (Simply Wall St.)
Oct-28-21 03:06PM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-21-21 09:32PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire) -5.18%
Oct-04-21 07:30AM	Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors (GlobeNewswire)
Sep-10-21 03:19PM	AcelRx Pharmaceuticals to Participate in Two September Investor Conferences (PR Newswire)

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Jun 14 '24	Buy	1.08	1,304	1,404	180,806	Jun 14 05:19 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Jun 13 '24	Buy	0.97	4,570	4,438	179,502	Jun 14 05:19 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Jun 12 '24	Buy	0.97	4,126	4,013	174,932	Jun 14 05:19 PM
Angotti Vincent J.	Chief Executive Officer	Dec 13 '23	Buy	0.73	10,000	7,268	101,805	Dec 14 08:11 AM
Angotti Vincent J.	Chief Executive Officer	Sep 11 '23	Buy	0.80	10,000	7,950	91,805	Sep 11 07:13 PM
Palmer Pamela P	Chief Medical Officer	Aug 25 '23	Sale	1.09	7,442	8,104	30,753	Aug 25 04:45 PM
Palmer Pamela P	Chief Medical Officer	Aug 24 '23	Sale	1.17	9,514	11,131	38,195	Aug 25 04:45 PM

Open in Screener

KPRX

Kiora Pharmaceuticals Inc

Jun 20 • 04:00PM ET

3.93

Dollar change -0.36
Percentage change -8.39	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

KPRX Kiora Pharmaceuticals Inc daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-14.31	Insider Own	8.64%	Shs Outstand	2.97M	Perf Week	-20.12%
Market Cap	11.67M	Forward P/E	-	EPS next Y	-2.70	Insider Trans	3.97%	Shs Float	2.71M	Perf Month	-23.99%
Income	2.28M	PEG	-	EPS next Q	-0.81	Inst Own	48.42%	Short Float	0.62%	Perf Quarter	-27.95%
Sales	16.00M	P/S	0.73	EPS this Y	103.97%	Inst Trans	-	Short Ratio	0.54	Perf Half Y	-19.14%
Book/sh	11.96	P/B	0.33	EPS next Y	-381.25%	ROA	9.52%	Short Interest	0.02M	Perf Year	-39.35%
Cash/sh	10.53	P/C	0.37	EPS next 5Y	-	ROE	12.46%	52W Range	3.60 - 8.98	Perf YTD	-16.41%
Dividend Est.	-	P/FCF	1.63	EPS past 5Y	56.98%	ROI	6.51%	52W High	-56.25%	Beta	-0.23
Dividend TTM	-	Quick Ratio	21.02	Sales past 5Y	-27.40%	Gross Margin	99.23%	52W Low	9.17%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	21.02	EPS Y/Y TTM	90.77%	Oper. Margin	38.92%	RSI (14)	40.78	Volatility	16.31% 13.11%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	14.23%	Recom	1.00	Target Price	33.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	138.31%	Payout	-	Rel Volume	0.93	Prev Close	4.29
Sales Surprise	0.00%	EPS Surprise	38.18%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	31.04K	Price	3.93
SMA20	-14.15%	SMA50	-15.93%	SMA200	-23.64%	Trades		Volume	28,796	Change	-8.39%

Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
07:00AM	Loading…
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
01:54PM	Loading…
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
07:00AM	Loading…
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)
Nov-09-22 06:45AM	Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End (Newsfile) -5.76%
Oct-31-22 08:01AM	KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 (News Direct)
Oct-17-22 08:00AM	Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease (Newsfile)
Oct-13-22 06:45AM	Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (Newsfile)
Sep-28-22 11:44AM	Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D. (Newsfile) +6.06%
Sep-26-22 06:45AM	Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split (Newsfile) -10.05%
Sep-13-22 06:45AM	Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance (Newsfile) +21.00%
Aug-15-22 06:30AM	KPRX: What a difference a year makes! (Zacks Small Cap Research)
Aug-12-22 06:45AM	Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results (Newsfile) -10.71%
Jul-28-22 06:45AM	Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics (Newsfile)
Jul-26-22 04:38PM	Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile)
Jul-22-22 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering (Newsfile) -39.76%
Jul-05-22 06:45AM	Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects (Newsfile)
Jun-27-22 06:53AM	Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa (Newsfile)
May-31-22 04:30PM	Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (Newsfile) +10.00% -5.41%
Apr-25-22 06:45AM	Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022 (Newsfile)
Apr-15-22 09:00AM	Kiora Pharmaceuticals Reports 2021 Results and Provides Business Update (Newsfile)
Mar-21-22 06:45AM	Kiora Pharmaceuticals to Participate in Maxim Group's 2022 Virtual Growth Conference March 28th - 30th (Newsfile)
Mar-18-22 12:00PM	Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate (Benzinga) -7.09%
06:45AM	Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP) (Newsfile)
Feb-08-22 06:45AM	Kiora Pharmaceuticals Announces Participation at 2022 BIO CEO & Investor Conference (Newsfile)
Feb-01-22 06:45AM	Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board (Newsfile)
Jan-05-22 07:00AM	Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference (Newsfile) -7.96%
Dec-15-21 07:00AM	Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors (Newsfile) -27.02%
Dec-14-21 07:15AM	Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease (Newsfile) -8.89%
Nov-15-21 07:30AM	Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Daniels Eric Joseph	Chief Development Officer	Jun 14 '24	Buy	5.29	1,431	7,570	11,222	Jun 14 03:40 PM
Tosca Melissa	EVP Finance	Jun 14 '24	Buy	5.25	100	525	3,979	Jun 14 04:47 PM
Parsons Erin	Director	Jun 13 '24	Buy	4.88	5,260	25,669	5,260	Jun 13 03:51 PM
Strem Brian M.	President and CEO	Jun 13 '24	Buy	5.00	3,000	14,997	14,531	Jun 13 03:49 PM

Open in Screener

TRDA

Entrada Therapeutics Inc

Jun 20 • 04:00PM ET

14.44

Dollar change -0.35
Percentage change -2.37	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

TRDA Entrada Therapeutics Inc daily Stock Chart

Held by: VTI IWM AVUV VXF IWN SCHA VTWO VHT IWC EES

Index	RUT	P/E	23.02	EPS (ttm)	0.63	Insider Own	45.76%	Shs Outstand	33.44M	Perf Week	-9.07%
Market Cap	487.49M	Forward P/E	-	EPS next Y	-3.66	Insider Trans	0.01%	Shs Float	18.31M	Perf Month	-5.74%
Income	23.48M	PEG	-	EPS next Q	0.36	Inst Own	46.89%	Short Float	8.93%	Perf Quarter	8.16%
Sales	162.87M	P/S	2.99	EPS this Y	-78.00%	Inst Trans	-0.82%	Short Ratio	21.92	Perf Half Y	-0.69%
Book/sh	8.02	P/B	1.80	EPS next Y	-927.53%	ROA	4.76%	Short Interest	1.63M	Perf Year	-3.80%
Cash/sh	9.70	P/C	1.49	EPS next 5Y	-	ROE	9.41%	52W Range	10.75 - 18.44	Perf YTD	-4.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.52%	ROI	7.17%	52W High	-21.69%	Beta	-0.25
Dividend TTM	-	Quick Ratio	2.38	Sales past 5Y	0.00%	Gross Margin	98.05%	52W Low	34.32%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	2.38	EPS Y/Y TTM	127.57%	Oper. Margin	14.57%	RSI (14)	43.31	Volatility	3.77% 4.79%
Employees	159	Debt/Eq	0.25	Sales Y/Y TTM	544.79%	Profit Margin	14.42%	Recom	1.00	Target Price	22.50
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	427.55%	Payout	-	Rel Volume	0.50	Prev Close	14.79
Sales Surprise	294.69%	EPS Surprise	214.48%	Sales Q/Q	134.05%	Earnings	May 07 BMO	Avg Volume	74.55K	Price	14.44
SMA20	-7.64%	SMA50	1.39%	SMA200	0.04%	Trades		Volume	37,272	Change	-2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Loading…
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
07:00AM	Loading…
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
06:36AM	Loading…
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks) -5.30%
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks) -19.76%
Dec-19-22 04:30PM	Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -6.09%
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-09-22 01:41PM	Entrada (TRDA) Surges on Collaboration With Vertex for DMI (Zacks) -9.19%
Dec-08-22 04:12PM	Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy (Investor's Business Daily) +18.51%
10:58AM	Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder (Benzinga)
08:24AM	Entrada Therapeutics shares jump on collaboration with Vertex (MarketWatch)
07:00AM	Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) (Business Wire)
Nov-22-22 07:00AM	Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-07-22 07:00AM	Entrada Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -10.02%
Aug-30-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 07:00AM	Entrada Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 07:00AM	Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-19-22 07:00AM	Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer (GlobeNewswire) +8.81%
Jul-14-22 10:47AM	We're Hopeful That Entrada Therapeutics (NASDAQ:TRDA) Will Use Its Cash Wisely (Simply Wall St.)
Jul-06-22 07:00AM	Entrada Therapeutics to Present at William Blair Biotech Focus Conference (GlobeNewswire)
Jun-01-22 07:00AM	Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference (GlobeNewswire) -15.24%
May-12-22 07:00AM	Entrada Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.25%
May-11-22 09:30AM	Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV) Therapeutics at TIDES USA 2022 (GlobeNewswire) -9.44%
May-10-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.84%
Mar-15-22 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) +9.78%
Feb-23-22 08:00AM	Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference (GlobeNewswire) -17.21%
Feb-04-22 01:27PM	We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth (Simply Wall St.) +12.79%
Feb-03-22 09:38AM	5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ... (GuruFocus.com)
Jan-05-22 08:00AM	Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel (GlobeNewswire) -15.44%
Dec-17-21 08:00AM	Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Dec-09-21 07:00AM	Entrada Therapeutics Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-18-21 08:00AM	Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-05-21 08:32AM	4 Stocks Insiders Are Buying (Benzinga)
Nov-02-21 04:26PM	Entrada Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +13.19%
Oct-28-21 10:21PM	Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doshi Dipal	CEO	Jun 13 '24	Sale	16.17	1,000	16,174	336,375	Jun 14 04:32 PM
KIM PETER S	Director	Jun 03 '24	Option Exercise	6.06	11,918	72,223	104,330	Jun 05 04:31 PM
Sethuraman Natarajan	Chief Scientific Officer	May 20 '24	Sale	15.19	9,675	146,944	190,052	May 20 05:26 PM
Sethuraman Natarajan	Chief Scientific Officer	May 17 '24	Sale	15.14	8,305	125,751	199,727	May 20 05:26 PM
Doshi Dipal	CEO	May 17 '24	Sale	15.11	1,200	18,129	337,375	May 20 05:21 PM
Doshi Dipal	CEO	May 16 '24	Sale	15.00	1,800	27,000	338,575	May 20 05:21 PM
Sethuraman Natarajan	Chief Scientific Officer	May 16 '24	Sale	15.00	1,000	15,000	208,032	May 20 05:26 PM
KIM PETER S	Director	May 14 '24	Buy	14.59	25,000	364,672	92,412	May 16 04:33 PM
KIM PETER S	Director	May 09 '24	Buy	14.25	2,200	31,341	67,412	May 10 04:35 PM
KIM PETER S	Director	May 08 '24	Buy	14.04	2,276	31,965	65,212	May 10 04:35 PM
KIM PETER S	Director	Apr 08 '24	Buy	13.57	2,600	35,290	62,936	Apr 10 04:35 PM
KIM PETER S	Director	Mar 28 '24	Buy	13.75	1,512	20,794	60,336	Apr 01 04:31 PM
KIM PETER S	Director	Mar 26 '24	Buy	13.64	2,750	37,509	58,824	Mar 26 05:57 PM
KIM PETER S	Director	Mar 25 '24	Buy	13.36	3,180	42,472	56,074	Mar 26 05:57 PM
KIM PETER S	Director	Mar 22 '24	Buy	13.76	3,118	42,901	52,894	Mar 26 05:57 PM
KIM PETER S	Director	Mar 21 '24	Buy	13.24	704	9,318	49,776	Mar 21 04:31 PM
KIM PETER S	Director	Mar 20 '24	Buy	12.66	1,128	14,281	49,072	Mar 21 04:31 PM
KIM PETER S	Director	Mar 19 '24	Buy	12.66	900	11,397	47,944	Mar 21 04:31 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 15 '24	Option Exercise	2.10	9,000	18,900	83,170	Mar 19 04:33 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 06 '24	Sale	12.31	4,086	50,285	74,170	Mar 08 04:36 PM
Dowden Nathan J	President & COO	Mar 06 '24	Sale	12.32	1,826	22,499	137,204	Mar 08 04:34 PM
Doshi Dipal	CEO	Feb 15 '24	Sale	15.00	1,000	15,000	243,279	Feb 20 04:37 PM
Doshi Dipal	CEO	Jan 16 '24	Sale	15.99	1,000	15,990	244,279	Jan 18 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 26 '23	Option Exercise	2.10	94	197	49,665	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 26 '23	Sale	16.67	94	1,567	49,571	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 22 '23	Option Exercise	2.10	10,206	21,433	59,777	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 22 '23	Sale	15.69	10,206	160,124	49,571	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 21 '23	Option Exercise	2.10	2,200	4,620	51,771	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 21 '23	Sale	15.07	2,200	33,155	49,571	Dec 26 04:35 PM
Doshi Dipal	President and CEO	Dec 20 '23	Sale	15.00	1,000	15,000	245,279	Dec 22 04:38 PM
Doshi Dipal	President and CEO	Nov 13 '23	Sale	16.23	1,000	16,230	246,279	Nov 13 04:35 PM
Doshi Dipal	President and CEO	Oct 17 '23	Sale	15.00	1,000	15,000	247,279	Oct 19 05:27 PM
Doshi Dipal	President and CEO	Sep 13 '23	Sale	15.00	1,000	15,000	248,279	Sep 15 04:21 PM
Dowden Nathan J	Chief Operating Officer	Sep 06 '23	Sale	13.47	972	13,089	48,168	Sep 06 05:07 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Sep 06 '23	Sale	13.48	950	12,806	49,571	Sep 06 05:11 PM
KREHER NERISSA	Chief Medical Officer	Sep 06 '23	Sale	13.48	892	12,022	40,037	Sep 06 05:08 PM
Doshi Dipal	President and CEO	Aug 14 '23	Sale	15.67	1,000	15,671	201,069	Aug 16 04:32 PM
KREHER NERISSA	Chief Medical Officer	Aug 04 '23	Option Exercise	2.10	6,898	14,486	34,028	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 04 '23	Sale	14.14	6,898	97,521	27,130	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 03 '23	Option Exercise	2.10	9,464	19,874	36,594	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 03 '23	Sale	14.74	9,464	139,530	27,130	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 02 '23	Option Exercise	2.10	10,348	21,731	37,478	Aug 04 04:50 PM
KREHER NERISSA	Chief Medical Officer	Aug 02 '23	Sale	15.19	10,348	157,168	27,130	Aug 04 04:50 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 11 '23	Option Exercise	2.10	3,884	8,156	40,631	Jul 12 04:34 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 11 '23	Sale	18.04	14,852	267,915	153,447	Jul 12 04:32 PM
Dowden Nathan J	Chief Operating Officer	Jul 11 '23	Sale	18.05	3,897	70,333	35,376	Jul 12 04:33 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 11 '23	Sale	18.00	3,884	69,904	36,747	Jul 12 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 10 '23	Option Exercise	2.10	6,116	12,844	42,863	Jul 12 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 10 '23	Sale	17.98	6,116	109,958	36,747	Jul 12 04:34 PM
Dowden Nathan J	Chief Operating Officer	Jul 10 '23	Sale	18.00	3,200	57,605	39,273	Jul 12 04:33 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 10 '23	Sale	18.00	3,026	54,474	168,299	Jul 12 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jun 29 '23	Option Exercise	2.10	8,790	18,459	36,747	Jun 30 04:32 PM
Dowden Nathan J	Chief Operating Officer	Jun 22 '23	Sale	16.02	7,097	113,700	42,473	Jun 22 04:46 PM

Open in Screener

UTHR

United Therapeutics Corp

Jun 20 • 04:00PM ET

308.98

Dollar change +2.94
Percentage change 0.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

UTHR United Therapeutics Corp daily Stock Chart

Held by: IJH VTI VB VBR VXF COWZ MDY IBB XBI SPMD

Index	-	P/E	14.61	EPS (ttm)	21.15	Insider Own	1.75%	Shs Outstand	47.04M	Perf Week	9.62%
Market Cap	13.71B	Forward P/E	11.31	EPS next Y	27.31	Insider Trans	-44.91%	Shs Float	43.59M	Perf Month	12.49%
Income	1.05B	PEG	1.51	EPS next Q	6.33	Inst Own	103.67%	Short Float	8.92%	Perf Quarter	30.52%
Sales	2.50B	P/S	5.49	EPS this Y	25.53%	Inst Trans	1.04%	Short Ratio	7.06	Perf Half Y	25.40%
Book/sh	120.76	P/B	2.56	EPS next Y	9.81%	ROA	16.36%	Short Interest	3.89M	Perf Year	38.31%
Cash/sh	61.03	P/C	5.06	EPS next 5Y	9.70%	ROE	20.08%	52W Range	208.62 - 306.78	Perf YTD	40.52%
Dividend Est.	-	P/FCF	18.16	EPS past 5Y	8.15%	ROI	18.97%	52W High	0.72%	Beta	0.55
Dividend TTM	-	Quick Ratio	3.64	Sales past 5Y	8.02%	Gross Margin	88.87%	52W Low	48.10%	ATR (14)	6.95
Dividend Ex-Date	-	Current Ratio	3.77	EPS Y/Y TTM	40.71%	Oper. Margin	50.31%	RSI (14)	84.40	Volatility	2.94% 2.40%
Employees	1168	Debt/Eq	0.11	Sales Y/Y TTM	26.09%	Profit Margin	42.05%	Recom	1.54	Target Price	300.91
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	27.02%	Payout	0.00%	Rel Volume	1.28	Prev Close	306.04
Sales Surprise	9.25%	EPS Surprise	8.13%	Sales Q/Q	33.70%	Earnings	May 01 BMO	Avg Volume	550.70K	Price	308.98
SMA20	10.89%	SMA50	18.26%	SMA200	30.85%	Trades		Volume	707,109	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125
Mar-10-20	Upgrade	Jefferies	Hold → Buy	$123
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform	$119 → $145
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight	$120
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy	$103 → $106
Aug-01-19	Upgrade	Jefferies	Underperform → Hold	$90

Show Previous Ratings

Jun-20-24 03:58PM	The 3 Best Medical Device Stocks to Buy in June 2024 (InvestorPlace)
Jun-18-24 07:00PM	Insider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jun-14-24 07:00PM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Jun-07-24 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Jun-05-24 07:00AM	United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
02:18PM	Loading…
Jun-04-24 02:18PM	The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-03-24 04:33PM	Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics (Investor's Business Daily)
May-31-24 11:31AM	Why Is United Therapeutics (UTHR) Up 4.8% Since Last Earnings Report? (Zacks)
May-30-24 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
May-27-24 10:11AM	3 Underappreciated Biotech Stocks to Buy Now: May 2024 (InvestorPlace)
May-23-24 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
May-22-24 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
04:56AM	Latest 340B ruling delivers blow to providers (Healthcare Dive)
May-20-24 01:34PM	7 Biotech Stocks That Could Breathe New Life Into Your Portfolio (InvestorPlace)
May-16-24 07:01PM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
07:01PM	Loading…
07:01PM	Insider Sale: CFO and Treasurer James Edgemond Sells 40,160 Shares of United Therapeutics Corp ... (GuruFocus.com)
May-15-24 02:05AM	Q1 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-24 04:39PM	United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing (MT Newswires)
May-10-24 04:41PM	United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing (MT Newswires)
May-09-24 11:47AM	MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 05:15PM	United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing (MT Newswires)
09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
May-07-24 05:00PM	United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing (MT Newswires)
02:23AM	Insider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
02:23AM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
May-06-24 04:43PM	United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing (MT Newswires)
02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
12:45PM	United Therapeutics (UTHR) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
09:15AM	United Therapeutics Corporation (UTHR) Hits Fresh High: Is There Still Room to Run? (Zacks)
08:19AM	Loading…
May-05-24 08:19AM	Bright Horizons Family Solutions Inc. (NYSE:BFAM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:50PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
04:39PM	United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing (MT Newswires)
02:41PM	30 Most Profitable Companies with Highest Margins in the World (Insider Monkey)
May-02-24 11:59AM	United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales (Zacks)
11:43AM	United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:35AM	UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating (MT Newswires)
09:54AM	Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating (MT Newswires)
03:12AM	United Therapeutics Corp (UTHR) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ... (GuruFocus.com)
01:06AM	Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight (GuruFocus.com)
12:07AM	Q1 2024 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
May-01-24 04:35PM	Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity (Benzinga) +8.88%
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics (Zacks)
08:46AM	United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell (MT Newswires)
07:51AM	United Therapeutics Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance (GuruFocus.com)
06:35AM	United Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports First Quarter 2024 Financial Results (Business Wire)
Apr-29-24 12:00PM	What Makes United Therapeutics (UTHR) a New Buy Stock (Zacks)
Apr-26-24 02:02PM	CORRECTING and REPLACING PHOTO United Therapeutics Announces Worlds First Successful Xenothymokidney Transplant (Business Wire)
Apr-24-24 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:01AM	United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? (Zacks)
09:00AM	United Therapeutics Announces Worlds First Successful Xenothymokidney Transplant (Business Wire)
07:00AM	United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024 (Business Wire)
Apr-23-24 04:39PM	United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing (MT Newswires)
11:06AM	United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says (MT Newswires)
Apr-16-24 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference (Business Wire)
Apr-10-24 01:46PM	Innovation in Healthcare: HTECs Q1 2024 Index Rebalance (ETF Trends)
Apr-06-24 01:55AM	Insider Sell: Chairperson & CEO Martine Rothblatt Sells 30,000 Shares of United ... (GuruFocus.com)
Apr-05-24 01:52AM	Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... (GuruFocus.com)
Apr-03-24 08:02PM	3 Underappreciated Healthcare Stocks to Buy Now: April 2024 (InvestorPlace)
Mar-29-24 07:00PM	United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells 29,125 Shares (GuruFocus.com)
Mar-27-24 07:00PM	United Therapeutics Corp (UTHR) CEO Martine Rothblatt Sells 30,000 Shares (GuruFocus.com) -5.57%
Mar-26-24 10:00AM	United Therapeutics' Robust Portfolio Fuels Double-Digit Growth (GuruFocus.com)
07:00AM	United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation (Business Wire)
Mar-25-24 07:00PM	Insider Sell: United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells ... (GuruFocus.com)
07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire)
Mar-22-24 09:04PM	Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... (GuruFocus.com)
11:30AM	Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report? (Zacks)
Mar-21-24 07:01PM	United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells 30,000 Shares (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-16-24 02:42PM	Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 10:54PM	Q4 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
03:12PM	The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024 (InvestorPlace)
Mar-11-24 07:01PM	United Therapeutics Corp Chairperson & CEO Martine Rothblatt Sells 30,000 Shares (GuruFocus.com)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 03:01AM	Insider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... (GuruFocus.com)
Mar-05-24 06:28AM	Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
06:00AM	United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024 (Business Wire)
Feb-27-24 06:00AM	United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-26-24 07:31PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace)
Feb-23-24 05:40AM	5 Fastest Growing Biotech Companies in the US (Insider Monkey)
Feb-22-24 12:22PM	United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates (Zacks)
09:55AM	Wall Street Analysts Think United Therapeutics (UTHR) Could Surge 32.73%: Read This Before Placing a Bet (Zacks)
09:54AM	United Therapeutics Corporation (NASDAQ:UTHR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
01:16AM	Q4 2023 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
12:03AM	Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 03:17PM	United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings (Benzinga)
09:30AM	United Therapeutics (UTHR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:51AM	UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application (Reuters)
06:31AM	United Therapeutics Corp Posts Record Annual Revenue, Net Income Soars in 2023 (GuruFocus.com)
06:24AM	United Therapeutics, in unusual step, sues FDA over rivals drug application (BioPharma Dive)
06:15AM	United Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:14AM	United Therapeutics Q4 Net Income Rises (RTT News)
06:04AM	United Therapeutics starts litigation with FDA for allowing Liquidia's drug application (Reuters)
06:00AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
05:55AM	United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process (Business Wire)
Feb-20-24 08:48AM	Why United Therapeutics (UTHR) Might Surprise This Earnings Season (Zacks)
Feb-19-24 09:15AM	Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 18 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 20 04:30 PM
CAUSEY CHRISTOPHER	Director	Jun 18 '24	Option Exercise	112.14	3,000	336,420	7,185	Jun 20 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 18 '24	Sale	303.64	3,600	1,093,104	130	Jun 20 04:30 PM
CAUSEY CHRISTOPHER	Director	Jun 18 '24	Sale	304.18	3,000	912,538	4,185	Jun 20 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 17 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 20 04:30 PM
PATUSKY CHRISTOPHER	Director	Jun 17 '24	Option Exercise	76.36	2,000	152,720	2,000	Jun 18 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 17 '24	Sale	293.51	3,600	1,056,624	130	Jun 20 04:30 PM
PATUSKY CHRISTOPHER	Director	Jun 17 '24	Sale	295.50	2,000	591,000	0	Jun 18 04:30 PM
Olian Judy D.	Director	Jun 17 '24	Sale	295.43	1,700	502,225	5,605	Jun 18 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 14 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 17 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 14 '24	Sale	287.22	3,600	1,033,984	130	Jun 17 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 13 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 14 04:30 PM
CAUSEY CHRISTOPHER	Director	Jun 13 '24	Option Exercise	112.14	2,000	224,280	6,185	Jun 14 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 13 '24	Sale	285.48	3,600	1,027,716	130	Jun 14 04:30 PM
CAUSEY CHRISTOPHER	Director	Jun 13 '24	Sale	281.53	2,000	563,055	4,185	Jun 14 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 12 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 13 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 12 '24	Sale	281.19	3,600	1,012,293	130	Jun 13 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 11 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 13 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 11 '24	Sale	275.71	3,600	992,558	130	Jun 13 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 10 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 11 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 10 '24	Sale	273.95	3,600	986,204	130	Jun 11 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 07 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 11 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 07 '24	Sale	277.13	3,600	997,658	130	Jun 11 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 06 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 07 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 06 '24	Sale	276.98	3,600	997,124	130	Jun 07 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 05 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 07 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 05 '24	Sale	277.50	3,600	998,995	130	Jun 07 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 04 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 05 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 04 '24	Sale	273.38	3,600	984,150	130	Jun 05 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 03 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 05 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Jun 03 '24	Sale	276.65	3,600	995,950	130	Jun 05 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	May 31 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 03 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	May 31 '24	Sale	272.48	3,600	980,940	130	Jun 03 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	May 30 '24	Option Exercise	129.49	3,600	466,164	3,730	Jun 03 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	May 30 '24	Sale	270.10	3,600	972,350	130	Jun 03 04:30 PM
ROTHBLATT MARTINE A	Director	May 29 '24	Option Exercise	129.49	3,600	466,164	3,730	May 30 04:30 PM
ROTHBLATT MARTINE A	Director	May 29 '24	Sale	267.13	3,600	961,663	130	May 30 04:30 PM
ROTHBLATT MARTINE A	Director	May 28 '24	Option Exercise	129.49	3,600	466,164	3,730	May 30 04:30 PM
ROTHBLATT MARTINE A	Director	May 28 '24	Sale	269.06	3,600	968,620	130	May 30 04:30 PM
ROTHBLATT MARTINE A	Director	May 24 '24	Option Exercise	129.49	3,600	466,164	3,730	May 28 04:30 PM
ROTHBLATT MARTINE A	Director	May 24 '24	Sale	272.53	3,600	981,119	130	May 28 04:30 PM
ROTHBLATT MARTINE A	Director	May 23 '24	Option Exercise	129.49	3,600	466,164	3,730	May 28 04:30 PM
ROTHBLATT MARTINE A	Director	May 23 '24	Sale	275.78	3,600	992,824	130	May 28 04:30 PM
ROTHBLATT MARTINE A	Director	May 21 '24	Option Exercise	129.49	3,600	466,164	3,730	May 22 04:30 PM
ROTHBLATT MARTINE A	Director	May 21 '24	Sale	275.85	1,468	404,947	130	May 22 04:30 PM
ROTHBLATT MARTINE A	Director	May 20 '24	Option Exercise	129.49	3,600	466,164	3,730	May 22 04:30 PM
ROTHBLATT MARTINE A	Director	May 20 '24	Sale	274.74	5,732	1,574,825	130	May 22 04:30 PM
ROTHBLATT MARTINE A	Director	May 17 '24	Option Exercise	129.49	3,600	466,164	3,730	May 20 04:30 PM
ROTHBLATT MARTINE A	Director	May 17 '24	Sale	273.27	3,600	983,765	130	May 20 04:30 PM
ROTHBLATT MARTINE A	Director	May 16 '24	Option Exercise	129.49	3,600	466,164	3,730	May 20 04:30 PM
ROTHBLATT MARTINE A	Director	May 16 '24	Sale	272.37	3,600	980,534	130	May 20 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	May 15 '24	Option Exercise	163.30	40,160	6,558,128	26,578	May 16 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 15 '24	Option Exercise	129.49	3,600	466,164	3,730	May 16 04:30 PM
CAUSEY CHRISTOPHER	Director	May 15 '24	Option Exercise	112.14	2,000	224,280	6,185	May 16 04:30 PM
EDGEMOND JAMES	CFO AND TREASURER	May 15 '24	Sale	272.69	40,160	10,951,230	1,578	May 16 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 15 '24	Sale	272.93	3,600	982,553	130	May 16 04:30 PM
CAUSEY CHRISTOPHER	Director	May 15 '24	Sale	272.90	2,000	545,800	4,185	May 16 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 14 '24	Option Exercise	129.49	3,600	466,164	3,730	May 16 04:30 PM
PATUSKY CHRISTOPHER	Director	May 14 '24	Option Exercise	76.26	1,310	99,901	1,310	May 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 14 '24	Sale	267.77	3,600	963,969	130	May 16 04:30 PM
PATUSKY CHRISTOPHER	Director	May 14 '24	Sale	264.35	1,310	346,299	0	May 15 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 13 '24	Option Exercise	129.49	3,600	466,164	3,730	May 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 13 '24	Sale	265.48	3,600	955,745	130	May 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 10 '24	Option Exercise	129.49	3,600	466,164	3,730	May 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 10 '24	Sale	265.50	3,600	955,788	130	May 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 09 '24	Option Exercise	129.49	3,600	466,164	3,730	May 10 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 09 '24	Sale	264.22	3,600	951,206	130	May 10 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 08 '24	Option Exercise	129.49	3,600	466,164	3,730	May 10 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 08 '24	Sale	263.11	3,600	947,186	130	May 10 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 07 '24	Option Exercise	129.49	3,600	466,164	3,730	May 08 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 07 '24	Sale	263.82	3,600	949,737	130	May 08 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	May 06 '24	Option Exercise	163.30	32,200	5,258,260	34,777	May 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 06 '24	Option Exercise	129.49	3,600	466,164	3,730	May 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 06 '24	Sale	259.70	3,600	934,929	130	May 07 04:30 PM
Olian Judy D.	Director	May 03 '24	Option Exercise	175.43	10,000	1,754,300	17,305	May 06 04:30 PM
SULLIVAN LOUIS W	Director	May 03 '24	Option Exercise	119.76	5,160	617,962	18,220	May 06 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 03 '24	Option Exercise	129.49	3,600	466,164	3,730	May 07 04:30 PM
CAUSEY CHRISTOPHER	Director	May 03 '24	Option Exercise	112.14	2,240	251,194	6,425	May 06 04:30 PM
Olian Judy D.	Director	May 03 '24	Sale	258.56	10,000	2,585,601	7,305	May 06 04:30 PM
SULLIVAN LOUIS W	Director	May 03 '24	Sale	258.39	5,160	1,333,285	13,060	May 06 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 03 '24	Sale	260.08	3,600	936,304	130	May 07 04:30 PM
CAUSEY CHRISTOPHER	Director	May 03 '24	Sale	259.91	2,240	582,195	4,185	May 06 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 02 '24	Option Exercise	129.49	3,600	466,164	3,730	May 03 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 02 '24	Sale	258.09	3,600	929,110	130	May 03 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 01 '24	Option Exercise	129.49	3,600	466,164	3,730	May 03 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 01 '24	Sale	250.22	3,600	900,793	130	May 03 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 30 '24	Option Exercise	129.49	3,600	466,164	3,730	May 01 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 30 '24	Sale	235.35	3,600	847,277	130	May 01 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 29 '24	Option Exercise	129.49	3,600	466,164	3,730	May 01 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 29 '24	Sale	238.64	3,600	859,088	130	May 01 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 26 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 26 '24	Sale	235.20	3,600	846,705	130	Apr 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 25 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 25 '24	Sale	235.53	3,600	847,920	130	Apr 29 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 24 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 25 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 24 '24	Sale	238.81	3,600	859,730	130	Apr 25 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 23 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 25 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 23 '24	Sale	236.38	3,600	850,983	130	Apr 25 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 22 '24	Option Exercise	129.49	3,600	466,164	3,730	Apr 23 04:30 PM
DWEK RAYMOND	Director	Apr 22 '24	Option Exercise	88.03	3,000	264,090	4,750	Apr 23 04:30 PM

Open in Screener

ARCT

Arcturus Therapeutics Holdings Inc

Jun 20 • 04:00PM ET

26.59

Dollar change +0.63
Percentage change 2.43	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ARCT Arcturus Therapeutics Holdings Inc daily Stock Chart

Held by: ARKG XBI VTI VXF IWM IWN IBB LABU VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-3.91	Insider Own	8.46%	Shs Outstand	26.83M	Perf Week	-14.39%
Market Cap	716.07M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	-4.29%	Shs Float	24.65M	Perf Month	-12.82%
Income	-104.16M	PEG	-	EPS next Q	0.24	Inst Own	97.30%	Short Float	16.69%	Perf Quarter	-19.79%
Sales	113.75M	P/S	6.30	EPS this Y	-206.40%	Inst Trans	-0.13%	Short Ratio	7.39	Perf Half Y	-7.25%
Book/sh	9.81	P/B	2.71	EPS next Y	63.07%	ROA	-23.41%	Short Interest	4.11M	Perf Year	1.88%
Cash/sh	12.75	P/C	2.09	EPS next 5Y	-	ROE	-35.12%	52W Range	17.52 - 45.00	Perf YTD	-15.67%
Dividend Est.	-	P/FCF	68.20	EPS past 5Y	12.40%	ROI	-35.72%	52W High	-40.91%	Beta	2.63
Dividend TTM	-	Quick Ratio	3.26	Sales past 5Y	310.16%	Gross Margin	-	52W Low	51.77%	ATR (14)	2.75
Dividend Ex-Date	-	Current Ratio	3.26	EPS Y/Y TTM	-193.29%	Oper. Margin	-51.90%	RSI (14)	37.78	Volatility	7.92% 8.85%
Employees	180	Debt/Eq	0.12	Sales Y/Y TTM	-59.44%	Profit Margin	-91.57%	Recom	1.00	Target Price	74.75
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-153.37%	Payout	-	Rel Volume	3.27	Prev Close	25.96
Sales Surprise	115.15%	EPS Surprise	18.94%	Sales Q/Q	-59.11%	Earnings	May 08 AMC	Avg Volume	556.70K	Price	26.59
SMA20	-22.83%	SMA50	-13.56%	SMA200	-10.80%	Trades		Volume	1,819,516	Change	2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Canaccord Genuity	Buy	$90
Jul-24-23	Initiated	William Blair	Outperform	$71
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy	$19 → $51
Nov-14-22	Resumed	Wells Fargo	Overweight	$35
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform	$18
Nov-03-22	Upgrade	Citigroup	Neutral → Buy	$22 → $35
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight	$16 → $25
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight	$86 → $39
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral	$21 → $18
Apr-21-22	Downgrade	Citigroup	Buy → Neutral	$86 → $29
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell	$29
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform	$31
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight	$71
Jun-25-21	Resumed	Goldman	Neutral	$29
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight	$33 → $25
Jun-04-21	Resumed	Robert W. Baird	Neutral	$31
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell

Show Previous Ratings

Jun-20-24 08:00AM	Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors (Business Wire)
Jun-15-24 02:49AM	Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT) (GuruFocus.com)
Jun-07-24 10:30AM	Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference (Business Wire) -25.31%
Jun-04-24 07:00PM	Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ... (GuruFocus.com) +7.17%
May-28-24 06:30AM	Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program (Business Wire) +26.31%
07:00AM	Loading…
May-22-24 07:00AM	Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines (GlobeNewswire) +8.48%
May-20-24 08:30AM	Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine (PR Newswire)
May-15-24 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire) +5.12%
May-09-24 11:13AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:48AM	Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ... (GuruFocus.com)
May-08-24 09:58PM	ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:43PM	Arcturus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
May-01-24 10:01AM	Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for (Zacks) +9.15%
Apr-25-24 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 (Business Wire)
01:34AM	Loading…
Mar-28-24 01:34AM	Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares (GuruFocus.com)
Mar-22-24 01:26AM	Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ... (GuruFocus.com)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 12:10PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:54AM	Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:42PM	Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments (GuruFocus.com)
05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:21PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress (Business Wire)
Mar-04-24 01:23PM	Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why (Zacks) -5.24%
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +9.41%
09:00AM	Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-22-24 08:30AM	Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis (Business Wire) +6.12%
Feb-21-24 01:04PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 (InvestorPlace)
Feb-20-24 04:39PM	3 Tech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
09:00AM	Loading…
09:00AM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 (Business Wire)
Feb-05-24 08:30AM	New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster (PR Newswire)
Jan-23-24 04:16AM	18 High Growth Low PE Stocks (Insider Monkey)
Jan-05-24 01:17PM	PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems (PR Newswire)
Dec-21-23 08:00AM	CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster (Business Wire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-13-23 10:39PM	3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 (InvestorPlace) +11.18% +8.05%
Dec-08-23 10:13AM	12 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Dec-04-23 08:30AM	Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-28-23 08:05AM	Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults (PR Newswire)
07:56AM	Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up (Zacks)
Nov-27-23 08:30AM	Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis (Business Wire) +7.90%
Nov-15-23 01:26PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Call Transcript (Insider Monkey) +16.08%
11:30AM	Q3 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 05:19PM	Arcturus Therapeutics Holdings Inc (ARCT) Reports Significant Revenue Growth in Q3 2023 (GuruFocus.com) +9.54%
04:13PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
10:56AM	The 3 Most Undervalued Biotech Stocks to Buy: November 2023 (InvestorPlace)
Oct-25-23 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 (Business Wire)
Oct-23-23 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire)
Oct-04-23 11:01PM	Insider Sell: Pad Chivukula Sells 5,000 Shares of Arcturus Therapeutics Holdings Inc (GuruFocus.com)
08:30AM	Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government (Business Wire)
Sep-26-23 08:30AM	Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis (Business Wire)
Sep-19-23 08:30AM	Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants (Business Wire)
Sep-05-23 08:30AM	Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19 (Business Wire)
Aug-17-23 08:30AM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Aug-14-23 09:00AM	Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government (Business Wire) +6.37%
Aug-10-23 07:15AM	New Strong Sell Stocks for August 10th (Zacks)
Aug-08-23 02:39PM	Why Shares of Arcturus Therapeutics Dropped on Tuesday (Motley Fool) -19.22%
01:09PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Call Transcript (Insider Monkey)
08:43AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
07:39AM	Q2 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 07:50PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:43PM	Arcturus Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
Aug-04-23 09:21AM	4 Biotech Stocks Set to Outpace Q2 Earnings Estimates (Zacks)
Jul-28-23 05:14PM	3 Biotech Stocks to Buy Before the Breakout (InvestorPlace)
Jul-24-23 04:01PM	Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023 (Business Wire) +5.38%
Jul-18-23 06:22AM	3 Biotech Stocks for Getting Rich in 2023 (InvestorPlace)
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jul-14-23 02:36PM	Biotech, Cboe Rally To New Highs, Top Buy Points (Investor's Business Daily) +15.03%
Jul-05-23 06:15AM	Calculating The Intrinsic Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) (Simply Wall St.)
Jun-14-23 08:24AM	Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholder returns have been stellar, earning 225% in 5 years (Simply Wall St.)
Jun-01-23 08:30AM	Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency (Business Wire)
May-18-23 07:16AM	Growth Investors: Industry Analysts Just Upgraded Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Revenue Forecasts By 76% (Simply Wall St.)
May-12-23 02:04AM	4 big analyst picks: Albemarle scores fresh Overweight rating (Investing.com) -5.50%
May-09-23 05:35PM	Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates (Zacks)
04:37PM	Arcturus Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
09:29AM	12 Best Fast Growth Stocks to Buy Now (Insider Monkey)
May-08-23 07:43AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? (Simply Wall St.) +5.24%
Apr-28-23 01:39PM	12 Best Fast Growth Stocks to Buy Now (Insider Monkey)
Apr-26-23 08:30AM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023 (Business Wire) -5.09%
Apr-17-23 07:10AM	Why Investors Shouldn't Be Surprised By Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 79% Share Price Surge (Simply Wall St.)
Mar-30-23 08:29AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 11:45AM	Why Arcturus Therapeutics Stock Is Soaring Today (Motley Fool) +30.13%
Mar-28-23 05:15PM	Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress (Business Wire)
Mar-27-23 09:11AM	Market Sentiment Around Loss-Making Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) (Simply Wall St.)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-07-23 08:00AM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023 (Business Wire)
Feb-06-23 08:30AM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Jan-31-23 08:30AM	Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis (Business Wire)
Dec-28-22 11:35AM	Swelling losses haven't held back gains for Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders since they're up 109% over 5 years (Simply Wall St.)
Dec-19-22 08:30AM	Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) -7.04%
Dec-13-22 08:30AM	Arcturus Appoints John Markels, Ph.D. to its Board of Directors (Business Wire) +7.29%
Dec-12-22 08:30AM	CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics (PR Newswire)
Dec-01-22 10:23AM	The Founder of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), Joseph Payne, Just Bought A Few More Shares (Simply Wall St.)
Nov-16-22 05:24AM	These Analysts Just Made A Significant Downgrade To Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) EPS Forecasts (Simply Wall St.)
Nov-12-22 07:04AM	Arcturus Therapeutics Holdings Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Markels John	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:00 PM
HOLMES EDWARD W	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:01 PM
Marantz Jing L.	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:01 PM
FARRELL PETER C	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	55,741	Jun 18 09:00 PM
BARLOW JAMES F	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	13,131	Jun 18 09:00 PM
Marquet Magda	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:00 PM
SASSINE ANDY	Chief Financial Officer	Jun 12 '24	Sale	32.03	50,000	1,601,500	220,526	Jun 14 04:06 PM
Chivukula Pad	Chief Scientific Officer & COO	Jun 05 '24	Sale	45.00	114	5,130	447,334	Jun 07 05:01 PM
Chivukula Pad	Chief Scientific Officer & COO	Jun 03 '24	Sale	40.01	26,000	1,040,234	447,448	Jun 04 04:05 PM
Chivukula Pad	Chief Scientific Officer & COO	Mar 25 '24	Sale	35.02	17,435	610,574	473,448	Mar 27 04:15 PM
Chivukula Pad	Chief Scientific Officer & COO	Mar 19 '24	Sale	35.01	8,565	299,839	490,883	Mar 21 05:27 PM
Chivukula Pad	Chief Scientific Officer & COO	Nov 01 '23	Sale	18.72	5,000	93,602	499,448	Nov 03 04:30 PM
Chivukula Pad	Chief Scientific Officer & COO	Oct 02 '23	Sale	25.61	5,000	128,062	504,448	Oct 04 04:06 PM
Chivukula Pad	Chief Scientific Officer & COO	Sep 01 '23	Sale	31.45	5,000	157,264	509,448	Sep 05 04:05 PM
Chivukula Pad	Chief Scientific Officer & COO	Aug 01 '23	Sale	34.91	5,000	174,550	514,448	Aug 03 04:15 PM
Kummerfeld Keith C	See Remarks	Jul 14 '23	Option Exercise	8.96	6,968	62,408	7,918	Jul 18 06:50 PM
Chivukula Pad	Chief Scientific Officer & COO	Jul 14 '23	Sale	35.01	25,000	875,250	519,448	Jul 18 06:50 PM
Kummerfeld Keith C	See Remarks	Jul 14 '23	Sale	35.00	6,968	243,880	950	Jul 18 06:50 PM
Chivukula Pad	Chief Scientific Officer & COO	Jul 03 '23	Sale	28.75	5,000	143,750	544,448	Jul 07 06:01 AM

Open in Screener

RZLT

Rezolute Inc

Jun 20 • 04:00PM ET

3.77

Dollar change -0.11
Percentage change -2.84	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFAT DFAS DFAC AVSC

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	22.98%	Shs Outstand	51.39M	Perf Week	-31.20%
Market Cap	193.74M	Forward P/E	-	EPS next Y	-0.93	Insider Trans	56.28%	Shs Float	39.58M	Perf Month	34.16%
Income	-58.21M	PEG	-	EPS next Q	-0.32	Inst Own	47.60%	Short Float	2.06%	Perf Quarter	97.38%
Sales	0.00M	P/S	-	EPS this Y	-17.70%	Inst Trans	-0.33%	Short Ratio	1.24	Perf Half Y	328.41%
Book/sh	1.77	P/B	2.14	EPS next Y	22.19%	ROA	-52.46%	Short Interest	0.81M	Perf Year	69.06%
Cash/sh	1.56	P/C	2.42	EPS next 5Y	-	ROE	-58.75%	52W Range	0.72 - 6.10	Perf YTD	279.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.08%	ROI	-80.09%	52W High	-38.20%	Beta	1.19
Dividend TTM	-	Quick Ratio	11.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	423.61%	ATR (14)	0.50
Dividend Ex-Date	-	Current Ratio	11.82	EPS Y/Y TTM	-6.90%	Oper. Margin	0.00%	RSI (14)	45.08	Volatility	6.81% 13.89%
Employees	51	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.57
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-10.10%	Payout	-	Rel Volume	0.99	Prev Close	3.88
Sales Surprise	-	EPS Surprise	-12.81%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	659.55K	Price	3.77
SMA20	-13.72%	SMA50	8.31%	SMA200	108.55%	Trades		Volume	653,160	Change	-2.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Loading…
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
08:00AM	Loading…
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
07:00AM	Loading…
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)
09:33AM	Rezolute, Inc. Announces Closing of Registered Direct Offering (GlobeNewswire)
May-01-22 11:25PM	Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (GlobeNewswire)
02:00PM	Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism (GlobeNewswire)
Apr-26-22 04:05PM	RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 (GlobeNewswire) -7.74% +5.06%
Mar-29-22 07:00AM	Rezolute Joins the Rare Disease Company Coalition (GlobeNewswire) -8.72%
Mar-23-22 07:00AM	Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +7.34%
Feb-22-22 07:00AM	Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME (GlobeNewswire) -6.18%
Feb-09-22 04:05PM	Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
Nov-12-21 04:05PM	Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-19-21 12:14PM	Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares? (Simply Wall St.)
Oct-13-21 08:10AM	Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering (GlobeNewswire) -14.19%
Oct-12-21 04:05PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering (GlobeNewswire)
Sep-22-21 04:05PM	Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 (GlobeNewswire)
Sep-15-21 04:56PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -8.69%
Sep-09-21 04:05PM	Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism (GlobeNewswire) +7.00%
Sep-07-21 04:05PM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +5.41%
Aug-10-21 07:00AM	Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolutes Oral PKI for Treatment of DME (GlobeNewswire) +6.37%
Aug-03-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Jun-28-21 07:00AM	Rezolute Added to Russell Microcap® Index (GlobeNewswire)
Jun-24-21 09:01PM	Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead (TipRanks) +25.12%
Jun-03-21 05:35AM	Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely? (Simply Wall St.)
May-31-21 10:17AM	3 Strong Buy Stocks with 100% Upside Potential (TipRanks)
May-27-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +40.31%
May-20-21 07:00AM	Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs (GlobeNewswire)
May-18-21 07:00AM	Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board (GlobeNewswire)
May-17-21 04:05PM	Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
07:00AM	Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit (GlobeNewswire)
May-04-21 08:00AM	Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema (GlobeNewswire)
Apr-19-21 08:00AM	Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners (GlobeNewswire)
Mar-22-21 08:00AM	Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021 (GlobeNewswire)
Mar-08-21 08:00AM	Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts (GlobeNewswire) +24.96%
Mar-02-21 05:16PM	Rezolute to Participate in Upcoming Investor Conferences in March (GlobeNewswire) -5.34%
Feb-10-21 04:05PM	Rezolute Reports Second Quarter Fiscal 2021 Financial Results (GlobeNewswire) -9.07% +5.51%
Jan-12-21 08:30AM	Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema (GlobeNewswire) +6.84%
Jan-11-21 07:56AM	What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)? (Simply Wall St.) -6.15%
Dec-28-20 04:05PM	Rezolute Announces Change of Transfer Agent (GlobeNewswire) -11.97%
Dec-03-20 08:00AM	FDA Clears Rezolutes IND Application for RZ402 (GlobeNewswire) +7.64%
Nov-19-20 08:00AM	Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-05-20 08:00AM	Rezolute Announces Uplisting to the Nasdaq Capital Market (GlobeNewswire) +11.11%
Oct-09-20 08:30AM	Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq (GlobeNewswire) +8.75%
Sep-10-20 08:00AM	Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors (GlobeNewswire)
Jul-27-20 08:00AM	Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism (GlobeNewswire)
Jun-15-20 08:30AM	Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science (GlobeNewswire) -10.58%
May-28-20 08:30AM	Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting (GlobeNewswire)

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans Daron	CFO	Jun 14 '24	Buy	4.04	40,000	161,568	40,000	Jun 14 12:06 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 14 '24	Buy	3.91	4,300	16,828	54,352	Jun 14 12:51 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 14 '24	Buy	3.91	3,300	12,916	13,000	Jun 14 12:51 PM
Evans Daron	CFO	May 29 '24	Buy	3.50	451	1,578	121,351	May 31 04:05 PM
Evans Daron	CFO	May 24 '24	Buy	3.23	2,942	9,503	13,000	May 28 02:48 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	May 23 '24	Buy	2.69	7,500	20,138	50,052	May 28 02:56 PM
Evans Daron	CFO	May 23 '24	Buy	2.85	58	165	10,058	May 28 02:48 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 28 '24	Buy	2.55	500	1,275	1,076	Mar 29 11:08 AM
Evans Daron	CFO	Mar 15 '24	Buy	1.69	20,000	33,830	20,000	Mar 19 09:17 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 14 '24	Buy	1.88	10,000	18,800	10,000	Mar 18 11:20 AM
Evans Daron	CFO	Mar 08 '24	Buy	1.93	50,000	96,345	120,900	Mar 08 12:37 PM
Kim Young-Jin	Director	Mar 07 '24	Buy	1.91	36,503	69,859	115,450	Mar 14 10:35 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 07 '24	Buy	1.85	500	925	500	Mar 11 10:35 AM
Elam Nevan C	CEO	Feb 26 '24	Buy	1.68	5,000	8,400	7,817	Feb 28 11:40 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 26 '24	Buy	1.70	2,000	3,400	42,552	Feb 27 08:47 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 23 '24	Buy	1.69	6,000	10,140	40,552	Feb 27 08:47 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.30	41,900	54,411	70,900	Feb 20 07:01 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.37	9,000	12,330	4,500	Feb 20 07:01 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 16 '24	Buy	1.31	7,000	9,142	34,552	Feb 21 11:55 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jul 03 '23	Buy	1.90	5,000	9,500	27,552	Jul 06 11:18 AM

Open in Screener

ANIX

Anixa Biosciences Inc

Jun 20 • 04:00PM ET

2.47

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ANIX Anixa Biosciences Inc daily Stock Chart

Held by: VTI VXF IWC DFAC

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	4.90%	Shs Outstand	31.15M	Perf Week	-6.44%
Market Cap	79.06M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	7.46%	Shs Float	30.44M	Perf Month	-13.03%
Income	-11.60M	PEG	-	EPS next Q	-0.10	Inst Own	16.36%	Short Float	1.80%	Perf Quarter	-33.78%
Sales	0.00M	P/S	-	EPS this Y	-34.37%	Inst Trans	6.48%	Short Ratio	5.51	Perf Half Y	-33.60%
Book/sh	0.74	P/B	3.35	EPS next Y	-4.65%	ROA	-44.64%	Short Interest	0.55M	Perf Year	-27.88%
Cash/sh	0.73	P/C	3.40	EPS next 5Y	-	ROE	-45.98%	52W Range	2.21 - 5.13	Perf YTD	-36.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	16.79%	ROI	-48.89%	52W High	-51.85%	Beta	0.91
Dividend TTM	-	Quick Ratio	14.40	Sales past 5Y	-55.51%	Gross Margin	77.14%	52W Low	11.76%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	14.40	EPS Y/Y TTM	-4.91%	Oper. Margin	0.00%	RSI (14)	41.08	Volatility	6.51% 6.66%
Employees	5	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-32.97%	Payout	-	Rel Volume	0.54	Prev Close	2.47
Sales Surprise	-	EPS Surprise	-11.11%	Sales Q/Q	-100.00%	Earnings	Mar 08	Avg Volume	99.48K	Price	2.47
SMA20	-3.51%	SMA50	-13.27%	SMA200	-27.94%	Trades		Volume	53,684	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-23-22	Initiated	Chardan Capital Markets	Buy	$8
Apr-12-21	Initiated	H.C. Wainwright	Buy	$11

Jun-04-24 09:52PM	ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024 (InvestorPlace)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-21-24 07:30AM	Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
May-09-24 04:21AM	Anixa expands cancer vaccine collaboration with Cleveland Clinic (Pharmaceutical Technology)
May-08-24 08:25AM	Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines (PR Newswire)
09:15AM	Loading…
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-06-24 08:05AM	Anixa Biosciences CEO Featured on 'Target: Cancer Podcast' by Oncologist Dr. Sanjay Juneja (PR Newswire)
Apr-30-24 07:45AM	Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 (PR Newswire)
Apr-18-24 08:20AM	Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board (PR Newswire)
Mar-14-24 08:45AM	Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties (PR Newswire)
Mar-11-24 08:00AM	Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress (PR Newswire)
Feb-12-24 07:30AM	Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Jan-29-24 08:50AM	Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference (PR Newswire)
Jan-23-24 07:55AM	Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology (PR Newswire)
Jan-16-24 08:47AM	Sidoti Events, LLC's Virtual January Micro-Cap Conference (ACCESSWIRE) +14.35%
09:00AM	Loading…
Jan-10-24 09:00AM	Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 (PR Newswire) +9.11%
Dec-14-23 07:15AM	Anixa Biosciences to Present at Biotech Showcase 2024 (PR Newswire)
Dec-11-23 12:26PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 (InvestorPlace)
Dec-06-23 06:00PM	Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine (PR Newswire) -8.40%
04:05PM	Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine (PR Newswire)
Nov-27-23 08:30AM	Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology (PR Newswire)
Oct-31-23 08:30AM	Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference (PR Newswire)
Oct-30-23 07:38AM	Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates (Zacks)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire)
Oct-20-23 05:36AM	Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals (Zacks)
Oct-13-23 09:55AM	Bears are Losing Control Over ANIXA BIOSCIENCES INC (ANIX), Here's Why It's a 'Buy' Now (Zacks)
08:30AM	Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks)
Oct-03-23 08:30AM	Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire)
Sep-21-23 12:00PM	ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:30AM	Loading…
Sep-19-23 08:30AM	Anixa Biosciences Establishes Cancer Business Advisory Board (PR Newswire) +5.62%
Sep-11-23 10:11PM	The 3 Most Undervalued Cheap Stocks to Buy in September 2023 (InvestorPlace)
Aug-31-23 08:30AM	Anixa Biosciences to Participate in September Investor Conferences (PR Newswire)
Aug-28-23 08:30AM	Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Aug-14-23 08:30AM	Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit (PR Newswire)
Aug-10-23 09:30AM	Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer? (ACCESSWIRE)
Aug-07-23 08:30AM	Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial (PR Newswire)
Jul-27-23 08:30AM	Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology (PR Newswire)
Jul-24-23 10:44AM	Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab (Zacks)
Jul-21-23 12:05PM	Vir Biotechnology (VIR) Down on Influenza Study Failure (Zacks)
Jul-14-23 10:56AM	Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study (Zacks) +14.47%
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-11-23 10:24AM	Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30% (Zacks) +7.02%
08:30AM	Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology (PR Newswire)
Jul-07-23 10:42AM	ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study (Zacks)
Jun-22-23 12:00PM	What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock (Zacks)
May-22-23 08:30AM	Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
Apr-25-23 09:40AM	Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year? (Zacks) -5.71%
Apr-18-23 11:43AM	Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data (Zacks)
Apr-17-23 03:27PM	Anixa Biosciences Clarifies Poster Presentation on Company Website (PR Newswire) -24.46%
01:35PM	Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine (PR Newswire)
Apr-14-23 08:50AM	Here's What Could Help ANIXA BIOSCIENCES INC (ANIX) Maintain Its Recent Price Strength (Zacks)
Apr-03-23 08:47AM	We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow (Simply Wall St.) +9.30%
Mar-27-23 08:30AM	Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting (PR Newswire) +6.19%
Mar-13-23 08:30AM	Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank (PR Newswire)
Mar-02-23 08:30AM	Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders (PR Newswire)
Feb-27-23 08:30AM	Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology (PR Newswire) +7.95%
Feb-21-23 08:30AM	Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board (PR Newswire)
Jan-24-23 07:59AM	Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 38%? (Simply Wall St.)
Dec-28-22 10:39AM	12 Best Biotech Stocks to Buy Under $10 (Insider Monkey)
06:11AM	Anixa Biosciences, Inc. (NASDAQ:ANIX): Is Breakeven Near? (Simply Wall St.)
Dec-19-22 08:30AM	Anixa Biosciences to Present at Biotech Showcase 2023 (PR Newswire)
Dec-08-22 08:30AM	Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine (PR Newswire) -5.52%
Nov-08-22 08:30AM	Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium (PR Newswire)
Oct-31-22 08:30AM	Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy (PR Newswire)
Oct-26-22 08:30AM	Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic (PR Newswire) +10.46%
Oct-25-22 07:51AM	Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Oct-10-22 08:30AM	Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
Sep-12-22 08:30AM	Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium (PR Newswire) +8.70%
Aug-31-22 08:30AM	Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-15-22 08:30AM	Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire) +12.07%
Jul-21-22 08:30AM	Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology (PR Newswire) +8.36%
Jun-21-22 08:30AM	Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology (PR Newswire)
May-18-22 06:16AM	Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its Business (Simply Wall St.)
May-05-22 08:30AM	Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference (PR Newswire) -9.34%
May-02-22 09:40AM	Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year? (Zacks)
Apr-28-22 08:30AM	Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-06-22 08:30AM	Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022 (PR Newswire) -5.05%
Mar-30-22 12:45PM	Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center (PR Newswire)
Mar-17-22 08:30AM	Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC (PR Newswire) +6.20%
Jan-25-22 08:30AM	Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine (PR Newswire)
Jan-24-22 08:30AM	Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor (PR Newswire)
Dec-16-21 08:30AM	Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference (PR Newswire)
Dec-09-21 04:38AM	Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation (Simply Wall St.) -8.43%
Dec-08-21 07:47AM	Anixa (ANIX) COVID Compounds Prove Effective Against Omicron (Zacks) +10.05%
Dec-07-21 08:30AM	Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant (PR Newswire)
Oct-26-21 08:35AM	Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study (PR Newswire) +6.81%
Oct-06-21 08:30AM	Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology (PR Newswire)
Oct-01-21 08:30AM	Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy (PR Newswire)
Sep-27-21 02:01PM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Sep-14-21 08:31AM	Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium (PR Newswire)
Sep-08-21 08:30AM	Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Sep-07-21 08:30AM	Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer (PR Newswire)
Aug-31-21 11:08AM	Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study (Zacks)
Aug-30-21 08:30AM	Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy (PR Newswire)
Aug-25-21 03:14PM	Anixa Biosciences' COVID-19 Compounds Show Potential Efficacy Against Delta Variant (Benzinga) +9.01%
08:30AM	Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant (PR Newswire)
Aug-23-21 08:30AM	Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer Initiative (PR Newswire) +6.83%
Aug-18-21 08:30AM	Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire) +8.91%
Jun-12-21 03:12AM	Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation (Simply Wall St.)

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, and Other. The CAR-T Therapeutics segment involves the development of immuno-therapy drugs against cancer. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Titterton Lewis H jr	Director	Jun 14 '24	Buy	2.68	4,000	10,720	860,612	Jun 18 09:22 AM
Titterton Lewis H jr	Director	Jun 13 '24	Buy	2.70	405	1,094	856,612	Jun 14 09:56 AM
Titterton Lewis H jr	Director	Jun 11 '24	Buy	2.66	7,102	18,891	856,207	Jun 12 11:18 AM
Titterton Lewis H jr	Director	Jun 10 '24	Buy	2.60	330	858	849,105	Jun 12 11:18 AM
KUMAR AMIT	Chief Executive Officer	Jun 07 '24	Buy	2.41	25,000	60,250	516,925	Jun 07 10:57 AM
Titterton Lewis H jr	Director	Jun 07 '24	Buy	2.52	10,738	27,060	848,775	Jun 10 10:03 AM
Catelani Michael	President, COO, & CFO	Jun 07 '24	Buy	2.40	6,250	15,000	35,211	Jun 07 12:24 PM
Titterton Lewis H jr	Director	Apr 09 '24	Buy	3.28	15,009	49,230	838,037	Apr 10 09:44 AM
KUMAR AMIT	Chief Executive Officer	Mar 15 '24	Buy	3.22	30,000	96,600	491,925	Mar 15 10:49 AM
Baskies Arnold M	Director	Mar 15 '24	Buy	3.63	10,000	36,300	110,000	Mar 15 02:15 PM
Titterton Lewis H jr	Director	Oct 10 '23	Option Exercise	2.58	16,000	41,200	823,028	Oct 11 10:35 AM
KUMAR AMIT	Chief Executive Officer	Jul 31 '23	Sale	3.57	11,800	42,126	461,925	Jul 31 06:34 PM
KUMAR AMIT	Chief Executive Officer	Jul 28 '23	Option Exercise	2.58	40,000	103,000	502,100	Jul 31 06:34 PM
Titterton Lewis H jr	Director	Jul 27 '23	Option Exercise	2.58	120,000	309,000	894,070	Jul 31 06:36 PM
Catelani Michael	President, COO & CFO	Jul 20 '23	Buy	3.64	5,500	20,020	26,655	Jul 21 10:06 AM

Open in Screener

DYN

Dyne Therapeutics Inc

Jun 20 • 04:00PM ET

32.39

Dollar change -0.76
Percentage change -2.29	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

DYN Dyne Therapeutics Inc daily Stock Chart

Held by: XBI VTI IWM VXF IBB IWN SCHA LABU VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-3.97	Insider Own	30.20%	Shs Outstand	97.88M	Perf Week	-1.88%
Market Cap	3.17B	Forward P/E	-	EPS next Y	-3.07	Insider Trans	-10.50%	Shs Float	68.32M	Perf Month	-8.45%
Income	-257.40M	PEG	-	EPS next Q	-0.72	Inst Own	68.25%	Short Float	14.81%	Perf Quarter	16.05%
Sales	0.00M	P/S	-	EPS this Y	23.78%	Inst Trans	-2.79%	Short Ratio	8.55	Perf Half Y	171.50%
Book/sh	5.49	P/B	5.90	EPS next Y	-1.88%	ROA	-63.48%	Short Interest	10.11M	Perf Year	175.19%
Cash/sh	4.63	P/C	6.99	EPS next 5Y	-	ROE	-71.50%	52W Range	6.40 - 35.98	Perf YTD	143.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-106.26%	ROI	-51.49%	52W High	-9.98%	Beta	1.06
Dividend TTM	-	Quick Ratio	21.83	Sales past 5Y	0.00%	Gross Margin	-	52W Low	406.09%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	21.83	EPS Y/Y TTM	-18.88%	Oper. Margin	0.00%	RSI (14)	55.30	Volatility	4.13% 5.37%
Employees	141	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	45.90
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-3.25%	Payout	-	Rel Volume	0.45	Prev Close	33.15
Sales Surprise	-100.00%	EPS Surprise	-1.25%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.18M	Price	32.39
SMA20	1.67%	SMA50	13.67%	SMA200	71.28%	Trades		Volume	535,718	Change	-2.29%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29
Oct-12-20	Initiated	Piper Sandler	Overweight	$34
Oct-12-20	Initiated	JP Morgan	Overweight	$27
Oct-12-20	Initiated	Jefferies	Buy	$47

Show Previous Ratings

Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-30-24 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 07:30AM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
May-21-24 08:39PM	Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock (GlobeNewswire) -7.77%
12:27PM	Loading…
12:27PM	Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies (Zacks)
07:17AM	Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept (MT Newswires)
May-20-24 05:53PM	Why Is Dyne Therapeutics Stock Soaring On Monday? (Benzinga) +27.82%
04:27PM	Dyne Therapeutics Launches $300 Million Share Offering (MT Newswires)
04:07PM	Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again (Investor's Business Daily)
04:01PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:22AM	Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
09:40AM	HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Mixed Pre-Bell Monday (MT Newswires)
08:02AM	Dyne shares jump on trial data for muscle disease drugs (BioPharma Dive)
07:47AM	Loading…
07:47AM	Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints (GlobeNewswire)
May-19-24 08:00AM	Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET (GlobeNewswire)
May-04-24 05:31AM	Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections (GuruFocus.com)
May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%
08:30AM	Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-25-24 12:28PM	United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024 (Associated Press Finance) -7.72%
07:30AM	Dyne Therapeutics Announces CEO Transition (GlobeNewswire)
Mar-13-24 07:30AM	Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-07-24 01:19PM	Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... (GuruFocus.com)
Mar-05-24 10:53AM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.64%
07:30AM	Loading…
07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-24 12:00AM	CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +7.69%
Feb-14-24 04:15PM	Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-01-24 07:30AM	Dyne Therapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-26-24 11:01PM	Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) +18.21%
Jan-22-24 10:14PM	7 Speculative Stocks to Double Your Money THIS Year (InvestorPlace)
Jan-12-24 01:12PM	Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Bill Ackman, Saba Capital Management, Moab Capital Partners, Eisler Capital, Dyne Therapeutics Inc. (DYN), and More (Insider Monkey)
Jan-11-24 04:05PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.36%
Jan-05-24 09:02AM	CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) -7.37%
07:30AM	Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-24 10:46PM	Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire) +31.28%
04:37PM	Todays Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
12:39PM	These Stocks Are Moving the Most Today: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
Jan-03-24 04:25PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.09%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
08:19AM	Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? (InvestorPlace)
06:30AM	Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Diseases (GlobeNewswire)
Jan-02-24 04:05PM	Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials (GlobeNewswire)
Nov-13-23 06:59PM	3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition (InvestorPlace) +18.97%
Nov-07-23 07:30AM	Dyne Therapeutics to Present at November Investor Conferences (GlobeNewswire) +14.58%
Oct-31-23 05:36AM	Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials (GuruFocus.com)
01:11AM	The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 07:30AM	Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones (GlobeNewswire) +10.57%
Sep-28-23 07:30AM	Dyne Therapeutics to Present at October Investor Conferences (GlobeNewswire)
Sep-20-23 04:05PM	Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) -5.48%
Sep-15-23 01:52PM	Why Shares of Dyne Therapeutics Fell This Week (Motley Fool)
Sep-14-23 01:22PM	Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc (GuruFocus.com)
Sep-05-23 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-03-23 07:30AM	Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-16-23 08:46AM	SMID Caps Are Poised for a Good Run, Says Oppenheimer And These 2 Stocks Fit the Bill With Over 100% Upside (TipRanks) -9.50%
Jun-01-23 07:30AM	Dyne Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 (GlobeNewswire) -7.56%
May-17-23 11:25AM	We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate (Simply Wall St.)
07:30AM	Dyne Therapeutics Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting (GlobeNewswire)
May-11-23 07:30AM	Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-03-23 07:35AM	Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 04:46PM	Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS (GlobeNewswire)
Mar-23-23 07:30AM	Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-20-23 07:30AM	Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Mar-07-23 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) +5.06%
Mar-01-23 09:00AM	How to chart anchored VWAP multiple time frames: Brian Shannon, CMT (Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga) +12.76%
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Jan-19-23 08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics (Zacks)
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation (Zacks)
Jan-10-23 12:00PM	All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy (Zacks)
Jan-03-23 07:30AM	Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 09:55AM	Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? (Zacks)
Dec-09-22 09:55AM	Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now (Zacks) -5.05%
Dec-08-22 08:10AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 09:55AM	Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know (Zacks) +8.43%
Nov-03-22 07:30AM	Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +9.63%
Nov-02-22 07:30AM	Dyne Therapeutics to Present at Investor Conferences in November (GlobeNewswire)
Oct-31-22 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Oct-12-22 06:45AM	Dyne founder heads up new RNA-editing startup (American City Business Journals)
Oct-11-22 04:10PM	Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress (GlobeNewswire)
Sep-27-22 07:30AM	Dyne Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -9.57%
Sep-12-22 07:00AM	Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During Spotlight on the Clinic Virtual Event (GlobeNewswire)
Sep-06-22 04:30PM	Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +5.32% +18.25%
07:01AM	Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
07:00AM	Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-29-22 07:30AM	Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development (GlobeNewswire)
Aug-10-22 07:30AM	Dyne Therapeutics Announces Breakthrough Article Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research (GlobeNewswire) +7.75%
Aug-04-22 07:30AM	Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-18-22 10:00AM	Best Momentum Stocks to Buy for July 18th (Zacks) -5.56%
Jul-12-22 02:54PM	Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew (Benzinga) +5.94%

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 12 '24	Option Exercise	5.54	40,000	221,600	188,792	Jun 13 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 12 '24	Sale	33.36	40,000	1,334,201	148,792	Jun 13 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 11 '24	Sale	31.23	5,270	164,582	148,792	Jun 11 07:34 PM
Farwell Wildon	Chief Medical Officer	Jun 11 '24	Sale	31.27	2,636	82,428	145,543	Jun 11 07:41 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jun 11 '24	Sale	31.34	2,136	66,942	147,511	Jun 11 07:42 PM
McNeill Jonathan	Chief Business Officer	Jun 11 '24	Sale	31.34	1,823	57,133	134,811	Jun 11 07:34 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jun 11 '24	Sale	31.34	1,331	41,714	113,774	Jun 11 07:28 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 10 '24	Option Exercise	5.54	80,000	443,200	234,062	Jun 11 07:34 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Jun 10 '24	Sale	30.24	80,000	2,419,200	154,062	Jun 11 07:34 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jun 10 '24	Sale	30.23	1,590	48,066	115,105	Jun 11 07:28 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 20 '24	Option Exercise	1.03	30,426	31,339	180,073	May 22 09:01 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 20 '24	Sale	32.96	30,426	1,002,751	149,647	May 22 09:01 PM
McNeill Jonathan	Chief Business Officer	May 16 '24	Sale	28.27	2,774	78,420	136,634	May 17 09:03 PM
HIGH SUSANNA GATTI	Chief Operating Officer	May 16 '24	Sale	28.27	2,738	77,402	154,062	May 17 09:05 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 16 '24	Sale	28.27	2,705	76,469	149,647	May 17 09:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	May 16 '24	Sale	28.27	2,588	73,162	116,695	May 17 09:04 PM
Farwell Wildon	Chief Medical Officer	May 16 '24	Sale	28.27	2,381	67,310	148,179	May 17 09:06 PM
Farwell Wildon	Chief Medical Officer	Mar 12 '24	Sale	25.58	1,030	26,347	150,560	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 11 '24	Option Exercise	5.54	50,000	277,000	604,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Option Exercise	5.54	17,825	98,750	159,009	Mar 13 06:04 AM
Brumm Joshua T	CEO & President	Mar 11 '24	Sale	25.67	66,387	1,704,142	537,998	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Sale	25.50	19,601	499,842	139,408	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '24	Sale	25.28	2,672	67,542	119,283	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 11 '24	Sale	25.70	2,292	58,904	156,800	Mar 13 06:04 AM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '24	Sale	25.70	2,081	53,482	152,352	Mar 12 09:42 PM
Farwell Wildon	Chief Medical Officer	Mar 11 '24	Sale	25.70	1,585	40,734	151,590	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Option Exercise	5.54	363,343	2,012,920	917,728	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Option Exercise	5.54	90,000	498,600	231,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Option Exercise	5.54	86,252	477,836	208,207	Mar 12 09:57 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Sale	25.93	363,343	9,421,634	554,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Sale	26.24	90,000	2,361,531	141,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Sale	26.22	86,252	2,261,465	121,955	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 08 '24	Sale	26.67	27,199	725,344	159,092	Mar 13 06:04 AM
Farwell Wildon	Chief Medical Officer	Mar 07 '24	Sale	25.86	9,921	256,585	153,175	Mar 11 09:52 PM
Brumm Joshua T	CEO & President	Mar 07 '24	Sale	25.85	9,086	234,873	554,385	Mar 11 09:57 PM
McNeill Jonathan	Chief Business Officer	Mar 07 '24	Sale	25.85	2,434	62,919	141,184	Mar 11 09:50 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 07 '24	Sale	25.85	2,373	61,342	154,433	Mar 11 09:56 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 07 '24	Sale	25.85	2,273	58,757	121,955	Mar 11 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 07 '24	Sale	25.85	1,591	41,127	186,291	Mar 11 09:56 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Option Exercise	5.54	94,480	523,419	657,951	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Option Exercise	0.73	24,260	17,710	167,878	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Option Exercise	1.03	9,311	9,590	133,539	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Sale	29.04	94,480	2,743,718	563,471	Mar 01 09:38 PM
Rhodes Jason P	Director	Mar 01 '24	Sale	30.05	46,534	1,398,347	847,388	Mar 05 05:08 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	29,435	884,522	1,458,691	Mar 05 05:07 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Sale	28.63	24,260	694,495	143,618	Mar 01 09:37 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	17,099	513,825	847,388	Mar 05 05:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Sale	28.25	9,311	262,999	124,228	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Option Exercise	5.54	5,520	30,581	568,991	Mar 01 09:38 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Option Exercise	1.03	3,429	3,532	127,657	Mar 01 09:37 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Option Exercise	0.73	4,268	3,116	147,886	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Sale	27.50	5,520	151,800	563,471	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Sale	27.50	4,268	117,370	143,618	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Sale	27.50	3,429	94,298	124,228	Mar 01 09:37 PM
Rhodes Jason P	Director	Feb 28 '24	Sale	24.84	190,920	4,741,804	864,487	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	154,674	3,841,576	5,698,091	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	36,246	900,228	864,487	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 27 '24	Sale	24.41	368,699	8,998,426	877,806	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	298,702	7,290,088	5,852,765	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	69,997	1,708,338	877,806	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 26 '24	Sale	23.72	248,219	5,886,673	903,527	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	201,095	4,769,096	6,151,467	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	47,124	1,117,577	903,527	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 23 '24	Sale	22.70	196,928	4,470,266	920,843	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	159,542	3,621,603	6,352,562	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	37,386	848,662	920,843	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:59 PM
Rhodes Jason P	Director	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:35 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:35 PM
Rhodes Jason P	Director	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:36 PM
Rhodes Jason P	Director	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:35 PM
Farwell Wildon	Chief Medical Officer	Feb 12 '24	Sale	25.07	5,493	137,710	163,503	Feb 14 04:27 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Option Exercise	0.73	20,000	14,600	163,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 26 07:47 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Sale	24.53	20,000	490,510	143,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Sale	24.34	13,000	316,420	124,228	Jan 26 07:47 PM
Farwell Wildon	Chief Medical Officer	Jan 26 '24	Sale	25.00	100	2,500	168,996	Jan 26 07:49 PM
Kersten Dirk	Director	Jan 09 '24	Buy	17.50	1,714,285	29,999,988	6,416,793	Jan 11 04:31 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Option Exercise	5.16	218,536	1,127,092	803,507	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Option Exercise	1.03	22,674	23,354	199,259	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Option Exercise	0.73	2,009	1,467	145,627	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Sale	18.51	218,536	4,045,958	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Sale	18.13	42,453	769,673	156,806	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Sale	18.04	2,009	36,242	143,618	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Option Exercise	1.03	51,183	52,718	636,154	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Option Exercise	1.03	45,326	46,686	221,911	Jan 04 09:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Option Exercise	0.73	17,991	13,133	161,609	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Sale	19.28	51,183	986,957	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Sale	18.98	45,326	860,313	176,585	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Sale	18.74	17,991	337,062	143,618	Jan 04 09:47 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Sale	18.81	13,000	244,530	124,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 02 '24	Sale	13.10	11,900	155,890	143,618	Jan 04 09:47 PM
Scalzo Richard William	See Remarks	Dec 14 '23	Sale	12.02	2,376	28,560	124,228	Dec 14 04:59 PM
Farwell Wildon	Chief Medical Officer	Dec 12 '23	Sale	10.55	978	10,318	169,096	Dec 12 05:33 PM

Open in Screener

NEXI

Neximmune Inc

Jun 20 • 04:00PM ET

2.71

Dollar change -0.08
Percentage change -2.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-249.84	Insider Own	15.78%	Shs Outstand	1.37M	Perf Week	-6.23%
Market Cap	3.71M	Forward P/E	3.53	EPS next Y	0.77	Insider Trans	0.00%	Shs Float	1.15M	Perf Month	-15.58%
Income	-25.86M	PEG	-	EPS next Q	-	Inst Own	11.16%	Short Float	1.07%	Perf Quarter	-52.62%
Sales	0.00M	P/S	-	EPS this Y	14.81%	Inst Trans	-52.82%	Short Ratio	0.54	Perf Half Y	10.97%
Book/sh	2.16	P/B	1.25	EPS next Y	14.52%	ROA	-130.41%	Short Interest	0.01M	Perf Year	-70.77%
Cash/sh	3.26	P/C	0.83	EPS next 5Y	-	ROE	-194.82%	52W Range	1.25 - 28.69	Perf YTD	22.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.25%	ROI	-871.54%	52W High	-90.56%	Beta	1.93
Dividend TTM	-	Quick Ratio	1.30	Sales past 5Y	0.00%	Gross Margin	-	52W Low	116.78%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	1.30	EPS Y/Y TTM	-332.35%	Oper. Margin	0.00%	RSI (14)	34.44	Volatility	3.48% 5.56%
Employees	6	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	73.16%	Payout	-	Rel Volume	0.24	Prev Close	2.79
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	-	Avg Volume	22.87K	Price	2.71
SMA20	-10.66%	SMA50	-17.35%	SMA200	-44.70%	Trades		Volume	5,393	Change	-2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-21	Initiated	Raymond James	Outperform	$30
Mar-09-21	Initiated	Cantor Fitzgerald	Overweight	$35
Mar-09-21	Initiated	Barclays	Overweight	$35

May-20-24 09:54PM	NEXI Stock Earnings: NexImmune Reported Results for Q1 2024 (InvestorPlace)
Apr-16-24 11:53PM	NEXI Stock Earnings: NexImmune Reported Results for Q4 2023 (InvestorPlace) -9.22%
Feb-06-24 04:42PM	NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -12.46%
Feb-02-24 02:00PM	NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.05%
Jan-09-24 12:16PM	NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation (InvestorPlace) +55.88%
03:11PM	Loading…
Jan-03-24 03:11PM	Dear NEXI Stock Fans, Mark Your Calendars for Jan. 18 (InvestorPlace) +161.05%
Dec-01-23 01:34PM	NEXI Stock Halted: What's Going on With NexImmune Shares Today? (InvestorPlace) +143.95%
08:38AM	Why Is NexImmune (NEXI) Stock Up 353% Today? (InvestorPlace)
07:41AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Nov-06-23 08:54AM	Why Is NexImmune (NEXI) Stock Down 10% Today? (InvestorPlace) -5.80%
Oct-24-23 08:00AM	NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes (GlobeNewswire)
Oct-19-23 08:00AM	NexImmune Announces Presentations at The Society for Immunotherapy of Cancers 38th Annual Meeting (GlobeNewswire) -20.00%
Oct-18-23 11:30AM	NexImmune Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -19.00%
Aug-31-23 04:45PM	NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy (GlobeNewswire)
Aug-10-23 04:01PM	NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
08:01AM	Loading…
Jun-05-23 08:01AM	NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting (GlobeNewswire)
May-22-23 04:01PM	NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting (GlobeNewswire) +7.73% -24.26%
May-15-23 04:01PM	NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-26-23 04:01PM	NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -6.39%
Mar-31-23 12:00PM	What Makes NexImmune, Inc. (NEXI) a New Buy Stock (Zacks)
Mar-28-23 04:01PM	NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire) -8.17%
Feb-16-23 09:02AM	NexImmune Shares Are Ripping Today - Read Why (Benzinga) +46.37%
07:00AM	NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-18-23 04:01PM	NexImmune Announces Publication in Frontiers in Medicine Highlighting the Companys AIM Platform to Treat Viral Diseases (GlobeNewswire)
Nov-21-22 03:23PM	NexImmune laying off 30% of workers following cuts to clinical programs (American City Business Journals)
05:05AM	Sol Barer Is The Independent Chairman of the Board of NexImmune, Inc. (NASDAQ:NEXI) And They Just Picked Up 5.7% More Shares (Simply Wall St.)
Nov-16-22 01:59PM	Analyst Downgrades NexImmune After Going Back To Preclinical Stage (Benzinga) +12.11%
Nov-15-22 08:04AM	NexImmune Shifts Focus On AIM Direct Injection Platform, Potential Candidates In Oncology & Autoimmune Diseases (Benzinga)
Nov-14-22 04:01PM	NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update (GlobeNewswire)
Oct-06-22 07:00AM	NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) (GlobeNewswire) +8.02%
04:01PM	Loading…
Sep-09-22 04:01PM	NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -9.82% -8.65%
Sep-08-22 09:51AM	NexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders (Benzinga) -11.11%
07:00AM	Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders (Business Wire)
Sep-03-22 08:19AM	Bullish insiders bet US$1.7m on NexImmune, Inc. (NASDAQ:NEXI) (Simply Wall St.)
Aug-15-22 04:05PM	NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers (GlobeNewswire)
Jul-20-22 11:42AM	Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More (Zacks)
Jul-18-22 08:20AM	Can NexImmune (NASDAQ:NEXI) Afford To Invest In Growth? (Simply Wall St.) -11.48%
Jul-15-22 11:00AM	NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug (Zacks) +24.49%
Jul-14-22 04:09PM	NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers (GlobeNewswire) -6.96%
Jun-10-22 12:00PM	What Makes NexImmune, Inc. (NEXI) a New Buy Stock (Zacks) -5.24%
May-12-22 04:01PM	NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
May-10-22 04:01PM	NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes (GlobeNewswire) -20.90%
07:30AM	NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors (GlobeNewswire)
Apr-26-22 07:30AM	NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Centers Herbert Irving Comprehensive Cancer Center (GlobeNewswire) -16.79%
Apr-14-22 04:01PM	NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer (GlobeNewswire) -9.76%
Mar-27-22 01:03PM	Sol Barer Is The Independent Chairman of the Board of NexImmune, Inc. (NASDAQ:NEXI) And Just Spent US$72k On Shares (Simply Wall St.)
Mar-17-22 09:44AM	NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation (Benzinga) +7.82%
07:30AM	NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation (GlobeNewswire)
Mar-14-22 07:30AM	NexImmune Announces Melanoma Research Collaboration with NYU Langones Perlmutter Cancer Center (GlobeNewswire)
Mar-10-22 04:26PM	NexImmune to Present at the Barclays 2022 Global Healthcare Conference (GlobeNewswire) -17.83% -5.29%
Mar-09-22 04:33PM	NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-17-22 04:15PM	NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors (GlobeNewswire)
Feb-07-22 10:38AM	Here's Why We're Watching NexImmune's (NASDAQ:NEXI) Cash Burn Situation (Simply Wall St.) -9.89%
Feb-01-22 07:00AM	NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets (GlobeNewswire)
Jan-24-22 02:48PM	It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. (American City Business Journals) +13.49%
Jan-18-22 04:01PM	NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on Expanding the Possible with Next-Generation Cell Therapies (GlobeNewswire) -12.40%
Jan-05-22 04:01PM	NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board (GlobeNewswire)
Dec-12-21 03:40PM	NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma (GlobeNewswire)
Nov-12-21 07:30AM	NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-08-21 04:01PM	NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021 (GlobeNewswire)
10:37AM	What Percentage Of NexImmune, Inc. (NASDAQ:NEXI) Shares Do Insiders Own? (Simply Wall St.)
Nov-03-21 08:00AM	NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting (GlobeNewswire)
Sep-27-21 04:01PM	NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-10-21 09:11AM	NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-10-21 03:54AM	Bullish insiders bet US$4.1m on NexImmune, Inc. (NASDAQ:NEXI) (Simply Wall St.) +18.10%
Aug-09-21 04:05PM	NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
04:01PM	NexImmune to Explore the Use of AIM Direct Injection Technology in Type 1 Diabetes (GlobeNewswire)
Jul-27-21 04:01PM	NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021 (GlobeNewswire) -9.27%
Jul-14-21 04:01PM	NexImmune Strengthens Management Team with Key Appointments (GlobeNewswire)
Jun-16-21 04:29PM	NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference (GlobeNewswire)
May-27-21 08:00AM	NexImmune Announces Formation of Scientific Advisory Board (GlobeNewswire)
May-19-21 04:21PM	NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-17-21 04:01PM	NexImmune Reports First Quarter 2021 Financial Results and Recent Updates (GlobeNewswire)
May-12-21 04:51AM	Here's What NexImmune, Inc.'s (NASDAQ:NEXI) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Apr-21-21 07:30AM	NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs (GlobeNewswire)
Apr-13-21 12:04PM	Raymond James Predicts Over 60% Rally for These 2 Stocks (TipRanks) +11.79%
Mar-31-21 04:54PM	NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates (GlobeNewswire) +9.22%
Mar-02-21 04:01PM	NexImmune to Present at the 2021 Barclays Global Healthcare Conference (GlobeNewswire) -5.01%
Feb-24-21 08:30AM	Rapha Capital Management Announces Successful Initial Public Offering of Portfolio Company NexImmune Inc. (PR Newswire) +13.38%
Feb-23-21 08:00AM	Barer & Son Capital and Hibiscus Capital Management Announce Successful Initial Public Offering of Portfolio Company NexImmune (PR Newswire) -7.63%
Feb-17-21 06:34PM	NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-11-21 10:03PM	NexImmune Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Kristi	President and CEO	Jun 11 '24	Buy	0.01	1	0	1	Jun 13 07:58 PM
Roemer Alan S.	Director	Nov 22 '23	Sale	1.94	3,992	7,758	0	Nov 22 05:18 PM
Roemer Alan S.	Director	Nov 21 '23	Sale	2.16	3,833	8,287	3,992	Nov 22 05:18 PM

Open in Screener

NRIX

Nurix Therapeutics Inc

Jun 20 • 04:00PM ET

20.97

Dollar change +2.53
Percentage change 13.72	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

NRIX Nurix Therapeutics Inc daily Stock Chart

Held by: ARKG XBI VTI IWM VXF IWN IBB DWAS SCHA LABU

Index	RUT	P/E	-	EPS (ttm)	-2.65	Insider Own	4.15%	Shs Outstand	59.32M	Perf Week	27.09%
Market Cap	1.24B	Forward P/E	-	EPS next Y	-3.03	Insider Trans	-2.00%	Shs Float	56.85M	Perf Month	29.52%
Income	-144.73M	PEG	-	EPS next Q	-0.64	Inst Own	81.12%	Short Float	12.99%	Perf Quarter	57.91%
Sales	80.89M	P/S	15.38	EPS this Y	-6.79%	Inst Trans	-4.59%	Short Ratio	6.84	Perf Half Y	133.00%
Book/sh	3.43	P/B	6.11	EPS next Y	-7.10%	ROA	-42.39%	Short Interest	7.39M	Perf Year	100.48%
Cash/sh	4.11	P/C	5.10	EPS next 5Y	-	ROE	-65.37%	52W Range	4.22 - 18.90	Perf YTD	103.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-59.00%	ROI	-75.94%	52W High	10.95%	Beta	2.20
Dividend TTM	-	Quick Ratio	2.86	Sales past 5Y	27.29%	Gross Margin	82.24%	52W Low	396.92%	ATR (14)	1.41
Dividend Ex-Date	-	Current Ratio	2.86	EPS Y/Y TTM	24.89%	Oper. Margin	-194.51%	RSI (14)	72.40	Volatility	13.85% 7.88%
Employees	284	Debt/Eq	0.17	Sales Y/Y TTM	94.02%	Profit Margin	-178.93%	Recom	1.33	Target Price	25.33
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-0.31%	Payout	-	Rel Volume	2.54	Prev Close	18.44
Sales Surprise	-3.20%	EPS Surprise	2.01%	Sales Q/Q	30.74%	Earnings	Apr 10 BMO	Avg Volume	1.08M	Price	20.97
SMA20	31.54%	SMA50	39.94%	SMA200	99.87%	Trades		Volume	2,738,807	Change	13.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Mar-09-23	Initiated	Barclays	Overweight	$20
Feb-28-23	Initiated	Oppenheimer	Outperform	$25
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight	$11
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$25
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$28
Dec-29-21	Initiated	H.C. Wainwright	Buy	$62
Oct-14-21	Initiated	SVB Leerink	Outperform	$50
Jun-04-21	Resumed	Robert W. Baird	Outperform	$45 → $46
Apr-30-21	Resumed	Piper Sandler	Overweight	$60
Apr-30-21	Initiated	RBC Capital Mkts	Outperform	$42
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform	$40
Aug-18-20	Initiated	Stifel	Buy	$34
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-18-20	Initiated	Needham	Buy	$35
Aug-18-20	Initiated	JP Morgan	Overweight	$35

Show Previous Ratings

Jun-20-24 07:02PM	Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX) (GuruFocus.com) +13.72%
05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire)
Jun-19-24 05:05AM	Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains? (Zacks)
Jun-17-24 04:06PM	Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment (Investor's Business Daily) +20.60%
08:45AM	Biotech Stock Nurix Therapeutics Jumps On Positive Leukemia Treatment Trial (Investor's Business Daily)
07:40AM	Loading…
07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-16-24 05:30AM	Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) (GlobeNewswire)
Jun-10-24 07:00AM	Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024) (GlobeNewswire)
May-29-24 07:00AM	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 07:00AM	Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer (GlobeNewswire)
May-20-24 04:41PM	Nurix Therapeutics Names New Board Chair (MT Newswires)
04:00PM	Nurix Therapeutics Announces Board Chair Transition (GlobeNewswire)
10:21AM	Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last? (Zacks)
May-14-24 10:00AM	Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) (GlobeNewswire) +7.25%
07:39AM	Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target (MT Newswires)
07:00AM	Loading…
May-07-24 07:00AM	Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +7.11%
Apr-16-24 06:21PM	Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.24%
Apr-11-24 11:38PM	Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering (GlobeNewswire) +9.69%
04:00PM	Nurix Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Apr-10-24 11:53AM	NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.24%
09:29AM	Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study (Zacks)
08:31AM	Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024 (GuruFocus.com)
08:10AM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-09-24 01:15PM	Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies (GlobeNewswire) +26.67%
07:00AM	Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 (GlobeNewswire)
Apr-03-24 07:00AM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-02-24 07:00AM	Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences (GlobeNewswire)
Mar-25-24 07:00AM	Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) (GlobeNewswire)
Mar-20-24 09:40AM	Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting (GlobeNewswire)
07:00AM	Loading…
Mar-11-24 07:00AM	Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial (GlobeNewswire)
Mar-06-24 04:00PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +17.39% -7.41%
Mar-05-24 04:30PM	Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Feb-23-24 06:20AM	Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Feb-16-24 07:04PM	Nurix Therapeutics Inc (NRIX) Reports Robust Year-End Financials and Clinical Progress (GuruFocus.com)
Feb-15-24 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.95%
04:00PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-01-24 04:01PM	Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader (GlobeNewswire)
10:01AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Jan-16-24 04:01PM	Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL (GlobeNewswire) -6.94%
Jan-08-24 07:00AM	Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases (GlobeNewswire)
Jan-02-24 04:01PM	Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.68%
Dec-21-23 05:01PM	CFO Houte Van Sells 10,906 Shares of Nurix Therapeutics Inc (GuruFocus.com) -6.41%
Dec-13-23 04:32PM	Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors (GlobeNewswire) +6.30%
Dec-11-23 12:00PM	Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-23 04:01PM	Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +8.68%
Nov-07-23 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.31%
Nov-02-23 09:00AM	Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 04:01PM	Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial (GlobeNewswire)
Oct-18-23 09:35AM	Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround (Zacks) -13.16%
Oct-14-23 06:01AM	Nurix Therapeutics Inc (NRIX) Reports Q3 Fiscal 2023 Financial Results (GuruFocus.com)
Oct-12-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.03%
04:01PM	Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-11-23 07:09AM	Nurix (NRIX) to Report Q3 Earnings: What's in Store? (Zacks)
Oct-05-23 09:35AM	Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-04-23 09:35AM	Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-28-23 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Sep-20-23 09:30AM	Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Sep-15-23 12:00PM	Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet (Zacks)
Sep-11-23 12:10PM	Nurix (NRIX) Stock Increases 9% in a Month: Here's Why (Zacks)
Sep-08-23 05:32AM	Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks) +5.23%
Sep-07-23 07:00AM	Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics (GlobeNewswire) +8.32%
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-02-23 05:01AM	Insider Sell: Gwenn Hansen Sells 1,884 Shares of Nurix Therapeutics Inc (GuruFocus.com)
Jul-24-23 09:55AM	Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade (Zacks)
Jul-15-23 08:12AM	Nurix Therapeutics Second Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Jul-13-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-11-23 10:00AM	Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy? (Zacks)
Jun-29-23 10:00AM	Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-14-23 07:00AM	Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications (GlobeNewswire)
May-25-23 06:28AM	Nurix Therapeutics (NASDAQ:NRIX) shareholders have earned a 25% return over the last year (Simply Wall St.)
May-24-23 09:55AM	Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect? (Zacks)
May-09-23 04:01PM	Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.21% +5.46%
May-04-23 09:55AM	Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should Know (Zacks)
Apr-19-23 06:05AM	Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 30% Price Boost Is Out Of Tune With Revenues (Simply Wall St.)
Apr-18-23 09:55AM	How Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94% (Zacks) -11.90%
Apr-17-23 02:30PM	Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations (GlobeNewswire) +8.67%
Apr-13-23 05:15PM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +12.43% +20.63%
04:01PM	Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-11-23 04:01PM	Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-23 10:00AM	Will Nurix Therapeutics, Inc. (NRIX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Mar-21-23 10:05AM	Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead (Zacks)
03:49AM	Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength? (Zacks)
Mar-20-23 12:17PM	Gilead Exercises First License Option Under Agreement With Nurix Therapeutics (Benzinga) +5.66%
09:00AM	Nurixs stock rallies on Gileads option (MarketWatch)
08:30AM	Gilead Exercises Option to License Nurixs IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 (GlobeNewswire)
Mar-17-23 09:22AM	Is Nurix Therapeutics (NASDAQ:NRIX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Mar-14-23 04:45PM	Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting (GlobeNewswire)
Mar-06-23 04:01PM	Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 11:57AM	Down More Than 40%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Feb-09-23 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-08-23 04:01PM	Nurix Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.03%
Jan-09-23 09:55AM	Bears are Losing Control Over Nurix Therapeutics, Inc. (NRIX), Here's Why It's a 'Buy' Now (Zacks) -6.39%
08:35AM	Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities (GlobeNewswire)
Jan-04-23 07:01AM	Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-28-22 09:35AM	After Plunging -15.8% in 4 Weeks, Here's Why the Trend Might Reverse for Nurix Therapeutics, Inc. (NRIX) (Zacks)

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
van Houte Hans	Chief Financial Officer	Jun 20 '24	Sale	20.01	20,000	400,216	48,333	Jun 20 04:58 PM
Ring Christine	Chief Legal Officer	Jun 13 '24	Option Exercise	1.86	1,864	3,467	21,702	Jun 13 06:39 PM
Ring Christine	Chief Legal Officer	Jun 13 '24	Sale	17.02	1,864	31,721	19,838	Jun 13 06:39 PM
Ring Christine	Chief Legal Officer	Jun 12 '24	Option Exercise	1.86	1,900	3,534	21,738	Jun 12 07:30 PM
Ring Christine	Chief Legal Officer	Jun 12 '24	Sale	17.01	1,900	32,319	19,838	Jun 12 07:30 PM
Ring Christine	Chief Legal Officer	Jun 05 '24	Option Exercise	1.86	400	744	20,238	Jun 05 06:01 PM
Ring Christine	Chief Legal Officer	Jun 05 '24	Sale	17.00	400	6,801	19,838	Jun 05 06:01 PM
Ring Christine	Chief Legal Officer	Jun 03 '24	Option Exercise	1.86	1,596	2,969	21,434	Jun 03 06:36 PM
Ring Christine	Chief Legal Officer	Jun 03 '24	Sale	17.01	1,596	27,153	19,838	Jun 03 06:36 PM
van Houte Hans	Chief Financial Officer	May 02 '24	Sale	12.83	3,499	44,878	68,333	May 02 06:01 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '24	Option Exercise	0.00	5,206	0	41,608	Apr 30 06:33 PM
van Houte Hans	Chief Financial Officer	Apr 30 '24	Option Exercise	0.00	4,886	0	73,219	Apr 30 06:33 PM
Ring Christine	Chief Legal Officer	Apr 30 '24	Option Exercise	0.00	3,924	0	21,351	Apr 30 06:33 PM
Hansen Gwenn	Chief Scientific Officer	Apr 30 '24	Sale	12.04	2,007	24,169	39,601	Apr 30 06:33 PM
Ring Christine	Chief Legal Officer	Apr 30 '24	Sale	12.04	1,513	18,220	19,838	Apr 30 06:33 PM
van Houte Hans	Chief Financial Officer	Apr 30 '24	Sale	12.04	1,387	16,703	71,832	Apr 30 06:33 PM
van Houte Hans	Chief Financial Officer	Feb 16 '24	Sale	10.02	6,812	68,223	68,333	Feb 16 07:20 PM
van Houte Hans	Chief Financial Officer	Jan 30 '24	Option Exercise	0.00	4,886	0	76,816	Jan 30 06:53 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '24	Option Exercise	0.00	5,207	0	38,736	Jan 30 06:52 PM
Ring Christine	Chief Legal Officer	Jan 30 '24	Option Exercise	0.00	3,924	0	19,187	Jan 30 06:52 PM
Hansen Gwenn	Chief Scientific Officer	Jan 30 '24	Sale	7.99	2,334	18,649	36,402	Jan 30 06:52 PM
Ring Christine	Chief Legal Officer	Jan 30 '24	Sale	7.99	1,760	14,063	17,427	Jan 30 06:52 PM
van Houte Hans	Chief Financial Officer	Jan 30 '24	Sale	7.99	1,671	13,352	75,145	Jan 30 06:53 PM
van Houte Hans	Chief Financial Officer	Dec 20 '23	Sale	10.00	3,541	35,421	71,930	Dec 21 05:19 PM
van Houte Hans	Chief Financial Officer	Dec 19 '23	Sale	10.00	10,906	109,093	75,471	Dec 20 04:55 PM
Hansen Gwenn	Chief Scientific Officer	Oct 31 '23	Sale	5.20	1,633	8,487	33,529	Nov 01 04:40 PM
Ring Christine	Chief Legal Officer	Oct 31 '23	Sale	5.20	1,232	6,403	15,263	Nov 01 04:40 PM
van Houte Hans	Chief Financial Officer	Oct 31 '23	Sale	5.20	1,080	5,613	86,377	Nov 01 04:41 PM
van Houte Hans	Chief Financial Officer	Oct 30 '23	Option Exercise	0.00	4,886	0	87,457	Nov 01 04:41 PM
Hansen Gwenn	Chief Scientific Officer	Oct 30 '23	Option Exercise	0.00	5,207	0	35,162	Nov 01 04:40 PM
Ring Christine	Chief Legal Officer	Oct 30 '23	Option Exercise	0.00	3,924	0	16,495	Nov 01 04:40 PM
Hansen Gwenn	Chief Scientific Officer	Jul 31 '23	Sale	9.65	1,884	18,189	29,955	Aug 01 04:26 PM
Ring Christine	General Counsel	Jul 31 '23	Sale	9.65	1,420	13,710	12,544	Aug 01 04:27 PM
van Houte Hans	Chief Financial Officer	Jul 31 '23	Sale	9.65	1,245	12,020	82,571	Aug 01 04:28 PM
van Houte Hans	Chief Financial Officer	Jul 30 '23	Option Exercise	0.00	4,886	0	83,816	Aug 01 04:28 PM
Ring Christine	General Counsel	Jul 30 '23	Option Exercise	0.00	3,924	0	13,964	Aug 01 04:27 PM
Hansen Gwenn	Chief Scientific Officer	Jul 30 '23	Option Exercise	0.00	5,207	0	31,839	Aug 01 04:26 PM

Open in Screener

ZOM

Zomedica Corp

Jun 20 • 04:00PM ET

0.1410

Dollar change -0.0004
Percentage change -0.28	%

Healthcare • Medical Devices • USA • AMEX

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	1.75%	Shs Outstand	979.95M	Perf Week	-7.30%
Market Cap	138.17M	Forward P/E	-	EPS next Y	-	Insider Trans	9.94%	Shs Float	962.81M	Perf Month	-22.87%
Income	-37.31M	PEG	-	EPS next Q	-	Inst Own	8.59%	Short Float	6.15%	Perf Quarter	6.17%
Sales	25.97M	P/S	5.32	EPS this Y	-	Inst Trans	-2.90%	Short Ratio	10.94	Perf Half Y	-26.94%
Book/sh	0.24	P/B	0.60	EPS next Y	-	ROA	-14.26%	Short Interest	59.17M	Perf Year	-30.20%
Cash/sh	0.08	P/C	1.67	EPS next 5Y	-	ROE	-15.07%	52W Range	0.12 - 0.25	Perf YTD	-29.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.70%	ROI	-15.97%	52W High	-42.45%	Beta	0.96
Dividend TTM	-	Quick Ratio	10.87	Sales past 5Y	78.21%	Gross Margin	48.78%	52W Low	17.50%	ATR (14)	0.01
Dividend Ex-Date	-	Current Ratio	11.50	EPS Y/Y TTM	-91.46%	Oper. Margin	-132.73%	RSI (14)	37.70	Volatility	3.26% 4.63%
Employees	144	Debt/Eq	0.01	Sales Y/Y TTM	25.68%	Profit Margin	-143.67%	Recom	3.00	Target Price	0.44
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-43.08%	Payout	-	Rel Volume	0.46	Prev Close	0.14
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	14.23%	Earnings	May 09 AMC	Avg Volume	5.41M	Price	0.14
SMA20	-12.39%	SMA50	-6.93%	SMA200	-10.48%	Trades		Volume	2,466,421	Change	-0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-23	Initiated	Dawson James	Buy	$6

Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-10-24 06:30AM	Zomedica to Present at the Sidoti Small Cap Conference June 12, 2024 (ACCESSWIRE)
Jun-06-24 06:30AM	Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference (ACCESSWIRE)
Jun-04-24 06:30AM	Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels (ACCESSWIRE)
May-29-24 06:30AM	Zomedica Enhances TRUFORMA(R) Platform With Launch of Advanced Canine Cortisol Assay (ACCESSWIRE)
06:30AM	Loading…
May-23-24 06:30AM	Zomedica Publishes White Paper Highlighting Expanded Market Opportunities for PulseVet(R) Therapy (ACCESSWIRE)
May-21-24 06:30AM	Zomedica to Present at the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (ACCESSWIRE)
May-15-24 06:30AM	Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform (ACCESSWIRE) +15.81%
May-10-24 04:02PM	Zomedica Corp (ZOM) Q1 2024 Earnings: Revenue Climbs Amidst Rising Costs, Aligns with Analyst ... (GuruFocus.com) -14.35%
May-09-24 04:15PM	Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity (ACCESSWIRE)
May-08-24 06:30AM	Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024 (ACCESSWIRE)
May-06-24 06:30AM	Zomedica Expands International Reach with CE Certification for VetGuardian(R) System (ACCESSWIRE) +11.57%
May-02-24 06:30AM	Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform (ACCESSWIRE)
Apr-30-24 06:30AM	Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET (ACCESSWIRE)
Apr-09-24 06:30AM	Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024 (ACCESSWIRE)
04:05PM	Loading…
Apr-01-24 04:05PM	Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity (ACCESSWIRE)
Mar-20-24 06:30AM	Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET (ACCESSWIRE)
Mar-14-24 06:30AM	Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform (ACCESSWIRE)
Mar-13-24 04:45PM	Zomedica Provides NYSE American Listing Update (ACCESSWIRE) +6.76%
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
06:30AM	Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences (ACCESSWIRE)
Mar-07-24 06:30AM	Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs (ACCESSWIRE)
Mar-05-24 06:30AM	Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024 (ACCESSWIRE)
Feb-08-24 06:30AM	Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences (ACCESSWIRE)
Feb-06-24 04:30PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split) (ACCESSWIRE)
06:30AM	Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET (ACCESSWIRE)
Jan-31-24 06:30AM	Open Letter to Zomedica Shareholders from your Chief Executive Officer (ACCESSWIRE)
Jan-30-24 06:30AM	Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference (ACCESSWIRE)
Jan-25-24 04:35PM	Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split (ACCESSWIRE)
Jan-17-24 04:00PM	Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split") (ACCESSWIRE) -11.31%
06:30AM	Loading…
Jan-10-24 06:30AM	Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Shareholders on February 28, 2024 (ACCESSWIRE)
Jan-04-24 06:30AM	Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel "X-Trode" Handpiece (ACCESSWIRE)
Dec-18-23 06:30AM	Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease (ACCESSWIRE) +13.53%
Dec-06-23 06:30AM	Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners (ACCESSWIRE)
Nov-28-23 06:30AM	Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference (ACCESSWIRE)
Nov-20-23 06:30AM	Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference (ACCESSWIRE)
Nov-13-23 04:20PM	Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies (ACCESSWIRE)
Nov-02-23 06:30AM	Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET (ACCESSWIRE) +6.93%
Oct-11-23 06:30AM	Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference (ACCESSWIRE)
Oct-05-23 06:30AM	Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development (ACCESSWIRE)
Sep-27-23 06:30AM	Zomedica, Inc. to Present at the LD Micro Main Event XVI (Newsfile)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-14-23 06:30AM	Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushings Disease in Horses (ACCESSWIRE)
Sep-13-23 04:30PM	Zomedica Provides Corporate Update (ACCESSWIRE)
Sep-05-23 04:30PM	Zomedica Closes Acquisition of Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio (ACCESSWIRE)
Aug-31-23 06:30AM	Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:25PM	Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity (ACCESSWIRE)
Aug-08-23 06:30AM	Zomedica to Present at Sidoti Virtual Investor Conference August 16-17 (ACCESSWIRE)
Aug-04-23 06:30AM	Zomedica to Host Second Quarter Financial Results Call on August 10 (ACCESSWIRE)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE)
Jun-09-23 07:30AM	Zomedica Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services (ACCESSWIRE)
May-12-23 04:15PM	Zomedica to Participate in the Lytham Partners Spring 2023 Investor Conference (ACCESSWIRE) -6.98%
May-11-23 04:25PM	Zomedica Announces Record First Quarter 2023 Financial Results: Revenue up 45% to $5.5 Million; Strong 70% Gross Margin & $147.5 Million in Liquidity (ACCESSWIRE)
May-08-23 06:30AM	Zomedica Exercises Option to Acquire Structured Monitoring Products (ACCESSWIRE)
May-02-23 06:30AM	Zomedica to Host First Quarter Financial Results Call on May 11 (ACCESSWIRE)
Apr-18-23 06:30AM	Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Mar-31-23 09:00AM	Zomedica Corp. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Mar-17-23 06:30AM	Zomedica Appoints New Chief Financial Officer (ACCESSWIRE) -18.31%
Mar-15-23 04:45PM	Zomedica Corporation Reports 2022 Results: $18.9 Million Revenue; 72% Gross Margin & $156 Million in Liquidity - Revenue up 361% from 2021 through combination of acquisitions and organic growth (ACCESSWIRE)
Mar-08-23 06:30AM	Zomedica to Host Fourth Quarter and Fiscal Year 2022 Financial Results Call on March 15 (ACCESSWIRE)
Feb-09-23 06:30AM	Zomedica Reports Preliminary Results for the Fourth Quarter and Full Year 2022 (ACCESSWIRE)
Feb-08-23 04:15PM	Zomedica Interview To Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Jan-25-23 08:00AM	RedChip CEO Dave Gentry Invited to Join Forbes Business Council (ACCESSWIRE)
Jan-24-23 06:00AM	Zomedica to Participate in the Lytham Partners Investor Select Conference (ACCESSWIRE)
Jan-18-23 06:00AM	Zomedica to Take Control of New Assay Development and Manufacturing of TRUFORMA Product Line through Long-Term Licensing Agreement with Qorvo Biotechnologies (ACCESSWIRE) -8.52%
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE) +17.01%
06:00AM	Zomedica Expands Relationship with Structured Medical Products and Begins Commercializing VetGuardian Wireless Monitors (ACCESSWIRE)
Jan-11-23 06:00AM	Zomedica to Present at Sidoti Virtual Investor Conference January 18-19 (ACCESSWIRE)
Dec-15-22 06:30AM	Zomedica CEO Interview with Wall Street Analyzer Updates Company Progress and Plans (ACCESSWIRE)
Nov-14-22 04:20PM	Zomedica Announces Third Quarter 2022 Financial Results: $4.78 Million Revenue; 75% Gross Margin & $158.49 Million in Cash, Cash Equivalents, and Available-For-Sale Securities (ACCESSWIRE) -7.23%
Oct-18-22 06:30AM	Zomedica to Present at LD Micro Main Event XV Conference (ACCESSWIRE)
Sep-28-22 06:30AM	Zomedica To Present at Dawson James Securities 7th Annual Small Cap Growth Conference (ACCESSWIRE)
Sep-13-22 06:30AM	Zomedica Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform (ACCESSWIRE)
Sep-12-22 06:30AM	Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE)
Sep-06-22 06:30AM	Zomedica Announces Designation of PulseVet® System as the Official Shock Wave Therapy of the National Cutting Horse Association (ACCESSWIRE) -9.88%
Aug-23-22 06:30AM	Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors (ACCESSWIRE)
Aug-15-22 05:20PM	Zomedica Announces Second Quarter 2022 Financial Results of $4.2 Million of Revenue; 71% Gross Margin & $186.8 Million in Cash; Revenue up 51% from 2021 Combined Revenues (ACCESSWIRE) -9.56%
Aug-09-22 07:00AM	Zomedica Corp. to Present at Investor Summit Group's Q3 Virtual Conference (Newsfile) -6.26%
Jul-18-22 06:15AM	Zomedica Acquires Assets of Leading tPEM(TM) Company Assisi Animal Health (ACCESSWIRE)
Jul-07-22 04:15PM	Zomedica Announces New Global Manufacturing & Distribution Center (ACCESSWIRE)
Jul-06-22 06:30AM	Zomedica Finalizes Acquisition of Veterinary Imaging Company Revo Squared (ACCESSWIRE) +13.86%
Jun-28-22 06:30AM	Zomedica Announces Designation of PulseVet(R) System as the Official Shock Wave Therapy Supplier of the United States Equestrian Team (ACCESSWIRE)
Jun-21-22 06:30AM	Zomedica to Participate in Panel Discussion at Animal Health Investment Forum (ACCESSWIRE)
Jun-15-22 06:15AM	Zomedica to Acquire Assets of Innovative Veterinary Imaging Company Revo Squared (ACCESSWIRE) +15.24%
Jun-13-22 06:30AM	Zomedica to Investigate Shock Wave Therapy of Exercised Induced Pulmonary Hemorrhage in Horses (ACCESSWIRE)
Jun-08-22 06:30AM	Zomedica to Present at JMP Securities Life Sciences Conference (ACCESSWIRE)
Jun-02-22 06:30AM	Karen DeHaan-Fullerton Joins Zomedica as General Counsel and Corporate Secretary (ACCESSWIRE) +5.76%
May-19-22 06:30AM	Zomedica Enters Into Strategic Investment and Potential Collaboration for VetGuardian Monitoring Product Line (ACCESSWIRE) -5.85%
May-18-22 08:00AM	Traders News Source Interviews Larry Heaton, CEO of Zomedica Corp. (ACCESSWIRE)
May-16-22 06:30AM	Zomedica CEO Interview with Wall Street Analyzer Discusses First Quarter 2022 Earnings and Future Plans (ACCESSWIRE)
May-10-22 04:25PM	Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues (ACCESSWIRE) -5.32%
May-04-22 06:30AM	Zomedica(R) Supports Feline Animal Health With American Association of Feline Practitioners' Sponsorship (ACCESSWIRE)
Apr-27-22 06:30AM	Zomedica to Present at H.C. Wainwright Global Investment Conference (ACCESSWIRE)
Apr-13-22 06:30AM	Zomedica's Announces Designation of Pulsevet System as the Official Shock Wave Therapy of the American Quarter Horse Association (ACCESSWIRE)
Apr-04-22 06:52AM	Zomedica Announces Launch of eACTH Assay for Truforma(R) Platform (ACCESSWIRE)
Mar-03-22 02:05PM	Will the PulseVet Acquisition Continue to Deliver Sales for Zomedica? (InvestorPlace)
Mar-01-22 04:50PM	Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results (ACCESSWIRE) +11.00% -7.13%
Feb-28-22 07:30AM	Zomedica Announces Participation in the Q1 Virtual Investor Summit (Newsfile)
Feb-25-22 04:20PM	Zomedica Announces Fourth Quarter and 2021 Revenues of $4.1 Million; 73.9% Gross Margin (ACCESSWIRE)

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klass Russell Kevin	Vice President of Sales	Jun 12 '24	Buy	0.16	299,993	46,529	2,000,050	Jun 13 06:32 PM
Klass Russell Kevin	Vice President of Sales	Jun 11 '24	Buy	0.15	500,000	75,100	1,700,057	Jun 12 04:15 PM
Klass Russell Kevin	Vice President of Sales	Jun 10 '24	Buy	0.15	200,007	29,941	1,200,057	Jun 12 04:15 PM
Donato Peter	Chief Financial Officer	Jun 10 '24	Buy	0.15	25,000	3,798	25,000	Jun 11 04:15 PM
POWERS JOHNNY D	Director	May 17 '24	Buy	0.17	100,000	17,450	2,225,000	May 17 03:08 PM
POWERS JOHNNY D	Director	May 16 '24	Buy	0.18	25,000	4,600	2,125,000	May 17 10:08 AM
POWERS JOHNNY D	Director	May 14 '24	Buy	0.14	50,000	6,981	2,100,000	May 15 04:30 PM
Blair Anthony K	COO	May 13 '24	Buy	0.14	150,000	21,000	150,000	May 14 04:31 PM
HEATON LARRY C II	CEO	May 13 '24	Buy	0.14	100,000	14,200	300,000	May 13 05:07 PM
POWERS JOHNNY D	Director	May 13 '24	Buy	0.14	100,000	14,000	2,050,000	May 14 04:31 PM
POWERS JOHNNY D	Director	Dec 15 '23	Buy	0.17	100,000	16,500	1,950	Dec 18 09:20 AM
POWERS JOHNNY D	Director	Nov 17 '23	Buy	0.17	100,000	16,600	1,850,000	Nov 20 04:31 PM
HEATON LARRY C II	CEO	Nov 17 '23	Buy	0.17	100,000	16,600	200,000	Nov 17 04:50 PM
POWERS JOHNNY D	Director	Nov 15 '23	Buy	0.17	150,000	25,950	1,750,000	Nov 16 04:31 PM

Open in Screener

PCRX

Pacira BioSciences Inc

Jun 20 • 04:00PM ET

28.00

Dollar change -0.19
Percentage change -0.67	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

PCRX Pacira BioSciences Inc daily Stock Chart

Held by: IJR CALF VTI VB IWM VXF VBK IJS SPSM IWO

Index	RUT	P/E	20.10	EPS (ttm)	1.39	Insider Own	3.03%	Shs Outstand	46.48M	Perf Week	-2.37%
Market Cap	1.30B	Forward P/E	7.81	EPS next Y	3.58	Insider Trans	-8.89%	Shs Float	45.14M	Perf Month	-8.53%
Income	70.47M	PEG	2.07	EPS next Q	0.68	Inst Own	107.91%	Short Float	14.23%	Perf Quarter	-6.73%
Sales	681.75M	P/S	1.91	EPS this Y	-1.29%	Inst Trans	2.33%	Short Ratio	9.55	Perf Half Y	-9.24%
Book/sh	19.18	P/B	1.46	EPS next Y	29.22%	ROA	4.54%	Short Interest	6.43M	Perf Year	-31.56%
Cash/sh	7.00	P/C	4.00	EPS next 5Y	9.70%	ROE	8.49%	52W Range	25.33 - 41.65	Perf YTD	-17.01%
Dividend Est.	-	P/FCF	7.53	EPS past 5Y	-	ROI	4.84%	52W High	-32.77%	Beta	0.87
Dividend TTM	-	Quick Ratio	4.78	Sales past 5Y	15.46%	Gross Margin	64.74%	52W Low	10.54%	ATR (14)	1.09
Dividend Ex-Date	-	Current Ratio	5.81	EPS Y/Y TTM	780.50%	Oper. Margin	13.70%	RSI (14)	42.74	Volatility	3.17% 3.46%
Employees	712	Debt/Eq	0.65	Sales Y/Y TTM	1.88%	Profit Margin	10.34%	Recom	1.22	Target Price	43.56
Option/Short	Yes / Yes	LT Debt/Eq	0.63	EPS Q/Q	145.11%	Payout	0.00%	Rel Volume	1.08	Prev Close	28.19
Sales Surprise	1.09%	EPS Surprise	-0.02%	Sales Q/Q	4.23%	Earnings	May 07 AMC	Avg Volume	672.70K	Price	28.00
SMA20	-5.00%	SMA50	-1.63%	SMA200	-6.37%	Trades		Volume	726,708	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform	$58 → $67
Jul-06-20	Reiterated	Needham	Buy	$52 → $64
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform	$50
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$44
Feb-24-20	Reiterated	H.C. Wainwright	Buy	$60 → $63
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy

Show Previous Ratings

Jun-14-24 02:41AM	Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) (GuruFocus.com)
Jun-06-24 11:31AM	Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report? (Zacks)
May-30-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-10-24 07:00AM	Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 (GlobeNewswire)
May-08-24 04:05PM	Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes (GlobeNewswire) +11.84%
11:35AM	Loading…
11:35AM	Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues (Zacks)
09:33AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:47AM	Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-07-24 09:01PM	PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:03PM	Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ... (GuruFocus.com)
05:30PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings (Zacks)
04:13PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program (GlobeNewswire)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Apr-30-24 08:00AM	Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 (GlobeNewswire)
11:33AM	Loading…
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-02-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-14-24 08:23AM	Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag (Zacks)
Mar-13-24 07:00AM	Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Mar-08-24 11:55PM	Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) (GuruFocus.com)
Mar-06-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:38AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues (Zacks)
12:28AM	Q4 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-29-24 10:00AM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings (Zacks)
09:15AM	Pacira (PCRX) Matches Q4 Earnings Estimates (Zacks)
08:32AM	Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023 (GuruFocus.com)
08:26AM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
08:00AM	Loading…
Feb-22-24 08:00AM	Pacira to Report 2023 Financial Results on Thursday February 29, 2024 (GlobeNewswire)
Feb-15-24 08:36AM	Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy (GlobeNewswire)
Feb-07-24 08:00AM	Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. (GlobeNewswire) -7.44%
Feb-01-24 10:45AM	G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams (PR Newswire)
Jan-05-24 12:21PM	Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong (Zacks) +5.71%
Jan-04-24 05:00PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues (GlobeNewswire)
Jan-03-24 08:00AM	Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-06-23 11:13AM	Hedge Funds are Betting on These 14 Sliding Stocks (Insider Monkey)
Nov-13-23 10:10AM	Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion (Zacks)
Nov-10-23 07:30AM	Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications (GlobeNewswire)
Nov-07-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-23 10:28AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 12:34PM	Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated (Zacks)
10:00AM	Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results (GuruFocus.com)
08:23AM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Pacira BioSciences Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 08:00AM	Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc. (GlobeNewswire)
Oct-10-23 08:00AM	Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors (GlobeNewswire)
Oct-02-23 08:00AM	American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care (GlobeNewswire)
Sep-27-23 12:07PM	Unraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key Metrics (GuruFocus.com) -6.51%
11:50AM	Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-26-23 04:30PM	Pacira BioSciences Announces Leadership Succession Plan (GlobeNewswire)
Sep-06-23 08:00AM	Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 10:03AM	Qualcomm downgraded, Wingstop upgraded: Wall Street's top analyst calls (The Fly) +5.56%
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
08:11AM	Pacira: Q2 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 08:00AM	Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023 (GlobeNewswire)
Jun-21-23 08:00PM	PCRX: Raising target price to $42.00 (Argus Research)
Jun-02-23 11:31AM	Why Is Pacira (PCRX) Down 11.8% Since Last Earnings Report? (Zacks)
May-31-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-03-23 11:42PM	Q1 2023 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -7.17%
05:25PM	Why Pacira BioSciences Shares Are Trading Lower Today (Benzinga)
03:11PM	Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat (Zacks)
08:11AM	Pacira: Q1 Earnings Snapshot (AP Finance)
08:00AM	Pacira BioSciences Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 08:00PM	PCRX: Lowering target price to $35.00 (Argus Research)
08:00AM	Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023 (GlobeNewswire)
Apr-20-23 09:20AM	A Look At The Fair Value Of Pacira BioSciences, Inc. (NASDAQ:PCRX) (Simply Wall St.)
08:00AM	Pacira BioSciences Partners with The Invited Celebrity Classic a PGA TOUR Champions Event to Make iovera° The Official Non-Opioid Pain Management Partner (GlobeNewswire)
Apr-19-23 08:00AM	Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer (GlobeNewswire)
Apr-12-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 08:00AM	Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources (GlobeNewswire)
Mar-30-23 11:30AM	Why Is Pacira (PCRX) Down 6% Since Last Earnings Report? (Zacks)
Mar-29-23 08:00AM	Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures (GlobeNewswire)
Mar-27-23 08:00AM	Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit (GlobeNewswire)
Mar-24-23 08:50AM	Pacira BioSciences (NASDAQ:PCRX) shareholders have lost 49% over 1 year, earnings decline likely the culprit (Simply Wall St.)
Mar-22-23 08:00AM	Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors (GlobeNewswire)
Mar-09-23 09:17AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference (GlobeNewswire)
Feb-28-23 11:39PM	Q4 2022 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results (GlobeNewswire)
Feb-23-23 08:00AM	LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions (GlobeNewswire)
Feb-21-23 08:00AM	Pacira to Report 2022 Financial Results on Tuesday February 28, 2023 (GlobeNewswire)
Jan-05-23 04:30PM	Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million (GlobeNewswire)
Jan-04-23 08:00AM	Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 10:06AM	Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
Dec-13-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022 (GlobeNewswire) -6.64%
Nov-18-22 01:38PM	Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance? (Zacks)
Nov-17-22 08:05AM	New Research Reveals Common Treatments for Knee Pain are Falling Short, Placing Physical, Social, and Mental Burden on Patients (PR Newswire)
Nov-14-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022 (GlobeNewswire)
Nov-09-22 05:14AM	Pacira BioSciences Third Quarter 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Nov-08-22 08:00AM	Pacira BioSciences to Present at Two Healthcare Conferences in November (GlobeNewswire)
Nov-04-22 10:54AM	Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat (Zacks)
Nov-03-22 09:15AM	Pacira (PCRX) Lags Q3 Earnings Estimates (Zacks)
08:00AM	Pacira BioSciences Reports Third Quarter 2022 Financial Results (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 13 '24	Sale	28.38	7,452	211,488	102,912	Jun 13 06:12 PM
GAUGLER DARYL	Chief Operating Officer	Jun 13 '24	Sale	28.38	1,000	28,380	116,040	Jun 13 06:13 PM
HASTINGS PAUL J	Director	Jun 13 '24	Sale	28.38	880	24,974	12,724	Jun 13 06:13 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 12 '24	Sale	28.72	3,970	114,018	38,075	Jun 13 06:15 PM
SLONIN JONATHAN	Chief Medical Officer	Jun 11 '24	Sale	28.57	5,012	143,193	44,569	Jun 13 06:15 PM
PACE GARY W	Director	Mar 08 '24	Sale	30.60	90,000	2,754,000	22,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 07 '24	Sale	30.81	28,257	870,598	112,127	Mar 08 05:33 PM
PACE GARY W	Director	Mar 06 '24	Sale	29.67	1,066	31,628	140,384	Mar 08 05:33 PM
WINSTON ROY	Chief Medical Officer	Aug 02 '23	Sale	34.88	509	17,751	52,440	Aug 04 04:47 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jul 05 '23	Sale	38.91	643	25,019	22,687	Jul 07 08:04 PM

Open in Screener

AKRO

Akero Therapeutics Inc

Jun 20 • 04:00PM ET

21.78

Dollar change -0.38
Percentage change -1.71	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

AKRO Akero Therapeutics Inc daily Stock Chart

Held by: XBI VTI IWM VXF IWO IBB SCHA LABU SURI VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.20	Insider Own	16.31%	Shs Outstand	69.15M	Perf Week	-10.33%
Market Cap	1.51B	Forward P/E	-	EPS next Y	-4.13	Insider Trans	-1.22%	Shs Float	57.87M	Perf Month	8.14%
Income	-179.27M	PEG	-	EPS next Q	-0.83	Inst Own	99.13%	Short Float	12.89%	Perf Quarter	-13.54%
Sales	0.00M	P/S	-	EPS this Y	-29.12%	Inst Trans	15.22%	Short Ratio	9.55	Perf Half Y	-0.95%
Book/sh	12.24	P/B	1.78	EPS next Y	-10.61%	ROA	-28.43%	Short Interest	7.46M	Perf Year	-60.44%
Cash/sh	13.07	P/C	1.67	EPS next 5Y	-	ROE	-31.11%	52W Range	11.25 - 55.56	Perf YTD	-6.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.03%	ROI	-20.33%	52W High	-60.80%	Beta	-0.29
Dividend TTM	-	Quick Ratio	30.12	Sales past 5Y	0.00%	Gross Margin	-	52W Low	93.60%	ATR (14)	1.42
Dividend Ex-Date	-	Current Ratio	30.12	EPS Y/Y TTM	-17.00%	Oper. Margin	0.00%	RSI (14)	50.91	Volatility	5.09% 7.01%
Employees	56	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.22	Target Price	46.56
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-63.47%	Payout	-	Rel Volume	0.67	Prev Close	22.16
Sales Surprise	-	EPS Surprise	0.24%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	780.74K	Price	21.78
SMA20	3.42%	SMA50	4.18%	SMA200	-10.68%	Trades		Volume	526,120	Change	-1.71%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

Jun-19-24 02:45PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-17-24 10:23AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-13-24 03:57PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-11-24 07:00AM	Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
10:14AM	Loading…
Jun-10-24 10:14AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-08-24 08:15AM	Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 (GlobeNewswire)
Jun-06-24 10:39AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-03-24 09:57AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-30-24 09:16PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-29-24 07:00AM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 02:12PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) -7.76%
May-15-24 09:26AM	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating (MT Newswires)
May-12-24 09:01PM	Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ... (GuruFocus.com)
May-10-24 01:54PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.53%
07:45AM	Loading…
07:45AM	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 (MT Newswires)
07:00AM	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 07:00AM	Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference (GlobeNewswire)
Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.00%
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Loading…
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
06:22AM	UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients (Reuters)
06:09AM	Akero's lead drug helps improve scarring in fatty liver disease patients (Reuters)
06:00AM	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study (GlobeNewswire)
04:00AM	Akero strengthens MASH drugs case with new study data (BioPharma Dive)
Mar-01-24 09:55AM	Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know (Zacks)
Feb-29-24 08:00AM	Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH (GlobeNewswire)
07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-06-24 10:48AM	Cramer's Stop Trading: Akero Therapeutics (CNBC TV) -12.25%
Feb-05-24 09:55AM	Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jan-30-24 09:40AM	Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.22%
Jan-03-24 08:15AM	Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.41%
Dec-18-23 07:00AM	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program (GlobeNewswire)
Dec-13-23 03:06AM	Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ... (GuruFocus.com)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
12:36PM	Hedge Fund and Insider Trading News: Jeff Ubben, Bill Ackman, Saba Capital Management, Akero Therapeutics Inc (AKRO), Verizon Communications Inc. (VZ) and More (Insider Monkey)
Nov-14-23 07:21PM	Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-13-23 07:00AM	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 08:57AM	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Nov-08-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Oct-17-23 04:05PM	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference (GlobeNewswire)
Oct-12-23 04:38PM	Why Akero Therapeutics Shares Are Slumping This Week (Motley Fool)
08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 05:35PM	Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward (Benzinga) -17.13%
11:11AM	Akero (AKRO) Slumps 63% on Mixed Results From NASH Study (Zacks)
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -62.61%
04:03PM	Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio (Investor's Business Daily)
12:10PM	PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023 (Associated Press Finance)
11:44AM	Why Akero Therapeutics Stock Is Crashing Today (Motley Fool)
10:37AM	Akero Therapeutics, Palantir, Hyatt Hotels: Trending tickers (Yahoo Finance Video)
09:29AM	Why Is Akero Therapeutics (AKRO) Stock Down 58% Today? (InvestorPlace)
07:15AM	Akero's drug for fatty liver disease misses main trial goal (Reuters)
07:00AM	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins (GlobeNewswire)
Oct-09-23 04:05PM	Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH (GlobeNewswire)
Oct-05-23 07:01AM	Insider Sell: Akero Therapeutics Inc CEO Andrew Cheng Sells 25,000 Shares (GuruFocus.com)
Oct-04-23 08:00AM	Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 07:56AM	Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA (Zacks)
Aug-31-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in September (GlobeNewswire)
Aug-28-23 07:00AM	Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 (GlobeNewswire)
Aug-11-23 06:00AM	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +6.59%
Jul-11-23 09:02AM	Infinity Pharma (INFI) Stock Up on Advancing Cancer Study (Zacks)
Jul-10-23 09:32AM	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why (Zacks)
09:29AM	Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand (Zacks)
08:58AM	Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study (Zacks)
Jul-07-23 08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-03-23 11:20AM	Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune (Zacks)
10:25AM	Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date (Zacks)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 10:04AM	Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe (Zacks)
09:59AM	Axsome (AXSM) Down on Public Offering of Common Stock (Zacks)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-28-23 10:53AM	Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks) -9.17%
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
10:36AM	Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate (Zacks)
08:50AM	Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why (Zacks)
08:21AM	Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata (Zacks)
06:41AM	Daily Vickers Top Buyers & Sellers for 06/26/2023 (Argus Research)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks)
09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
07:00AM	Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology (GlobeNewswire)
Jun-22-23 09:18AM	Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate (Zacks)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
10:46AM	Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal (Zacks)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cheng Andrew	President and CEO	Jun 11 '24	Sale	22.64	7,894	178,728	581,553	Jun 13 06:01 PM
White William Richard	Chief Financial Officer	Jun 11 '24	Sale	22.64	2,831	64,094	46,799	Jun 13 06:09 PM
Yale Catriona	Chief Development Officer	Jun 11 '24	Sale	22.64	2,825	63,961	74,867	Jun 13 06:11 PM
Young Jonathan	Chief Operating Officer	Jun 11 '24	Sale	22.64	2,516	56,965	250,790	Jun 13 06:13 PM
Rolph Timothy	Chief Scientific Officer	Jun 11 '24	Sale	22.64	2,380	53,886	180,178	Jun 13 06:06 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jun 11 '24	Sale	22.64	569	12,883	18,562	Jun 13 06:04 PM
Young Jonathan	Chief Operating Officer	Jun 03 '24	Sale	19.29	5,000	96,440	253,306	Jun 05 05:05 PM
Young Jonathan	Chief Operating Officer	May 01 '24	Sale	20.15	5,000	100,750	258,306	May 02 09:07 PM
Young Jonathan	Chief Operating Officer	Apr 01 '24	Sale	24.38	5,000	121,913	263,306	Apr 03 06:55 PM
Cheng Andrew	President and CEO	Mar 13 '24	Sale	28.33	1,969	55,782	589,447	Mar 15 04:43 PM
White William Richard	Chief Financial Officer	Mar 13 '24	Sale	28.33	724	20,511	49,630	Mar 15 04:44 PM
Yale Catriona	Chief Development Officer	Mar 13 '24	Sale	28.33	723	20,483	77,692	Mar 15 04:45 PM
Young Jonathan	Chief Operating Officer	Mar 13 '24	Sale	28.33	651	18,443	268,306	Mar 15 04:42 PM
Rolph Timothy	Chief Scientific Officer	Mar 13 '24	Sale	28.33	619	17,536	182,558	Mar 15 04:42 PM
Cheng Andrew	President and CEO	Mar 04 '24	Option Exercise	17.17	75,000	1,288,062	666,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Option Exercise	13.96	20,646	288,124	99,061	Mar 06 08:13 PM
Cheng Andrew	President and CEO	Mar 04 '24	Sale	32.87	75,000	2,465,063	591,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Sale	35.49	20,646	732,727	78,415	Mar 06 08:13 PM
Young Jonathan	Chief Operating Officer	Mar 01 '24	Option Exercise	0.61	83,321	51,242	268,957	Mar 05 05:16 PM
Cheng Andrew	President and CEO	Jan 02 '24	Option Exercise	0.61	40,000	24,600	590,911	Jan 03 05:00 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Option Exercise	6.36	5,414	34,433	190,545	Dec 29 08:30 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Sale	24.00	5,414	129,936	185,131	Dec 29 08:30 PM
Cheng Andrew	President and CEO	Dec 14 '23	Sale	20.76	1,628	33,797	550,911	Dec 18 08:37 PM
White William Richard	Chief Financial Officer	Dec 14 '23	Sale	20.76	611	12,684	50,354	Dec 18 08:40 PM
Yale Catriona	Chief Development Officer	Dec 14 '23	Sale	20.76	597	12,394	77,910	Dec 18 08:49 PM
Young Jonathan	Chief Operating Officer	Dec 14 '23	Sale	20.76	543	11,273	185,131	Dec 18 08:39 PM
Rolph Timothy	Chief Scientific Officer	Dec 14 '23	Sale	20.76	514	10,671	182,672	Dec 18 08:29 PM
Cheng Andrew	President and CEO	Dec 11 '23	Option Exercise	6.36	7,405	47,096	559,944	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 11 '23	Sale	20.02	7,405	148,273	552,539	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 08 '23	Option Exercise	6.36	12,873	81,872	473,871	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 08 '23	Buy	19.83	100,000	1,982,940	800,000	Dec 11 09:06 PM
Cheng Andrew	President and CEO	Dec 08 '23	Sale	20.01	12,873	257,571	460,998	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Option Exercise	6.36	6,700	42,612	467,698	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Sale	20.02	6,700	134,125	460,998	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 01 '23	Buy	16.99	50,000	849,730	700,000	Dec 05 08:37 AM
Graham G. Walmsley	Director	Nov 30 '23	Buy	16.90	50,000	844,835	650,000	Dec 05 08:37 AM
Young Jonathan	Chief Operating Officer	Nov 17 '23	Sale	14.68	30,000	440,259	153,177	Nov 21 05:30 PM
Cheng Andrew	President and CEO	Oct 02 '23	Option Exercise	6.36	25,000	159,000	485,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Option Exercise	21.10	490	10,339	183,667	Oct 04 08:33 PM
Cheng Andrew	President and CEO	Oct 02 '23	Sale	47.91	25,000	1,197,827	460,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Sale	51.10	490	25,039	183,177	Oct 04 08:33 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Option Exercise	6.36	5,000	31,800	51,010	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Sale	48.07	5,000	240,356	46,010	Sep 25 08:31 PM
Graham G. Walmsley	Director	Sep 19 '23	Buy	26.00	400,000	10,400,000	400,000	May 23 09:55 PM
Cheng Andrew	President and CEO	Sep 13 '23	Sale	50.34	1,682	84,672	460,998	Sep 25 08:36 PM
White William Richard	Chief Financial Officer	Sep 13 '23	Sale	50.34	632	31,815	18,468	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 13 '23	Sale	50.34	617	31,060	46,010	Sep 25 08:31 PM
Young Jonathan	Chief Operating Officer	Sep 13 '23	Sale	50.34	562	28,291	183,177	Sep 25 08:28 PM
Rolph Timothy	Chief Scientific Officer	Sep 13 '23	Sale	50.34	531	26,731	150,689	Sep 25 08:30 PM
Cheng Andrew	President and CEO	Sep 01 '23	Option Exercise	6.36	25,000	159,000	487,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Sep 01 '23	Sale	49.77	25,000	1,244,248	462,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Aug 30 '23	Option Exercise	0.61	15,000	9,225	462,680	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Option Exercise	6.36	5,745	36,538	52,372	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Sale	49.99	5,745	287,191	46,627	Aug 30 07:04 PM
Graham G. Walmsley	Director	Aug 08 '23	Buy	42.06	25,000	1,051,475	600,000	Aug 10 04:46 PM
Cheng Andrew	President and CEO	Aug 01 '23	Option Exercise	6.36	25,000	159,000	472,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Aug 01 '23	Buy	43.26	25,000	1,081,525	575,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Aug 01 '23	Sale	43.15	25,000	1,078,867	447,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Jul 28 '23	Buy	42.69	30,000	1,280,709	550,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Jul 03 '23	Option Exercise	6.36	25,000	159,000	472,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jul 03 '23	Sale	44.88	25,000	1,122,041	447,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jun 27 '23	Option Exercise	0.61	40,000	24,600	447,680	Jun 27 07:12 PM
Yale Catriona	Chief Development Officer	Jun 23 '23	Sale	50.76	11,000	558,360	46,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 22 '23	Sale	52.18	11,000	573,935	57,627	Jun 23 08:06 PM

Open in Screener

ACRS

Aclaris Therapeutics Inc

Jun 20 • 04:00PM ET

1.13

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ACRS Aclaris Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB SCHA VTWO VHT ONEQ IWC

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	8.11%	Shs Outstand	70.89M	Perf Week	-1.74%
Market Cap	80.52M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	60.16%	Shs Float	65.48M	Perf Month	-5.04%
Income	-77.26M	PEG	-	EPS next Q	-0.20	Inst Own	74.10%	Short Float	7.04%	Perf Quarter	-5.04%
Sales	31.12M	P/S	2.59	EPS this Y	37.10%	Inst Trans	0.40%	Short Ratio	6.69	Perf Half Y	20.51%
Book/sh	1.99	P/B	0.57	EPS next Y	21.28%	ROA	-38.27%	Short Interest	4.61M	Perf Year	-89.36%
Cash/sh	1.80	P/C	0.63	EPS next 5Y	-	ROE	-48.47%	52W Range	0.59 - 11.12	Perf YTD	7.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.67%	ROI	-53.29%	52W High	-89.84%	Beta	0.28
Dividend TTM	-	Quick Ratio	6.74	Sales past 5Y	74.29%	Gross Margin	67.36%	52W Low	91.46%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	6.74	EPS Y/Y TTM	24.52%	Oper. Margin	-287.76%	RSI (14)	50.44	Volatility	7.63% 6.58%
Employees	91	Debt/Eq	0.02	Sales Y/Y TTM	0.95%	Profit Margin	-248.28%	Recom	2.78	Target Price	1.84
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	43.39%	Payout	-	Rel Volume	0.71	Prev Close	1.13
Sales Surprise	24.33%	EPS Surprise	16.00%	Sales Q/Q	-5.14%	Earnings	May 07 AMC	Avg Volume	688.67K	Price	1.13
SMA20	3.39%	SMA50	-3.41%	SMA200	-52.59%	Trades		Volume	492,352	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform	$22
Dec-14-22	Initiated	Stifel	Buy	$29
Dec-01-22	Initiated	Goldman	Buy	$25
Oct-06-22	Initiated	BTIG Research	Buy	$32
Jul-23-21	Resumed	Jefferies	Buy	$27 → $32
Jun-15-21	Initiated	Piper Sandler	Overweight	$30
Apr-21-21	Initiated	H.C. Wainwright	Buy	$40
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform	$13
Mar-28-18	Resumed	Leerink Partners	Outperform	$52
Feb-09-18	Initiated	Guggenheim	Buy	$53
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight	$50
Nov-29-16	Initiated	Leerink Partners	Outperform	$54
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy	$35
Nov-02-15	Initiated	Jefferies	Buy	$20

Show Previous Ratings

Jun-06-24 07:00AM	Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-08-24 12:06PM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.96%
07:43AM	Q1 2024 Aclaris Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-07-24 10:56PM	ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Loading…
05:15PM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Aclaris: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:00AM	Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update (GlobeNewswire)
Apr-23-24 08:00AM	Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer (PR Newswire)
Apr-05-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Mar-20-24 09:40AM	Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire) -8.00%
Mar-04-24 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's Why (Zacks)
09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
09:35AM	Loading…
Feb-27-24 09:35AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:38AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-15-24 10:00AM	Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-13-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Jan-17-24 11:14AM	Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO (Zacks)
Jan-16-24 07:00AM	Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review (GlobeNewswire) +25.54%
Jan-10-24 07:00AM	Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis (GlobeNewswire) -21.48%
Jan-04-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Dec-19-23 04:01PM	Aclaris Therapeutics Provides Corporate Update (GlobeNewswire) +8.78% -8.33%
Dec-05-23 04:01PM	Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia (GlobeNewswire)
Dec-04-23 09:35AM	Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.74%
Nov-16-23 09:35AM	Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS) (Zacks) +10.42%
Nov-14-23 10:57AM	Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study (Zacks) +5.46%
Nov-13-23 07:17AM	UPDATE 1-Aclaris Therapeutics to stop development of rheumatoid arthritis drug (Reuters) -86.44%
07:06AM	Loading…
07:06AM	Aclaris Therapeutics to stop development of rheumatoid arthritis drug (Reuters)
07:00AM	Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update (GlobeNewswire)
Nov-06-23 08:03AM	Aclaris Therapeutics Inc (ACRS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:06AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-03-23 07:00AM	Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202) (GlobeNewswire)
Sep-20-23 07:00AM	Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -8.51%
Sep-18-23 07:00AM	Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor (GlobeNewswire)
Sep-14-23 07:03PM	Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday (Motley Fool) +5.54% -5.62%
Sep-08-23 05:06PM	Insider Buying: CFO Kevin Balthaser Acquires 9,490 Shares of Aclaris Therapeutics Inc (GuruFocus.com)
Aug-10-23 06:07AM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-08-23 08:40AM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Just Slashed This Year's Revenue Estimates By 11% (Simply Wall St.) -5.25%
Aug-07-23 08:15AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -7.21%
07:10AM	Aclaris: Q2 Earnings Snapshot (AP Finance)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-01-23 07:53AM	Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 363% gain (Simply Wall St.)
Jul-06-23 08:19AM	Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last? (Zacks)
Jun-26-23 10:15AM	2 Low-Priced Stocks That Could Make You Richer (Motley Fool)
Jun-13-23 06:30PM	Why Aclaris Therapeutics Topped the Market on Tuesday (Motley Fool)
07:01AM	Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202) (GlobeNewswire)
Jun-02-23 07:00AM	Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences (GlobeNewswire)
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-10-23 06:04AM	Aclaris Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-08-23 11:55PM	Q1 2023 Aclaris Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.46%
08:15AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:08AM	Aclaris: Q1 Earnings Snapshot (AP Finance)
07:00AM	Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-23 06:49AM	What Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) P/S Is Not Telling You (Simply Wall St.)
May-02-23 07:01AM	Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire)
Apr-27-23 04:35AM	Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? (Zacks)
Apr-24-23 02:37PM	3 Biotech Stocks to Sell Before Theyre 6 Feet Under (InvestorPlace)
Apr-04-23 07:40AM	Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation (Simply Wall St.)
Mar-27-23 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-10-23 11:34AM	Lab Notes: Fox Chase Cancer Center researcher gets $1M grant; NRx raises funds (American City Business Journals)
Mar-06-23 03:59PM	As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris (Benzinga) -44.68%
02:32PM	These 2 Biotech Stocks Made Big Monday Moves (Motley Fool)
01:03PM	Why Aclaris Therapeutics Stock Is Plunging Today (Benzinga)
11:50AM	Why Aclaris Therapeutics Is Crashing Today (Motley Fool)
07:00AM	Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa (GlobeNewswire)
Feb-23-23 08:35AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-22-23 06:01AM	Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 943% gain (Simply Wall St.)
Feb-09-23 04:01PM	Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-06-23 07:01AM	Aclaris Therapeutics Provides 2023 Outlook (GlobeNewswire) +8.67%
Nov-29-22 07:00AM	Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China (GlobeNewswire) -7.06%
Nov-26-22 01:39PM	Lab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wine (American City Business Journals)
Nov-22-22 04:01PM	Aclaris Therapeutics Announces Key Leadership Transitions (GlobeNewswire)
Nov-16-22 12:10PM	Aclaris Therapeutics Looks Promising on the Charts (TheStreet.com)
Nov-10-22 04:01PM	Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences (GlobeNewswire)
Nov-08-22 08:25AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-26-22 06:44AM	We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely (Simply Wall St.)
Sep-27-22 07:00AM	Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations (GlobeNewswire)
Sep-15-22 06:46AM	Aclaris Therapeutics (NASDAQ:ACRS) pulls back 7.4% this week, but still delivers shareholders massive 110% CAGR over 3 years (Simply Wall St.)
Aug-30-22 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-25-22 07:00AM	Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata (GlobeNewswire) +5.26%
Aug-05-22 07:59AM	Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt? (Simply Wall St.) +7.33%
Aug-03-22 08:25AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-01-22 07:00AM	Aclaris Therapeutics Expands Leadership Team (GlobeNewswire) -11.62%
Jul-15-22 12:00PM	Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy (Zacks)
Jul-08-22 09:40AM	Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-01-22 09:36AM	Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options (American City Business Journals)
Jun-27-22 07:00AM	Aclaris Therapeutics Expands Leadership Team (GlobeNewswire)
Jun-22-22 09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-20-22 08:20AM	Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Jun-13-22 09:55AM	Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect? (Zacks) -10.39%
Jun-06-22 09:40AM	Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year? (Zacks)
Jun-01-22 04:01PM	Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire) +8.22%
May-27-22 09:55AM	Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade (Zacks)

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Braden Michael	10% Owner	Jun 18 '24	Buy	1.13	50,000	56,505	11,552,134	Jun 18 04:04 PM
Leonard Braden Michael	10% Owner	Jun 17 '24	Buy	1.13	150,000	169,500	11,502,134	Jun 18 04:04 PM
Leonard Braden Michael	10% Owner	Jun 14 '24	Buy	1.17	345,000	402,201	11,352,134	Jun 18 04:04 PM
Leonard Braden Michael	10% Owner	Jun 13 '24	Buy	1.15	528,621	607,757	11,007,134	Jun 13 06:04 PM
Leonard Braden Michael	10% Owner	Jun 12 '24	Buy	1.14	82,579	94,140	10,478,513	Jun 13 06:04 PM
Leonard Braden Michael	10% Owner	Jun 11 '24	Buy	1.08	1,000,000	1,080,000	10,395,934	Jun 13 06:04 PM
Powell Andrew Kenneth William	Director	Mar 04 '24	Buy	1.25	6,000	7,500	28,863	Mar 05 04:58 PM
Powell Andrew Kenneth William	Director	Mar 01 '24	Buy	1.23	8,500	10,455	22,863	Mar 05 04:58 PM
Monahan Joseph	Chief Scientific Officer	Oct 23 '23	Sale	5.08	6,000	30,460	129,724	Oct 25 04:28 PM
Balthaser Kevin	Chief Financial Officer	Sep 06 '23	Buy	7.90	9,490	74,971	15,461	Sep 07 04:16 PM
Loerop James	Chief Business Officer	Aug 28 '23	Buy	6.80	14,705	99,959	21,688	Aug 28 04:39 PM
Monahan Joseph	Chief Scientific Officer	Aug 21 '23	Sale	7.32	6,000	43,895	135,724	Aug 22 04:31 PM

Open in Screener

PEPG

PepGen Inc

Jun 20 • 04:00PM ET

16.80

Dollar change +0.44
Percentage change 2.69	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO IWO IWC AVSC IWV VTWV

Index	RUT	P/E	-	EPS (ttm)	-3.25	Insider Own	20.88%	Shs Outstand	32.42M	Perf Week	-5.14%
Market Cap	544.66M	Forward P/E	-	EPS next Y	-2.78	Insider Trans	59.96%	Shs Float	25.65M	Perf Month	24.54%
Income	-80.33M	PEG	-	EPS next Q	-0.72	Inst Own	70.01%	Short Float	1.54%	Perf Quarter	12.98%
Sales	0.00M	P/S	-	EPS this Y	13.20%	Inst Trans	-0.43%	Short Ratio	6.27	Perf Half Y	138.98%
Book/sh	5.53	P/B	3.04	EPS next Y	2.92%	ROA	-39.37%	Short Interest	0.39M	Perf Year	66.34%
Cash/sh	5.40	P/C	3.11	EPS next 5Y	-	ROE	-46.72%	52W Range	3.72 - 18.38	Perf YTD	147.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-172.30%	ROI	-41.04%	52W High	-8.60%	Beta	1.73
Dividend TTM	-	Quick Ratio	15.78	Sales past 5Y	0.00%	Gross Margin	-	52W Low	351.61%	ATR (14)	1.18
Dividend Ex-Date	-	Current Ratio	15.78	EPS Y/Y TTM	2.65%	Oper. Margin	0.00%	RSI (14)	55.43	Volatility	5.55% 8.16%
Employees	64	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.60
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	8.44%	Payout	-	Rel Volume	0.96	Prev Close	16.36
Sales Surprise	-	EPS Surprise	18.85%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	62.83K	Price	16.80
SMA20	2.75%	SMA50	18.15%	SMA200	71.01%	Trades		Volume	60,608	Change	2.69%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	H.C. Wainwright	Buy	$26

Jun-11-24 07:00AM	PepGen Announces Executive Team Promotions (Business Wire)
May-15-24 01:20PM	PepGen Q1 Loss Narrows (MT Newswires)
May-14-24 10:55PM	PEPG Stock Earnings: PepGen Beats EPS for Q1 2024 (InvestorPlace) +5.19%
04:02PM	PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-12-24 01:30PM	Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More (Insider Monkey)
04:05PM	Loading…
Mar-13-24 04:05PM	PepGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-12-24 09:55AM	Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-11-24 12:00PM	PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-06-24 11:54PM	PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 (InvestorPlace) -7.34% -7.98%
04:01PM	PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +14.68%
Feb-20-24 08:00AM	PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Feb-07-24 07:30AM	PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock (GlobeNewswire) +17.63%
07:00AM	Loading…
Jan-17-24 07:00AM	Mary Beth DeLena Joins PepGen as General Counsel and Secretary (GlobeNewswire)
Jan-08-24 07:00AM	PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping (GlobeNewswire)
Dec-18-23 08:00AM	PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +6.03%
Nov-15-23 08:00AM	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors (GlobeNewswire)
Nov-08-23 08:00AM	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire) -10.40%
Oct-12-23 07:00AM	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +7.22%
Sep-27-23 04:16PM	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology (GlobeNewswire)
Sep-06-23 04:05PM	PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 (GlobeNewswire)
08:00AM	PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences (GlobeNewswire)
Sep-01-23 08:00AM	PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:15AM	PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-13-23 04:05PM	PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 (GlobeNewswire) +10.87% -7.99%
May-31-23 11:44AM	PepGen (PEPG) Down on Clinical Hold for DM1 Candidate (Zacks) -5.07%
May-30-23 04:05PM	PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-18-23 07:00AM	PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
07:00AM	Loading…
May-11-23 07:00AM	PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-04-23 08:00AM	PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-17-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire) +23.09%
Apr-13-23 04:05PM	PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.07% -10.09%
Mar-27-23 02:25AM	PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript (Insider Monkey) -16.15%
Mar-23-23 04:05PM	PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -9.77%
Mar-22-23 08:00AM	PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Mar-21-23 04:05PM	PepGen to Participate in the Stifel 2023 CNS Days Conference (GlobeNewswire)
Mar-16-23 08:00AM	PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call (GlobeNewswire) +6.99%
Mar-13-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Feb-27-23 08:50AM	PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.02%
Feb-09-23 08:00AM	PepGen to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.07%
Jan-31-23 08:50AM	Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going (Zacks)
Jan-16-23 05:10AM	Companies Like PepGen (NASDAQ:PEPG) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-13-23 08:50AM	Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength (Zacks)
Dec-21-22 02:25PM	Why This PepGen Analyst Is Bullish On The Biotech Stock (Benzinga)
Dec-07-22 08:00AM	PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High? (Zacks) -6.42%
Nov-21-22 08:50AM	What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing' (Zacks) +5.54%
Nov-15-22 09:55AM	Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know (Zacks)
Nov-14-22 08:00AM	PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates (GlobeNewswire) +8.33%
Nov-10-22 08:00AM	PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.92%
Nov-08-22 08:00AM	PepGen to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Oct-13-22 01:00PM	PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress (GlobeNewswire)
Sep-28-22 01:59PM	PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst (Benzinga) +110.19%
09:25AM	PepGen Touts Encouraging Early-Stage Data From Duchenne Program (Benzinga)
06:00AM	PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-22-22 08:00AM	PepGen Appoints Habib Dable to Board of Directors (GlobeNewswire)
Sep-04-22 07:17AM	3 IPO Stocks to Watch in September (TipRanks)
Aug-12-22 08:00AM	PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -6.70%
Aug-08-22 10:51AM	We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-22-22 07:45AM	PepGen Appoints Caroline Godfrey, Ph.D. to the Companys Scientific Advisory Board (GlobeNewswire)
Jun-16-22 08:30AM	PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.70%
May-27-22 05:22PM	Covetrus and PepGen Stock See Action From Activist Investors (Barrons.com) +5.63%
May-05-22 11:34PM	PepGen Announces Pricing of Initial Public Offering (GlobeNewswire)

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mellion Michelle L	Chief Medical Officer	Jun 12 '24	Option Exercise	10.21	1,086	11,088	1,086	Jun 13 04:46 PM
Mellion Michelle L	Chief Medical Officer	Jun 12 '24	Sale	18.06	1,086	19,615	0	Jun 13 04:46 PM
Mellion Michelle L	Chief Medical Officer	Jun 11 '24	Option Exercise	10.21	500	5,105	500	Jun 13 04:46 PM
Mellion Michelle L	Chief Medical Officer	Jun 11 '24	Sale	18.04	500	9,022	0	Jun 13 04:46 PM
Mellion Michelle L	SVP, Clinical Development	Jun 06 '24	Option Exercise	10.21	1,411	14,406	1,411	Jun 07 04:12 PM
Mellion Michelle L	SVP, Clinical Development	Jun 06 '24	Sale	18.00	1,411	25,398	0	Jun 07 04:12 PM
Mellion Michelle L	SVP, Clinical Development	Jun 05 '24	Option Exercise	10.21	7,245	73,971	7,245	Jun 07 04:12 PM
Mellion Michelle L	SVP, Clinical Development	Jun 05 '24	Sale	18.09	7,245	131,062	0	Jun 07 04:12 PM
Svenstrup Niels	SVP, Chem. Mfg & Controls	May 17 '24	Sale	13.41	10,000	134,100	0	May 17 08:51 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 09 '24	Buy	10.64	2,557,593	27,212,790	9,179,273	Feb 13 04:33 PM
McArthur James G	President and CEO	Nov 30 '23	Buy	4.17	1,694	7,056	1,694	Dec 05 07:34 AM

Open in Screener

NUVB

Nuvation Bio Inc

Jun 20 • 04:00PM ET

3.03

Dollar change +0.13
Percentage change 4.48	%

Healthcare • Biotechnology • USA • NYSE

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT IWC PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.31	Insider Own	33.92%	Shs Outstand	218.05M	Perf Week	3.77%
Market Cap	751.96M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.20%	Shs Float	163.99M	Perf Month	-12.93%
Income	-68.87M	PEG	-	EPS next Q	-0.06	Inst Own	48.16%	Short Float	3.73%	Perf Quarter	57.81%
Sales	0.00M	P/S	-	EPS this Y	20.45%	Inst Trans	-7.65%	Short Ratio	3.61	Perf Half Y	116.43%
Book/sh	2.71	P/B	1.12	EPS next Y	-52.91%	ROA	-10.84%	Short Interest	6.12M	Perf Year	70.22%
Cash/sh	2.41	P/C	1.26	EPS next 5Y	-	ROE	-11.15%	52W Range	0.95 - 4.16	Perf YTD	100.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-11.56%	52W High	-27.16%	Beta	1.39
Dividend TTM	-	Quick Ratio	38.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	218.95%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	38.58	EPS Y/Y TTM	34.50%	Oper. Margin	0.00%	RSI (14)	52.02	Volatility	5.45% 6.77%
Employees	51	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.60
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	32.02%	Payout	-	Rel Volume	0.83	Prev Close	2.90
Sales Surprise	-	EPS Surprise	23.66%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	1.70M	Price	3.03
SMA20	2.49%	SMA50	0.74%	SMA200	52.21%	Trades		Volume	1,415,740	Change	4.48%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-24	Upgrade	Jefferies	Hold → Buy	$1.40 → $10
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy	$5
Jan-06-23	Downgrade	Jefferies	Buy → Hold	$5 → $2
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$8 → $2.50
May-04-22	Initiated	H.C. Wainwright	Buy	$14
Oct-15-21	Resumed	BTIG Research	Buy	$16
Apr-06-21	Initiated	RBC Capital Mkts	Outperform	$15
Mar-08-21	Initiated	Wedbush	Outperform	$20
Mar-08-21	Initiated	Jefferies	Buy	$20
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	BTIG Research	Buy	$16
Mar-08-21	Initiated	BMO Capital Markets	Outperform	$16

Show Previous Ratings

Jun-02-24 01:13AM	Innovent Announces TaletrectinibROS1 InhibitorUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting (PR Newswire)
Jun-01-24 08:10AM	Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting (Business Wire)
May-29-24 04:05PM	Nuvation Bio to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 10:54PM	NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024 (InvestorPlace)
05:08PM	Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours (MT Newswires)
04:05PM	Loading…
04:05PM	Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Apr-24-24 10:01AM	Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Apr-10-24 04:01PM	Nuvation Bio Completes Acquisition of AnHeart Therapeutics (Business Wire) -5.57%
Mar-28-24 08:00AM	Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer (Business Wire) -8.31%
Mar-25-24 07:00AM	Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (Business Wire)
Mar-14-24 04:05PM	Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors (Business Wire) -9.13%
08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-08-24 12:00PM	Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know (Zacks)
Feb-29-24 04:01PM	Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (Business Wire) -5.08% +19.25%
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
04:10PM	Loading…
Jan-08-24 04:10PM	Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors (Business Wire)
04:05PM	Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors (Business Wire)
Nov-13-23 04:05PM	Nuvation Bio Announces Departure of Chief Financial Officer (Business Wire) +5.47%
Nov-02-23 06:04PM	Nuvation Bio Inc (NUVB) Reports Q3 2023 Financial Results (GuruFocus.com) +10.34% +5.47%
04:10PM	Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Aug-03-23 04:10PM	Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jun-01-23 04:05PM	Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board (Business Wire)
May-16-23 06:23AM	Nuvation Bio Insider Ups Holding During Year \ (Simply Wall St.)
May-04-23 04:05PM	Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Mar-21-23 05:10PM	12 Best Biotech Stocks To Buy Under $20 (Insider Monkey) -5.17%
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-15-23 04:05PM	Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (Business Wire)
Feb-17-23 05:05AM	With 48% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest (Simply Wall St.)
Jan-17-23 08:19AM	Companies Like Nuvation Bio (NYSE:NUVB) Are In A Position To Invest In Growth (Simply Wall St.)
04:05PM	Loading…
Dec-19-22 04:05PM	Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868 (Business Wire) -5.08% +15.48%
Dec-07-22 05:03AM	Trade Alert: The Independent Director Of Nuvation Bio Inc. (NYSE:NUVB), Kathryn Falberg, Has Just Spent US$484k Buying A Few More Shares (Simply Wall St.)
Nov-03-22 04:05PM	Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-11-22 10:01AM	ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox (GlobeNewswire)
Aug-10-22 08:45AM	Nuvation Bio (NYSE:NUVB) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-04-22 04:05PM	Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) +5.06%
Aug-01-22 04:00PM	David Hung's Nuvation to cut 30 jobs, end cancer drug program (American City Business Journals) -9.78% -8.03%
09:52AM	After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program (Benzinga)
08:00AM	Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program (Business Wire)
Jul-27-22 12:00PM	Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jul-18-22 07:00AM	Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer (Business Wire)
Jun-27-22 08:52AM	FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why (Benzinga) -13.13%
07:00AM	Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors (Business Wire)
May-23-22 11:36AM	Legendary Value Investor Seth Klarman is Buying These 10 Stocks (Insider Monkey) -8.70%
May-09-22 04:05PM	Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.21%
Feb-28-22 04:05PM	Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire) -5.07%
Jan-21-22 10:21AM	Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate (Zacks)
Jan-20-22 08:43AM	FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors (Benzinga)
07:00AM	Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors (PR Newswire)
Jan-14-22 12:31PM	Where Do Hedge Funds Stand On Nuvation Bio Inc. (NUVB)? (Insider Monkey)
Jan-10-22 07:00AM	Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones (PR Newswire)
Dec-17-21 08:00AM	Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies (PR Newswire) -8.74%
Dec-15-21 07:00AM	Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme (PR Newswire)
Dec-13-21 10:33AM	Billionaire Israel Englander Snaps Up These 3 Strong Buy Stocks (TipRanks) +8.98%
07:00AM	Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer (PR Newswire)
Dec-08-21 07:00AM	Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer (PR Newswire)
Nov-19-21 08:24AM	Is Nuvation Bio Inc. (NYSE:NUVB) Popular Amongst Insiders? (Simply Wall St.)
Nov-10-21 04:05PM	Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Oct-25-21 09:12AM	Is Nuvation Bio Inc. (NUVB) A Good Stock To Buy? (Insider Monkey) +6.52%
Sep-20-21 04:14PM	15 Best Stocks to Invest in Today According to David Abrams (Insider Monkey)
Aug-12-21 04:05PM	Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire) +5.35%
Jul-06-21 10:20AM	Should I Buy Nuvation Bio Inc. (NUVB)? (Insider Monkey)
Jun-01-21 07:00AM	Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer (PR Newswire)
May-26-21 07:00AM	Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference (PR Newswire)
May-21-21 04:34PM	David Abrams Buys 3 Stocks in 1st Quarter (GuruFocus.com)
May-17-21 05:00PM	Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update (PR Newswire) +8.08%
May-11-21 05:51AM	How Much Of Nuvation Bio Inc. (NYSE:NUVB) Do Insiders Own? (Simply Wall St.)
Apr-17-21 09:36PM	Top Insider Buys Highlight for the Week of April 16 (GuruFocus.com)
Mar-11-21 05:15PM	Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update (PR Newswire) +7.28%
07:00AM	Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas (PR Newswire)

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BLICKENSTAFF KIM D	Director	Jun 11 '24	Buy	2.90	172,189	500,089	172,189	Jun 13 04:33 PM
WELCH DANIEL G	Director	May 24 '24	Option Exercise	1.68	659,947	1,111,633	659,947	May 29 04:38 PM

Open in Screener

SPRY

ARS Pharmaceuticals Inc

Jun 20 • 04:00PM ET

7.73

Dollar change -0.35
Percentage change -4.33	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

SPRY ARS Pharmaceuticals Inc daily Stock Chart

Held by: VTI XBI VXF IWM DWAS IBB SCHA IWN VHT VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.52	Insider Own	51.31%	Shs Outstand	96.41M	Perf Week	-15.05%
Market Cap	749.04M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	-0.41%	Shs Float	47.17M	Perf Month	-15.89%
Income	-49.70M	PEG	-	EPS next Q	-0.12	Inst Own	34.87%	Short Float	14.46%	Perf Quarter	-11.15%
Sales	0.01M	P/S	74903.70	EPS this Y	-21.05%	Inst Trans	15.32%	Short Ratio	12.41	Perf Half Y	48.08%
Book/sh	2.32	P/B	3.33	EPS next Y	44.93%	ROA	-19.93%	Short Interest	6.82M	Perf Year	23.48%
Cash/sh	2.31	P/C	3.35	EPS next 5Y	-	ROE	-20.49%	52W Range	2.55 - 11.27	Perf YTD	41.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.44%	ROI	-22.20%	52W High	-31.41%	Beta	0.84
Dividend TTM	-	Quick Ratio	60.84	Sales past 5Y	-34.76%	Gross Margin	-540.00%	52W Low	203.14%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	60.84	EPS Y/Y TTM	78.60%	Oper. Margin	-619990.00%	RSI (14)	29.78	Volatility	5.17% 4.06%
Employees	26	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-496960.00%	Recom	1.00	Target Price	19.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	32.81%	Payout	-	Rel Volume	1.17	Prev Close	8.08
Sales Surprise	-	EPS Surprise	-11.22%	Sales Q/Q	-100.00%	Earnings	May 09 AMC	Avg Volume	549.38K	Price	7.73
SMA20	-12.69%	SMA50	-13.18%	SMA200	14.56%	Trades		Volume	641,322	Change	-4.33%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

May-12-24 09:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ... (GuruFocus.com)
May-09-24 11:54PM	SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 (InvestorPlace)
04:05PM	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 09:01AM	ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand (GlobeNewswire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
09:01AM	Loading…
Apr-03-24 09:01AM	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) (GlobeNewswire)
Apr-01-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know (Zacks) -7.34%
Mar-26-24 08:50AM	Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why (Zacks) +9.53%
Mar-21-24 10:53PM	SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-15-24 06:00AM	Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 (InvestorPlace)
Mar-07-24 04:05PM	ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day (GlobeNewswire)
Mar-06-24 09:01AM	ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 09:01AM	ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study (GlobeNewswire)
09:01AM	Loading…
Feb-22-24 09:01AM	ARS Pharmaceuticals to Host Virtual neffy Investor Day on March 7, 2024 (GlobeNewswire)
Feb-20-24 09:01AM	ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter (GlobeNewswire)
Feb-05-24 09:01AM	ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy (epinephrine nasal spray) at 2024 AAAAI Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +8.75%
11:02AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)
Oct-06-23 09:03AM	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy (epinephrine nasal spray) (GlobeNewswire) +7.02%
Oct-03-23 09:03AM	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
03:01AM	Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc (GuruFocus.com)
Sep-29-23 07:50PM	ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors (Barrons.com)
01:39PM	Hedge Fund and Insider Trading News: Dan Loeb, Crispin Odey, Ray Dalio, D. E. Shaw, Eisler Capital, Glazer Capital, Gatos Silver Inc (GATO), ARS Pharmaceuticals Inc (SPRY), and More (Insider Monkey)
10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-21-23 12:28PM	ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray (Zacks) +25.68%
10:43AM	Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down (Zacks)
06:28AM	Feds Message Is Louder Than Its Rate Call. Why Thats Critical for Investors. (Barrons.com)
12:42PM	Loading…
Sep-20-23 12:42PM	Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday (Motley Fool) -55.79%
10:31AM	FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies (AP Finance)
10:26AM	FDAs Surprise Rejection of No-Shot Alternative to EpiPen Halves Shares of ARS Pharma (Barrons.com)
09:49AM	FDA Declines to Approve Epinephrine Nasal Spray, Asks for Additional Data (The Wall Street Journal)
06:13AM	ARS Pharma shares plummet after FDA asks for extra test of nasal spray (Investing.com)
Sep-19-23 10:49PM	FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study (GlobeNewswire) -11.22%
Sep-08-23 07:10PM	Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist Investors (Barrons.com)
Aug-10-23 04:00PM	ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-20-23 08:00AM	ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-15-23 02:11PM	ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray (Zacks)
09:00AM	ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-12-23 11:51AM	Why ARS Pharmaceuticals Stock Is Soaring Today (Benzinga) +77.88%
May-11-23 07:01PM	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-09-23 09:10AM	ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire) -14.31%
Apr-21-23 10:05AM	Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-28-23 09:39AM	ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
Mar-25-23 09:10AM	ARS Pharmaceuticals Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-23-23 04:01PM	ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-22-23 06:19AM	One ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider upped their stake in the previous year (Simply Wall St.) -5.56%
Feb-23-23 04:01PM	ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors (GlobeNewswire)
Feb-22-23 04:05PM	ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire)
Feb-09-23 06:30AM	ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 (GlobeNewswire) +5.76%
05:43AM	Insiders own 34% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares but individual investors control 36% of the company (Simply Wall St.)
Nov-10-22 08:00AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lowenthal Richard E	PRESIDENT AND CEO	Jun 12 '24	Sale	9.15	95,862	876,663	1,546,494	Jun 13 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Jun 12 '24	Sale	9.15	95,862	876,663	1,546,494	Jun 13 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Jun 11 '24	Sale	9.00	4,138	37,254	1,594,328	Jun 13 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Jun 11 '24	Sale	9.00	4,138	37,254	1,594,328	Jun 13 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 16 '24	Sale	9.06	89,096	807,023	1,597,447	May 16 07:52 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 16 '24	Sale	9.06	89,096	807,023	1,597,447	May 16 07:51 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 15 '24	Sale	9.05	5,147	46,565	1,642,193	May 16 07:51 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 15 '24	Sale	9.05	5,147	46,565	1,642,193	May 16 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 14 '24	Sale	9.01	5,757	51,854	1,644,574	May 16 07:52 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 14 '24	Sale	9.01	5,757	51,854	1,644,574	May 16 07:51 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	May 07 '24	Sale	9.34	100,000	934,365	1,596,494	May 09 06:59 PM
Lowenthal Richard E	PRESIDENT AND CEO	May 07 '24	Sale	9.34	100,000	934,365	1,596,494	May 09 06:57 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 23 '24	Option Exercise	1.06	130,993	138,990	3,407,847	Apr 24 06:18 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 23 '24	Option Exercise	1.06	130,993	138,990	3,407,847	Apr 24 06:17 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 19 '24	Option Exercise	1.06	188,491	199,999	4,315,313	Apr 22 07:23 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 19 '24	Option Exercise	1.06	188,491	199,999	4,315,313	Apr 22 07:22 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 16 '24	Sale	9.28	100,000	928,005	1,647,447	Apr 17 06:42 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 16 '24	Sale	9.28	100,000	928,005	1,647,447	Apr 17 06:40 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Apr 09 '24	Sale	9.28	100,000	927,735	1,646,494	Apr 10 05:39 PM
Lowenthal Richard E	PRESIDENT AND CEO	Apr 09 '24	Sale	9.28	100,000	927,735	1,646,494	Apr 10 05:36 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '24	Buy	9.79	505,954	4,953,290	9,958,073	Mar 27 07:37 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 26 '24	Buy	9.55	457,745	4,371,465	9,452,119	Mar 27 07:37 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 25 '24	Buy	9.06	437,600	3,964,656	8,994,374	Mar 27 07:37 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 25 '24	Sale	9.12	95,267	869,188	1,697,447	Mar 26 06:47 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 25 '24	Sale	9.12	95,267	869,188	1,697,447	Mar 26 06:48 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 22 '24	Sale	9.02	2,343	21,135	1,745,082	Mar 26 06:48 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 22 '24	Sale	9.02	2,343	21,135	1,745,082	Mar 26 06:47 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 21 '24	Sale	9.00	472	4,248	1,746,099	Mar 21 09:50 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 21 '24	Sale	9.00	472	4,248	1,746,099	Mar 21 09:51 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 19 '24	Sale	9.03	1,918	17,324	1,746,471	Mar 21 09:51 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 19 '24	Sale	9.03	1,918	17,324	1,746,471	Mar 21 09:50 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 15 '24	Sale	9.14	96,756	884,485	1,696,494	Mar 15 07:55 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 15 '24	Sale	9.14	96,756	884,485	1,696,494	Mar 15 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 14 '24	Sale	9.00	444	3,996	1,744,789	Mar 15 07:52 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 14 '24	Sale	9.00	444	3,996	1,744,789	Mar 15 07:55 PM
Lowenthal Richard E	PRESIDENT AND CEO	Mar 13 '24	Sale	9.00	2,800	25,200	1,744,994	Mar 15 07:55 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Mar 13 '24	Sale	9.00	2,800	25,200	1,744,994	Mar 15 07:52 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Feb 29 '24	Sale	9.02	3,782	34,101	1,746,494	Mar 01 08:21 PM
Lowenthal Richard E	PRESIDENT AND CEO	Feb 29 '24	Sale	9.02	3,782	34,101	1,746,494	Mar 01 08:17 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Feb 28 '24	Sale	9.02	98,778	891,061	1,747,294	Feb 28 09:08 PM
Lowenthal Richard E	PRESIDENT AND CEO	Feb 28 '24	Sale	9.02	98,778	891,061	1,747,294	Feb 28 09:04 PM
Lowenthal Richard E	PRESIDENT AND CEO	Feb 26 '24	Sale	9.01	700	6,307	1,772,750	Feb 28 09:04 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Feb 26 '24	Sale	9.01	700	6,307	1,772,750	Feb 28 09:08 PM
Fitzpatrick Alexander A	Chief Legal Officer	Sep 29 '23	Buy	3.78	46,258	174,994	89,227	Oct 02 04:23 PM
Fitzpatrick Alexander A	Chief Legal Officer	Sep 28 '23	Buy	3.62	40,000	144,960	42,969	Oct 02 04:23 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 21 '23	Buy	3.03	2,700,000	8,183,526	8,556,774	Sep 25 04:30 PM
Shawver Laura	Director	Sep 01 '23	Option Exercise	1.27	100,000	127,000	310,346	Sep 05 08:04 PM
Shawver Laura	Director	Sep 01 '23	Sale	7.71	100,000	770,520	210,346	Sep 05 08:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Aug 29 '23	Buy	6.20	3,750,000	23,250,000	5,856,774	Aug 31 05:26 PM
ORBIMED ADVISORS LLC	Director	Aug 29 '23	Buy	6.20	500,000	3,100,000	8,019,187	Aug 31 05:26 PM
Thompson Peter A.	Director	Aug 29 '23	Buy	6.20	500,000	3,100,000	8,019,187	Aug 31 05:18 PM
Shawver Laura	Director	Aug 04 '23	Option Exercise	1.27	18,897	23,999	229,243	Aug 07 05:05 PM
Shawver Laura	Director	Aug 04 '23	Sale	7.06	18,897	133,471	210,346	Aug 07 05:05 PM
Shawver Laura	Director	Aug 03 '23	Option Exercise	1.27	26,107	33,156	236,453	Aug 07 05:05 PM
Shawver Laura	Director	Aug 03 '23	Sale	7.01	26,107	183,018	210,346	Aug 07 05:05 PM
Shawver Laura	Director	Aug 02 '23	Option Exercise	1.27	36,281	46,077	246,627	Aug 03 06:03 PM
Shawver Laura	Director	Aug 02 '23	Sale	7.09	36,281	257,265	210,346	Aug 03 06:03 PM
Shawver Laura	Director	Aug 01 '23	Option Exercise	1.27	18,715	23,768	229,061	Aug 03 06:03 PM
Shawver Laura	Director	Aug 01 '23	Sale	7.19	18,715	134,576	210,346	Aug 03 06:03 PM
Shawver Laura	Director	Jul 07 '23	Option Exercise	1.27	8,858	11,250	219,204	Jul 07 08:16 PM
Shawver Laura	Director	Jul 07 '23	Sale	6.36	8,858	56,372	210,346	Jul 07 08:16 PM
Shawver Laura	Director	Jul 06 '23	Option Exercise	1.27	33,510	42,558	243,856	Jul 06 08:55 PM
Shawver Laura	Director	Jul 06 '23	Sale	6.34	33,510	212,554	210,346	Jul 06 08:55 PM
Shawver Laura	Director	Jul 05 '23	Option Exercise	1.27	31,112	39,512	241,458	Jul 06 08:55 PM
Shawver Laura	Director	Jul 05 '23	Sale	6.41	31,112	199,552	210,346	Jul 06 08:55 PM
Shawver Laura	Director	Jul 03 '23	Option Exercise	1.27	26,520	33,680	236,866	Jul 06 08:55 PM
Shawver Laura	Director	Jul 03 '23	Sale	6.72	26,520	178,347	210,346	Jul 06 08:55 PM

Open in Screener

FGEN

FibroGen Inc

Jun 20 • 04:00PM ET

1.10

Dollar change +0.07
Percentage change 6.80	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO VHT FESM VTWV RSSL IWV

Index	RUT	P/E	-	EPS (ttm)	-2.45	Insider Own	7.12%	Shs Outstand	98.77M	Perf Week	-5.17%
Market Cap	109.43M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	1.03%	Shs Float	92.39M	Perf Month	-8.33%
Income	-240.46M	PEG	-	EPS next Q	-0.32	Inst Own	61.93%	Short Float	8.08%	Perf Quarter	-53.39%
Sales	167.49M	P/S	0.65	EPS this Y	55.25%	Inst Trans	2.87%	Short Ratio	3.18	Perf Half Y	73.06%
Book/sh	-2.29	P/B	-	EPS next Y	56.12%	ROA	-53.17%	Short Interest	7.46M	Perf Year	-93.41%
Cash/sh	1.79	P/C	0.62	EPS next 5Y	-	ROE	-42790.17%	52W Range	0.33 - 17.46	Perf YTD	24.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.23%	ROI	-	52W High	-93.70%	Beta	0.73
Dividend TTM	-	Quick Ratio	1.27	Sales past 5Y	-2.51%	Gross Margin	75.46%	52W Low	230.03%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	1.41	EPS Y/Y TTM	25.09%	Oper. Margin	-133.85%	RSI (14)	43.55	Volatility	7.38% 8.66%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	44.30%	Profit Margin	-143.56%	Recom	4.00	Target Price	1.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.93%	Payout	-	Rel Volume	0.58	Prev Close	1.03
Sales Surprise	52.47%	EPS Surprise	21.07%	Sales Q/Q	54.59%	Earnings	May 06 AMC	Avg Volume	2.35M	Price	1.10
SMA20	-6.38%	SMA50	-7.51%	SMA200	-5.09%	Trades		Volume	1,350,770	Change	6.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

Jun-18-24 08:00AM	FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 (GlobeNewswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-03-24 04:05PM	FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO in Upcoming Clinical Trials (GlobeNewswire)
04:02PM	FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors (GlobeNewswire)
09:17AM	Loading…
09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:00AM	FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-23-24 05:05PM	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
08:58PM	Loading…
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	Loading…
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)
07:02AM	FibroGen's neuromuscular disease drug fails to meet main goal in late-stage study (Reuters)
06:55AM	FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-06-23 04:01PM	FibroGen to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
02:06PM	FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 (Investor's Business Daily)
May-18-23 07:30AM	FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia (GlobeNewswire)
May-09-23 10:22AM	Q1 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:12PM	FibroGen: Q1 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports First Quarter 2023 Financial Results (GlobeNewswire)
04:00PM	FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics (GlobeNewswire)
May-05-23 01:19PM	FibroGen, Inc. (NASDAQ:FGEN) Investors Are Less Pessimistic Than Expected (Simply Wall St.)
07:37AM	FibroGen's anemia drug fails to meet main goal in late-stage trial (Reuters)
07:30AM	FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS) (GlobeNewswire)
May-03-23 03:43AM	ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains? (Zacks)
May-01-23 07:00AM	FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value (GlobeNewswire)
Apr-24-23 07:00AM	FibroGen to Report First Quarter 2023 Financial Results (GlobeNewswire) -17.21%
Apr-03-23 07:00AM	FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Mar-24-23 10:21AM	FibroGen (NASDAQ:FGEN investor five-year losses grow to 60% as the stock sheds US$145m this past week (Simply Wall St.)
Mar-11-23 03:27AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-28-23 02:43PM	Q4 2022 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-23 05:25PM	FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
07:00AM	FibroGen to Present at Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-23-23 11:33AM	Should You Buy FibroGen (FGEN) Ahead of Earnings? (Zacks)
07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks)
Feb-22-23 10:00AM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for (Zacks)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adib Deyaa	Chief Medical Officer	Jun 12 '24	Buy	1.17	22,123	25,884	82,123	Jun 13 04:30 PM
Wettig Thane	CEO	Mar 07 '24	Buy	1.91	50,000	95,470	470,178	Mar 11 07:06 PM
Henderson Jeffrey William	Director	Sep 01 '23	Sale	1.03	2,000	2,060	28,866	Sep 06 08:54 PM
Henderson Jeffrey William	Director	Aug 04 '23	Sale	1.91	2,000	3,820	30,866	Aug 08 07:10 PM
Henderson Jeffrey William	Director	Jul 11 '23	Sale	2.69	2,000	5,380	32,866	Jul 13 08:28 PM
Conterno Enrique A	Chief Executive Officer	Jul 07 '23	Sale	2.80	1,880	5,264	374,722	Jul 10 07:36 PM
Wettig Thane	Chief Commercial Officer	Jun 23 '23	Sale	16.53	791	13,075	108,261	Jun 26 04:27 PM

Open in Screener

VRTX

Vertex Pharmaceuticals, Inc.

Jun 20 • 04:00PM ET

471.38

Dollar change +4.10
Percentage change 0.88	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

VRTX Vertex Pharmaceuticals, Inc. daily Stock Chart

Held by: VTI VOO QQQ SPY IVV VUG XLV IBB JEPI VHT

Index	NDX, S&P 500	P/E	30.58	EPS (ttm)	15.41	Insider Own	0.26%	Shs Outstand	257.70M	Perf Week	-0.93%
Market Cap	121.64B	Forward P/E	25.98	EPS next Y	18.14	Insider Trans	-15.88%	Shs Float	257.37M	Perf Month	5.72%
Income	4.02B	PEG	2.44	EPS next Q	4.15	Inst Own	92.83%	Short Float	1.69%	Perf Quarter	14.38%
Sales	10.17B	P/S	11.96	EPS this Y	10.90%	Inst Trans	1.21%	Short Ratio	4.06	Perf Half Y	16.49%
Book/sh	71.80	P/B	6.56	EPS next Y	7.42%	ROA	18.74%	Short Interest	4.35M	Perf Year	37.55%
Cash/sh	39.42	P/C	11.96	EPS next 5Y	12.53%	ROE	24.38%	52W Range	335.82 - 486.42	Perf YTD	15.85%
Dividend Est.	-	P/FCF	32.72	EPS past 5Y	11.42%	ROI	20.86%	52W High	-3.09%	Beta	0.39
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	27.16%	Gross Margin	86.85%	52W Low	40.37%	ATR (14)	8.57
Dividend Ex-Date	-	Current Ratio	3.50	EPS Y/Y TTM	22.70%	Oper. Margin	40.81%	RSI (14)	59.65	Volatility	1.72% 1.90%
Employees	5400	Debt/Eq	0.04	Sales Y/Y TTM	12.74%	Profit Margin	39.51%	Recom	1.85	Target Price	470.73
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	56.65%	Payout	0.00%	Rel Volume	1.31	Prev Close	467.28
Sales Surprise	4.24%	EPS Surprise	16.87%	Sales Q/Q	14.21%	Earnings	May 06 AMC	Avg Volume	1.07M	Price	471.38
SMA20	1.14%	SMA50	9.18%	SMA200	17.71%	Trades		Volume	1,407,539	Change	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold
Jan-24-24	Downgrade	Canaccord Genuity	Hold → Sell	$332 → $379
Dec-14-23	Reiterated	RBC Capital Mkts	Sector Perform	$347 → $379
May-30-23	Initiated	William Blair	Outperform	$382
May-04-23	Resumed	Piper Sandler	Overweight	$385
Mar-21-23	Initiated	Bernstein	Outperform	$344
Jan-18-23	Initiated	Canaccord Genuity	Hold	$311
Jan-17-23	Upgrade	SVB Leerink	Mkt Perform → Outperform	$374
Dec-19-22	Downgrade	Jefferies	Buy → Hold	$340
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$365
Jun-01-22	Upgrade	Maxim Group	Hold → Buy	$325
May-23-22	Initiated	SVB Leerink	Mkt Perform	$265
May-06-22	Downgrade	Robert W. Baird	Outperform → Neutral	$250
May-03-22	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$250
Feb-03-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$269

Show Previous Ratings

Jun-20-24 07:09PM	Asian Stocks Set to Track US Lower, Yen in Focus: Markets Wrap (Bloomberg)
Jun-19-24 09:26AM	Vertex Pharmaceuticals (NASDAQ:VRTX): The Best Healthcare Stock to Buy in 2024? (Insider Monkey)
Jun-18-24 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts (Zacks)
06:50AM	3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation (Motley Fool)
04:30AM	Analyst Recommends 10 Best Stocks to Diversify Your Portfolio Away from Mega-Cap Tech and AI Stocks (Insider Monkey)
06:50AM	Loading…
Jun-15-24 06:50AM	3 Growth Stocks You Can Buy Right Now Without Any Hesitation (Motley Fool)
Jun-14-24 07:04PM	Vertex Pharmaceuticals Incorporated (VRTX): A Promising Feminist Stock To Buy? (Insider Monkey)
10:33AM	Vertex says Casgevy benefit extends to nearly five years in sickle cell disease (Clinical Trials Arena)
03:03AM	Vertex Presents Positive Long-Term Data On CASGEVY (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress (Business Wire)
Jun-13-24 07:00PM	Insider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) (GuruFocus.com)
Jun-12-24 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors (Zacks)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
07:45AM	2 Healthcare Stocks to Buy Hand Over Fist in June (Motley Fool)
Jun-09-24 06:20AM	Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought (Motley Fool)
Jun-07-24 12:00PM	Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA (Business Wire)
07:01PM	Loading…
Jun-05-24 07:01PM	Insider Sale: EVP & CFO Charles F. Wagner Jr. Sells Shares of Vertex Pharmaceuticals Inc (VRTX) (GuruFocus.com)
11:30AM	Why Is Vertex (VRTX) Up 15.8% Since Last Earnings Report? (Zacks)
Jun-04-24 02:38AM	Insider Sale at Vertex Pharmaceuticals Inc (VRTX) by EVP, Chief Regulatory & Quality ... (GuruFocus.com)
Jun-03-24 04:24PM	Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) the Leading Gene Therapy Stock to Buy Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
Jun-02-24 06:00AM	3 No-Brainer Stocks to Buy in June (Motley Fool)
05:47AM	5 Top Stocks to Buy in June (Motley Fool)
Jun-01-24 08:00AM	S&P 500 Giants Lead Five Healthy Stocks Near Buy Points (Investor's Business Daily)
03:12AM	Insider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) (GuruFocus.com)
May-31-24 02:44AM	Insider Sale: EVP & CFO Charles F. Wagner Jr. Sells Shares of Vertex Pharmaceuticals Inc (VRTX) (GuruFocus.com)
May-30-24 09:45AM	Why Vertex Pharmaceuticals (VRTX) is a Top Growth Stock for the Long-Term (Zacks)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
05:50AM	Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals? (Motley Fool)
May-26-24 10:15AM	Got $500? 3 Pharma Stocks to Buy and Hold Forever (Motley Fool)
09:45AM	Is It Too Late to Buy Vertex Pharmaceuticals Stock? (Motley Fool)
11:10PM	Loading…
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
10:00AM	2 Biotech Stocks to Buy in May (Motley Fool)
06:47AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
02:41AM	Insider Selling: Director Bruce Sachs Sells Shares of Vertex Pharmaceuticals Inc (VRTX) (GuruFocus.com)
May-24-24 04:28PM	New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout (Investor's Business Daily)
May-23-24 07:10AM	The 2030 Millionaire's Club: 3 Biotech Stocks to Buy Now (InvestorPlace)
May-22-24 07:06PM	Insider Sale: CEO & President Reshma Kewalramani Sells 15,202 Shares of Vertex ... (GuruFocus.com)
04:40PM	Stocks Step Back After Fed Minutes; Loar, Monday.com, VRTX In Focus (Investor's Business Daily)
04:05PM	Vertex to Participate in Upcoming June Investor Conferences (Business Wire)
May-21-24 11:47AM	Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress (Zacks)
May-17-24 09:30AM	Is CRISPR Therapeutics Stock a Buy? (Motley Fool)
May-15-24 11:11AM	Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. (Motley Fool)
10:30AM	Jennifer Schneider Elected to Vertex Board of Directors (Business Wire)
May-14-24 01:47PM	Vertex Stock Hit All-Time High, Paused, Rising Again (Investor's Business Daily)
10:24AM	3 Cheap Biotech Stocks to Buy Now: May 2024 (InvestorPlace)
09:45AM	Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock (Zacks)
05:43AM	Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 (MT Newswires)
03:00AM	Vertex Stock (Investor's Business Daily)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey)
May-12-24 02:47PM	Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy (Motley Fool)
12:20PM	2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
May-10-24 03:32PM	Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone (MT Newswires)
12:46PM	Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ... (GuruFocus.com)
May-09-24 04:00PM	Alpine Immune Sciences Reports First Quarter 2024 Financial Results (Business Wire)
01:04AM	Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight (GuruFocus.com)
May-08-24 12:36PM	Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets (Insider Monkey)
09:30AM	Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:43AM	5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip (Motley Fool)
May-07-24 04:06PM	Vertex's Pain Drug Could Be Worth Up To $11.4 Billion Ongoing Debate Sparks Shares (Investor's Business Daily)
02:21PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
11:24AM	Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:50AM	Q1 2024 Vertex Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:44AM	Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales (Zacks)
06:30AM	Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 (MT Newswires)
06:29AM	Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 (MT Newswires)
05:45AM	Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating (MT Newswires)
05:45AM	Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating (MT Newswires)
05:41AM	RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating (MT Newswires)
05:41AM	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating (MT Newswires)
05:41AM	Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating (MT Newswires)
03:08AM	Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)
May-06-24 08:45PM	Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript (Motley Fool)
06:33PM	UPDATE 1-Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments (Reuters)
05:42PM	Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions (GuruFocus.com)
05:10PM	Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
04:59PM	Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key (Investor's Business Daily)
04:38PM	Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase (MT Newswires)
04:17PM	Vertex: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook (Investor's Business Daily)
04:11PM	Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments (Reuters)
04:01PM	Vertex Reports First Quarter 2024 Financial Results (Business Wire)
02:30PM	3 Biotech Stocks to Double Your Money in the Next 24 Months (InvestorPlace)
May-05-24 07:00AM	What To Expect in the Markets This Week (Investopedia)
06:55AM	3 No-Brainer Stocks to Buy in May (Motley Fool)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-03-24 07:01PM	Insider Sale at Vertex Pharmaceuticals Inc (VRTX): Director Sangeeta Bhatia Sells Shares (GuruFocus.com)
02:18PM	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar (InvestorPlace)
08:45AM	3 Growth Stocks You'll Kick Yourself for Not Buying Today (InvestorPlace)
06:15AM	Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar (InvestorPlace)
May-02-24 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
07:15AM	3 Biotech Stocks to Buy and Hold Through 2030 and Beyond (Motley Fool)
May-01-24 09:15AM	Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-30-24 05:36AM	Vertex (VRTX) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-29-24 10:00AM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-28-24 08:45AM	2 Top Growth Stocks to Buy Right Now and Hold Forever (Motley Fool)
Apr-27-24 05:50AM	Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades. (Motley Fool)
Apr-26-24 12:22PM	Pioneer Institute study finds IRA discourages non-opioid drug innovation (Pharmaceutical Technology)
12:11PM	Vertex Pharmaceuticals Gets European Commission Approval for Cystic Fibrosis Treatment for Infants (MT Newswires)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Jun 12 '24	Sale	478.00	7,288	3,483,664	15,972	Jun 13 04:09 PM
Bozic Carmen	EVP and CMO	Jun 12 '24	Sale	478.00	2,280	1,089,840	32,379	Jun 13 04:11 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jun 03 '24	Sale	460.00	3,250	1,495,000	47,137	Jun 05 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Jun 03 '24	Sale	460.00	2,175	1,000,500	49,098	Jun 05 04:08 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 31 '24	Sale	445.00	2,250	1,001,250	51,273	Jun 03 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 30 '24	Sale	439.11	2,350	1,031,908	53,523	Jun 03 04:09 PM
Bozic Carmen	EVP and CMO	May 29 '24	Sale	445.56	2,280	1,015,877	34,659	May 31 04:19 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	May 28 '24	Sale	454.79	3,250	1,478,068	50,387	May 30 04:07 PM
Kewalramani Reshma	CEO & President	May 24 '24	Option Exercise	187.53	1,565	293,484	122,939	May 29 04:08 PM
Kewalramani Reshma	CEO & President	May 24 '24	Sale	457.00	1,565	715,205	121,374	May 29 04:08 PM
SACHS BRUCE I	Director	May 22 '24	Option Exercise	93.51	7,073	661,396	47,073	May 24 04:13 PM
SACHS BRUCE I	Director	May 22 '24	Sale	448.00	7,073	3,168,704	40,000	May 24 04:13 PM
Kewalramani Reshma	CEO & President	May 20 '24	Sale	447.00	15,202	6,795,294	121,374	May 22 04:21 PM
Arbuckle Stuart A	EVP, COO	May 15 '24	Sale	430.93	69	29,734	49,691	May 17 04:24 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '24	Sale	430.93	54	23,270	25,813	May 17 04:22 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	May 15 '24	Sale	430.93	32	13,790	55,325	May 17 04:27 PM
Bhatia Sangeeta N.	Director	May 02 '24	Sale	402.95	467	188,178	4,435	May 03 04:05 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Apr 02 '24	Sale	419.00	240	100,560	7,500	Apr 03 04:02 PM
Arbuckle Stuart A	EVP, COO	Feb 26 '24	Sale	425.70	5,034	2,142,974	49,691	Feb 27 04:37 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 26 '24	Sale	425.70	4,239	1,804,542	25,813	Feb 27 04:24 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 26 '24	Sale	425.70	3,004	1,278,803	55,325	Feb 27 04:59 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 26 '24	Sale	425.70	883	375,893	7,965	Feb 27 04:29 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 26 '24	Sale	425.70	883	375,893	15,972	Feb 27 04:44 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 26 '24	Sale	425.70	354	150,698	55,804	Feb 27 05:02 PM
Arbuckle Stuart A	EVP, COO	Feb 21 '24	Sale	421.77	3,603	1,519,637	59,439	Feb 23 04:12 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 21 '24	Sale	421.77	3,191	1,345,868	60,798	Feb 23 04:20 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 21 '24	Sale	421.77	3,002	1,266,154	34,022	Feb 23 04:10 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 21 '24	Sale	421.77	1,201	506,546	18,509	Feb 23 04:16 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 21 '24	Sale	421.77	360	151,837	59,467	Feb 23 04:28 PM
Arbuckle Stuart A	EVP, COO	Feb 20 '24	Sale	420.79	4,804	2,021,475	63,042	Feb 21 04:19 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 20 '24	Sale	420.79	4,254	1,790,041	63,989	Feb 21 04:38 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 20 '24	Sale	420.79	4,002	1,684,002	37,024	Feb 21 04:13 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 20 '24	Sale	420.79	801	337,053	19,710	Feb 21 04:23 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 20 '24	Sale	420.79	480	201,979	59,827	Feb 21 04:43 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 15 '24	Sale	419.16	4,655	1,951,190	17,896	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 14 '24	Sale	419.04	4,356	1,825,338	22,551	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 13 '24	Sale	419.13	737	308,899	26,907	Feb 14 04:04 PM
Arbuckle Stuart A	EVP, COO	Feb 12 '24	Sale	420.24	4,295	1,804,931	75,718	Feb 13 04:51 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 12 '24	Sale	420.24	3,222	1,354,013	74,364	Feb 13 05:15 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 12 '24	Sale	420.24	3,145	1,321,655	47,588	Feb 13 04:46 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 12 '24	Sale	419.51	2,656	1,114,205	27,644	Feb 14 04:04 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 12 '24	Sale	418.77	1,738	727,822	18,280	Feb 13 04:56 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 12 '24	Sale	420.24	1,374	577,410	9,676	Feb 13 04:48 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 12 '24	Sale	420.24	913	383,679	23,137	Feb 13 04:54 PM
LEIDEN JEFFREY M	Executive Chairman	Jan 08 '24	Sale	419.07	6,648	2,785,977	2,423	Jan 10 04:06 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jan 02 '24	Sale	405.00	3,000	1,215,000	43,693	Jan 04 04:17 PM
Kewalramani Reshma	CEO & President	Dec 15 '23	Option Exercise	181.83	17,135	3,115,593	125,846	Dec 19 04:15 PM
Kewalramani Reshma	CEO & President	Dec 15 '23	Sale	407.00	17,135	6,973,945	108,711	Dec 19 04:15 PM
Arbuckle Stuart A	EVP, COO	Dec 13 '23	Option Exercise	187.53	8,603	1,613,321	65,159	Dec 15 04:20 PM
LEIDEN JEFFREY M	Executive Chairman	Dec 13 '23	Sale	399.42	13,354	5,333,799	9,071	Dec 15 04:33 PM
Arbuckle Stuart A	EVP, COO	Dec 13 '23	Sale	399.00	8,603	3,432,597	56,556	Dec 15 04:20 PM
Kewalramani Reshma	CEO & President	Dec 13 '23	Sale	397.00	5,098	2,023,906	108,711	Dec 15 04:23 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 20 '23	Sale	349.88	3,000	1,049,640	46,693	Nov 21 04:07 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Nov 15 '23	Sale	369.92	35	12,947	58,814	Nov 17 04:16 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 15 '23	Sale	369.92	19	7,028	32,038	Nov 17 04:11 PM
Bozic Carmen	EVP and CMO	Nov 14 '23	Sale	380.82	5,650	2,151,633	29,302	Nov 16 04:15 PM
Kewalramani Reshma	CEO & President	Nov 13 '23	Sale	377.00	5,097	1,921,569	113,809	Nov 15 04:16 PM
SACHS BRUCE I	Director	Nov 06 '23	Option Exercise	127.54	11,250	1,434,825	51,250	Nov 08 04:11 PM
SACHS BRUCE I	Director	Nov 06 '23	Sale	385.00	11,250	4,331,250	40,000	Nov 08 04:11 PM
Bozic Carmen	EVP and CMO	Oct 31 '23	Sale	355.92	5,651	2,011,304	34,952	Nov 02 04:07 PM
Bozic Carmen	EVP and CMO	Oct 17 '23	Sale	373.25	5,651	2,109,236	40,603	Oct 19 04:18 PM
Bhatia Sangeeta N.	Director	Oct 17 '23	Sale	375.00	243	91,125	3,901	Oct 19 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Oct 16 '23	Sale	374.00	12,962	4,847,788	22,425	Oct 18 04:17 PM
Bhatia Sangeeta N.	Director	Oct 06 '23	Sale	360.00	242	87,120	4,144	Oct 11 04:14 PM
Bozic Carmen	EVP and CMO	Oct 03 '23	Sale	345.28	5,651	1,951,177	46,254	Oct 05 04:30 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '23	Sale	346.76	610	211,524	10,569	Oct 03 04:07 PM
Bozic Carmen	EVP and CMO	Sep 19 '23	Sale	351.00	5,651	1,983,501	51,905	Sep 21 04:15 PM
Bozic Carmen	EVP and CMO	Sep 05 '23	Sale	352.66	5,651	1,992,882	57,556	Sep 07 04:29 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Aug 23 '23	Sale	355.00	2,500	887,500	48,637	Aug 25 04:14 PM
Kearney Terrence C	Director	Aug 10 '23	Option Exercise	127.54	10,000	1,275,400	16,536	Aug 14 04:09 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 10 '23	Sale	350.00	10,031	3,510,850	58,814	Aug 14 04:05 PM
Kearney Terrence C	Director	Aug 10 '23	Sale	350.00	10,000	3,500,000	6,536	Aug 14 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Aug 10 '23	Sale	345.79	5,750	1,988,293	51,137	Aug 14 04:08 PM
Bhatia Sangeeta N.	Director	Aug 09 '23	Sale	345.51	242	83,613	4,386	Aug 11 04:05 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 09 '23	Sale	345.51	63	21,767	32,038	Aug 11 04:05 PM
SACHS BRUCE I	Director	Jul 17 '23	Option Exercise	127.54	11,250	1,434,825	51,250	Jul 18 04:17 PM
SACHS BRUCE I	Director	Jul 17 '23	Sale	356.75	11,250	4,013,459	40,000	Jul 18 04:17 PM
Kewalramani Reshma	CEO & President	Jul 17 '23	Sale	355.00	7,828	2,778,940	118,906	Jul 18 04:13 PM

Open in Screener

REGN

Regeneron Pharmaceuticals, Inc.

Jun 20 • 04:00PM ET

1044.39

Dollar change +5.28
Percentage change 0.51	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart

Held by: VTI VOO QQQ SPY IVV VTV XLV IBB JEPI VHT

Index	NDX, S&P 500	P/E	30.85	EPS (ttm)	33.85	Insider Own	3.56%	Shs Outstand	107.60M	Perf Week	1.63%
Market Cap	115.06B	Forward P/E	22.05	EPS next Y	47.36	Insider Trans	-6.63%	Shs Float	106.24M	Perf Month	5.79%
Income	3.86B	PEG	3.12	EPS next Q	10.58	Inst Own	85.58%	Short Float	1.64%	Perf Quarter	8.01%
Sales	13.10B	P/S	8.78	EPS this Y	0.74%	Inst Trans	-0.34%	Short Ratio	4.09	Perf Half Y	22.74%
Book/sh	244.93	P/B	4.26	EPS next Y	7.37%	ROA	11.98%	Short Interest	1.75M	Perf Year	33.69%
Cash/sh	95.48	P/C	10.94	EPS next 5Y	9.90%	ROE	15.28%	52W Range	684.80 - 1052.34	Perf YTD	18.91%
Dividend Est.	-	P/FCF	28.31	EPS past 5Y	10.31%	ROI	12.99%	52W High	-0.76%	Beta	0.13
Dividend TTM	-	Quick Ratio	4.51	Sales past 5Y	19.99%	Gross Margin	83.00%	52W Low	52.51%	ATR (14)	17.86
Dividend Ex-Date	-	Current Ratio	5.27	EPS Y/Y TTM	-7.49%	Oper. Margin	30.81%	RSI (14)	72.94	Volatility	1.87% 1.71%
Employees	13450	Debt/Eq	0.10	Sales Y/Y TTM	5.90%	Profit Margin	29.45%	Recom	1.82	Target Price	1069.40
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-12.56%	Payout	0.00%	Rel Volume	1.38	Prev Close	1039.11
Sales Surprise	-2.49%	EPS Surprise	-6.11%	Sales Q/Q	-0.54%	Earnings	May 02 BMO	Avg Volume	427.22K	Price	1044.39
SMA20	4.37%	SMA50	8.85%	SMA200	15.96%	Trades		Volume	590,462	Change	0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line	$760
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$625 → $851
Sep-09-22	Upgrade	Jefferies	Underperform → Hold	$536 → $675
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$630
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$625
Jun-06-22	Initiated	Jefferies	Underperform	$536
May-23-22	Initiated	SVB Leerink	Outperform	$738

Show Previous Ratings

Jun-20-24 05:04PM	Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy? (TipRanks)
Jun-18-24 01:22PM	Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead? (Zacks)
Jun-17-24 11:53AM	Regeneron touts success with bispecific antibody in multiple myeloma trial (Clinical Trials Arena)
11:23AM	EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma (Clinical Trials Arena)
Jun-16-24 06:10AM	Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma (GlobeNewswire)
07:30PM	Loading…
Jun-14-24 07:30PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Jun-13-24 08:00AM	Why It's A New Day For COPD Patients And Regeneron, Sanofi, Verona Stocks (Investor's Business Daily)
Jun-12-24 10:35PM	REGN, CI, BSX: Which Strong Buy Healthcare Stock Is the Best Bet? (TipRanks)
04:03PM	Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club (Investor's Business Daily)
10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-11-24 02:06PM	Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion (Zacks)
07:00AM	Kevzara (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) (GlobeNewswire)
Jun-07-24 10:10AM	Stock Split Watch: 3 Growth Stocks That Could Be Next (Motley Fool)
Jun-03-24 04:22PM	Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
11:23AM	Loading…
May-31-24 11:23AM	FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease (Benzinga)
01:05AM	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (GlobeNewswire)
01:05AM	Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD (GlobeNewswire)
01:00AM	Update on FDA Priority Review of Dupixent (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation (GlobeNewswire)
01:00AM	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (GlobeNewswire)
May-30-24 04:45AM	Biohaven doses first subject in Phase I/II tumour treatment study (Clinical Trials Arena)
May-29-24 07:15AM	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors (PR Newswire)
May-27-24 03:02AM	The Biggest Biotechnology Company in Europe (Insider Monkey)
May-25-24 11:15PM	The Biggest Publicly Traded Biotech Company (Insider Monkey)
11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
10:00AM	2 Biotech Stocks to Buy in May (Motley Fool)
May-24-24 09:57AM	Ireland the jewel in the life sciences crown? (Medical Device Network)
09:28AM	Regeneron (REGN) Announces Positive Data on Oncology Candidate (Zacks)
May-23-24 05:03PM	Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo (cemiplimab) to be Reported at ASCO (GlobeNewswire)
06:15AM	3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years (Motley Fool)
07:00AM	Loading…
May-22-24 07:00AM	Regeneron faces new biosimilar threats; an AI biotech lays off staff (BioPharma Dive)
May-20-24 03:33PM	Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate (MT Newswires)
02:49PM	Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 (MT Newswires)
02:15PM	Press Release: Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM (GlobeNewswire)
02:15PM	Dupixent (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine (GlobeNewswire)
01:34PM	7 Biotech Stocks That Could Breathe New Life Into Your Portfolio (InvestorPlace)
07:38AM	Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25 (MT Newswires)
May-19-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm (GlobeNewswire)
May-17-24 06:01PM	Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing (MT Newswires)
04:23PM	More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 (PR Newswire)
02:39PM	Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,115 From $1,060 (MT Newswires)
May-16-24 03:54PM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) (Business Wire)
07:15AM	These 2 No-Brainer Growth Stocks Are Breaking New Ground (Motley Fool)
03:35AM	Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing (MT Newswires)
May-13-24 11:02AM	Dupixent set for FDA review in adolescent chronic inflammatory sinus disease (Pharmaceutical Technology)
04:41AM	Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review (MT Newswires)
04:01AM	Pipeline Moves: Phase III completion for Corcepts relaorilant (Clinical Trials Arena)
01:00AM	Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) (GlobeNewswire)
May-09-24 11:53PM	Q1 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
06:51AM	Regenerons gene therapy triumphs twice, restoring hearing in children (Clinical Trials Arena)
May-08-24 07:30AM	Regeneron gene therapy improves hearing in two children (BioPharma Dive)
06:07AM	Regeneron's experimental gene therapy improves hearing in one patient (Reuters)
06:00AM	Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks (GlobeNewswire)
May-07-24 10:45AM	UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating (MT Newswires)
May-06-24 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
May-05-24 08:46PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-03-24 10:20AM	Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept (MT Newswires)
10:15AM	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:56AM	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 (MT Newswires)
06:15AM	Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar (InvestorPlace)
03:10AM	Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
01:08AM	Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight (GuruFocus.com)
May-02-24 04:03PM	Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms (Investor's Business Daily)
02:51PM	Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177 (MT Newswires)
01:54PM	Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016 (MT Newswires)
01:52PM	RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189 (MT Newswires)
10:53AM	REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:01AM	Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales (Zacks)
09:30AM	Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:32AM	Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ... (GuruFocus.com)
07:15AM	3 Biotech Stocks to Buy and Hold Through 2030 and Beyond (Motley Fool)
07:09AM	Regeneron Pharmaceuticals' Q1 Non-GAAP Net Income, Revenue Decline (MT Newswires)
06:45AM	Regeneron Earnings Miss; Biotech Giant's Stock Falls (Investor's Business Daily)
06:44AM	UPDATE 3-Regeneron's blockbuster eye drug posts weaker sales due to inventory impact (Reuters)
06:44AM	Regeneron: Q1 Earnings Snapshot (Associated Press Finance)
06:39AM	Regeneron's blockbuster eye drug posts weaker sales due to inventory impact (Reuters)
06:34AM	Regeneron misses profit estimates on weaker Eylea and Dupixent sales (Reuters)
06:30AM	Regeneron Reports First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-01-24 06:42AM	Roches VABYSMO has successful Q1 sales despite Regeneron and Bayers EYLEA HD launch (Pharmaceutical Technology)
Apr-30-24 08:47AM	Should You Consider Regeneron (REGN) Ahead of Q1 Earnings? (Zacks)
Apr-29-24 09:35AM	Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround (Zacks)
09:16AM	Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
07:00AM	EYLEA HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases (GlobeNewswire)
Apr-28-24 06:32PM	11 Oversold Growth Stocks to Buy Right Now (Insider Monkey)
Apr-26-24 12:24PM	Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says (MT Newswires)
08:24AM	Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 (MT Newswires)
Apr-25-24 11:42AM	Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma (The Wall Street Journal)
10:02AM	Regeneron (REGN) Reports Next Week: What You Should Expect (Zacks)
08:44AM	UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study (Reuters)
08:15AM	REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study (Reuters)
07:00AM	Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth (Reuters)
07:00AM	Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases (GlobeNewswire)
03:00AM	Regeneron expands in gene editing with Mammoth deal (BioPharma Dive)
Apr-24-24 10:05AM	Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO (GlobeNewswire)
Apr-22-24 05:54PM	Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-16-24 12:10PM	Why Regeneron (REGN) Could Beat Earnings Estimates Again (Zacks)
Apr-15-24 07:59PM	UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation (Reuters)
07:24PM	Regeneron to defend against DOJ complaint on drug-price manipulation (Reuters)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROWN MICHAEL S	Director	Jun 14 '24	Option Exercise	625.60	1,535	960,296	2,917	Jun 17 04:01 PM
BROWN MICHAEL S	Director	Jun 14 '24	Sale	1040.00	1,535	1,596,400	1,382	Jun 17 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 12 '24	Sale	1015.94	16,149	16,406,406	0	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 11 '24	Sale	1015.43	9,064	9,203,823	55,134	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 06 '24	Sale	1015.02	787	798,821	64,198	Jun 10 04:03 PM
Bassler Bonnie L	Director	Jun 05 '24	Option Exercise	380.95	827	315,046	2,209	Jun 07 04:06 PM
Bassler Bonnie L	Director	Jun 05 '24	Sale	1011.00	827	836,097	1,382	Jun 07 04:06 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Option Exercise	372.46	1,138	423,859	14,069	Jun 05 04:07 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Sale	980.16	1,138	1,115,422	12,931	Jun 05 04:07 PM
RYAN ARTHUR F	Director	Jun 03 '24	Sale	994.50	100	99,450	17,982	Jun 05 04:06 PM
BROWN MICHAEL S	Director	May 28 '24	Option Exercise	625.60	1,172	733,203	2,554	May 29 04:01 PM
BROWN MICHAEL S	Director	May 28 '24	Sale	974.86	1,172	1,142,536	1,382	May 29 04:01 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 21 '24	Sale	994.90	1,865	1,855,488	34,678	May 22 04:02 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 17 '24	Sale	979.23	22,830	22,355,714	466,877	May 17 05:57 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 16 '24	Sale	972.73	50,000	48,636,545	786,383	May 17 04:06 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 15 '24	Sale	975.87	50,000	48,793,727	836,383	May 17 04:04 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 15 '24	Sale	980.34	10,941	10,725,946	397,259	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 14 '24	Sale	979.25	25,000	24,481,164	408,200	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 13 '24	Option Exercise	399.66	203,204	81,212,511	577,633	May 15 06:10 PM
SING GEORGE L	Director	May 03 '24	Option Exercise	413.33	2,000	826,660	28,349	May 06 04:20 PM
McCourt Marion	EVP Commercial	May 01 '24	Sale	889.41	250	222,352	12,931	May 03 04:02 PM
RYAN ARTHUR F	Director	May 01 '24	Sale	899.61	100	89,961	18,082	May 03 04:01 PM
McCourt Marion	EVP Commercial	Apr 01 '24	Sale	964.73	250	241,182	13,181	Apr 03 04:05 PM
RYAN ARTHUR F	Director	Apr 01 '24	Sale	962.53	100	96,253	18,182	Apr 03 04:06 PM
MURPHY ANDREW J	EVP Research	Mar 14 '24	Sale	956.47	5,783	5,531,290	48,306	Mar 15 04:01 PM
MURPHY ANDREW J	EVP Research	Mar 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Mar 15 04:01 PM
McCourt Marion	EVP Commercial	Mar 01 '24	Sale	967.50	358	346,365	13,431	Mar 05 04:01 PM
RYAN ARTHUR F	Director	Mar 01 '24	Sale	982.05	100	98,205	18,282	Mar 05 04:01 PM
SING GEORGE L	Director	Feb 26 '24	Option Exercise	413.33	1,000	413,330	26,849	Feb 28 04:04 PM
Bassler Bonnie L	Director	Feb 26 '24	Option Exercise	391.92	854	334,700	2,236	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 26 '24	Sale	992.50	1,000	992,500	26,349	Feb 28 04:04 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 26 '24	Sale	990.00	1,000	990,000	36,543	Feb 28 04:04 PM
Bassler Bonnie L	Director	Feb 26 '24	Sale	979.25	854	836,280	1,382	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 23 '24	Option Exercise	413.33	500	206,665	26,849	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 23 '24	Sale	985.00	500	492,500	26,349	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 22 '24	Option Exercise	413.33	3,000	1,239,990	27,349	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 22 '24	Sale	965.00	3,000	2,895,000	26,349	Feb 26 04:07 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 22 '24	Sale	967.65	1,000	967,650	37,543	Feb 26 04:07 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Feb 15 '24	Option Exercise	399.66	172,723	69,030,474	925,209	Feb 20 04:03 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Feb 14 '24	Sale	942.28	10,434	9,831,727	20,378	Feb 16 04:15 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Feb 09 '24	Option Exercise	378.30	35,375	13,382,510	47,153	Feb 13 04:04 PM
SING GEORGE L	Director	Feb 09 '24	Option Exercise	413.33	500	206,665	26,849	Feb 12 04:02 PM
Fenimore Christopher R.	SVP Finance & CFO	Feb 09 '24	Sale	953.31	4,919	4,689,320	14,372	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 09 '24	Sale	955.00	500	477,500	26,349	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 08 '24	Option Exercise	413.33	500	206,665	26,849	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 08 '24	Sale	945.00	500	472,500	26,349	Feb 12 04:02 PM
STAHL NEIL	EVP Research and Development	Feb 07 '24	Sale	950.35	8,037	7,637,954	52,019	Feb 08 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 07 '24	Sale	950.00	1,000	950,000	38,543	Feb 09 04:12 PM
McCourt Marion	EVP Commercial	Feb 05 '24	Sale	934.71	1,000	934,710	13,789	Feb 06 04:08 PM
STAHL NEIL	EVP Research and Development	Feb 02 '24	Option Exercise	399.66	30,750	12,289,545	82,769	Feb 06 04:08 PM
Landry Robert E	EVP Finance CFO	Feb 02 '24	Option Exercise	378.98	400	151,592	23,974	Feb 06 04:08 PM
McCourt Marion	EVP Commercial	Feb 01 '24	Sale	945.61	273	258,152	14,789	Feb 02 04:02 PM
RYAN ARTHUR F	Director	Feb 01 '24	Sale	954.22	100	95,422	18,382	Feb 05 04:05 PM
Landry Robert E	EVP Finance CFO	Jan 31 '24	Option Exercise	378.98	400	151,592	23,856	Feb 02 04:02 PM
Bassler Bonnie L	Director	Jan 30 '24	Option Exercise	380.95	827	315,046	2,209	Jan 31 04:52 PM
Bassler Bonnie L	Director	Jan 30 '24	Sale	959.00	827	793,093	1,382	Jan 31 04:52 PM
Landry Robert E	EVP Finance CFO	Jan 24 '24	Option Exercise	378.98	500	189,490	23,808	Jan 25 04:17 PM
Fenimore Christopher R.	SVP Controller	Jan 23 '24	Option Exercise	477.67	10,000	4,776,650	22,874	Jan 25 04:17 PM
GOLDSTEIN JOSEPH L	Director	Jan 23 '24	Option Exercise	625.60	2,707	1,693,499	9,089	Jan 25 04:18 PM
Landry Robert E	EVP Finance CFO	Jan 23 '24	Option Exercise	378.98	1,100	416,878	24,084	Jan 25 04:17 PM
GOLDSTEIN JOSEPH L	Director	Jan 23 '24	Sale	950.00	2,707	2,571,650	6,382	Jan 25 04:18 PM
Landry Robert E	EVP Finance CFO	Jan 17 '24	Option Exercise	378.98	500	189,490	23,338	Jan 18 04:02 PM
Landry Robert E	EVP Finance CFO	Jan 12 '24	Option Exercise	378.98	800	303,184	23,406	Jan 17 04:03 PM
Landry Robert E	EVP Finance CFO	Jan 04 '24	Option Exercise	378.98	500	189,490	22,948	Jan 08 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jan 03 '24	Option Exercise	399.66	34,000	13,588,440	64,036	Jan 04 04:19 PM
Fenimore Christopher R.	SVP Controller	Jan 03 '24	Option Exercise	477.67	10,000	4,776,650	20,329	Jan 04 04:22 PM
Landry Robert E	EVP Finance CFO	Jan 03 '24	Option Exercise	378.98	1,100	416,878	23,136	Jan 04 04:19 PM
Bassler Bonnie L	Director	Jan 03 '24	Option Exercise	380.95	826	314,665	2,208	Jan 04 04:11 PM
Bassler Bonnie L	Director	Jan 03 '24	Sale	914.00	826	754,964	1,382	Jan 04 04:11 PM
Zoghbi Huda Y	Director	Jan 02 '24	Option Exercise	391.92	1,117	437,775	2,364	Jan 04 04:11 PM
Landry Robert E	EVP Finance CFO	Jan 02 '24	Option Exercise	378.98	650	246,337	22,457	Jan 04 04:19 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Jan 02 '24	Sale	900.00	16,848	15,163,200	180,000	May 01 04:00 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Jan 02 '24	Sale	900.00	16,848	15,163,200	180,000	Jan 04 04:20 PM
Zoghbi Huda Y	Director	Jan 02 '24	Sale	900.00	1,117	1,005,300	1,247	Jan 04 04:11 PM
McCourt Marion	EVP Commercial	Jan 02 '24	Sale	873.91	274	239,451	15,062	Jan 04 04:17 PM
RYAN ARTHUR F	Director	Jan 02 '24	Sale	899.90	100	89,990	18,347	Jan 04 04:08 PM
Landry Robert E	EVP Finance CFO	Dec 28 '23	Option Exercise	378.98	850	322,133	22,419	Dec 29 04:05 PM
BROWN MICHAEL S	Director	Dec 27 '23	Option Exercise	482.68	2,049	989,011	3,296	Dec 29 04:06 PM
Landry Robert E	EVP Finance CFO	Dec 27 '23	Option Exercise	378.98	750	284,235	22,111	Dec 29 04:05 PM
Fenimore Christopher R.	SVP Controller	Dec 27 '23	Sale	856.71	2,448	2,097,226	14,372	Dec 29 04:04 PM
BROWN MICHAEL S	Director	Dec 27 '23	Sale	898.00	2,049	1,840,002	1,247	Dec 29 04:06 PM
Fenimore Christopher R.	SVP Controller	Dec 22 '23	Sale	846.27	250	211,568	16,820	Dec 26 04:08 PM
Fenimore Christopher R.	SVP Controller	Dec 21 '23	Sale	844.01	1,680	1,417,934	17,070	Dec 26 04:08 PM
Landry Robert E	EVP Finance CFO	Dec 13 '23	Option Exercise	378.98	1,000	378,980	22,084	Dec 14 04:08 PM
Bassler Bonnie L	Director	Dec 13 '23	Option Exercise	376.69	610	229,781	1,857	Dec 14 04:07 PM
Bassler Bonnie L	Director	Dec 13 '23	Sale	870.00	610	530,700	1,247	Dec 14 04:07 PM
McCourt Marion	EVP Commercial	Dec 11 '23	Sale	838.44	270	226,379	20,814	Dec 12 04:04 PM
MURPHY ANDREW J	EVP Research	Dec 05 '23	Sale	817.44	6,536	5,342,787	59,421	Dec 06 04:02 PM
MURPHY ANDREW J	EVP Research	Dec 04 '23	Option Exercise	270.43	20,000	5,408,600	79,421	Dec 06 04:02 PM
RYAN ARTHUR F	Director	Dec 01 '23	Sale	817.30	100	81,730	18,447	Dec 04 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 14 '23	Sale	799.17	6,492	5,188,213	59,421	Nov 15 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 13 '23	Option Exercise	270.43	20,000	5,408,600	79,421	Nov 15 04:02 PM
RYAN ARTHUR F	Director	Nov 07 '23	Sale	827.90	100	82,790	18,547	Nov 08 04:07 PM
McCourt Marion	EVP Commercial	Nov 01 '23	Option Exercise	381.40	1,000	381,400	20,803	Nov 02 04:03 PM
McCourt Marion	EVP Commercial	Nov 01 '23	Sale	783.91	1,000	783,910	19,803	Nov 02 04:03 PM
Zoghbi Huda Y	Director	Oct 13 '23	Option Exercise	391.92	1,000	391,920	2,247	Oct 17 04:06 PM
Zoghbi Huda Y	Director	Oct 13 '23	Sale	850.00	1,000	850,000	1,247	Oct 17 04:06 PM
McCourt Marion	EVP Commercial	Oct 02 '23	Option Exercise	372.46	1,038	386,613	20,841	Oct 03 04:04 PM
McCourt Marion	EVP Commercial	Oct 02 '23	Sale	827.00	1,038	858,426	19,803	Oct 03 04:04 PM
McCourt Marion	EVP Commercial	Sep 01 '23	Sale	834.55	250	208,638	19,803	Sep 06 04:03 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc.

Jun 20 • 04:00PM ET

38.02

Dollar change +0.60
Percentage change 1.60	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart

Held by: VTI VB XBI VXF VBK IBB SCHA IWP VHT IWF

Index	-	P/E	-	EPS (ttm)	-8.03	Insider Own	6.26%	Shs Outstand	90.57M	Perf Week	-14.83%
Market Cap	3.44B	Forward P/E	-	EPS next Y	-5.21	Insider Trans	-1.92%	Shs Float	84.90M	Perf Month	-8.45%
Income	-613.35M	PEG	-	EPS next Q	-1.67	Inst Own	89.73%	Short Float	5.26%	Perf Quarter	-19.12%
Sales	442.59M	P/S	7.78	EPS this Y	19.11%	Inst Trans	-3.13%	Short Ratio	5.60	Perf Half Y	-16.73%
Book/sh	1.69	P/B	22.52	EPS next Y	21.89%	ROA	-45.59%	Short Interest	4.47M	Perf Year	-24.16%
Cash/sh	4.62	P/C	8.23	EPS next 5Y	8.90%	ROE	-340.05%	52W Range	31.52 - 54.56	Perf YTD	-20.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.75%	ROI	-60.31%	52W High	-30.32%	Beta	0.54
Dividend TTM	-	Quick Ratio	2.28	Sales past 5Y	63.06%	Gross Margin	86.59%	52W Low	20.62%	ATR (14)	2.01
Dividend Ex-Date	-	Current Ratio	2.43	EPS Y/Y TTM	21.74%	Oper. Margin	-131.15%	RSI (14)	40.05	Volatility	5.48% 4.51%
Employees	1276	Debt/Eq	6.65	Sales Y/Y TTM	15.29%	Profit Margin	-138.58%	Recom	1.20	Target Price	90.45
Option/Short	Yes / Yes	LT Debt/Eq	6.25	EPS Q/Q	13.10%	Payout	-	Rel Volume	1.21	Prev Close	37.42
Sales Surprise	-6.20%	EPS Surprise	-16.19%	Sales Q/Q	8.30%	Earnings	May 02 AMC	Avg Volume	797.76K	Price	38.02
SMA20	-6.38%	SMA50	-10.41%	SMA200	-10.44%	Trades		Volume	966,449	Change	1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144
May-06-21	Upgrade	Citigroup	Neutral → Buy	$160 → $151

Show Previous Ratings

Jun-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-13-24 08:49PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.44%
10:15AM	Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug (Zacks)
05:12AM	Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last? (Zacks)
03:14AM	Loading…
03:14AM	Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ... (GuruFocus.com)
Jun-12-24 04:05PM	Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +7.83%
04:00PM	Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
10:46AM	Ultragenyx (RARE) Posts New Data From Bone Disease Study (Zacks)
07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive)
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Jun-04-24 04:05PM	Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 10:36AM	Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study (Zacks)
May-30-24 04:00PM	Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
May-22-24 02:27PM	Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells (Benzinga)
04:30PM	Loading…
May-17-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-24 04:30PM	Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference (GlobeNewswire)
May-04-24 10:24AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:01PM	Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ... (GuruFocus.com)
12:22PM	Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks)
May-02-24 08:58PM	RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ... (GuruFocus.com)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-30-24 04:00PM	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease (GlobeNewswire)
08:00AM	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Apr-25-24 04:30PM	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-19-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:33AM	Loading…
Apr-16-24 11:33AM	Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study (Zacks)
Apr-15-24 07:30AM	Ultragenyx says Angelman therapy is working, but safety questions remain (BioPharma Dive) -8.79%
07:00AM	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 (GlobeNewswire)
Apr-12-24 04:22PM	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome (GlobeNewswire) -7.30%
08:00AM	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-22-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
Mar-12-24 05:00PM	Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ... (GuruFocus.com)
Mar-11-24 03:00PM	Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE) (GuruFocus.com)
Mar-08-24 09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
Feb-27-24 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire) +6.79%
Feb-23-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-24 10:43AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.75%
10:35AM	Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
07:53AM	Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
Feb-15-24 04:15PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.91%
Feb-08-24 04:00PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-24 08:00AM	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-05-24 04:05PM	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
Jan-25-24 04:05PM	Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jan-19-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 02:41PM	Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 (Investor's Business Daily)
Jan-09-24 06:20PM	After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright (Zacks)
Jan-08-24 12:18PM	Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint (Zacks)
07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Jan-07-24 11:00AM	Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones (GlobeNewswire)
Jan-04-24 08:12AM	Ultragenyx (RARE) Posts Update From AS Study of GTX-102 (Zacks)
08:00AM	Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Jan-03-24 08:00AM	Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome (GlobeNewswire)
Jan-02-24 04:05PM	Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-21-23 05:21PM	Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims (The Wall Street Journal)
04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-18-23 09:29AM	Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome (PR Newswire)
08:00AM	Ultragenyx Receives European Commission Decision for Evkeeza (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-15-23 10:18AM	5 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Nov-20-23 04:30PM	Ultragenyx to Participate at Investor Conferences in November (GlobeNewswire)
Nov-17-23 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 05:00PM	Ultragenyx to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-23 01:12PM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks) +6.09%
Nov-02-23 06:26PM	Ultragenyx Pharmaceutical Inc (RARE) Reports Q3 2023 Earnings: Revenue Grows by 8% Year-Over-Year (GuruFocus.com)
04:36PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Oct-26-23 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire) +5.12%
Oct-25-23 06:17AM	Insider Sell: CBO & EVP Thomas Kassberg Sells 39,878 Shares of Ultragenyx Pharmaceutical Inc (GuruFocus.com)
Oct-23-23 04:01PM	Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire)
Oct-20-23 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-18-23 09:16PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -13.85% +5.42%
Oct-17-23 04:02PM	Ultragenyx Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-16-23 08:00AM	Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease (GlobeNewswire) +10.28%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-12-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.98%
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-05-23 08:00AM	Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023 (GlobeNewswire)
Sep-25-23 05:13PM	Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Sep-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 12:36PM	Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com) +6.06%
Aug-31-23 09:00AM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire)
Aug-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.36%
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 11:14AM	Henrietta Lacks' estate sues Ultragenyx over Mass.-made gene therapies (American City Business Journals)
Aug-10-23 06:27PM	Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line (Reuters)
Aug-08-23 07:11AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate (Simply Wall St.)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-04-23 08:34AM	Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents) -8.79%

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 12 '24	Sale	45.00	9,806	441,270	57,981	Jun 12 07:47 PM
Sanders Corazon (Corsee) D.	Director	Jun 10 '24	Sale	41.10	1,737	71,391	7,248	Jun 10 07:58 PM
Crombez Eric	EVP and Chief Medical Officer	May 02 '24	Sale	43.66	354	15,456	48,431	May 03 03:23 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 18 '24	Sale	44.10	142	6,262	48,785	Apr 19 04:35 PM
Kassberg Thomas Richard	CBO & EVP	Mar 11 '24	Sale	49.93	11,509	574,644	252,823	Mar 12 01:41 PM
Fust Matthew K	Director	Mar 07 '24	Sale	50.88	12,195	620,443	14,860	Mar 11 12:54 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 01 '24	Sale	53.76	4,768	256,328	67,163	Mar 05 08:08 PM
Pinion John Richard	See Remarks	Mar 01 '24	Sale	53.76	4,173	224,340	89,268	Mar 05 08:15 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 01 '24	Sale	53.76	3,756	201,923	67,340	Mar 05 08:22 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 01 '24	Sale	53.76	1,238	66,555	48,927	Mar 05 08:10 PM
Kassberg Thomas Richard	CBO & EVP	Mar 01 '24	Sale	53.76	1,011	54,351	264,332	Mar 05 08:19 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 01 '24	Sale	53.76	341	18,332	41,380	Mar 05 08:13 PM
KAKKIS EMIL D	President & CEO	Feb 07 '24	Sale	45.00	30,000	1,350,000	539,770	Feb 08 03:49 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Jan 02 '24	Option Exercise	21.00	3,000	63,000	27,892	Jan 02 04:06 PM
KAKKIS EMIL D	President & CEO	Dec 29 '23	Sale	47.87	30,000	1,436,100	569,770	Jan 02 04:07 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Option Exercise	6.86	39,878	273,563	286,738	Oct 24 05:22 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Sale	32.78	39,878	1,307,201	246,860	Oct 24 05:22 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Option Exercise	6.86	47,853	328,272	647,029	Oct 23 05:14 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Sale	33.52	47,853	1,604,033	599,743	Oct 23 05:14 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Option Exercise	21.00	2,000	42,000	25,777	Sep 11 01:52 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Sale	40.80	2,163	88,249	23,614	Sep 11 01:52 PM
Harris Erik	EVP & Chief Commercial Officer	Sep 05 '23	Sale	37.96	6,000	227,760	51,281	Sep 06 05:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 01 '23	Sale	37.15	970	36,032	23,777	Sep 06 05:50 PM
Sanders Corazon (Corsee) D.	Director	Jun 30 '23	Sale	46.76	585	27,355	8,985	Jun 30 02:34 PM

Open in Screener

KRON

Kronos Bio Inc

Jun 20 • 04:00PM ET

1.04

Dollar change +0.03
Percentage change 2.97	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-2.00	Insider Own	35.23%	Shs Outstand	58.95M	Perf Week	-18.75%
Market Cap	62.49M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	16.15%	Shs Float	38.92M	Perf Month	0.00%
Income	-116.39M	PEG	-	EPS next Q	-0.36	Inst Own	27.40%	Short Float	1.77%	Perf Quarter	-14.05%
Sales	7.59M	P/S	8.23	EPS this Y	17.18%	Inst Trans	-2.16%	Short Ratio	1.41	Perf Half Y	-28.77%
Book/sh	2.28	P/B	0.46	EPS next Y	7.33%	ROA	-49.32%	Short Interest	0.69M	Perf Year	-33.33%
Cash/sh	2.53	P/C	0.41	EPS next 5Y	-	ROE	-64.20%	52W Range	0.69 - 2.29	Perf YTD	-16.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-72.78%	ROI	-72.10%	52W High	-54.59%	Beta	1.85
Dividend TTM	-	Quick Ratio	8.32	Sales past 5Y	0.00%	Gross Margin	54.67%	52W Low	50.72%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	8.32	EPS Y/Y TTM	8.48%	Oper. Margin	-1445.17%	RSI (14)	54.59	Volatility	11.83% 12.06%
Employees	63	Debt/Eq	0.20	Sales Y/Y TTM	521.38%	Profit Margin	-1534.11%	Recom	1.00	Target Price	4.12
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-9.63%	Payout	-	Rel Volume	0.80	Prev Close	1.01
Sales Surprise	152.00%	EPS Surprise	-18.34%	Sales Q/Q	106.39%	Earnings	May 09 AMC	Avg Volume	489.76K	Price	1.04
SMA20	14.65%	SMA50	5.79%	SMA200	-6.23%	Trades		Volume	390,112	Change	2.97%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-14-22	Initiated	Berenberg	Buy	$12
Oct-20-21	Resumed	Cowen	Outperform
Jun-24-21	Initiated	H.C. Wainwright	Buy	$35
Nov-03-20	Initiated	Piper Sandler	Overweight	$50
Nov-03-20	Initiated	Jefferies	Buy	$36
Nov-03-20	Initiated	Goldman	Buy	$45
Nov-03-20	Initiated	Cowen	Outperform

May-23-24 05:15PM	Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -22.09%
May-22-24 04:30PM	Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events (GlobeNewswire)
May-21-24 08:15AM	Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer (GlobeNewswire)
May-16-24 09:35AM	Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround (Zacks)
May-09-24 10:55PM	KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	Loading…
05:45PM	Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Kronos Bio Reports First-Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:01PM	Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-27-24 12:00PM	Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-21-24 01:53PM	KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:05AM	Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 04:05PM	Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway (GlobeNewswire) +7.50%
Mar-05-24 04:44PM	Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting (GlobeNewswire) +17.65%
Feb-27-24 04:05PM	Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference (GlobeNewswire) +11.40%
Jan-25-24 08:00AM	Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement (GlobeNewswire)
04:06PM	Loading…
Dec-18-23 04:06PM	Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate (GlobeNewswire) -13.01%
Dec-04-23 08:00AM	Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire)
Nov-27-23 04:05PM	Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 05:25PM	Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.51%
04:05PM	Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 04:05PM	Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study (GlobeNewswire) -5.10% +15.00%
12:00PM	Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting (GlobeNewswire)
Oct-27-23 08:00AM	Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting (GlobeNewswire)
Oct-13-23 12:30PM	Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC (GlobeNewswire) -13.70%
Oct-04-23 04:05PM	Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 (GlobeNewswire)
Aug-17-23 08:00AM	Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development (GlobeNewswire)
Aug-08-23 05:50PM	Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results (GlobeNewswire)
Jul-19-23 07:27AM	With 47% ownership, Kronos Bio, Inc. (NASDAQ:KRON) has piqued the interest of institutional investors (Simply Wall St.)
Jun-06-23 08:00AM	Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance (GlobeNewswire)
04:05PM	Loading…
Jun-01-23 04:05PM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-12-23 07:00AM	The past year for Kronos Bio (NASDAQ:KRON) investors has not been profitable (Simply Wall St.)
May-10-23 05:35PM	Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results (GlobeNewswire)
Apr-24-23 04:05PM	Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors (GlobeNewswire)
Apr-18-23 02:24PM	Kronos Bio, Inc. (NASDAQ:KRON) insider upped their holding by 11% earlier this year (Simply Wall St.)
Apr-11-23 04:05PM	Kronos Bio Announces Changes to Board of Directors (GlobeNewswire)
Mar-15-23 04:05PM	Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results (GlobeNewswire) -5.66%
Feb-28-23 04:05PM	Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Jan-09-23 09:25AM	Deals, data kick off biotech's big JPM Week (American City Business Journals) +15.12%
08:23AM	Kronos Bios stock rallies after announcing drug-discovery deal with Roche (MarketWatch)
07:00AM	Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology (GlobeNewswire)
Dec-20-22 10:28AM	We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate (Simply Wall St.) -5.19%
Dec-12-22 09:35AM	Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks (Zacks) +10.23%
Dec-11-22 10:00AM	Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting (GlobeNewswire)
Dec-07-22 04:05PM	Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-22-22 04:05PM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
09:35AM	Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks (Zacks)
Nov-09-22 12:04PM	Insiders might want to re-evaluate their US$2.4m stock purchase as Kronos Bio, Inc. (NASDAQ:KRON) drops to US$145m (Simply Wall St.) -9.38%
Nov-08-22 04:10PM	Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results (GlobeNewswire)
04:05PM	Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742 (GlobeNewswire)
Oct-12-22 04:04AM	Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022 (GlobeNewswire)
Sep-06-22 04:05PM	Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +10.95%
Aug-22-22 11:33AM	Kronos Bio Starts Dosing In Early-Stage Leukemia Study With Next-Gen SYK Inhibitor (Benzinga) -6.10%
08:00AM	Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia (GlobeNewswire)
Aug-16-22 04:05PM	Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML (PR Newswire) -6.01% -6.39%
Aug-09-22 09:55AM	Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect? (Zacks) -9.47%
Aug-04-22 04:05PM	Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results (GlobeNewswire)
Jul-25-22 08:48AM	7 Nasdaq Stocks to Buy on the Dip (InvestorPlace)
Jul-10-22 10:27AM	We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate (Simply Wall St.)
Jul-08-22 12:00PM	Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-10-22 03:04AM	Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress (GlobeNewswire) -13.07%
Jun-01-22 04:05PM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -7.26%
May-22-22 08:04AM	Norbert Bischofberger Is The President of Kronos Bio, Inc. (NASDAQ:KRON) And They Just Picked Up 11% More Shares (Simply Wall St.)
May-17-22 07:00AM	Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference (GlobeNewswire) +8.54%
May-12-22 10:23AM	Kronos Bios Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress (GlobeNewswire)
May-06-22 12:23PM	Could The Kronos Bio, Inc. (NASDAQ:KRON) Ownership Structure Tell Us Something Useful? (Simply Wall St.) -7.01%
May-04-22 04:05PM	Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results (GlobeNewswire) -5.80%
Apr-08-22 01:07PM	Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR (GlobeNewswire)
Mar-08-22 05:08PM	Kronos Bios Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire) +8.51%
Mar-01-22 07:00AM	Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-24-22 04:05PM	Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results (GlobeNewswire) +6.41%
Feb-01-22 04:05PM	Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development (GlobeNewswire) -10.79%
Jan-31-22 01:45PM	We're Not Very Worried About Kronos Bio's (NASDAQ:KRON) Cash Burn Rate (Simply Wall St.)
Dec-17-21 08:00AM	Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies (PR Newswire) +9.14%
Dec-09-21 10:15AM	Kronos Bio Inc (KRON) President & CEO Norbert W Bischofberger Bought $173,564 of Shares (GuruFocus.com)
Dec-06-21 07:00AM	Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-29-21 07:00AM	Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742 (GlobeNewswire) -5.78%
Nov-24-21 07:00AM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-11-21 04:05PM	Kronos Bio Appoints Roshawn Blunt to Board of Directors (GlobeNewswire)
Nov-09-21 04:10PM	Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results (GlobeNewswire)
Nov-08-21 04:44PM	Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus Platform (GlobeNewswire)
Nov-04-21 07:00AM	Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology (GlobeNewswire)
Oct-11-21 09:41AM	Is Kronos Bio, Inc.'s (NASDAQ:KRON) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Oct-05-21 12:17PM	Chief Scientific Officer Of Kronos Bio Trades $220K In Company Stock (Benzinga)
Sep-30-21 04:36PM	Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021 (GlobeNewswire)
Sep-14-21 08:00AM	Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations (GlobeNewswire)
Sep-07-21 07:00AM	Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-12-21 04:05PM	Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results (GlobeNewswire)
Jul-27-21 05:36PM	Is Kronos Bio, Inc. (KRON) A Good Stock To Buy? (Insider Monkey)
08:00AM	Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jul-12-21 04:56AM	Have Insiders Been Buying Kronos Bio, Inc. (NASDAQ:KRON) Shares This Year? (Simply Wall St.)
May-26-21 08:00AM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-25-21 08:00AM	Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today (GlobeNewswire)
May-11-21 04:05PM	Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day (GlobeNewswire)
May-06-21 08:00AM	Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference (GlobeNewswire) -5.10%
Apr-11-21 05:53AM	What Type Of Shareholders Own The Most Number of Kronos Bio, Inc. (NASDAQ:KRON) Shares? (Simply Wall St.)
Apr-10-21 08:30AM	Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 (GlobeNewswire)
Mar-31-21 11:25AM	Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D. (GlobeNewswire) +5.10%
Mar-26-21 08:00AM	Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors (GlobeNewswire)

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BISCHOFBERGER NORBERT W	PRESIDENT & CEO	Jun 12 '24	Buy	1.24	881,913	1,096,041	7,375,616	Jun 12 07:23 PM
BISCHOFBERGER NORBERT W	PRESIDENT & CEO	Jun 11 '24	Buy	1.09	744,308	814,571	6,493,703	Jun 12 07:23 PM
BISCHOFBERGER NORBERT W	PRESIDENT & CEO	Jun 10 '24	Buy	0.88	1,378,901	1,208,469	5,749,395	Jun 12 07:23 PM
Frisbee Allison	SR VP, CORP OPERATIONS & LEGAL	Feb 21 '24	Sale	1.05	12,105	12,757	204,510	Feb 23 08:04 PM
Lin Charles Y	SR VP, RESEARCH & DEVELOPMENT	Feb 21 '24	Sale	1.05	12,036	12,685	234,603	Feb 23 08:07 PM
Olek Elizabeth A	SR VP, CLINICAL SCIENCE	Feb 21 '24	Sale	1.05	7,368	7,765	193,275	Feb 23 08:12 PM
DiMartino Jorge	Chief Medical Officer & VP	Jan 04 '24	Sale	1.18	12,009	14,214	315,246	Jan 05 06:27 PM
Kosacz Barbara	COO & General Counsel	Jan 04 '24	Sale	1.18	10,676	12,636	928,966	Jan 05 06:26 PM
Dinsmore Christopher	Chief Scientific Officer	Jan 04 '24	Sale	1.18	7,366	8,718	260,969	Jan 05 06:30 PM
DiMartino Jorge	Chief Medical Officer & VP	Dec 12 '23	Sale	1.30	17,367	22,664	327,255	Dec 13 04:09 PM
Dinsmore Christopher	Chief Scientific Officer	Dec 12 '23	Sale	1.30	10,032	13,092	268,335	Dec 13 04:10 PM
BISCHOFBERGER NORBERT W	President & CEO	Nov 17 '23	Buy	1.08	97,935	106,162	2,540,665	Nov 17 05:41 PM
BISCHOFBERGER NORBERT W	President & CEO	Nov 16 '23	Buy	1.00	262,433	261,514	2,442,730	Nov 17 05:41 PM
BISCHOFBERGER NORBERT W	President & CEO	Nov 15 '23	Buy	0.80	1,370,688	1,102,718	2,180,297	Nov 17 05:41 PM
DiMartino Jorge	Chief Medical Officer & VP	Jul 06 '23	Sale	1.75	10,818	18,956	344,622	Jul 07 04:07 PM
Al-Wakeel Yasir B.	Chief Financial Officer	Jul 06 '23	Sale	1.75	9,617	16,852	346,102	Jul 07 04:06 PM
Dinsmore Christopher	Chief Scientific Officer	Jul 06 '23	Sale	1.75	6,634	11,625	278,367	Jul 07 04:08 PM

Open in Screener

ALRN

Aileron Therapeutics Inc

Jun 20 • 04:00PM ET

3.04

Dollar change -0.08
Percentage change -2.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ALRN Aileron Therapeutics Inc daily Stock Chart

Held by: VXF ONEQ

Index	-	P/E	-	EPS (ttm)	-3.19	Insider Own	11.83%	Shs Outstand	21.59M	Perf Week	-6.46%
Market Cap	65.63M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-2.84%	Shs Float	19.04M	Perf Month	-17.62%
Income	-18.07M	PEG	-	EPS next Q	-0.20	Inst Own	12.06%	Short Float	1.26%	Perf Quarter	-44.73%
Sales	0.00M	P/S	-	EPS this Y	72.81%	Inst Trans	-2.74%	Short Ratio	2.44	Perf Half Y	1.33%
Book/sh	2.66	P/B	1.14	EPS next Y	-49.46%	ROA	-31.05%	Short Interest	0.24M	Perf Year	67.96%
Cash/sh	0.56	P/C	5.44	EPS next 5Y	2.10%	ROE	-34.21%	52W Range	1.01 - 7.42	Perf YTD	-0.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.67%	ROI	-19.78%	52W High	-59.03%	Beta	2.23
Dividend TTM	-	Quick Ratio	2.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	200.99%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	2.82	EPS Y/Y TTM	38.81%	Oper. Margin	0.00%	RSI (14)	28.63	Volatility	5.64% 6.00%
Employees	15	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	13.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	18.59%	Payout	-	Rel Volume	0.42	Prev Close	3.12
Sales Surprise	-	EPS Surprise	-514.29%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	97.86K	Price	3.04
SMA20	-8.39%	SMA50	-24.98%	SMA200	-11.16%	Trades		Volume	41,240	Change	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-24-17	Initiated	William Blair	Outperform
Jul-24-17	Initiated	Jefferies	Buy	$20
Jul-24-17	Initiated	BofA/Merrill	Buy	$19

May-15-24 10:53PM	ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024 (InvestorPlace)
05:13PM	Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-07-24 09:35AM	Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround (Zacks) -6.58%
May-06-24 04:05PM	Aileron Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +5.05%
May-03-24 04:33PM	Aileron Therapeutics Closes Direct Offering of Shares, Warrants (MT Newswires)
04:05PM	Loading…
04:05PM	Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million (GlobeNewswire)
May-02-24 07:24AM	Aileron reports data from cohort one of Phase Ib inhaled IPF treatment trial (Clinical Trials Arena) -8.17%
May-01-24 08:45AM	Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million (GlobeNewswire) -8.57%
08:30AM	Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
Apr-16-24 09:52AM	ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023 (InvestorPlace) -9.78%
Apr-15-24 05:20PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Aileron Therapeutics Announces CEO Transition (GlobeNewswire) -5.41%
Feb-15-24 04:05PM	Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event (GlobeNewswire)
Feb-01-24 04:30PM	Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 (GlobeNewswire) -6.06% +13.44%
Oct-31-23 12:30PM	Aileron Therapeutics Announces Acquisition of Lung Therapeutics (PR Newswire)
09:55AM	Loading…
Apr-04-23 09:55AM	Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now (Zacks)
Mar-14-23 09:55AM	Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +12.12%
Feb-22-23 11:49AM	Cancer drugmaker down to 3 employees after trial failure (American City Business Journals) +6.16%
Feb-21-23 02:50PM	Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall (Benzinga) -37.77%
08:30AM	Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives (GlobeNewswire)
Dec-29-22 12:00PM	What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock (Zacks)
Nov-30-22 07:00AM	Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-24-22 09:55AM	Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-10-22 08:00AM	Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split (GlobeNewswire) -11.98%
Nov-04-22 12:00PM	Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +10.94%
Nov-01-22 08:15AM	Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-22 06:05AM	Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference (GlobeNewswire) -5.83%
Sep-30-22 08:41AM	Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 (GlobeNewswire) -8.13%
Sep-22-22 08:00AM	Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)
Sep-06-22 07:00AM	Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
04:15PM	Loading…
Aug-15-22 04:15PM	Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Aug-01-22 07:51AM	Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer (GlobeNewswire) -15.68%
Jul-08-22 08:31AM	Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 (GlobeNewswire)
Jun-29-22 09:46AM	Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting (Benzinga) -27.14%
06:30AM	Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer (GlobeNewswire)
May-19-22 07:00AM	Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer (GlobeNewswire)
06:40AM	3 Oversold Biotech Stocks to Buy Now (InvestorPlace)
May-17-22 07:00AM	Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +12.92%
May-13-22 07:00AM	Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 (GlobeNewswire) +9.15%
May-11-22 07:57AM	Will Aileron Therapeutics (NASDAQ:ALRN) Spend Its Cash Wisely? (Simply Wall St.)
May-10-22 12:43PM	Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting (GlobeNewswire)
May-05-22 04:15PM	Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Apr-21-22 09:40AM	Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year? (Zacks) -6.12%
08:00AM	Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations (GlobeNewswire)
Apr-05-22 09:40AM	Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.88%
Mar-28-22 04:20PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -7.41%
Mar-22-22 08:04AM	Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Jan-27-22 01:38PM	Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ... (GuruFocus.com) -9.48%
Jan-05-22 08:04AM	Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones (GlobeNewswire) -7.27%
Jan-04-22 08:45AM	Aileron Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
07:00AM	CEO Presenting on the Emerging Growth Conference on January 5 Register Now (GlobeNewswire)
Dec-30-21 04:32AM	As Aileron Therapeutics, Inc.'s market cap (NASDAQ:ALRN) drops to US$47m, insiders might be questioning their decision to buy earlier this year (Simply Wall St.)
Dec-20-21 10:56AM	Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs (GlobeNewswire)
Nov-12-21 07:50AM	Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire) -6.13%
Oct-07-21 09:22AM	Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity (GlobeNewswire)
Sep-30-21 04:30PM	Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 (GlobeNewswire)
Sep-16-21 02:33PM	Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent (Benzinga) -6.09%
08:15AM	Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924s Best-in-Class Potential as a Chemoprotective Agent (GlobeNewswire)
Sep-10-21 08:30AM	Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924 (GlobeNewswire) +6.72%
Sep-07-21 04:05PM	Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference (GlobeNewswire)
Aug-27-21 09:48AM	Aileron Unveils Initial Data For Its Chemo Protective Agent (Benzinga)
07:45AM	Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting (GlobeNewswire)
Aug-11-21 04:20PM	Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) +8.00%
Jul-08-21 08:15AM	Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jul-01-21 01:39PM	Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings (Benzinga)
08:00AM	Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire)
Jun-30-21 09:33AM	Hedge Funds Are Betting On Aileron Therapeutics, Inc. (ALRN) (Insider Monkey) -6.02%
Jun-24-21 07:00AM	Aileron Therapeutics to be Added to the Russell Microcap® Index (GlobeNewswire) +8.66%
May-19-21 07:00AM	Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities (GlobeNewswire)
May-11-21 04:18PM	Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-24-21 04:36PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-04-21 08:30AM	Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -5.52%
Mar-02-21 07:00AM	Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire) -7.78%
Jan-11-21 06:30AM	Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners (GlobeNewswire) +42.22%
Jan-06-21 09:30AM	Aileron Therapeutics Announces $35.9 Million Registered Direct Offering (GlobeNewswire) -5.38%
Dec-23-20 03:41AM	Medicenna vs Aileron: Which Penny Stock Could Surge Over 200%? (TipRanks) +9.43%
Dec-21-20 08:00AM	Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities (GlobeNewswire)
Dec-14-20 08:32AM	New Strong Sell Stocks for December 14th (Zacks) -6.62%
Dec-01-20 10:12AM	New Strong Sell Stocks for December 1st (Zacks)
Nov-29-20 08:33PM	Is Aileron Therapeutics, Inc. (ALRN) A Good Stock To Buy? (Insider Monkey)
Nov-24-20 08:28AM	New Strong Sell Stocks for November 24th (Zacks)
Nov-19-20 10:02AM	New Strong Sell Stocks for November 19th (Zacks)
Nov-12-20 07:03PM	Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights (GlobeNewswire)
Oct-24-20 04:35AM	Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium (GlobeNewswire)
Oct-20-20 09:24AM	Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium (GlobeNewswire) +31.61%
Oct-13-20 08:30AM	Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher (Zacks) +15.15%
Oct-12-20 07:00AM	Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium (GlobeNewswire) +6.45%
Sep-21-20 06:07PM	Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital (GlobeNewswire) -5.88%
Sep-10-20 08:45AM	Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference (GlobeNewswire)
Aug-25-20 01:25PM	The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics (Zacks)
Aug-05-20 04:10PM	Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) +34.55%
Aug-04-20 03:31PM	3 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +21.33%
Aug-03-20 08:10AM	Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August (GlobeNewswire)
08:00AM	Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924 (GlobeNewswire)
Jun-29-20 08:30AM	Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan (GlobeNewswire) +7.27%
Jun-12-20 11:42AM	Largest Insider Trades of the Week (GuruFocus.com)
Jun-10-20 09:54AM	Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares (GlobeNewswire) +10.62%
Jun-04-20 09:15AM	Aileron Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -15.27%
Jun-03-20 04:01PM	Aileron Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +12.93%
Jun-02-20 10:22AM	The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics (Zacks) -21.09%

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 17 '24	Sale	3.25	4,707	15,298	1,746,549	Jun 17 07:03 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 14 '24	Sale	3.30	1,900	6,270	1,751,256	Jun 17 07:03 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 12 '24	Sale	3.25	9,342	30,362	1,753,156	Jun 12 06:18 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 11 '24	Sale	3.26	5,752	18,744	1,762,498	Jun 12 06:18 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 10 '24	Sale	3.30	9,577	31,604	1,768,250	Jun 12 06:18 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 07 '24	Sale	3.26	1,740	5,664	1,777,827	Jun 07 06:59 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 06 '24	Sale	3.29	4,284	14,104	1,779,567	Jun 07 06:59 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Jun 05 '24	Sale	3.30	6,291	20,760	1,783,851	Jun 07 06:59 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	May 01 '24	Sale	4.21	20,315	85,473	1,779,306	May 01 07:15 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Apr 30 '24	Sale	4.97	90	448	1,799,621	May 01 07:15 PM
UNIVERSITY OF TEXAS/TEXAS AM I	10% Owner	Apr 29 '24	Sale	4.95	10,746	53,182	1,799,711	May 01 07:15 PM
WINDSOR JAMES BRIAN	President and COO	Dec 15 '23	Buy	3.37	225	758	225	Dec 18 05:56 PM
WINDSOR JAMES BRIAN	President and COO	Nov 20 '23	Buy	1.97	5,076	9,987	5,122	Nov 21 04:43 PM

Open in Screener

ASRT

Assertio Holdings Inc

Jun 20 • 04:00PM ET

1.16

Dollar change +0.06
Percentage change 5.45	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ASRT Assertio Holdings Inc daily Stock Chart

Held by: VTI IWM VXF IWN PRFZ BSVO VTWO FDM IWC EES

Index	RUT	P/E	-	EPS (ttm)	-3.95	Insider Own	6.67%	Shs Outstand	94.67M	Perf Week	11.54%
Market Cap	110.34M	Forward P/E	26.77	EPS next Y	0.04	Insider Trans	0.39%	Shs Float	88.78M	Perf Month	11.54%
Income	-332.97M	PEG	-	EPS next Q	-0.01	Inst Own	46.12%	Short Float	11.90%	Perf Quarter	11.54%
Sales	142.05M	P/S	0.78	EPS this Y	-113.94%	Inst Trans	11.52%	Short Ratio	13.33	Perf Half Y	10.48%
Book/sh	1.41	P/B	0.82	EPS next Y	156.52%	ROA	-95.65%	Short Interest	10.57M	Perf Year	-81.23%
Cash/sh	0.85	P/C	1.37	EPS next 5Y	25.00%	ROE	-172.90%	52W Range	0.73 - 6.41	Perf YTD	8.41%
Dividend Est.	-	P/FCF	3.26	EPS past 5Y	-	ROI	-190.85%	52W High	-81.90%	Beta	0.89
Dividend TTM	-	Quick Ratio	1.45	Sales past 5Y	-7.51%	Gross Margin	57.88%	52W Low	58.38%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.87	EPS Y/Y TTM	-294.15%	Oper. Margin	-0.72%	RSI (14)	64.95	Volatility	8.13% 6.40%
Employees	53	Debt/Eq	0.30	Sales Y/Y TTM	-12.40%	Profit Margin	-234.40%	Recom	1.00	Target Price	2.92
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	30.45%	Payout	-	Rel Volume	0.76	Prev Close	1.10
Sales Surprise	10.74%	EPS Surprise	233.33%	Sales Q/Q	-23.59%	Earnings	May 06 AMC	Avg Volume	792.96K	Price	1.16
SMA20	14.05%	SMA50	19.94%	SMA200	-14.04%	Trades		Volume	604,265	Change	5.45%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-22	Initiated	Lake Street	Buy	$7
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-06-24 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 08:30AM	Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024 (GlobeNewswire)
May-29-24 07:00AM	Assertio Announces the Appointment of Brendan P. O'Grady as New CEO (GlobeNewswire)
May-17-24 09:15AM	Assertio to Participate in Benchmark Healthcare Conference on May 21-22 (GlobeNewswire)
07:30AM	Loading…
07:30AM	BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS (PR Newswire)
May-16-24 09:16AM	Assertio to Participate in AGP Healthcare Conference on May 21 (GlobeNewswire)
May-13-24 05:52PM	BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE 'AGAINST' DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS (PR Newswire) +9.38%
May-10-24 03:12PM	Assertio to Present at the Citizens JMP Life Sciences Conference in New York City (GlobeNewswire) -8.57%
May-07-24 10:28AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.02%
05:35AM	Q1 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	Assertio Holdings Inc (ASRT) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
May-06-24 08:59PM	ASRT Stock Earnings: Assertio Holdings Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +18.45%
05:46PM	Assertio Holdings Inc (ASRT) Surpasses Revenue Estimates But Reports Wider Loss in Q1 2024 (GuruFocus.com)
04:21PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Assertio Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 08:00AM	Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) -9.30%
Apr-03-24 08:00AM	Sig Kirk Joins Assertio Board of Directors (GlobeNewswire)
Apr-01-24 09:00AM	Assertio to Present at LD Micro Invitational Conference in New York City (GlobeNewswire)
Mar-12-24 11:11AM	Assertio Holdings Inc (ASRT) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.06%
08:31AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:49AM	Q4 2023 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-24 04:26PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-04-24 05:07PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Feb-29-24 04:05PM	Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 (GlobeNewswire)
Feb-28-24 10:15AM	Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Investors of March 5, 2024 Lead Plaintiff Deadline and Urges Investors with Substantial Losses to Contact the Firm (PR Newswire)
Feb-26-24 07:57PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
Feb-23-24 11:30AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
05:45AM	Investors in Assertio Holdings, Inc. Should Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT (PR Newswire)
12:35PM	Loading…
Feb-22-24 12:35PM	Assertio Holdings, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ASRT (GlobeNewswire)
Feb-19-24 12:39PM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Feb-16-24 12:41PM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire)
11:28AM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Feb-13-24 05:45AM	Shareholders of Assertio Holdings, Inc. Should Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT (PR Newswire) -7.27%
Feb-12-24 10:30AM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire) +7.90%
Feb-09-24 02:51PM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Feb-05-24 03:56PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
10:24AM	Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why (Zacks)
10:08AM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Feb-02-24 12:32PM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire)
12:19PM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-29-24 12:30PM	Assertio Holdings (ASRT) Faces Lawsuit, Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire) +5.96%
Jan-26-24 09:15AM	Analyst Slashes Assertio Holdings (ASRT) Price Target Amid CEO's Departure and Securities Fraud Suit Hagens Berman (GlobeNewswire)
Jan-24-24 06:54PM	Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm (GlobeNewswire)
10:15AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-22-24 03:42PM	Assertio Holdings (ASRT) Faces Lawsuit as Analyst Slashes Price Target Amid CEO's Departure Hagens Berman (GlobeNewswire)
Jan-19-24 09:36AM	Assertio Holdings, Inc. (NASDAQ: ASRT) Securities Fraud: Contact Berger Montague To Discuss Your Rights (GlobeNewswire)
Jan-17-24 10:15AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
09:35AM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-15-24 03:29PM	Assertio Holdings (ASRT) Faces Lawsuit After CEO Sacked Hagens Berman (GlobeNewswire)
Jan-10-24 10:45AM	ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-08-24 12:14PM	Assertio Holdings Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire) -5.39%
Jan-05-24 06:56PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +12.79%
Jan-04-24 09:46AM	Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO (Zacks) -10.91%
Jan-03-24 08:59AM	Assertio Holdings, Inc. Announces Leadership Transition (GlobeNewswire) -10.96%
Dec-25-23 02:06PM	Pre-Surge Penny Picks: 3 Stocks to Buy Before They Boom (InvestorPlace)
Nov-14-23 08:00AM	Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors (GlobeNewswire)
Nov-10-23 01:11PM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.44%
Nov-09-23 08:49AM	Q3 2023 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -43.19%
Nov-08-23 06:46PM	Assertio Holdings Inc (ASRT) Faces Headwinds in Q3 2023 Despite Revenue Growth (GuruFocus.com)
04:30PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 12:06PM	Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-06-23 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-22-23 08:38AM	Is the Options Market Predicting a Spike in Assertio (ASRT) Stock? (Zacks)
Sep-14-23 01:12PM	Insider Sell: SVP, General Counsel Sam Schlessinger Sells 45,236 Shares of Assertio Holdings Inc (GuruFocus.com) -5.44%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-25-23 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-23-23 08:48AM	Is the Options Market Predicting a Spike in Assertio (ASRT) Stock? (Zacks)
Aug-08-23 04:45PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -7.27%
09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Aug-06-23 08:05AM	Industry Analysts Just Upgraded Their Assertio Holdings, Inc. (NASDAQ:ASRT) Revenue Forecasts By 13% (Simply Wall St.)
07:14AM	10 Oversold Value Stocks To Buy (Insider Monkey)
Aug-03-23 04:29PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance) -45.61%
04:04PM	Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition (GlobeNewswire)
Jul-31-23 07:27PM	Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction (GlobeNewswire) -5.45%
Jul-27-23 04:01PM	Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals (GlobeNewswire) +6.37%
Jul-24-23 08:30AM	Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023 (GlobeNewswire) +6.17%
Jul-19-23 07:38AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Jul-07-23 09:16AM	3 Cheap Penny Stocks to Buy Before They Bounce Back (InvestorPlace)
Jun-26-23 07:00AM	Assertio Holdings Joins Russell 3000® Index (GlobeNewswire)
Jun-16-23 06:30AM	Investors in Assertio Holdings (NASDAQ:ASRT) have seen strong returns of 122% over the past year (Simply Wall St.)
May-26-23 12:06PM	Does Assertio Holdings (NASDAQ:ASRT) Deserve A Spot On Your Watchlist? (Simply Wall St.)
May-10-23 06:12AM	Assertio Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) +8.17%
01:34AM	Q1 2023 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 07:28AM	Assertio: Q1 Earnings Snapshot (AP Finance) +11.50%
07:15AM	Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook (GlobeNewswire)
06:02AM	Assertio Holdings, Inc.'s (NASDAQ:ASRT) largest shareholders are individual investors with 58% ownership, institutions own 40% (Simply Wall St.)
May-05-23 08:00AM	Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time (GlobeNewswire)
May-04-23 10:54AM	Artificial Intelligence Engine Predicts ASRT Stock to Gain 3% by June 1 (InvestorPlace)
06:10AM	7 A-Rated Stocks to Buy for May 2023 (InvestorPlace)
Apr-27-23 09:00AM	Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (GlobeNewswire)
Apr-25-23 01:03PM	Assertio Scoops Up Spectrum Pharma In $248M Stock Deal (Benzinga) -16.09%
06:00AM	Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
09:00AM	Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits (GlobeNewswire)
Apr-17-23 06:43AM	The Market Doesn't Like What It Sees From Assertio Holdings, Inc.'s (NASDAQ:ASRT) Earnings Yet (Simply Wall St.)
Apr-10-23 09:00AM	Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know (Zacks)
Apr-07-23 04:00PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vacirca Jeff L	Director	Jun 11 '24	Buy	1.11	10,000	11,100	151,159	Jun 12 06:00 PM
Mason Heather L	Interim Executive Officer	Jun 05 '24	Buy	0.97	25,000	24,250	212,650	Jun 06 06:00 PM
Schlessinger Sam	SVP, General Counsel	May 12 '24	Option Exercise	0.00	38,017	0	138,895	May 14 08:01 PM
Patel Ajay	SVP and CFO	May 12 '24	Option Exercise	0.00	38,017	0	171,271	May 14 08:00 PM
Schwichtenberg Paul	SVP, CCO	May 12 '24	Option Exercise	0.00	38,017	0	141,941	May 14 08:01 PM
Tyree James L	Director	Mar 14 '24	Sale	1.12	10,251	11,463	188,251	Mar 15 08:01 PM
Schlessinger Sam	SVP, General Counsel	Feb 21 '24	Option Exercise	0.00	17,151	0	109,384	Feb 23 05:32 PM
Patel Ajay	SVP and CFO	Feb 21 '24	Option Exercise	0.00	17,151	0	141,760	Feb 23 05:30 PM
Schwichtenberg Paul	SVP, CCO	Feb 21 '24	Option Exercise	0.00	17,151	0	112,430	Feb 23 05:31 PM
Schlessinger Sam	SVP, General Counsel	Feb 11 '24	Option Exercise	0.00	18,939	0	98,785	Feb 13 07:02 PM
Patel Ajay	SVP and CFO	Feb 11 '24	Option Exercise	0.00	47,348	0	140,991	Feb 13 07:00 PM
Schwichtenberg Paul	See Remarks	Feb 11 '24	Option Exercise	0.00	47,348	0	111,661	Feb 13 07:01 PM
Schlessinger Sam	SVP, General Counsel	Oct 01 '23	Option Exercise	0.00	19,404	0	88,442	Oct 03 07:27 PM
Peisert Daniel A.	President & CEO	Sep 12 '23	Sale	2.97	31,121	92,432	324,939	Sep 13 08:15 PM
Peisert Daniel A.	President & CEO	Sep 11 '23	Sale	3.04	127,281	386,972	356,060	Sep 13 08:15 PM
Schwichtenberg Paul	SVP and CFO	Sep 11 '23	Sale	3.07	104,980	322,593	64,313	Sep 13 08:16 PM
Patel Ajay	SVP and CAO	Sep 11 '23	Sale	3.04	64,313	195,794	93,643	Sep 13 08:17 PM
Schlessinger Sam	SVP, General Counsel	Sep 11 '23	Sale	3.04	45,236	137,441	69,038	Sep 13 08:18 PM
MCKEE WILLIAM	Director	Aug 14 '23	Sale	3.14	22,000	69,045	238,780	Aug 15 06:00 PM
Schlessinger Sam	SVP, General Counsel	Aug 05 '23	Option Exercise	0.00	7,135	0	117,434	Aug 08 07:00 PM

Open in Screener

MRUS

Merus N.V

Jun 20 • 04:00PM ET

53.94

Dollar change -0.30
Percentage change -0.55	%

Healthcare • Biotechnology • Netherlands • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IBB VHT SPDW DWAS PTH SBIO NUSC FYX KOMP FYC

Index	-	P/E	-	EPS (ttm)	-2.72	Insider Own	23.24%	Shs Outstand	57.83M	Perf Week	-4.80%
Market Cap	3.57B	Forward P/E	-	EPS next Y	-3.31	Insider Trans	-0.49%	Shs Float	50.84M	Perf Month	23.63%
Income	-149.65M	PEG	-	EPS next Q	-0.76	Inst Own	65.76%	Short Float	9.26%	Perf Quarter	18.94%
Sales	38.34M	P/S	93.19	EPS this Y	2.11%	Inst Trans	-1.60%	Short Ratio	4.95	Perf Half Y	116.19%
Book/sh	5.95	P/B	9.06	EPS next Y	-12.85%	ROA	-35.78%	Short Interest	4.71M	Perf Year	101.12%
Cash/sh	5.10	P/C	10.59	EPS next 5Y	-8.20%	ROE	-52.79%	52W Range	19.81 - 61.61	Perf YTD	96.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.50%	ROI	-41.65%	52W High	-12.45%	Beta	1.11
Dividend TTM	-	Quick Ratio	5.23	Sales past 5Y	7.00%	Gross Margin	-	52W Low	172.36%	ATR (14)	2.89
Dividend Ex-Date	-	Current Ratio	5.23	EPS Y/Y TTM	17.30%	Oper. Margin	-434.58%	RSI (14)	54.27	Volatility	4.07% 5.95%
Employees	229	Debt/Eq	0.03	Sales Y/Y TTM	-11.73%	Profit Margin	-390.36%	Recom	1.00	Target Price	84.31
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	30.85%	Payout	-	Rel Volume	0.65	Prev Close	54.24
Sales Surprise	-17.72%	EPS Surprise	26.75%	Sales Q/Q	-41.56%	Earnings	May 08 AMC	Avg Volume	949.96K	Price	53.94
SMA20	1.37%	SMA50	13.13%	SMA200	52.46%	Trades		Volume	621,700	Change	-0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Truist	Buy	$69
Mar-04-24	Reiterated	Needham	Buy	$42 → $65
Nov-02-23	Initiated	Canaccord Genuity	Buy	$45
Aug-21-23	Initiated	TD Cowen	Outperform
Aug-02-22	Initiated	Stifel	Buy	$38
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$45
Feb-10-22	Initiated	Needham	Buy	$45
Nov-17-21	Resumed	Guggenheim	Buy	$44
Jun-07-21	Upgrade	Citigroup	Neutral → Buy	$24 → $31
Apr-08-21	Initiated	William Blair	Outperform
Mar-16-21	Initiated	SVB Leerink	Outperform	$33
Jun-26-20	Initiated	H.C. Wainwright	Buy	$23
May-27-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16
Nov-20-19	Resumed	Guggenheim	Buy
Jun-28-19	Initiated	ROTH Capital	Buy	$20
Apr-12-19	Resumed	Guggenheim	Buy
Apr-03-19	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-27-19	Initiated	Berenberg	Buy	$35
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$28

Show Previous Ratings

Jun-03-24 02:30PM	Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
Jun-02-24 12:30PM	Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-29-24 09:30PM	Merus Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) +6.11%
08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 04:01PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire) -8.53%
07:00AM	Loading…
07:00AM	Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC (GlobeNewswire)
May-27-24 11:37AM	Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data (Zacks)
May-24-24 04:05PM	Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High (Investor's Business Daily) +36.12% -8.53%
03:41PM	Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? (Benzinga)
01:31PM	Merus Clears Wall Street's Bar With Cancer Data (Barrons.com)
12:00PM	Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know. (Barrons.com)
08:47AM	ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:01AM	ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations (FierceBiotech.com)
May-23-24 05:00PM	Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting (GlobeNewswire)
05:00PM	Loading…
05:00PM	Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-13-24 09:58AM	Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab (MT Newswires)
08:00AM	Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA (GlobeNewswire)
May-09-24 12:53AM	MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-08-24 04:15PM	Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update (GlobeNewswire)
May-06-24 04:05PM	Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC (GlobeNewswire)
Apr-26-24 07:58AM	Merus (MRUS) Moves 7.1% Higher: Will This Strength Last? (Zacks)
Apr-25-24 10:01AM	Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know (Zacks) +7.05%
Apr-24-24 10:00AM	Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-08-24 12:00PM	Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-24 10:11AM	Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab (FierceBiotech.com)
08:00AM	Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers (Business Wire)
06:15AM	Loading…
06:15AM	Gilead bets on trispecifics in latest cancer drug deal (BioPharma Dive)
Mar-05-24 04:30PM	Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression (GlobeNewswire)
Mar-04-24 08:00AM	Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 04:15PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update (GlobeNewswire)
Feb-20-24 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +5.89%
Jan-31-24 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-09-24 05:07AM	Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains? (Zacks)
Dec-28-23 09:55AM	Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High? (Zacks)
Dec-12-23 09:55AM	Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet (Zacks)
Dec-05-23 12:00PM	Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-04-23 12:15PM	Merus shares dip as interim lung cancer data reveal 3 patient deaths (FierceBiotech.com) -6.13%
Dec-02-23 08:40PM	Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023 (GlobeNewswire)
Nov-26-23 11:05AM	Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023 (GlobeNewswire)
Nov-23-23 09:55AM	Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High? (Zacks)
Nov-07-23 09:55AM	Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet (Zacks)
Nov-02-23 04:12PM	Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update (GlobeNewswire) +5.53% +13.40%
Nov-01-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 10:01AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-26-23 10:02AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-23 07:30AM	Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer (GlobeNewswire)
Oct-17-23 05:00AM	Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-23 07:58PM	Merus Announces Business Update Conference Call (GlobeNewswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Oct-06-23 09:32AM	Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023 (GlobeNewswire)
Sep-11-23 03:45AM	GSK (GSK) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-07-23 07:36PM	Merus NV (MRUS): A Deep Dive into Its Overvalued Status (GuruFocus.com)
Aug-31-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 09:44AM	XPeng upgraded, Napco downgraded: Wall Street's top analyst calls (The Fly)
Aug-09-23 09:53PM	Merus Announces Pricing of Public Offering of Common Shares (GlobeNewswire)
04:01PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Aug-07-23 07:15PM	Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.34%
04:26PM	Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update (GlobeNewswire)
Jul-28-23 08:00AM	Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023 (GlobeNewswire)
Jul-05-23 04:01PM	Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration (GlobeNewswire)
Jun-29-23 04:30PM	Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer (GlobeNewswire)
Jun-28-23 07:35AM	Institutional investors may overlook Merus N.V.'s (NASDAQ:MRUS) recent US$113m market cap drop as long-term gains remain positive (Simply Wall St.)
Jun-15-23 07:47AM	Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer (GlobeNewswire)
May-31-23 08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-21-23 03:28PM	7 Stocks That Wall Street Analysts Are Loving in May (InvestorPlace)
May-11-23 12:00PM	Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy (Zacks)
May-10-23 09:55AM	Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade (Zacks)
May-05-23 10:24AM	Some Confidence Is Lacking In Merus N.V.'s (NASDAQ:MRUS) P/S (Simply Wall St.) +10.58%
May-04-23 08:15PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update (GlobeNewswire)
May-02-23 10:01AM	Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-01-23 10:00AM	Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-23 10:15AM	Merus Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire) +10.07%
Apr-14-23 11:10AM	Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update (GlobeNewswire) +11.42%
11:10AM	Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
Apr-10-23 10:16AM	Merus' (NASDAQ:MRUS) investors will be pleased with their respectable 53% return over the last three years (Simply Wall St.)
Mar-14-23 04:30PM	Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023 (GlobeNewswire) +8.74%
04:30PM	Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
09:08AM	We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Feb-28-23 04:25PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update (GlobeNewswire)
Feb-23-23 11:37AM	Is a Surprise Coming for Merus (MRUS) This Earnings Season? (Zacks)
Feb-20-23 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-15-23 06:22AM	Is Merus N.V. (NASDAQ:MRUS) Trading At A 21% Discount? (Simply Wall St.)
Feb-10-23 03:44AM	Strength Seen in Merus N.V. (MRUS): Can Its 12.6% Jump Turn into More Strength? (Zacks)
Feb-01-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-19-23 11:06AM	14 Small-Cap Stocks with High Potential (Insider Monkey)
05:37AM	With 62% ownership, Merus N.V. (NASDAQ:MRUS) boasts of strong institutional backing (Simply Wall St.)
Jan-09-23 06:05AM	CORRECTING and REPLACING --Merus Provides 2023 Outlook (GlobeNewswire)
Jan-08-23 09:00AM	Merus Provides 2023 Outlook (GlobeNewswire)
Nov-09-22 08:00AM	Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference (GlobeNewswire)
07:09AM	Merus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-03-22 09:05AM	Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -25.02%
07:51AM	Merus Announces Financial Results for the Third Quarter and Provides Business Update (GlobeNewswire)
Oct-26-22 04:00AM	Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -9.81%

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silverman Peter B.	COO & GC	Jun 17 '24	Option Exercise	24.36	62,000	1,510,280	62,000	Jun 20 04:30 PM
Silverman Peter B.	COO & GC	Jun 17 '24	Sale	56.52	62,000	3,504,178	0	Jun 20 04:30 PM
Shuman Harry	VP Controller, PAO	Jun 12 '24	Sale	57.84	7,300	422,232	7,002	Jun 12 05:02 PM
Shuman Harry	VP Controller, PAO	Jun 10 '24	Sale	53.22	1,000	53,224	7,002	Jun 12 05:02 PM
Shuman Harry	VP Controller, PAO	Jun 04 '24	Sale	52.89	6,000	317,354	7,002	Jun 06 04:05 PM
Shuman Harry	VP Controller, PAO	Dec 19 '23	Sale	26.68	115	3,068	7,002	Dec 20 04:05 PM
Silverman Peter B.	COO & GC	Dec 15 '23	Sale	25.00	22,386	559,650	0	Dec 18 05:15 PM
Shuman Harry	VP Controller, PAO	Dec 08 '23	Sale	24.44	250	6,110	7,117	Dec 12 04:04 PM
Shuman Harry	VP Controller, PAO	Dec 01 '23	Option Exercise	0.00	2,500	0	7,942	Dec 04 04:05 PM
Shuman Harry	VP Controller, PAO	Dec 01 '23	Sale	24.58	575	14,133	7,367	Dec 04 04:05 PM

Open in Screener

BMEA

Biomea Fusion Inc

Jun 20 • 04:00PM ET

5.19

Dollar change +0.34
Percentage change 7.01	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

BMEA Biomea Fusion Inc daily Stock Chart

Held by: XBI VTI VXF IWM LABU IBB VHT IWO VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.56	Insider Own	22.63%	Shs Outstand	35.87M	Perf Week	12.10%
Market Cap	186.53M	Forward P/E	-	EPS next Y	-3.44	Insider Trans	0.15%	Shs Float	27.81M	Perf Month	-58.87%
Income	-127.27M	PEG	-	EPS next Q	-1.07	Inst Own	88.06%	Short Float	42.89%	Perf Quarter	-67.11%
Sales	0.00M	P/S	-	EPS this Y	-18.58%	Inst Trans	-10.86%	Short Ratio	9.39	Perf Half Y	-62.90%
Book/sh	3.77	P/B	1.38	EPS next Y	15.75%	ROA	-90.54%	Short Interest	11.93M	Perf Year	-85.77%
Cash/sh	4.03	P/C	1.29	EPS next 5Y	-	ROE	-116.52%	52W Range	3.61 - 37.09	Perf YTD	-64.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-204.86%	ROI	-88.85%	52W High	-86.01%	Beta	-0.56
Dividend TTM	-	Quick Ratio	5.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	43.77%	ATR (14)	1.05
Dividend Ex-Date	-	Current Ratio	5.84	EPS Y/Y TTM	-10.86%	Oper. Margin	0.00%	RSI (14)	32.50	Volatility	14.48% 10.58%
Employees	103	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.75	Target Price	24.43
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-10.84%	Payout	-	Rel Volume	1.28	Prev Close	4.85
Sales Surprise	-	EPS Surprise	-9.64%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.27M	Price	5.19
SMA20	-39.87%	SMA50	-50.64%	SMA200	-61.22%	Trades		Volume	1,620,365	Change	7.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-24	Downgrade	Truist	Buy → Hold
Jun-07-24	Downgrade	Barclays	Overweight → Equal Weight	$30 → $5
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral	$51 → $14
Feb-06-24	Initiated	Truist	Buy	$55
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$41
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight	$50
Mar-29-23	Reiterated	Oppenheimer	Outperform	$25 → $47
Mar-28-23	Reiterated	H.C. Wainwright	Buy	$37 → $44
Feb-24-23	Initiated	Citigroup	Buy	$20
Jun-02-22	Resumed	H.C. Wainwright	Buy	$16
Jan-12-22	Initiated	H.C. Wainwright	Buy	$13
Dec-17-21	Initiated	Oppenheimer	Outperform	$22
May-11-21	Initiated	Piper Sandler	Overweight	$27
May-11-21	Initiated	JP Morgan	Overweight	$26
May-11-21	Initiated	Jefferies	Buy	$26

Show Previous Ratings

Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire) -9.75%
Jun-11-24 11:34AM	Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays (Insider Monkey)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 04:23PM	Biomea Fusion Crashes 63% After FDA Puts Diabetes Treatment Studies On Hold (Investor's Business Daily) -63.27%
08:16AM	Why Is Biomea Fusion (BMEA) Stock Down 63% Today? (InvestorPlace)
07:22AM	Loading…
07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace)
04:25AM	FDA places full clinical hold on Biomea Fusions diabetes trials of BMF-219 (Clinical Trials Arena)
Jun-06-24 04:05PM	Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold (GlobeNewswire)
01:14PM	Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations (InvestorPlace)
Jun-03-24 04:05PM	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-24 09:12AM	Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes (GlobeNewswire)
May-02-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
11:02AM	Loading…
Apr-19-24 11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -16.34%
01:52PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023 (InvestorPlace)
09:02AM	Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219 (GlobeNewswire)
09:00AM	Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-06-24 03:04AM	Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function (GlobeNewswire) -9.82%
Mar-01-24 04:16PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-24 03:18PM	Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For (InvestorPlace)
Feb-18-24 03:41PM	3 Speculative Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 04:19PM	3 Long-Term Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Jan-09-24 11:02AM	Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-24 09:00AM	Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219 (GlobeNewswire) +8.36%
Jan-02-24 04:05PM	Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 09:27AM	Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why (Zacks) +15.29%
09:25AM	Loading…
Dec-11-23 09:25AM	Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting (GlobeNewswire) -30.31%
Dec-09-23 05:30PM	Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts (GlobeNewswire)
Dec-08-23 09:00AM	Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) +12.38%
Dec-07-23 09:15AM	Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -18.54%
Dec-05-23 08:30AM	Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Nov-27-23 08:30AM	Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024 (GlobeNewswire)
Nov-16-23 08:30AM	Biomea Fusion Abstract BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control' Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (GlobeNewswire)
Nov-08-23 04:05PM	Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -5.40%
Nov-02-23 09:05AM	Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023 (GlobeNewswire)
Nov-01-23 05:58AM	Biomea Fusion Inc (BMEA) Reports Q3 2023 Financial Results and Corporate Highlights (GuruFocus.com)
Oct-31-23 01:19AM	The Biomea Fusion Inc (BMEA) Company: A Short SWOT Analysis (GuruFocus.com) -7.59%
Oct-30-23 04:01PM	Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-18-23 10:13AM	Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up (Zacks)
Oct-17-23 08:30AM	Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103) (GlobeNewswire) +6.72%
Oct-05-23 09:40AM	Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Sep-28-23 08:30AM	Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study (GlobeNewswire)
Aug-31-23 08:30AM	Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer (GlobeNewswire)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Jul-31-23 04:01PM	Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) -6.70%
Jul-24-23 09:00AM	BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population (GlobeNewswire) -14.58%
Jul-13-23 10:08AM	We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-26-23 10:54AM	Biomea Fusion Stock Is Trading Higher Today - Here's Why (Benzinga) -20.39%
Jun-23-23 09:54PM	Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment (GlobeNewswire) -5.89%
Jun-20-23 04:30PM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023 (GlobeNewswire)
Jun-05-23 06:44AM	Daily Vickers Top Buyers & Sellers for 06/05/2023 (Argus Research)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
May-02-23 04:01PM	Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) -8.55% +5.76%
May-01-23 08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) +7.60%
Apr-27-23 07:02AM	Daily Vickers Top Buyers & Sellers for 04/27/2023 (Argus Research) -8.20%
Apr-23-23 09:28AM	individual investors who own 31% along with institutions invested in Biomea Fusion, Inc. (NASDAQ:BMEA) saw increase in their holdings value last week (Simply Wall St.)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia) +5.77%
08:30AM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June (GlobeNewswire)
Apr-13-23 04:30PM	Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting (GlobeNewswire) -7.20%
09:00AM	Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-07-23 07:44AM	Daily Vickers Top Buyers & Sellers for 04/07/2023 (Argus Research)
Mar-30-23 02:35PM	Why Biomea Fusion Stock Crushed It This Week (Motley Fool)
Mar-29-23 11:15PM	Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.34%
12:01PM	Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study (Zacks)
11:24AM	Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback (Zacks)
06:30AM	Biomea Fusion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-28-23 04:02PM	Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) +99.03%
08:00AM	Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28 (GlobeNewswire)
Mar-23-23 08:00AM	Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET (GlobeNewswire) +5.26%
Mar-21-23 09:40AM	Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-20-23 08:50AM	What Makes Biomea Fusion, Inc. (BMEA) a Good Fit for 'Trend Investing' (Zacks)
Mar-02-23 08:30AM	Biomea Fusion To Participate In Upcoming Investor Events (GlobeNewswire) -8.13%
Jan-20-23 11:30AM	Why Shares of Biomea Fusion Jumped This Week (Motley Fool) +7.44%
Jan-18-23 11:27AM	Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up (Zacks) +13.00%
Jan-17-23 08:00AM	Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors (GlobeNewswire) +11.69%
Jan-09-23 08:00AM	Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones (GlobeNewswire)
Jan-04-23 09:00AM	Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219 (GlobeNewswire) -9.67%
Dec-14-22 04:30PM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes (GlobeNewswire)
05:44AM	Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation (Simply Wall St.)
Dec-12-22 08:00AM	Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date (GlobeNewswire)
Nov-14-22 08:12AM	Institutional owners may take dramatic actions as Biomea Fusion, Inc.'s (NASDAQ:BMEA) recent 29% drop adds to one-year losses (Simply Wall St.)
Nov-11-22 08:30AM	Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -6.17%
Nov-07-22 04:27PM	Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) -10.17% -6.06%
Nov-03-22 09:19AM	Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219 (GlobeNewswire) +7.00%
Oct-27-22 08:00AM	Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial (GlobeNewswire)
Oct-14-22 09:00AM	BMF-219 Enters the Clinic for KRAS Solid Tumors (GlobeNewswire)
Sep-22-22 09:30AM	Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Sep-20-22 07:30AM	Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Sep-19-22 12:01PM	Despite Biomea Fusion, Inc.'s recent decline, insiders have made a around US$30k profit after buying earlier this year. (Simply Wall St.)
Aug-26-22 01:13PM	Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate (Benzinga)
08:30AM	Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting (GlobeNewswire)
Aug-01-22 04:05PM	Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Valle Franco	Chief Financial Officer	Jun 11 '24	Buy	4.43	12,509	55,361	42,500	Jun 12 04:30 PM

Open in Screener

DAWN

Day One Biopharmaceuticals Inc

Jun 20 • 04:00PM ET

13.12

Dollar change -0.27
Percentage change -2.02	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

DAWN Day One Biopharmaceuticals Inc daily Stock Chart

Held by: VTI XBI IWM VXF VB VBR IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	30.65%	Shs Outstand	87.23M	Perf Week	0.92%
Market Cap	1.15B	Forward P/E	-	EPS next Y	-2.15	Insider Trans	-1.04%	Shs Float	60.61M	Perf Month	-17.85%
Income	-208.94M	PEG	-	EPS next Q	-0.61	Inst Own	73.25%	Short Float	17.59%	Perf Quarter	-10.57%
Sales	0.00M	P/S	-	EPS this Y	-19.34%	Inst Trans	2.05%	Short Ratio	9.42	Perf Half Y	-7.41%
Book/sh	3.40	P/B	3.86	EPS next Y	24.12%	ROA	-64.27%	Short Interest	10.66M	Perf Year	-4.93%
Cash/sh	3.64	P/C	3.61	EPS next 5Y	-	ROE	-69.97%	52W Range	9.67 - 18.07	Perf YTD	-10.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-84.59%	ROI	-70.39%	52W High	-27.39%	Beta	-1.52
Dividend TTM	-	Quick Ratio	10.93	Sales past 5Y	0.00%	Gross Margin	-	52W Low	35.68%	ATR (14)	0.76
Dividend Ex-Date	-	Current Ratio	10.93	EPS Y/Y TTM	-9.93%	Oper. Margin	0.00%	RSI (14)	44.77	Volatility	5.95% 5.41%
Employees	155	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.55	Target Price	35.89
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-22.24%	Payout	-	Rel Volume	0.76	Prev Close	13.39
Sales Surprise	-	EPS Surprise	-8.58%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	1.13M	Price	13.12
SMA20	-0.95%	SMA50	-10.95%	SMA200	-5.51%	Trades		Volume	856,489	Change	-2.02%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

Jun-19-24 12:14PM	Day One targets the growing ADC market with MabCare acquisition (Pharmaceutical Technology)
10:29AM	Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up (Zacks)
Jun-18-24 08:30AM	Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers (GlobeNewswire) +11.31%
Jun-11-24 07:46AM	Exclusive: Day One Ventures closes its third fund at $150 million (Fortune)
May-30-24 08:30AM	Day One Announces Sale of Priority Review Voucher for $108 Million (GlobeNewswire)
09:25AM	Loading…
May-07-24 09:25AM	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating (MT Newswires)
May-06-24 10:53PM	DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Day One Reports First Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
03:22AM	Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing (MT Newswires)
May-04-24 02:31AM	Insider Sale at Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Apr-23-24 03:56PM	Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor (GlobeNewswire) +8.19%
03:54PM	Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment (MT Newswires)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Feb-26-24 04:30PM	Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress (GlobeNewswire) +11.05%
05:12PM	Loading…
Jan-31-24 05:12PM	Dwayne 'The Rock' Johnson's net worth: How the new TKO Board Member built his wealth from $7 (TheStreet)
Jan-17-24 08:00AM	Day One Announces Two New Appointments to Board of Directors (GlobeNewswire)
Dec-19-23 08:00AM	Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-27-23 10:00AM	Milei to Send Shock Package to Argentinas Congress on Day One (Bloomberg)
Nov-17-23 07:00AM	Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine (GlobeNewswire)
Nov-14-23 08:00AM	Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) +6.85%
Nov-06-23 05:16PM	Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:30PM	Day One Reports Third Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-30-23 07:27PM	Apples Journal app has arrived heres whats good and bad (TechCrunch) +17.01%
08:00AM	Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Oct-23-23 01:20PM	Hedge Fund and Insider Trading News: Bill Ackman, Nelson Peltz, Dan Loeb, Coltrane Asset Management, Day One Biopharmaceuticals, Inc. (DAWN), Central Securities Corp. (CET), and More (Insider Monkey)
Oct-20-23 10:20AM	Tesla Stock Had a Horrible Day. Heres What Comes Next. (Barrons.com)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-11-23 09:02PM	Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
08:00AM	Loading…
Aug-16-23 08:00AM	Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience (GlobeNewswire)
Aug-10-23 02:28PM	FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc (GuruFocus.com)
Aug-07-23 04:30PM	Day One Reports Second Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +5.66%
Jun-17-23 08:29AM	Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is favoured by institutional owners who hold 54% of the company (Simply Wall St.)
Jun-12-23 08:00AM	Day One Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-08-23 12:38PM	Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More (Zacks) -8.19%
07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
Jun-06-23 10:31PM	Day One Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-05-23 04:06PM	ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips (Investor's Business Daily)
12:30PM	Why Shares of Day One Pharmaceuticals Are Up Monday (Motley Fool)
Jun-04-23 12:45PM	Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
May-30-23 08:00AM	Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference (GlobeNewswire)
May-25-23 08:30PM	CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
05:00PM	Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-01-23 09:00AM	Day One Reports First Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +16.69%
Apr-30-23 09:57AM	We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-26-23 09:31AM	Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +8.18%
Apr-21-23 01:02PM	Leaked: Apple's Secret Health Play Could Push Out Smaller Apps (TheStreet.com) +5.38%
11:44AM	A Daily Journal For iPhone: Apple Weighs Day One-Like Health App For iPhone Users (Benzinga)
Apr-12-23 08:00AM	Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress (GlobeNewswire)
Mar-21-23 05:30AM	Credit Suisse sets up Hong Kong-style hawker stalls to treat investors to dim sum, pineapple buns at what could be its swan song conference (South China Morning Post)
Mar-06-23 04:30PM	Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress (GlobeNewswire) +7.46%
Feb-27-23 08:00AM	Day One to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-15-23 10:24AM	Billionaire Steve Cohen Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
Jan-09-23 08:57AM	Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses (Benzinga)
08:30AM	Day One to submit its glioma drug to the FDA this year (MarketWatch)
Jan-08-23 05:00PM	Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
Jan-03-23 01:04AM	Startups spring from ashes of Big Tech purge (Reuters) -5.90%
01:00AM	REFILE-FOCUS-Startups spring from ashes of Big Tech purge (Reuters)
Dec-20-22 08:00AM	Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 01:02PM	This Pediatric Cancer Company Makes It To Analyst's Conviction List (Benzinga) +7.51%
Dec-05-22 09:05AM	Is This the DAWN of a Rally for Day One Biopharmaceuticals? (TheStreet.com)
Nov-21-22 08:33AM	We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate (Simply Wall St.)
Nov-17-22 07:00AM	Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-11-22 07:00AM	Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting (GlobeNewswire)
Nov-07-22 04:30PM	Day One Reports Third Quarter 2022 Financial Results and Corporate Progress (GlobeNewswire)
Oct-17-22 08:00AM	Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101) (GlobeNewswire) -5.80%
Sep-12-22 08:30AM	Day One Appoints Garry Nicholson as Chairman of the Board of Directors (GlobeNewswire)
Aug-09-22 08:50AM	Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength (Zacks) -6.72%
Aug-04-22 04:30PM	Day One Reports Second Quarter 2022 Financial Results and Corporate Progress (GlobeNewswire) +6.90% +15.60%
Aug-02-22 08:00AM	Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire) +6.63%
Jul-29-22 11:33AM	What Percentage Of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Do Insiders Own? (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet (Zacks) -5.28%
Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform (Zacks)
Jun-23-22 07:26PM	Insiders Are Flashing a Strong Buy Signal for These 2 Stocks (TipRanks) +8.99%
Jun-21-22 08:30AM	Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-15-22 02:45PM	Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade (Investor's Business Daily)
05:41AM	Here's How Day One Biopharmaceuticals Stock Could Keep Climbing (Motley Fool)
Jun-14-22 08:00PM	Day One Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.82%
05:42PM	Day One Stock Is up 139% This Week. How Much Higher Can It Go? (TipRanks)
05:34PM	Peninsula biotech looks to raise $144M after childhood brain cancer data, big stock jump (American City Business Journals)
09:05AM	We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate (Simply Wall St.)
07:30AM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-13-22 04:17PM	Day One Biopharmaceuticals Scores Triple-Digit Gain With Bullish Numbers In Brain Cancer (Investor's Business Daily) +125.98%
07:56AM	Why Day One Biopharma Shares Are Surging Today (Benzinga)
Jun-12-22 05:00PM	Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma (GlobeNewswire)
May-23-22 08:30AM	Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors (GlobeNewswire)
May-12-22 04:30PM	Day One Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +10.07%
May-10-22 04:26PM	EXCLUSIVE: Play Ball! USA Pickleball And Day One Beverages Team Up, Launch Co-Branded CBD Recovery Cream (Benzinga) -7.96%
Apr-06-22 08:30AM	Day One to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-07-22 07:30AM	Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress (GlobeNewswire)
Feb-28-22 04:05PM	Day One to Participate in the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Jan-24-22 04:51AM	Is Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Trading At A 41% Discount? (Simply Wall St.)
Jan-05-22 08:00AM	Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-21 10:49AM	Judge Orders Live Nation To Stop Promoting Coachella Day One 22 Festival (TheStreet.com)
Nov-25-21 04:55AM	We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-22-21 07:00AM	Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors (GlobeNewswire) -5.37%
Nov-18-21 08:00AM	Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-08-21 04:50PM	Day One Reports Third Quarter 2021 Financial Results and Corporate Progress (GlobeNewswire) -5.70%

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Blackman Samuel C.	HEAD OF R&D	Jun 10 '24	Sale	12.62	30,000	378,588	1,141,081	Jun 12 04:29 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '24	Sale	16.08	7,873	126,588	654,728	May 17 06:27 PM
Dubow Adam	GENERAL COUNSEL	May 16 '24	Sale	16.08	3,253	52,304	21,731	May 17 06:11 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '24	Sale	16.08	2,675	43,011	224,868	May 17 06:15 PM
Blackman Samuel C.	HEAD OF R&D	May 16 '24	Sale	16.08	2,267	36,450	1,171,081	May 17 06:18 PM
Blackman Samuel C.	HEAD OF R&D	May 10 '24	Sale	16.37	10,000	163,743	1,164,662	May 14 06:13 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 03 '24	Sale	17.85	9,154	163,417	642,602	May 03 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 03 '24	Sale	17.85	8,078	144,214	217,293	May 03 06:44 PM
York Charles N II	COO, CFO AND SECRETARY	May 02 '24	Sale	17.90	200	3,579	225,371	May 03 06:44 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 02 '24	Sale	17.94	6	108	651,756	May 03 06:48 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	17.88	70,051	1,252,183	651,762	May 03 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 01 '24	Sale	17.89	52,183	933,397	225,571	May 03 06:44 PM
Blackman Samuel C.	HEAD OF R&D	Apr 18 '24	Sale	16.02	10,000	160,163	1,174,662	Apr 22 06:36 PM
Blackman Samuel C.	HEAD OF R&D	Mar 25 '24	Sale	16.01	10,000	160,055	1,184,662	Mar 26 06:09 PM
Blackman Samuel C.	HEAD OF R&D	Mar 11 '24	Sale	15.24	30,000	457,314	1,194,662	Mar 13 04:24 PM
Blackman Samuel C.	HEAD OF R&D	Feb 27 '24	Sale	16.11	20,000	322,166	1,224,662	Feb 28 07:55 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.25	7,615	116,114	721,813	Feb 20 06:14 PM
Dubow Adam	GENERAL COUNSEL	Feb 16 '24	Sale	15.25	3,242	49,434	16,585	Feb 20 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	Feb 16 '24	Sale	15.25	2,666	40,651	277,754	Feb 20 06:36 PM
Blackman Samuel C.	HEAD OF RESEARCH AND DEVELOPME	Feb 16 '24	Sale	15.25	2,258	34,430	1,244,662	Feb 20 06:26 PM
Dubow Adam	General Counsel	Nov 16 '23	Sale	11.69	5,313	62,109	11,428	Nov 17 06:30 PM
Bender Jeremy	Chief Executive Officer	Nov 16 '23	Sale	11.69	3,107	36,321	709,429	Nov 17 06:20 PM
York Charles N II	COO, CFO and Secretary	Nov 16 '23	Sale	11.69	956	11,176	270,170	Nov 17 06:33 PM
Blackman Samuel C.	Head of Research and Developme	Nov 16 '23	Sale	11.69	709	8,288	1,238,234	Nov 17 06:26 PM
AI Day1 LLC	10% Owner	Oct 20 '23	Buy	9.97	111,387	1,110,907	12,929,322	Oct 20 04:02 PM
AI Day1 LLC	10% Owner	Oct 19 '23	Buy	10.06	384,400	3,867,372	12,817,935	Oct 20 04:02 PM
AI Day1 LLC	10% Owner	Oct 18 '23	Buy	10.21	979,667	10,000,049	12,433,535	Oct 20 04:02 PM
Bender Jeremy	Chief Executive Officer	Aug 17 '23	Sale	13.86	2,996	41,525	704,224	Aug 17 06:16 PM
York Charles N II	COO, CFO and Secretary	Aug 17 '23	Sale	13.86	922	12,779	267,501	Aug 17 07:02 PM
Blackman Samuel C.	Head of Research and Developme	Aug 17 '23	Sale	13.86	668	9,258	1,236,319	Aug 17 06:21 PM

Open in Screener

INSM

Insmed Inc

Jun 20 • 04:00PM ET

64.71

Dollar change -0.87
Percentage change -1.33	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VB XBI VBK VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-5.24	Insider Own	2.75%	Shs Outstand	161.23M	Perf Week	4.96%
Market Cap	10.43B	Forward P/E	-	EPS next Y	-4.01	Insider Trans	-15.14%	Shs Float	156.78M	Perf Month	153.37%
Income	-746.89M	PEG	-	EPS next Q	-1.17	Inst Own	92.71%	Short Float	6.92%	Perf Quarter	143.45%
Sales	315.49M	P/S	33.07	EPS this Y	14.58%	Inst Trans	-4.11%	Short Ratio	3.46	Perf Half Y	125.39%
Book/sh	-3.13	P/B	-	EPS next Y	12.08%	ROA	-55.80%	Short Interest	10.86M	Perf Year	220.19%
Cash/sh	3.69	P/C	17.51	EPS next 5Y	-	ROE	-1453.41%	52W Range	19.68 - 65.98	Perf YTD	108.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-4.82%	ROI	-111.25%	52W High	-1.92%	Beta	1.16
Dividend TTM	-	Quick Ratio	1.61	Sales past 5Y	275.45%	Gross Margin	76.46%	52W Low	228.81%	ATR (14)	3.28
Dividend Ex-Date	-	Current Ratio	1.80	EPS Y/Y TTM	-22.78%	Oper. Margin	-215.75%	RSI (14)	83.35	Volatility	5.04% 6.41%
Employees	912	Debt/Eq	-	Sales Y/Y TTM	22.54%	Profit Margin	-236.74%	Recom	1.06	Target Price	68.62
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	9.69%	Payout	-	Rel Volume	0.75	Prev Close	65.58
Sales Surprise	-2.90%	EPS Surprise	14.36%	Sales Q/Q	15.77%	Earnings	May 09 BMO	Avg Volume	3.14M	Price	64.71
SMA20	25.41%	SMA50	79.16%	SMA200	121.95%	Trades		Volume	2,365,562	Change	-1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-24	Initiated	Truist	Buy	$48
Feb-15-24	Initiated	Wolfe Research	Outperform	$42
Dec-08-23	Initiated	Wells Fargo	Overweight	$55
Nov-20-23	Resumed	JP Morgan	Overweight	$36
Jul-26-23	Initiated	Guggenheim	Buy	$50
Dec-09-22	Initiated	Mizuho	Buy	$28
Dec-07-22	Initiated	Barclays	Overweight	$37
Nov-18-22	Initiated	BofA Securities	Buy	$39
Apr-27-22	Initiated	Goldman	Buy	$56
Dec-06-21	Initiated	JP Morgan	Overweight	$45
Oct-19-21	Resumed	Morgan Stanley	Overweight	$56 → $52
Oct-19-21	Resumed	Monness Crespi & Hardt	Buy	$52
Oct-08-21	Initiated	Cantor Fitzgerald	Overweight	$60
Apr-26-21	Resumed	Credit Suisse	Outperform	$60
Dec-17-20	Initiated	Berenberg	Buy	$48
Oct-12-20	Resumed	Stifel	Buy	$44
Sep-03-19	Initiated	Goldman	Buy	$30
Apr-09-19	Reiterated	H.C. Wainwright	Buy	$43 → $52
Feb-15-19	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$40
Jan-17-19	Upgrade	Goldman	Neutral → Buy

Show Previous Ratings

Jun-14-24 07:50AM	Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing (BioPharma Dive)
Jun-07-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-05-24 08:00AM	Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-30-24 04:05PM	Insmed to Host Commercial Webinar on June 4, 2024 (PR Newswire) +6.41%
08:00AM	Loading…
08:00AM	Insmed Announces Pricing of $650 Million Public Offering of Common Stock (PR Newswire)
May-29-24 12:20PM	Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data (Zacks) +11.42%
06:05AM	Insmed stocks soar as Phase III lung disease drug exceeds expectations (Clinical Trials Arena)
May-28-24 07:25PM	Insmed CEO on lung disease treatment and path forward (CNBC TV) +118.45%
06:21PM	Insmed Announces Proposed $500 Million Public Offering of Common Stock (PR Newswire)
04:49PM	Insmed Stock More Than Doubled in Value Tuesday Here's Why (Investopedia)
04:02PM	The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease. (Investor's Business Daily)
03:41PM	Insmed stock blasts off over lung condition study results (Yahoo Finance Video)
02:24PM	Chart of the Day: Insmed (CNBC TV)
02:21PM	Insmed Stock Surges on Trial Win for Lung-Condition Drug. We Hit the Mark, CEO Says. (Barrons.com)
01:16PM	Loading…
01:16PM	Stocks to Watch Tuesday: GameStop, Apple, Nvidia, Hess (The Wall Street Journal)
12:20PM	Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 (Associated Press Finance)
10:58AM	Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday? (Benzinga)
10:01AM	Insmed's shares double as lung disease med powers past expectations in phase 3 (FierceBiotech.com)
09:36AM	Insmed Shares Rocket After Drug Eases Lung Disease Symptoms (Bloomberg)
09:04AM	Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market (Investor's Business Daily)
09:00AM	Insmed Stock More Than Doubles on Trial Win for Lung-Condition Drug (Barrons.com)
08:40AM	Why Is Insmed (INSM) Stock Up 134% Today? (InvestorPlace)
07:27AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
06:30AM	Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis (PR Newswire)
03:25AM	Nvidia, Apple and GameStop rise premarket; Tesla, DraftKings fall (Investing.com)
May-27-24 06:47PM	Is Insmed Incorporated (NASDAQ:INSM) a Buy According to Hedge Funds? (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
04:00PM	Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis (PR Newswire)
May-20-24 05:58PM	Insmed Lung Infections Treatment Study Shows Improvement (MT Newswires)
04:28PM	Loading…
04:28PM	Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session (PR Newswire)
May-17-24 07:00PM	Insider Sale: Chief Medical Officer Martina Flammer Sells Shares of Insmed Inc (INSM) (GuruFocus.com)
May-15-24 08:36AM	Goldman Sachs Adjusts Price Target on Insmed to $49 From $40, Maintains Buy Rating (MT Newswires)
May-10-24 03:33PM	Insmed Incorporated (NASDAQ:INSM) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:48PM	Insmed Inc (INSM) Reports Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows Amidst Clinical ... (GuruFocus.com)
11:14AM	Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates (Zacks)
10:36AM	Mizuho Securities Raises Price Target on Insmed to $36 From $35, Keeps Buy Rating (MT Newswires)
May-09-24 11:55AM	INSM Stock Earnings: Insmed Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:00AM	Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:45AM	Insmed's Q1 Net Loss Narrows as Revenue Advances (MT Newswires)
07:16AM	Insmed: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-08-24 10:19AM	Should You Buy Insmed (INSM) Ahead of Earnings? (Zacks)
May-07-24 08:00AM	Insmed To Present at the BofA Securities Health Care Conference 2024 (PR Newswire)
May-03-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-02-24 10:01AM	Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-25-24 08:00AM	Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 (PR Newswire)
Apr-10-24 12:40PM	What Makes Insmed (INSM) a Lucrative Investment? (Insider Monkey)
Apr-05-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Mar-27-24 04:05PM	Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference (PR Newswire)
Mar-05-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-29-24 08:00AM	Insmed To Present at Three March Conferences (PR Newswire)
Feb-28-24 04:05PM	Actress Jane Seymour and Insmed Raise Awareness of 'Unseenism' and Empower People to Speak Up When It Comes to Their Health (PR Newswire)
Feb-23-24 12:23PM	Insmed Incorporated (NASDAQ:INSM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:35PM	Q4 2023 Insmed Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:28AM	Insmed: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-15-24 10:00AM	Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-13-24 01:35PM	5 Best Strong Buy Stocks To Invest In (Insider Monkey)
Feb-08-24 08:00AM	Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024 (PR Newswire)
Feb-02-24 04:05PM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-13-24 05:13PM	Insmed Inc Chief Medical Officer Martina Flammer Sells 4,667 Shares (GuruFocus.com)
Jan-12-24 05:02PM	Insmed Inc Chief People Strategy Officer Sells Company Shares (GuruFocus.com)
Jan-06-24 02:32AM	Insmed Inc Chief Commercial Officer John Wise Sells 21,238 Shares (GuruFocus.com)
Jan-05-24 08:00AM	Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-04-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-02-24 08:00AM	Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-23 11:01AM	Insmed Inc Chief Medical Officer Martina Flammer Sells 28,310 Shares (GuruFocus.com)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-29-23 08:00AM	Insmed To Present at the Nasdaq 49th Investor Conference (PR Newswire) +5.46%
Nov-14-23 03:56PM	Vanguard Group Inc Adds Shares in Insmed Inc (GuruFocus.com)
Nov-08-23 08:00AM	Insmed To Present at Two November Conferences (PR Newswire)
Nov-03-23 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-02-23 08:00AM	Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe (PR Newswire)
Oct-30-23 01:53AM	The Insmed Inc (INSM) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-28-23 03:19PM	Insmed Incorporated (NASDAQ:INSM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 04:05PM	Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List (PR Newswire) -6.54%
09:32AM	Insmed Inc (INSM) Reports Q3 2023 Earnings and Provides Business Update (GuruFocus.com)
08:50AM	Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Insmed: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Oct-24-23 10:00AM	Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
08:00AM	Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI (PR Newswire)
Oct-19-23 10:02AM	Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-12-23 08:00AM	Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023 (PR Newswire)
Oct-06-23 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-26-23 08:00AM	Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference (PR Newswire)
Sep-08-23 02:09PM	Why Shares of Insmed Are Soaring This Week (Motley Fool)
08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-06-23 08:00AM	Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
07:46AM	Insmed (INSM) Up on Positive Data From MAC Lung Disease Study (Zacks)
Sep-05-23 07:32PM	Insmed (INSM): A Hidden Gem or Just Modestly Undervalued? (GuruFocus.com) +16.48%
04:10PM	Insmed Is Making A Comeback Why Shares Hit A Year High In Record Volume (Investor's Business Daily)
12:18PM	Insmed Inc's Meteoric Rise: Unpacking the 34% Surge in Just 3 Months (GuruFocus.com)
11:52AM	Why Insmed Stock Is Soaring Today (Motley Fool)
07:00AM	INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC (PR Newswire)
Aug-04-23 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flammer Martina M.D.	Chief Medical Officer	Jun 10 '24	Option Exercise	23.75	21,195	503,381	127,329	Jun 12 04:21 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 10 '24	Sale	60.00	21,195	1,271,700	106,134	Jun 12 04:21 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 03 '24	Option Exercise	21.09	55,000	1,159,812	163,760	Jun 05 04:23 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 03 '24	Sale	55.33	55,000	3,043,150	108,760	Jun 05 04:23 PM
Flammer Martina M.D.	Chief Medical Officer	May 30 '24	Option Exercise	23.75	21,195	503,381	127,329	May 30 05:43 PM
Flammer Martina M.D.	Chief Medical Officer	May 30 '24	Sale	55.00	21,195	1,165,725	106,134	May 30 05:43 PM
Bonstein Sara	Chief Financial Officer	May 29 '24	Option Exercise	26.57	220,564	5,861,212	358,769	May 30 05:41 PM
Bonstein Sara	Chief Financial Officer	May 29 '24	Sale	50.00	220,564	11,028,200	117,481	May 30 05:41 PM
Flammer Martina M.D.	Chief Medical Officer	May 28 '24	Option Exercise	23.66	103,806	2,456,050	209,940	May 30 05:43 PM
Smith Michael Alexander	Chief Legal Officer	May 28 '24	Option Exercise	14.27	38,971	556,079	133,550	May 30 05:45 PM
Bonstein Sara	Chief Financial Officer	May 28 '24	Option Exercise	26.26	20,724	544,247	326,613	May 30 05:41 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 28 '24	Option Exercise	12.58	27,500	345,950	136,260	May 30 05:44 PM
Wise John Drayton	Chief Commercial Officer	May 28 '24	Option Exercise	12.58	6,250	78,625	127,907	May 30 05:46 PM
Flammer Martina M.D.	Chief Medical Officer	May 28 '24	Sale	49.62	103,806	5,150,854	106,134	May 30 05:43 PM
Smith Michael Alexander	Chief Legal Officer	May 28 '24	Sale	49.53	44,722	2,215,081	88,828	May 30 05:45 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 28 '24	Sale	49.53	27,500	1,362,075	108,760	May 30 05:44 PM
Bonstein Sara	Chief Financial Officer	May 28 '24	Sale	50.01	20,724	1,036,407	338,045	May 30 05:41 PM
Wise John Drayton	Chief Commercial Officer	May 28 '24	Sale	49.79	7,852	390,918	121,657	May 30 05:46 PM
Adsett Roger	Chief Operating Officer	May 17 '24	Sale	25.09	5,945	149,160	149,275	May 17 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	May 17 '24	Sale	25.09	4,642	116,468	106,134	May 17 04:16 PM
Lewis William	Chair and CEO	May 14 '24	Sale	25.52	22,198	566,493	384,125	May 15 04:34 PM
Bonstein Sara	Chief Financial Officer	May 14 '24	Sale	25.32	11,088	280,748	117,481	May 15 04:32 PM
Flammer Martina M.D.	Chief Medical Officer	May 14 '24	Sale	25.47	10,640	271,001	110,776	May 15 04:33 PM
Adsett Roger	Chief Operating Officer	May 14 '24	Sale	25.50	7,857	200,354	155,220	May 15 04:31 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 14 '24	Sale	25.53	6,508	166,149	108,760	May 15 04:36 PM
Wise John Drayton	Chief Commercial Officer	May 14 '24	Sale	25.47	5,088	129,591	123,259	May 15 04:39 PM
Smith Michael Alexander	Chief Legal Officer	May 14 '24	Sale	25.40	5,093	129,362	94,579	May 15 04:37 PM
Lewis William	Chair and CEO	Feb 28 '24	Option Exercise	12.58	50,000	629,000	50,500	Feb 29 04:08 PM
Adsett Roger	Chief Operating Officer	Jan 12 '24	Sale	28.63	5,251	150,336	148,559	Jan 12 04:05 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 12 '24	Sale	28.63	4,667	133,616	106,898	Jan 12 04:06 PM
Adsett Roger	Chief Operating Officer	Jan 10 '24	Sale	28.90	3,536	102,190	153,810	Jan 11 04:06 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 10 '24	Sale	28.90	1,245	35,980	111,565	Jan 11 04:08 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 09 '24	Option Exercise	20.49	503	10,306	105,652	Jan 11 04:10 PM
Lewis William	Chair and CEO	Jan 09 '24	Sale	28.72	9,887	283,955	363,651	Jan 10 04:15 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 09 '24	Sale	29.01	4,715	136,782	112,810	Jan 11 04:08 PM
Bonstein Sara	Chief Financial Officer	Jan 09 '24	Sale	29.18	4,497	131,222	114,051	Jan 11 04:07 PM
Adsett Roger	Chief Operating Officer	Jan 09 '24	Sale	29.25	3,837	112,232	157,346	Jan 11 04:06 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 09 '24	Sale	28.85	3,668	105,831	101,984	Jan 11 04:10 PM
Smith Michael Alexander	General Counsel, Senior VP	Jan 09 '24	Sale	28.76	2,373	68,247	86,364	Jan 11 04:11 PM
Wise John Drayton	Chief Commercial Officer	Jan 09 '24	Sale	28.78	1,861	53,560	113,829	Jan 11 04:13 PM
Lewis William	Chair and CEO	Jan 08 '24	Option Exercise	20.49	45,120	924,509	398,489	Jan 10 04:15 PM
Lewis William	Chair and CEO	Jan 08 '24	Sale	29.45	45,120	1,328,973	373,538	Jan 10 04:15 PM
Lewis William	Chair and CEO	Jan 05 '24	Sale	29.26	6,979	204,195	373,538	Jan 05 05:29 PM
Adsett Roger	Chief Operating Officer	Jan 05 '24	Sale	29.21	3,042	88,864	161,183	Jan 05 05:26 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 05 '24	Sale	29.28	1,457	42,661	105,149	Jan 05 05:32 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 05 '24	Sale	29.20	1,386	40,478	117,525	Jan 05 05:29 PM
Wise John Drayton	Chief Commercial Officer	Jan 05 '24	Sale	29.32	1,167	34,216	115,690	Jan 05 05:33 PM
Smith Michael Alexander	General Counsel, Senior VP	Jan 05 '24	Sale	29.30	627	18,374	88,737	Jan 05 05:32 PM
Wise John Drayton	Chief Commercial Officer	Jan 03 '24	Option Exercise	19.11	20,071	383,557	124,055	Jan 05 05:33 PM
Wise John Drayton	Chief Commercial Officer	Jan 03 '24	Sale	29.19	20,071	585,872	103,984	Jan 05 05:33 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Dec 28 '23	Option Exercise	20.49	22,288	456,681	116,837	Jan 02 04:04 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Dec 28 '23	Sale	32.00	22,288	713,216	94,549	Jan 02 04:04 PM
Flammer Martina M.D.	Chief Medical Officer	Dec 22 '23	Option Exercise	23.66	28,310	669,815	134,348	Dec 22 04:04 PM
Flammer Martina M.D.	Chief Medical Officer	Dec 22 '23	Sale	30.00	28,310	849,300	106,038	Dec 22 04:04 PM
Bonstein Sara	Chief Financial Officer	Dec 22 '23	Sale	30.00	13,199	395,970	105,241	Dec 22 04:03 PM
Lewis William	Chair and CEO	Oct 27 '23	Option Exercise	14.24	112,500	1,602,000	289,274	Oct 31 04:04 PM
Lewis William	Chair and CEO	Oct 27 '23	Sale	24.08	112,000	2,696,449	0	Oct 31 04:04 PM
Smith Michael Alexander	General Counsel, Senior VP	Jul 11 '23	Sale	20.18	740	14,933	77,142	Jul 13 04:01 PM

Open in Screener

GERN

Geron Corp.

Jun 20 • 04:00PM ET

4.46

Dollar change -0.03
Percentage change -0.67	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: XBI VTI IWM VXF IWO IBB PJP SCHA LABU VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	15.62%	Shs Outstand	544.91M	Perf Week	-12.38%
Market Cap	2.65B	Forward P/E	-	EPS next Y	-0.15	Insider Trans	-1.43%	Shs Float	500.46M	Perf Month	19.57%
Income	-201.40M	PEG	-	EPS next Q	-0.10	Inst Own	58.60%	Short Float	10.99%	Perf Quarter	29.65%
Sales	0.52M	P/S	5087.23	EPS this Y	-10.16%	Inst Trans	-1.65%	Short Ratio	4.58	Perf Half Y	98.22%
Book/sh	0.58	P/B	7.65	EPS next Y	56.60%	ROA	-44.41%	Short Interest	55.01M	Perf Year	48.67%
Cash/sh	0.75	P/C	5.96	EPS next 5Y	5.00%	ROE	-60.04%	52W Range	1.64 - 5.34	Perf YTD	111.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.08%	ROI	-56.11%	52W High	-16.48%	Beta	0.49
Dividend TTM	-	Quick Ratio	3.67	Sales past 5Y	46.26%	Gross Margin	-	52W Low	171.95%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	3.67	EPS Y/Y TTM	-0.29%	Oper. Margin	-40381.92%	RSI (14)	56.66	Volatility	5.46% 6.34%
Employees	141	Debt/Eq	0.25	Sales Y/Y TTM	5.26%	Profit Margin	-38730.00%	Recom	1.38	Target Price	6.94
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-31.14%	Payout	-	Rel Volume	0.67	Prev Close	4.49
Sales Surprise	955.56%	EPS Surprise	5.96%	Sales Q/Q	1347.62%	Earnings	May 02 BMO	Avg Volume	12.01M	Price	4.46
SMA20	8.19%	SMA50	14.42%	SMA200	71.92%	Trades		Volume	7,999,685	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Downgrade	Robert W. Baird	Outperform → Neutral	$4.50
Apr-29-24	Initiated	TD Cowen	Buy	$10
Mar-15-24	Reiterated	Needham	Buy	$4 → $5
Sep-12-23	Upgrade	Goldman	Neutral → Buy	$4
Mar-28-23	Initiated	Goldman	Neutral	$3
Oct-28-22	Initiated	Wedbush	Outperform	$5
Jul-28-22	Resumed	B. Riley Securities	Buy	$4
Nov-02-21	Initiated	Robert W. Baird	Outperform	$4
Feb-18-21	Resumed	B. Riley Securities	Buy	$4
Aug-03-20	Initiated	Stifel	Buy	$3
Nov-19-19	Resumed	B. Riley FBR	Buy	$4
Sep-03-19	Initiated	H.C. Wainwright	Buy	$4
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight	$4
Apr-09-19	Upgrade	Needham	Hold → Buy	$3
Jan-31-19	Upgrade	B. Riley FBR	Neutral → Buy	$1.50 → $3.25
Oct-02-18	Downgrade	B. Riley FBR	Buy → Neutral	$5.75 → $1.50
Jul-05-18	Initiated	B. Riley FBR, Inc.	Buy	$5.75
Sep-13-16	Reiterated	FBR Capital	Outperform	$6 → $5
Sep-13-16	Reiterated	FBR & Co.	Outperform	$6 → $5
Dec-07-15	Reiterated	Piper Jaffray	Overweight	$5 → $10

Show Previous Ratings

Jun-20-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-24 10:00AM	3 Penny Stocks to Buy if You Want to Spend Less and Earn More (InvestorPlace)
Jun-10-24 11:58AM	Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up (Zacks) +9.80%
Jun-07-24 03:51PM	Geron stock pops on FDA approval for blood cancer drug (Yahoo Finance Video) +17.99%
03:24PM	Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers (Investopedia)
01:10PM	Loading…
01:10PM	Stocks shrug off hot jobs report, GameStop sinks, Nvidia stock split on tap: Yahoo Finance (Yahoo Finance Video)
11:21AM	FDA Reverses Juul Ban. What Comes Next? (InvestorPlace)
11:02AM	Why Is Geron (GERN) Stock Up 18% Today? (InvestorPlace)
07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-06-24 09:58PM	Geron Announces FDA Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia (Business Wire)
May-16-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-24 10:34AM	Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 12:55PM	GERN Stock Earnings: Geron Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:20AM	Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:46AM	Loading…
06:46AM	The Top 3 Penny Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 04:30PM	Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 (Business Wire) +6.46%
Apr-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-03-24 04:30PM	Geron to Participate at Upcoming Investor Conferences in April (Business Wire)
Mar-19-24 09:07AM	Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Mar-15-24 03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video) +92.00%
01:29PM	Stocks to Watch Friday: Adobe, Ulta, Fisker (The Wall Street Journal)
10:47AM	Why Is Geron (GERN) Stock Up 94% Today? (InvestorPlace)
08:57AM	Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up (Zacks)
05:00AM	Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat (FierceBiotech.com)
Mar-14-24 03:54PM	Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS (Business Wire)
Mar-13-24 10:48AM	Implied Volatility Surging for Geron (GERN) Stock Options (Zacks) -6.91%
Mar-12-24 12:28PM	Geron faces uphill battle at FDA meeting, as agency questions benefit-risk profile of imetelstat (FierceBiotech.com) -12.15%
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Feb-28-24 07:05AM	Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -5.57%
04:30PM	Loading…
Feb-22-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-14-24 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (Business Wire)
Jan-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-24 08:30AM	Geron to Participate in the B. Riley Securities Virtual Oncology Conference (Business Wire)
Dec-21-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-23 04:15PM	Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS (Business Wire) -6.76%
Dec-06-23 08:00AM	Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis (Business Wire)
Dec-04-23 05:00AM	Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS (Business Wire) -6.53%
Nov-28-23 08:00AM	Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors (Business Wire)
Nov-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.35%
Nov-07-23 04:30PM	Geron to Participate at Upcoming Investor Conferences in November (Business Wire)
Nov-02-23 09:00AM	Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS (Business Wire) -7.77%
08:00AM	Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 04:30PM	Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-12-23 03:26PM	Buy These 2 Beaten-Down Stocks, Goldman Sachs Says, Forecasting up to 130% Upside (TipRanks) -5.41%
Sep-29-23 08:00AM	Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Sep-11-23 04:30PM	Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer (Business Wire)
Sep-07-23 08:00AM	Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting (Business Wire)
Sep-05-23 04:30PM	Geron to Participate in the Baird 2023 Global Healthcare Conference (Business Wire)
Aug-22-23 08:00AM	Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS (Business Wire) -13.31%
Aug-21-23 08:00AM	Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Aug-17-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.56%
Aug-03-23 04:05PM	Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results (Business Wire) -6.33%
Jul-27-23 04:30PM	Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire) +5.65%
Jul-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-23 08:30AM	Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS (Business Wire)
Jun-22-23 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-20-23 09:00AM	Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat (Business Wire) +5.00%
Jun-13-23 09:00AM	Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS (Business Wire)
Jun-12-23 08:00AM	Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients (Business Wire) -5.83%
Jun-07-23 04:30PM	Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-06-23 04:30PM	Geron to Host Virtual Investor Event on June 14, 2023 (Business Wire)
Jun-02-23 03:30PM	Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients (Business Wire) +6.51%
May-25-23 05:02PM	Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
May-18-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-11-23 10:02AM	Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
08:00AM	Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-04-23 04:30PM	Geron to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-26-23 10:05AM	Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial (Business Wire)
Apr-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.37%
Apr-12-23 04:40PM	Geron to Present at Upcoming Investor Conferences in April (Business Wire)
Mar-16-23 05:45PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:05PM	Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones (Business Wire)
Mar-09-23 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023 (Business Wire)
Feb-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-23 01:19PM	10 Hot Healthcare Stocks To Buy Now (Insider Monkey)
Jan-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-23 07:30AM	Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (Business Wire)
Jan-11-23 07:30AM	Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S. (Business Wire)
Jan-10-23 04:30PM	Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million (Business Wire) +11.86%
Jan-05-23 11:15PM	Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -22.26%
Jan-04-23 04:19PM	Geron Corporation Announces Proposed Public Offering of Common Stock (Business Wire) +32.92%
06:55AM	Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS (Business Wire)
Jan-03-23 04:30PM	Geron Announces Conference Call for Top-Line Results from IMerge Phase 3 (Business Wire)
Dec-22-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-22 11:10AM	10 Penny Stocks That Can Grow Big in 2023 (Insider Monkey)
Dec-12-22 08:00AM	Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients (Business Wire)
Dec-08-22 11:30AM	Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-22 11:30AM	Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report? (Zacks)
Dec-04-22 05:19PM	TipRanks Perfect 10 List: 2 Stocks Under $5 That Are Worth Looking Into (TipRanks)
Nov-17-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-22 04:30PM	Geron to Participate in Stifel 2022 Healthcare Conference (Business Wire)
Nov-04-22 12:00AM	Geron (GERN) Q3 2022 Earnings Call Transcript (Motley Fool)
Nov-03-22 09:25AM	Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.58%
09:01AM	Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS (Business Wire)
08:00AM	Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones (Business Wire)
Oct-27-22 04:30PM	Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022 (Business Wire)
Oct-25-22 06:15AM	Investing in Geron (NASDAQ:GERN) a year ago would have delivered you a 55% gain (Simply Wall St.)
Oct-24-22 09:40AM	Is Geron (GERN) Outperforming Other Medical Stocks This Year? (Zacks)

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapur Anil	EVP, Corp Strategy & CCO	Jun 10 '24	Option Exercise	1.06	421,875	447,188	421,875	Jun 12 04:05 PM
Feller Faye	EVP, Chief Medical Officer	Jun 10 '24	Option Exercise	1.19	287,900	341,693	155,400	Jun 12 04:05 PM
Kapur Anil	EVP, Corp Strategy & CCO	Jun 10 '24	Sale	4.64	421,875	1,959,609	0	Jun 12 04:05 PM
Feller Faye	EVP, Chief Medical Officer	Jun 10 '24	Sale	4.63	287,900	1,334,129	0	Jun 12 04:05 PM
SCARLETT JOHN A	Chairman, President and CEO	Jun 04 '24	Option Exercise	2.54	600,000	1,524,000	600,000	Jun 05 04:05 PM
SCARLETT JOHN A	Chairman, President and CEO	Jun 04 '24	Sale	4.00	600,000	2,400,000	600,000	Jun 05 04:05 PM
LAWLIS V BRYAN	Director	May 15 '24	Option Exercise	1.94	35,000	67,900	35,000	May 17 04:05 PM
LAWLIS V BRYAN	Director	May 15 '24	Sale	3.75	35,000	131,250	0	May 17 04:05 PM
O'Farrell Elizabeth G.	Director	Aug 24 '23	Buy	2.28	6,607	15,064	7,407	Aug 24 08:52 PM
O'Farrell Elizabeth G.	Director	Aug 24 '23	Buy	2.28	6,579	15,000	26,220	Aug 24 08:52 PM

IRWD Ironwood Pharmaceuticals Inc daily Stock Chart

Held by: IJR XBI CALF VTI VB IWM VXF VBK SPSM PBE

Index	RUT	P/E	-	EPS (ttm)	-6.79	Insider Own	2.50%	Shs Outstand	156.35M	Perf Week	-12.54%
Market Cap	887.00M	Forward P/E	7.52	EPS next Y	0.74	Insider Trans	-10.98%	Shs Float	154.99M	Perf Month	-13.08%
Income	-1052.12M	PEG	-	EPS next Q	0.16	Inst Own	109.99%	Short Float	14.62%	Perf Quarter	-38.75%
Sales	413.55M	P/S	2.14	EPS this Y	106.82%	Inst Trans	-3.21%	Short Ratio	8.34	Perf Half Y	-49.91%
Book/sh	-2.08	P/B	-	EPS next Y	68.56%	ROA	-132.00%	Short Interest	22.66M	Perf Year	-48.19%
Cash/sh	0.76	P/C	7.30	EPS next 5Y	-	ROE	-559.14%	52W Range	5.55 - 15.70	Perf YTD	-51.22%
Dividend Est.	-	P/FCF	6.00	EPS past 5Y	-28.37%	ROI	-670.29%	52W High	-64.46%	Beta	0.50
Dividend TTM	-	Quick Ratio	0.82	Sales past 5Y	5.56%	Gross Margin	99.56%	52W Low	0.63%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	0.82	EPS Y/Y TTM	-671.31%	Oper. Margin	30.18%	RSI (14)	32.59	Volatility	5.14% 5.75%
Employees	267	Debt/Eq	-	Sales Y/Y TTM	-0.86%	Profit Margin	-254.41%	Recom	1.17	Target Price	15.83
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-110.53%	Payout	-	Rel Volume	0.85	Prev Close	5.70
Sales Surprise	-29.19%	EPS Surprise	-114.85%	Sales Q/Q	-28.05%	Earnings	May 09 BMO	Avg Volume	2.72M	Price	5.58
SMA20	-10.33%	SMA50	-21.05%	SMA200	-42.63%	Trades		Volume	2,320,700	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral
Jul-23-18	Initiated	H.C. Wainwright	Sell	$12.50
May-09-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-06-17	Downgrade	Mizuho	Buy → Neutral	$16
Jul-21-17	Downgrade	JP Morgan	Overweight → Neutral
May-03-17	Initiated	Wells Fargo	Outperform

Show Previous Ratings

Jun-12-24 07:00PM	Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD) (GuruFocus.com) -6.27%
Jun-10-24 07:00PM	Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ... (GuruFocus.com)
May-30-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 06:00AM	Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire) +5.61%
May-10-24 01:58PM	Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements (GuruFocus.com)
12:59PM	Loading…
12:59PM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:16AM	Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
May-09-24 03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires) -17.00%
01:55PM	Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading (MT Newswires)
01:39PM	Sector Update: Health Care (MT Newswires)
11:57AM	IRWD Stock Earnings: Ironwood Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:54AM	Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut (MT Newswires)
07:11AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports First Quarter 2024 Results (Business Wire)
May-06-24 04:01PM	Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference (Business Wire)
02:33PM	Loading…
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
10:01AM	Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline (Zacks)
May-01-24 07:30AM	Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week 2024 (Business Wire) +6.06%
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
Apr-25-24 04:01PM	Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call (Business Wire)
Apr-21-24 10:39AM	5 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Mar-28-24 07:30AM	Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) (Business Wire)
Mar-05-24 01:05PM	Its Time! 3 Failing Biotech Stocks to Sell Right Now (InvestorPlace)
Feb-29-24 04:19PM	Ironwood Pharmaceuticals Ran Up 38% Over Three Months And Just Lost It All (Investor's Business Daily) -37.63%
08:37AM	Why Is Ironwood Pharmaceuticals (IRWD) Stock Down 27% Today? (InvestorPlace)
06:26AM	UPDATE 1-Ironwood's bowel disease treatment meets main goal in late-stage trial (Reuters)
06:08AM	Ironwood says bowel disease treatment meets main goal in late-stage trial (Reuters)
06:00AM	Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire)
Feb-23-24 07:30AM	Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference (Business Wire)
Feb-16-24 10:15AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:36AM	Loading…
09:36AM	Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally (Zacks)
Feb-15-24 10:45PM	Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4 (Zacks)
07:26AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance (Business Wire)
Feb-05-24 08:50AM	Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-01-24 04:01PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call (Business Wire)
Jan-23-24 09:55AM	Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet (Zacks)
Jan-08-24 07:00PM	Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation (Business Wire)
06:00AM	Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance (Business Wire)
Jan-03-24 04:01PM	Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 04:01PM	Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio (Business Wire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-21-23 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-10-23 02:45PM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript (Insider Monkey)
11:09AM	Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises (Zacks)
Nov-09-23 10:25PM	Q3 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:39AM	Ironwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year Guidance (GuruFocus.com)
07:46AM	Top 11 Extreme Value Stocks To Buy (Insider Monkey)
07:22AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2023 Results (Business Wire)
Oct-26-23 04:01PM	Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call (Business Wire)
Oct-23-23 07:30AM	Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting (Business Wire)
Oct-17-23 12:02PM	Decoding Ownership and Performance: Ironwood Pharmaceuticals Inc(IRWD) (GuruFocus.com)
Oct-16-23 06:00AM	Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week (Business Wire)
Oct-05-23 07:30AM	Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old (Business Wire)
Oct-03-23 11:43AM	Ironwood Pharmaceuticals (IRWD): A Hidden Gem or a Potential Risk? An In-Depth Look at Its Valuation (GuruFocus.com)
Oct-01-23 07:15AM	Here's How to Lock in a Trade on a Promising Biopharma Name (TheStreet.com)
Sep-26-23 11:48AM	Unveiling Ironwood Pharmaceuticals (IRWD)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-20-23 07:36AM	Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Sep-19-23 12:08PM	Ironwood Pharmaceuticals Inc (IRWD): A Deep Dive into Its Performance Potential (GuruFocus.com) +7.55%
11:39AM	Ironwood Pharmaceuticals (IRWD): A Comprehensive Analysis of Its Market Value (GuruFocus.com)
Sep-12-23 08:32AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-07-23 11:30AM	Why Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report? (Zacks)
Aug-12-23 08:50AM	Is There An Opportunity With Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) 49% Undervaluation? (Simply Wall St.)
Aug-09-23 09:24AM	Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises (Zacks) -6.79%
Aug-08-23 11:12PM	Q2 2023 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.16%
11:05AM	Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates (Zacks)
09:56AM	Ironwood: Q2 Earnings Snapshot (AP Finance)
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance (Business Wire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-25-23 04:01PM	Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call (Business Wire)
Jun-29-23 08:30AM	Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares (Business Wire)
Jun-21-23 08:00PM	IRWD: Lowering target price to $11.00 (Argus Research)
Jun-16-23 07:00AM	Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio (Business Wire)
Jun-13-23 09:18AM	Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion (Zacks)
Jun-12-23 04:05PM	Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old (Business Wire)
09:54AM	Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround (Motley Fool)
May-25-23 10:32AM	Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates (Zacks)
May-23-23 12:07PM	Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6% (Zacks)
May-22-23 05:43PM	Why Ironwood Pharmaceuticals Stock Bumped Higher Today (Motley Fool)
04:08PM	VectivBio Stock Catapults 39% After Ironwood Agrees To Buy It For $1 Billion (Investor's Business Daily)
01:11PM	Ironwood spends $1B to acquire Swiss biotech (American City Business Journals)
12:02PM	Why Shares of VectivBio Holding Are Up Today (Motley Fool)
08:40AM	Ironwood Pharmaceuticals to Buy VectivBio in $1 Billion Deal. The Sector Is Hot for M&A. (Barrons.com)
07:24AM	UPDATE 1-Ironwood Pharma to acquire VectivBio for $1.15 bln (Reuters)
07:22AM	Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy (Reuters)
06:57AM	Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases (Business Wire)
May-09-23 04:01PM	Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference (Business Wire)
May-08-23 07:30AM	Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023 (Business Wire)
May-05-23 09:31AM	Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up (Zacks)
May-04-23 08:55AM	Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:00AM	Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance (Business Wire)
Apr-26-23 08:00PM	IRWD: What does Argus have to say about IRWD? (Argus Research)
Apr-24-23 07:30AM	Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old (Business Wire)
Apr-20-23 04:01PM	Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call (Business Wire)
Mar-22-23 02:53PM	Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
Mar-14-23 02:56AM	Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength? (Zacks)
Mar-02-23 07:09AM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Could Be 40% Below Their Intrinsic Value Estimate (Simply Wall St.)
Feb-27-23 04:01PM	Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McHugh Julie	Director	Jun 10 '24	Sale	6.29	22,766	143,198	139,528	Jun 12 04:05 PM
Moukheibir Catherine	Director	Jun 07 '24	Sale	6.61	35,574	235,144	48,633	Jun 10 04:58 PM
Moukheibir Catherine	Director	Jun 06 '24	Sale	6.36	44,426	282,549	84,207	Jun 10 04:58 PM
MCCOURT Thomas A	Chief Executive Officer	May 20 '24	Sale	6.45	67,618	436,136	1,150,330	May 22 04:05 PM
Davis Andrew	SVP, Chief Business Officer	May 20 '24	Sale	6.45	22,725	146,576	288,031	May 22 04:05 PM
John Minardo	Chief Legal Officer	May 20 '24	Sale	6.45	17,404	112,256	294,571	May 22 04:05 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	May 20 '24	Sale	6.45	16,128	104,026	413,719	May 22 04:05 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	Mar 08 '24	Option Exercise	0.00	34,936	0	429,847	Mar 12 04:05 PM
John Minardo	Chief Legal Officer	Mar 08 '24	Option Exercise	0.00	32,752	0	311,975	Mar 12 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Mar 08 '24	Option Exercise	0.00	120,298	0	1,217,948	Mar 12 04:05 PM
Davis Andrew	SVP, Chief Business Officer	Mar 08 '24	Option Exercise	0.00	37,120	0	310,756	Mar 12 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Mar 08 '24	Option Exercise	0.00	37,120	0	338,853	Mar 12 04:05 PM
Duane Jon R	Director	Mar 06 '24	Buy	8.70	6,920	60,204	121,028	Mar 08 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Mar 04 '24	Buy	9.38	10,684	100,216	301,733	Mar 06 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 12 '24	Sale	15.24	177,164	2,699,979	832,774	Feb 14 08:35 PM
John Minardo	Chief Legal Officer	Feb 12 '24	Sale	15.24	47,380	722,071	224,796	Feb 14 09:01 PM
Shetzline Michael	CMO,SVP,Head-Res&Drug	Feb 12 '24	Sale	15.24	38,618	588,538	340,484	Feb 14 08:53 PM
Davis Andrew	SVP, Chief Business Officer	Feb 12 '24	Sale	15.24	9,846	150,053	208,324	Feb 14 08:42 PM
Silver Ronald	Principal Accounting Officer	Feb 12 '24	Sale	15.24	7,908	120,518	134,264	Feb 14 08:50 PM
Kessler Marla L	Director	Dec 14 '23	Sale	11.19	9,926	111,072	96,572	Dec 18 04:09 PM
Davis Andrew	SVP, Chief Business Officer	Nov 20 '23	Sale	9.69	3,287	31,851	217,374	Nov 22 04:05 PM
Emany Sravan Kumar	SVP, Chief Financial Officer	Sep 15 '23	Buy	8.32	36,072	300,119	188,730	Sep 18 05:07 PM
John Minardo	Chief Legal Officer	Aug 14 '23	Sale	10.04	7,045	70,732	192,195	Aug 16 04:20 PM
Silver Ronald	Principal Accounting Officer	Aug 14 '23	Sale	10.04	1,976	19,839	134,172	Aug 16 04:21 PM

Open in Screener

JAZZ

Jazz Pharmaceuticals plc

Jun 20 • 04:00PM ET

107.36

Dollar change -5.32
Percentage change -4.72	%

Healthcare • Biotechnology • Ireland • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

JAZZ Jazz Pharmaceuticals plc daily Stock Chart

Held by: IJH VTI VB COWZ VBR VXF MDY SPMD IJJ VHT

Index	-	P/E	23.35	EPS (ttm)	4.60	Insider Own	3.32%	Shs Outstand	62.26M	Perf Week	-3.30%
Market Cap	6.77B	Forward P/E	5.16	EPS next Y	20.81	Insider Trans	0.15%	Shs Float	60.97M	Perf Month	-1.16%
Income	330.79M	PEG	5.43	EPS next Q	4.80	Inst Own	95.99%	Short Float	5.60%	Perf Quarter	-13.97%
Sales	3.84B	P/S	1.76	EPS this Y	1.40%	Inst Trans	-0.76%	Short Ratio	4.62	Perf Half Y	-11.38%
Book/sh	58.65	P/B	1.83	EPS next Y	12.22%	ROA	2.96%	Short Interest	3.41M	Perf Year	-16.16%
Cash/sh	28.84	P/C	3.72	EPS next 5Y	4.30%	ROE	9.41%	52W Range	103.01 - 146.70	Perf YTD	-12.72%
Dividend Est.	-	P/FCF	6.69	EPS past 5Y	-3.53%	ROI	3.73%	52W High	-26.82%	Beta	0.59
Dividend TTM	-	Quick Ratio	1.78	Sales past 5Y	15.52%	Gross Margin	73.55%	52W Low	4.22%	ATR (14)	3.17
Dividend Ex-Date	-	Current Ratio	2.15	EPS Y/Y TTM	310.66%	Oper. Margin	15.83%	RSI (14)	45.18	Volatility	2.45% 2.59%
Employees	2800	Debt/Eq	1.57	Sales Y/Y TTM	2.81%	Profit Margin	8.61%	Recom	1.53	Target Price	178.72
Option/Short	Yes / Yes	LT Debt/Eq	1.40	EPS Q/Q	-124.85%	Payout	0.00%	Rel Volume	2.11	Prev Close	112.68
Sales Surprise	-5.45%	EPS Surprise	-35.87%	Sales Q/Q	1.03%	Earnings	May 01 AMC	Avg Volume	738.52K	Price	107.36
SMA20	-0.64%	SMA50	-1.90%	SMA200	-11.23%	Trades		Volume	1,561,852	Change	-4.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight	$150 → $175
Jan-29-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-16-20	Initiated	UBS	Buy	$174
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$185 → $195
Oct-09-20	Reiterated	H.C. Wainwright	Buy	$175 → $185

Show Previous Ratings

Jun-20-24 04:08PM	Jazz Dives But Key Rival Praxis Surges On Essential Tremor Drug Failure (Investor's Business Daily)
10:08AM	Jazz Dives And Takes Praxis With It On Essential Tremor Drug Failure (Investor's Business Daily)
07:45AM	Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor (PR Newswire)
Jun-14-24 06:13AM	3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition (InvestorPlace)
Jun-11-24 10:42AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
02:27PM	Loading…
Jun-03-24 02:27PM	7 Overlooked Stocks Offering Long-Term Stability From the Shadows (InvestorPlace)
Jun-01-24 08:05AM	Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 (PR Newswire)
May-31-24 11:31AM	Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report? (Zacks)
May-30-24 07:30AM	Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 (PR Newswire)
May-29-24 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences (PR Newswire)
07:45AM	Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer (PR Newswire)
May-28-24 07:00AM	NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer (GlobeNewswire)
May-26-24 10:09AM	3 Cannabis Stocks to Buy Now: May 2024 (InvestorPlace)
May-23-24 06:00AM	7 Blue-Chip Stocks to Buy Now: May 2024 (InvestorPlace)
May-22-24 07:01PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
04:00PM	Loading…
04:00PM	Jazz Pharmaceuticals Announces Collaboration With Life Science Cares To Improve the Wellbeing of Under Resourced Communities Through Employee Volunteerism (ACCESSWIRE)
May-17-24 02:32PM	3 Cheap Blue-Chip Stocks to Buy Now: May 2024 (InvestorPlace)
May-09-24 09:19AM	7 Cannabis Stocks to Buy for a Smoking-Hot 2024 (InvestorPlace)
May-08-24 04:30PM	The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy? (InvestorPlace)
01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 05:37PM	Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing (MT Newswires)
10:57AM	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-06-24 09:29AM	Jazz (JAZZ) International Revenue Performance Explored (Zacks)
May-03-24 12:41PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
11:49AM	UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating (MT Newswires)
May-02-24 11:26AM	Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates (Zacks)
03:53AM	Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook (MT Newswires)
May-01-24 08:56PM	JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00PM	Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:24PM	Jazz: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Loading…
04:10PM	Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference (PR Newswire)
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance (PR Newswire)
Apr-30-24 09:50AM	Jazz Pharmaceuticals Focuses on Taking Actions To Positively Impact the Planet This Earth Month (ACCESSWIRE)
Apr-24-24 04:05PM	Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 (PR Newswire)
10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
05:21AM	3 No-Brainer Stocks to Buy With $300 Right Now (Motley Fool)
Apr-23-24 11:15AM	Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community (ACCESSWIRE)
Apr-17-24 04:15PM	Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 (PR Newswire)
Apr-10-24 07:45AM	Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting (PR Newswire)
Apr-04-24 09:15AM	Following the Money Trail: Where are Hedge Funds Investing? (Insider Monkey)
Apr-02-24 07:30AM	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer (PR Newswire)
Mar-29-24 11:30AM	Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report? (Zacks)
Mar-28-24 10:15AM	Cancer and the Combination Approach (ACCESSWIRE)
Mar-20-24 10:15AM	Jazz Pharmaceuticals Celebrates International Womens Day (ACCESSWIRE)
Mar-18-24 03:28PM	20 States with the Cheapest Weed in America (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 12:00PM	Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month (ACCESSWIRE)
10:00AM	Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth (GuruFocus.com)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 05:34PM	11 Stocks Insiders are Buying Now (Insider Monkey)
04:15PM	Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 (PR Newswire)
Mar-09-24 11:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Mar-07-24 01:51PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
01:10PM	Q4 2023 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
10:08AM	10 Mid-Cap Stocks with Insider Purchases (Insider Monkey)
Feb-29-24 10:45AM	Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates (Zacks) -8.33%
10:35AM	Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 06:30PM	Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings (Zacks)
05:20PM	Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates (Zacks)
04:33PM	Jazz Pharmaceuticals PLC (JAZZ) Reports Strong Revenue Growth and Robust Pipeline Progress (GuruFocus.com)
04:29PM	Jazz: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance (PR Newswire)
Feb-27-24 10:15PM	Q4 2023 Ligand Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:45AM	Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors (PR Newswire)
Feb-24-24 05:06AM	4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Feb-23-24 09:15AM	Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-21-24 08:50AM	Jazz Pharmaceuticals Names Eli Lillys Philip Johnson as Next CFO (The Wall Street Journal)
07:45AM	Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer (PR Newswire)
Feb-20-24 05:00PM	3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-14-24 04:15PM	Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024 (PR Newswire)
Feb-13-24 10:15AM	Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals (ACCESSWIRE)
Feb-09-24 09:15AM	How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1 (ACCESSWIRE)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
02:00AM	Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program (PR Newswire)
Feb-03-24 05:06AM	4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Jan-31-24 03:33PM	25 Most Cannabis Consuming-Countries in the World (Insider Monkey)
12:03PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024 (InvestorPlace)
Jan-22-24 05:16AM	2 Incredible Growth Stocks That Are Screaming Buys for 2024 (Motley Fool)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-13-24 05:06AM	4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Dec-28-23 10:06PM	7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World (InvestorPlace)
Dec-22-23 12:07PM	Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals (Zacks)
11:16AM	Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study (Benzinga)
Dec-21-23 04:17PM	UPDATE 1-Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial (Reuters)
04:09PM	Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial (Reuters)
04:05PM	Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder (PR Newswire)
Dec-20-23 04:15PM	Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
05:21AM	3 No-Brainer Stocks to Buy With $500 Right Now (Motley Fool)
Dec-08-23 01:20PM	Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer (PR Newswire)
11:30AM	Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report? (Zacks)
09:15AM	Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities (ACCESSWIRE)
Dec-01-23 09:02AM	Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting (PR Newswire)
Nov-30-23 07:45AM	Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings (PR Newswire)
Nov-29-23 11:15AM	Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly (ACCESSWIRE)
Nov-28-23 08:48AM	3 Top-Rated Biotech Stocks That Analysts Are Loving Now (InvestorPlace)
Nov-27-23 09:49AM	5 Best Upside Stocks To Buy Now (Insider Monkey)
Nov-15-23 05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
Nov-14-23 12:50PM	12 Best Value Stocks To Buy Heading Into 2024 (Picked By Seth Klarman) (Insider Monkey)
02:00AM	Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders (Business Wire)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carr Patricia	SVP, Chief Accounting Officer	Jun 07 '24	Sale	108.83	163	17,738	6,596	Jun 11 08:15 PM
Patil Neena M	EVP & Chief Legal Officer	May 03 '24	Sale	109.65	5,000	548,250	36,629	May 07 05:31 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 07 '24	Sale	116.98	1,768	206,821	6,596	Mar 08 06:07 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 06 '24	Sale	119.64	1,936	231,628	8,364	Mar 08 06:07 PM
Johnson Philip L	EVP & Chief Financial Officer	Mar 01 '24	Buy	119.65	12,000	1,435,800	27,932	Mar 05 07:28 PM
Cook Jennifer E.	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888	Dec 06 04:31 PM
Smith Mark Douglas	Director	Dec 04 '23	Sale	119.27	417	49,736	6,888	Dec 06 04:39 PM
Patil Neena M	EVP & Chief Legal Officer	Sep 01 '23	Sale	144.25	1,500	216,375	29,186	Sep 06 05:09 PM
Carr Patricia	SVP, Chief Accounting Officer	Aug 29 '23	Sale	143.47	142	20,373	5,986	Aug 31 06:44 PM
Patil Neena M	EVP & Chief Legal Officer	Aug 15 '23	Sale	139.59	750	104,695	30,686	Aug 17 05:21 PM
McSharry Heather Ann	Director	Aug 14 '23	Sale	138.16	1,344	185,685	16,778	Aug 15 05:52 PM
ENRIGHT PATRICK G	Director	Aug 14 '23	Sale	138.16	1,241	171,455	20,946	Aug 15 05:45 PM
Sohn Catherine A.	Director	Aug 14 '23	Sale	138.16	1,241	171,455	14,868	Aug 15 06:02 PM
O'Keefe Kenneth W	Director	Aug 14 '23	Sale	138.16	1,241	171,455	24,723	Aug 15 07:49 PM
Winningham Rick E	Director	Aug 14 '23	Sale	138.16	1,241	171,455	10,444	Aug 15 06:08 PM
Gray Peter	Director	Aug 14 '23	Sale	138.16	1,241	171,455	16,068	Aug 15 05:47 PM
RIEDEL NORBERT G	Director	Aug 14 '23	Sale	138.16	1,241	171,454	13,705	Aug 15 05:58 PM
Cook Jennifer E.	Director	Aug 14 '23	Sale	138.16	1,241	171,454	7,305	Aug 15 05:44 PM
ORiordan Anne	Director	Aug 14 '23	Sale	138.16	1,241	171,454	12,551	Aug 15 07:51 PM
Smith Mark Douglas	Director	Aug 14 '23	Sale	138.16	1,241	171,454	7,305	Aug 15 06:00 PM
Carr Patricia	SVP, Chief Accounting Officer	Aug 14 '23	Sale	138.16	158	21,829	6,128	Aug 15 05:43 PM

Open in Screener

YMAB

Y-Mabs Therapeutics Inc

Jun 20 • 04:00PM ET

11.75

Dollar change -0.16
Percentage change -1.34	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

YMAB Y-Mabs Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWN IWO SCHA VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.50	Insider Own	17.33%	Shs Outstand	43.67M	Perf Week	-2.25%
Market Cap	515.59M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-2.19%	Shs Float	36.28M	Perf Month	-0.59%
Income	-21.67M	PEG	-	EPS next Q	-0.11	Inst Own	55.66%	Short Float	9.39%	Perf Quarter	-24.14%
Sales	84.50M	P/S	6.10	EPS this Y	11.10%	Inst Trans	-3.46%	Short Ratio	9.40	Perf Half Y	88.30%
Book/sh	2.26	P/B	5.19	EPS next Y	30.85%	ROA	-16.62%	Short Interest	3.41M	Perf Year	57.72%
Cash/sh	1.73	P/C	6.81	EPS next 5Y	-	ROE	-20.93%	52W Range	4.60 - 20.90	Perf YTD	72.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.06%	ROI	-21.78%	52W High	-43.78%	Beta	0.65
Dividend TTM	-	Quick Ratio	5.67	Sales past 5Y	37.03%	Gross Margin	86.41%	52W Low	155.43%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	6.15	EPS Y/Y TTM	70.66%	Oper. Margin	-29.68%	RSI (14)	38.96	Volatility	3.09% 5.03%
Employees	100	Debt/Eq	0.01	Sales Y/Y TTM	12.62%	Profit Margin	-25.64%	Recom	1.86	Target Price	21.14
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-3.49%	Payout	-	Rel Volume	0.62	Prev Close	11.91
Sales Surprise	-12.50%	EPS Surprise	-10.29%	Sales Q/Q	-1.58%	Earnings	May 07 AMC	Avg Volume	362.45K	Price	11.75
SMA20	-3.44%	SMA50	-13.24%	SMA200	14.30%	Trades		Volume	225,472	Change	-1.34%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-23	Upgrade	Wedbush	Neutral → Outperform	$5 → $13
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$4
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral	$23 → $5
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral	$6
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight	$16 → $7
Jul-06-22	Resumed	Canaccord Genuity	Buy	$35
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$27
Feb-03-22	Resumed	Guggenheim	Buy	$22
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$25
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral	$57 → $30
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight	$57 → $52
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral	$56
Nov-09-20	Reiterated	H.C. Wainwright	Buy	$52 → $65
May-05-20	Initiated	Barclays	Overweight	$44
May-01-20	Initiated	Janney	Buy

Show Previous Ratings

Jun-07-24 07:05AM	Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 07:05AM	Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer (GlobeNewswire) +5.91%
Jun-01-24 08:15AM	Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting (GlobeNewswire)
08:05AM	Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting (GlobeNewswire)
May-09-24 11:58AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.44%
03:04AM	Loading…
03:04AM	Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 09:57PM	Q1 2024 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM	YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:12PM	Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates (GuruFocus.com)
05:55PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
Apr-26-24 07:05AM	Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Y-mAbs to Present at 2024 ASCO Annual Meeting (GlobeNewswire)
Mar-28-24 09:55AM	Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet (Zacks)
Mar-20-24 07:37AM	YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
09:05AM	Loading…
Mar-14-24 09:05AM	Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (GlobeNewswire) -5.30%
Mar-12-24 09:55AM	Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High? (Zacks)
Mar-05-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice (Zacks)
Mar-04-24 08:45AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.28%
07:30AM	Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors (GlobeNewswire)
Mar-01-24 09:42PM	Q4 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:37PM	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-22-24 10:00AM	Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 07:30AM	Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 (GlobeNewswire)
Feb-13-24 04:10AM	Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Jan-02-24 04:05PM	Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 04:05PM	Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-12-23 01:05AM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (GuruFocus.com)
03:04AM	Loading…
Dec-03-23 03:04AM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (GuruFocus.com)
Nov-30-23 11:04PM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB) (GuruFocus.com)
Nov-15-23 01:14PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
01:33AM	Q3 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 05:31PM	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational Streamlining (GuruFocus.com) +9.84%
05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-08-23 12:00PM	All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy (Zacks)
Oct-31-23 07:05AM	Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023 (GlobeNewswire)
Oct-18-23 04:05PM	Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director (GlobeNewswire)
Oct-17-23 04:05PM	Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA (GlobeNewswire)
Oct-16-23 04:05PM	Y-mAbs Announces Publication in Cancers (GlobeNewswire)
Sep-21-23 04:05PM	Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology (GlobeNewswire)
Sep-06-23 04:05PM	Y-mAbs to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-23-23 09:55AM	Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet (Zacks)
Aug-13-23 06:25AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 05:15PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.48% -9.90%
04:05PM	Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Aug-02-23 04:05PM	Y-mAbs to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-01-23 04:05PM	Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023 (GlobeNewswire)
Jul-26-23 12:35PM	Institutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year losses (Simply Wall St.)
Jun-02-23 03:15PM	Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week (Simply Wall St.) +5.01%
May-26-23 09:00AM	Y-mAbs Announces Presentation of Naxitamab Data at ASCO (GlobeNewswire)
09:00AM	Y-mAbs Announces Presentation of GD2-SADA Study at ASCO (GlobeNewswire)
May-23-23 09:00AM	Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil (GlobeNewswire)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research) +8.39%
May-13-23 08:18AM	New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) (Simply Wall St.)
May-10-23 06:14AM	Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.) +7.26%
02:52AM	Q1 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +36.34%
04:01PM	Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance (GlobeNewswire)
May-01-23 10:01AM	Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-28-23 09:00AM	Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 (GlobeNewswire) +5.46%
Apr-18-23 09:00AM	Y-mAbs Announces Presentation of Naxitamab data at AACR (GlobeNewswire)
Apr-17-23 10:57AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Surges 104% Yet Its Low P/S Is No Reason For Excitement (Simply Wall St.)
Apr-05-23 07:44PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade (Zacks)
09:00AM	Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA (GlobeNewswire)
Apr-04-23 05:12AM	Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Mar-30-23 05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates (Zacks) +52.28%
04:01PM	Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
02:42PM	Dow futures down 0.1%, Virgin Orbit tanks 41.2% after-hours (Investing.com)
Mar-21-23 04:01PM	Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023 (GlobeNewswire) -5.35%
Mar-15-23 10:22AM	Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Feb-20-23 10:00AM	Analysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-16-23 10:01AM	Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) -8.37%
07:57AM	With 51% ownership, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) boasts of strong institutional backing (Simply Wall St.)
Feb-02-23 09:00AM	Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab (GlobeNewswire)
Jan-05-23 10:34AM	Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce (Benzinga) -7.83%
Jan-04-23 04:01PM	Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA (GlobeNewswire) +6.24%
Jan-03-23 09:00AM	Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 09:00AM	Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe (GlobeNewswire)
Dec-16-22 04:01PM	The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe (GlobeNewswire) -8.80%
Dec-14-22 09:00AM	Y-mAbs Announces Pipeline Update (GlobeNewswire)
Dec-08-22 09:00AM	Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China (GlobeNewswire)
Dec-07-22 09:19AM	Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) are in the red if they invested three years ago (Simply Wall St.) +7.42%
Dec-06-22 09:00AM	Y-mAbs to Host Annual Research and Development Day in New York (GlobeNewswire)
Dec-01-22 05:34PM	Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application (GlobeNewswire) -5.78%
Nov-07-22 05:15PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +16.12%
04:01PM	Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-02-22 04:01PM	Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022 (GlobeNewswire) -8.54%
Oct-31-22 03:01PM	Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful (Benzinga) -59.57%
08:52AM	Y-mAbs Therapeutics shares fall 42% following last week's FDA advisory committee vote (MarketWatch)
05:34AM	FDA's AdComm Gives Thumbs Down To Pediatric Cancer Therapy (Benzinga)
Oct-28-22 03:33PM	Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab (GlobeNewswire)
Oct-06-22 09:34AM	Here's Why We're Watching Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation (Simply Wall St.)
Oct-03-22 09:00AM	Y-mAbs Announces Pivotal Data for Omburtamab (GlobeNewswire) -7.91%
Sep-29-22 02:53AM	YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-22 09:00AM	Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil (GlobeNewswire)
Sep-09-22 08:35AM	With 55% ownership of the shares, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is heavily dominated by institutional owners (Simply Wall St.)

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gad Thomas	CHIEF BUSINESS OFFICER	Jun 11 '24	Sale	12.00	35,000	420,000	162,681	Jun 11 07:53 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Jun 10 '24	Sale	12.03	35,000	421,050	197,681	Jun 11 07:53 PM
Ber Gerard	Director	Jun 10 '24	Sale	12.00	722	8,664	1,608	Jun 11 07:54 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 31 '24	Option Exercise	2.00	31,371	62,742	242,248	May 31 09:36 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 31 '24	Sale	12.07	31,371	378,648	210,877	May 31 09:36 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 30 '24	Option Exercise	2.00	28,629	57,258	239,506	May 31 09:36 PM
Kruse Bo	EVP, CFO, SECRY & TREAS.	May 30 '24	Sale	12.03	28,629	344,407	210,877	May 31 09:36 PM
Gad Thomas	CHIEF BUSINESS OFFICER	May 23 '24	Sale	13.00	7,351	95,563	232,681	May 23 06:54 PM
Gad Thomas	CHIEF BUSINESS OFFICER	May 21 '24	Sale	12.00	25,000	300,000	240,032	May 23 06:54 PM
Gad Thomas	CHIEF BUSINESS OFFICER	Mar 05 '24	Sale	16.44	3,900	64,116	158,700	Mar 07 05:01 PM
Rajah Vignesh	SVP & CHIEF MEDICAL OFFICER	Mar 05 '24	Sale	16.53	1,711	28,283	33,889	Mar 07 05:02 PM
Smith Susan Laura	SVP & CHIEF COMMERCIAL OFFICER	Mar 05 '24	Sale	16.55	1,682	27,837	33,918	Mar 07 04:59 PM
Gad Thomas	Chief Business Officer	Dec 21 '23	Option Exercise	2.00	50,000	100,000	140,500	Dec 26 04:15 PM
Gad Thomas	Chief Business Officer	Dec 15 '23	Sale	6.61	50,000	330,500	265,032	Dec 15 07:40 PM
Gad Thomas	Chief Business Officer	Dec 14 '23	Sale	6.83	50,000	341,500	315,032	Dec 15 07:40 PM
Gad Thomas	Chief Business Officer	Dec 13 '23	Sale	6.58	50,000	329,000	365,032	Dec 15 07:40 PM
WG Biotech ApS	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233	Dec 12 08:26 AM
WG Biotech ApS	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233	Dec 12 08:27 AM
WG Biotech ApS	Director	Dec 08 '23	Buy	6.99	18,503	129,379	4,449,915	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 08 '23	Buy	6.99	18,503	129,379	4,449,915	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 07 '23	Buy	6.50	6,183	40,190	4,431,412	Dec 11 05:25 PM
WG Biotech ApS	Director	Dec 07 '23	Buy	6.50	6,183	40,190	4,431,412	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Nov 29 '23	Buy	5.97	51,837	309,477	4,425,229	Dec 01 05:14 PM
WG Biotech ApS	Director	Nov 29 '23	Buy	5.97	51,837	309,477	4,425,229	Dec 01 05:15 PM
WG Biotech ApS	Director	Nov 28 '23	Buy	5.81	30,671	178,275	4,373,392	Nov 29 05:14 PM
Wedell-Wedellsborg Johan	Director	Nov 28 '23	Buy	5.81	30,671	178,275	4,373,392	Nov 29 05:15 PM
Wedell-Wedellsborg Johan	Director	Nov 27 '23	Buy	5.49	62,516	343,019	4,342,721	Nov 29 05:15 PM
WG Biotech ApS	Director	Nov 27 '23	Buy	5.49	62,516	343,019	4,342,721	Nov 29 05:14 PM
Gad Thomas	Chief Business Officer	Nov 21 '23	Sale	5.31	75,000	397,988	415,032	Nov 22 05:00 PM
Gad Thomas	Chief Business Officer	Nov 20 '23	Sale	5.30	75,000	397,395	490,032	Nov 22 05:00 PM

AMPH Amphastar Pharmaceuticals Inc daily Stock Chart

Held by: IJR VTI IWM VXF AVUV IJT SPSM IWO PJP SLYG

Index	RUT	P/E	13.71	EPS (ttm)	2.90	Insider Own	28.05%	Shs Outstand	48.07M	Perf Week	-1.66%
Market Cap	1.95B	Forward P/E	9.41	EPS next Y	4.23	Insider Trans	-2.75%	Shs Float	35.19M	Perf Month	-7.64%
Income	154.69M	PEG	0.61	EPS next Q	0.80	Inst Own	69.64%	Short Float	10.70%	Perf Quarter	-9.65%
Sales	676.21M	P/S	2.88	EPS this Y	14.31%	Inst Trans	-2.06%	Short Ratio	10.91	Perf Half Y	-31.48%
Book/sh	13.77	P/B	2.89	EPS next Y	11.42%	ROA	13.18%	Short Interest	3.76M	Perf Year	-28.70%
Cash/sh	5.97	P/C	6.66	EPS next 5Y	22.60%	ROE	25.34%	52W Range	38.43 - 67.66	Perf YTD	-35.68%
Dividend Est.	-	P/FCF	12.09	EPS past 5Y	-	ROI	11.94%	52W High	-41.21%	Beta	0.79
Dividend TTM	-	Quick Ratio	1.72	Sales past 5Y	17.24%	Gross Margin	53.22%	52W Low	3.51%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	2.18	EPS Y/Y TTM	66.32%	Oper. Margin	31.69%	RSI (14)	36.02	Volatility	2.38% 2.88%
Employees	1761	Debt/Eq	0.93	Sales Y/Y TTM	30.38%	Profit Margin	22.88%	Recom	1.83	Target Price	62.60
Option/Short	Yes / Yes	LT Debt/Eq	0.93	EPS Q/Q	62.61%	Payout	0.00%	Rel Volume	0.72	Prev Close	40.05
Sales Surprise	-1.61%	EPS Surprise	34.49%	Sales Q/Q	22.72%	Earnings	May 08 AMC	Avg Volume	345.11K	Price	39.78
SMA20	-4.51%	SMA50	-4.21%	SMA200	-18.36%	Trades		Volume	249,265	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-24	Initiated	JP Morgan	Overweight	$60
Nov-17-23	Initiated	BofA Securities	Neutral	$63
Jul-25-23	Resumed	Jefferies	Buy	$70
Oct-21-22	Resumed	Jefferies	Buy	$36
Jul-29-22	Initiated	CapitalOne	Overweight	$44
Jan-07-22	Upgrade	Piper Sandler	Neutral → Overweight	$21 → $28
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$21
Oct-05-20	Upgrade	Northland Capital	Market Perform → Outperform	$24
May-01-20	Initiated	Northland Capital	Outperform	$23
Mar-13-19	Downgrade	Piper Jaffray	Overweight → Neutral	$24 → $23
Mar-13-19	Downgrade	Needham	Buy → Hold
Aug-10-18	Reiterated	Needham	Buy	$24 → $22
Mar-13-18	Reiterated	Needham	Buy	$23 → $24
Dec-01-17	Reiterated	Needham	Buy	$20 → $23
Nov-09-17	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-27-17	Reiterated	Needham	Buy	$18 → $20
Mar-14-17	Downgrade	Raymond James	Strong Buy → Outperform
Aug-09-16	Reiterated	Needham	Buy	$20 → $22
May-10-16	Reiterated	Needham	Buy	$21 → $20
Feb-19-16	Initiated	Wells Fargo	Outperform

Show Previous Ratings

Jun-14-24 04:30PM	BetterInvesting Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC (PR Newswire)
Jun-12-24 02:36AM	Insider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH) (GuruFocus.com)
Jun-04-24 06:00AM	Amphastar Announces Additional $50 Million Increase to its Share Buyback Program (ACCESSWIRE)
Jun-03-24 06:00AM	Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (ACCESSWIRE)
May-22-24 06:00AM	Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol (ACCESSWIRE)
06:15AM	Loading…
May-16-24 06:15AM	Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade (InvestorPlace)
May-15-24 08:36AM	Implied Volatility Surging for Amphastar (AMPH) Stock Options (Zacks)
May-10-24 01:23PM	Amphastar Pharmaceuticals Reports Strong First Quarter Earnings, Surpassing Analyst Revenue ... (GuruFocus.com)
May-09-24 04:05PM	Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference (ACCESSWIRE)
01:46PM	Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:41AM	Q1 2024 Amphastar Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:53AM	Amphastar Pharmaceuticals Inc (AMPH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-08-24 10:57PM	AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:13PM	Amphastar: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 (ACCESSWIRE)
May-01-24 10:01AM	Amphastar Pharmaceuticals (AMPH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-30-24 04:05PM	Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024 (ACCESSWIRE)
12:10PM	Why Amphastar (AMPH) Could Beat Earnings Estimates Again (Zacks)
Apr-04-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know (Zacks)
Apr-01-24 06:00AM	Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference (ACCESSWIRE)
Mar-27-24 09:30AM	Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Mar-26-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Mar-20-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-11-24 09:30AM	Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet (Zacks)
Mar-08-24 11:31PM	Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares (GuruFocus.com)
Mar-06-24 11:29PM	Amphastar Pharmaceuticals Inc Director Michael Zasloff Sells 12,500 Shares (GuruFocus.com)
04:05PM	Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference (ACCESSWIRE)
Mar-02-24 08:24AM	Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 08:09AM	Q4 2023 Amphastar Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -14.93%
05:25PM	Loading…
Feb-28-24 05:25PM	Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:12PM	Amphastar Pharmaceuticals Inc Reports Robust Revenue Growth and Strong Full-Year Performance (GuruFocus.com)
04:25PM	Amphastar: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 (ACCESSWIRE)
Feb-23-24 02:09PM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
Feb-22-24 05:45PM	Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
09:30AM	Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy? (Zacks)
Feb-21-24 06:54AM	Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-20-24 04:01PM	Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024 (ACCESSWIRE)
Feb-16-24 08:00AM	It May Be Time To Revisit Amphastar Once It Settles After A Plunge (Investor's Business Daily)
Feb-15-24 05:45PM	Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know (Zacks)
Feb-09-24 05:45PM	Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why (Zacks)
Feb-05-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Market: What You Should Know (Zacks)
12:41PM	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential (InvestorPlace)
Jan-30-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Jan-23-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-17-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know (Zacks)
Jan-11-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Jan-05-24 05:50PM	Amphastar Pharmaceuticals (AMPH) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -5.24%
Jan-02-24 06:00AM	Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Jan-01-24 12:00PM	Amphastar Pharmaceuticals (AMPH) Is Up 1.53% in One Week: What You Should Know (Zacks)
Dec-27-23 09:30AM	Wall Street Analysts Think Amphastar (AMPH) Is a Good Investment: Is It? (Zacks)
Dec-25-23 08:23PM	3 Stocks at the Forefront of Medical Innovation (InvestorPlace)
12:45PM	3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock (Zacks)
Dec-21-23 08:00AM	Will Eli Lilly's Emergency Diabetes Drug Give Amphastar Wings? (Investor's Business Daily)
Dec-08-23 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH) (Zacks)
Dec-05-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Amphastar Pharmaceuticals (AMPH) is a Great Choice (Zacks)
Dec-04-23 03:02PM	Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal (Investor's Business Daily)
Nov-30-23 06:13PM	This Biotech Stock Nears A Buy Point After 200% Profit Growth (Investor's Business Daily)
Nov-29-23 09:30AM	Amphastar (AMPH) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Nov-22-23 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH) (Zacks)
Nov-21-23 01:03AM	Insider Sell Alert: Director Richard Prins Sells 4,000 Shares of Amphastar Pharmaceuticals Inc ... (GuruFocus.com)
Nov-20-23 04:20PM	Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference (ACCESSWIRE)
Nov-17-23 11:04AM	Insider Sell: CFO William Peters Sells Shares of Amphastar Pharmaceuticals Inc (GuruFocus.com)
Nov-16-23 05:10AM	Insider Sell: Director Richard Prins Sells 5,000 Shares of Amphastar Pharmaceuticals Inc (AMPH) (GuruFocus.com)
Nov-13-23 09:30AM	Wall Street Analysts See Amphastar (AMPH) as a Buy: Should You Invest? (Zacks)
Nov-10-23 03:43PM	Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade (Investor's Business Daily)
01:15PM	Plenty Of IBD 50 Companies' Earnings Impress, And Some Remain Actionable (Investor's Business Daily)
Nov-09-23 04:05PM	Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference (ACCESSWIRE) +15.39%
01:27PM	Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:38AM	Q3 2023 Amphastar Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
05:42AM	Amphastar: Q3 Earnings Snapshot (Associated Press Finance)
Nov-08-23 04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023 (ACCESSWIRE)
Nov-01-23 04:10PM	Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023 (ACCESSWIRE)
Oct-31-23 05:45PM	Amphastar Pharmaceuticals (AMPH) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
06:43AM	Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies (Zacks)
Oct-30-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why (Zacks)
Oct-23-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Rises As Market Takes a Dip: Key Facts (Zacks)
Oct-16-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why (Zacks)
Oct-10-23 09:40AM	Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year? (Zacks)
Oct-09-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Rises Higher Than Market: Key Facts (Zacks)
Oct-02-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know (Zacks)
Sep-25-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know (Zacks)
Sep-19-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know (Zacks)
Sep-14-23 09:30AM	Should You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views? (Zacks)
Sep-13-23 05:50PM	Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know (Zacks)
12:37AM	Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes (ACCESSWIRE)
Sep-11-23 04:05PM	Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes (ACCESSWIRE) -9.21%
Sep-09-23 01:01AM	Insider Sell: CFO, EVP & Treasurer William Peters Sells 60,743 Shares of Amphastar ... (GuruFocus.com)
Aug-31-23 04:05PM	Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference (ACCESSWIRE)
Aug-18-23 01:54PM	Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why (Zacks)
Aug-14-23 07:01AM	Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical (Zacks)
Aug-11-23 12:45PM	Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
10:33AM	3 Generic Drug Stocks to Watch Amid Improving Market Prospects (Zacks)
09:40AM	Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-10-23 09:15AM	Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run? (Zacks) -14.16%
Aug-09-23 07:18AM	Q2 2023 Amphastar Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 08:30PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
07:19PM	Amphastar: Q2 Earnings Snapshot (AP Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 (ACCESSWIRE)

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zhang Jack Y.	CEO & CHIEF SCIENTIFIC OFFICER	Jun 10 '24	Option Exercise	14.69	100,000	1,469,000	2,533,554	Jun 11 06:35 PM
Petersen Floyd F.	Director	Jun 10 '24	Sale	41.40	3,000	124,200	78,409	Jun 11 06:32 PM
Petersen Floyd F.	Director	Jun 03 '24	Sale	42.65	500	21,326	78,333	Jun 05 06:54 PM
Petersen Floyd F.	Director	May 01 '24	Sale	41.67	500	20,837	78,833	May 02 04:56 PM
Petersen Floyd F.	Director	Apr 01 '24	Sale	43.43	500	21,714	79,333	Apr 02 09:31 PM
Zhang Jack Y.	CEO & Chief Scientific Officer	Mar 15 '24	Option Exercise	12.46	722,046	8,996,693	2,858,043	Mar 19 06:55 PM
Zhang Jack Y.	CEO & Chief Scientific Officer	Mar 15 '24	Option Exercise	12.46	310,930	3,874,188	1,439,466	Mar 19 06:55 PM
PETERS WILLIAM J	CFO, EVP & TREASURER	Mar 06 '24	Option Exercise	11.33	8,826	99,999	129,626	Mar 08 04:52 PM
PETERS WILLIAM J	CFO, EVP & TREASURER	Mar 06 '24	Sale	46.48	18,136	842,883	111,490	Mar 08 04:52 PM
ZASLOFF MICHAEL A	Director	Mar 05 '24	Sale	47.18	12,500	589,724	21,326	Mar 06 05:57 PM
Petersen Floyd F.	Director	Mar 01 '24	Sale	45.69	500	22,847	79,833	Mar 04 08:35 PM
Petersen Floyd F.	Director	Feb 01 '24	Sale	53.10	500	26,548	80,333	Feb 02 07:37 PM
Luo Mary Z.	COO,Chief Scientist & Chairman	Jan 10 '24	Sale	54.59	131,386	7,171,768	1,104,416	Jan 11 04:37 PM
Luo Mary Z.	COO,Chief Scientist & Chairman	Jan 09 '24	Sale	57.14	86,156	4,923,232	1,235,802	Jan 10 06:27 PM
Luo Mary Z.	COO,Chief Scientist & Chairman	Jan 08 '24	Sale	58.93	133,644	7,875,476	1,321,958	Jan 10 06:27 PM
Petersen Floyd F.	Director	Jan 02 '24	Sale	61.37	500	30,683	80,833	Jan 03 07:25 PM
Zhou Rong	Senior EVP, Production Center	Dec 04 '23	Option Exercise	16.19	3,514	56,892	115,934	Dec 05 06:25 PM
Zhou Rong	Senior EVP, Production Center	Dec 04 '23	Sale	59.58	3,514	209,364	112,420	Dec 05 06:25 PM
Zhou Rong	Senior EVP, Production Center	Dec 01 '23	Option Exercise	14.40	4,316	62,150	116,736	Dec 05 06:25 PM
Zhou Rong	Senior EVP, Production Center	Dec 01 '23	Sale	58.58	4,316	252,831	112,420	Dec 05 06:25 PM
Petersen Floyd F.	Director	Dec 01 '23	Sale	57.90	500	28,952	81,333	Dec 04 08:49 PM
PRINS RICHARD K	Director	Nov 17 '23	Sale	55.86	4,000	223,446	31,895	Nov 20 05:23 PM
PETERS WILLIAM J	CFO, EVP & Treasurer	Nov 14 '23	Option Exercise	15.61	59,250	925,028	160,610	Nov 16 04:05 PM
PETERS WILLIAM J	CFO, EVP & Treasurer	Nov 14 '23	Sale	55.67	59,250	3,298,475	101,360	Nov 16 04:05 PM
Deflin Gayle	Director	Nov 14 '23	Sale	55.45	4,163	230,838	2,716	Nov 15 04:30 PM
PRINS RICHARD K	Director	Nov 13 '23	Sale	52.50	5,000	262,500	35,895	Nov 15 04:31 PM
Petersen Floyd F.	Director	Nov 01 '23	Sale	45.30	500	22,651	81,833	Nov 02 08:37 PM
Petersen Floyd F.	Director	Oct 02 '23	Sale	45.78	500	22,890	82,333	Oct 03 06:38 PM
PETERS WILLIAM J	CFO, EVP & Treasurer	Sep 06 '23	Option Exercise	16.93	56,500	956,795	162,103	Sep 08 04:08 PM
PETERS WILLIAM J	CFO, EVP & Treasurer	Sep 06 '23	Sale	51.75	60,743	3,143,195	101,360	Sep 08 04:08 PM
Liawatidewi Yakob	EVP Corp Admin Center	Aug 28 '23	Option Exercise	14.86	28,816	428,095	98,485	Aug 29 06:54 PM
Liawatidewi Yakob	EVP Corp Admin Center	Aug 28 '23	Sale	53.13	28,816	1,530,994	69,669	Aug 29 06:54 PM
PRINS RICHARD K	Director	Aug 18 '23	Sale	52.50	2,000	105,006	40,895	Aug 21 04:05 PM
ZASLOFF MICHAEL A	Director	Aug 15 '23	Sale	57.22	12,759	730,025	33,826	Aug 16 08:23 PM
PRINS RICHARD K	Director	Aug 15 '23	Sale	57.39	4,163	238,911	42,895	Aug 16 08:22 PM

Open in Screener

ACAD

Acadia Pharmaceuticals Inc

Jun 20 • 04:00PM ET

14.75

Dollar change -0.12
Percentage change -0.81	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ACAD Acadia Pharmaceuticals Inc daily Stock Chart

Held by: VTI XBI VB IWM FBT VXF VBK IBB IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.02	Insider Own	0.73%	Shs Outstand	164.65M	Perf Week	-4.03%
Market Cap	2.44B	Forward P/E	12.89	EPS next Y	1.14	Insider Trans	-7.31%	Shs Float	164.01M	Perf Month	-2.32%
Income	-1.71M	PEG	-	EPS next Q	0.19	Inst Own	97.84%	Short Float	7.40%	Perf Quarter	-20.95%
Sales	813.81M	P/S	2.99	EPS this Y	273.76%	Inst Trans	0.91%	Short Ratio	7.44	Perf Half Y	-49.17%
Book/sh	2.81	P/B	5.24	EPS next Y	77.99%	ROA	-0.23%	Short Interest	12.14M	Perf Year	-38.13%
Cash/sh	2.85	P/C	5.18	EPS next 5Y	-	ROE	-0.41%	52W Range	14.55 - 33.99	Perf YTD	-52.89%
Dividend Est.	-	P/FCF	38.28	EPS past 5Y	28.03%	ROI	-0.33%	52W High	-56.60%	Beta	0.37
Dividend TTM	-	Quick Ratio	1.86	Sales past 5Y	27.73%	Gross Margin	92.27%	52W Low	1.37%	ATR (14)	0.49
Dividend Ex-Date	-	Current Ratio	2.04	EPS Y/Y TTM	98.70%	Oper. Margin	-0.56%	RSI (14)	38.98	Volatility	3.01% 2.94%
Employees	598	Debt/Eq	0.13	Sales Y/Y TTM	56.43%	Profit Margin	-0.21%	Recom	1.65	Target Price	27.29
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	137.50%	Payout	-	Rel Volume	0.69	Prev Close	14.87
Sales Surprise	-1.19%	EPS Surprise	104.92%	Sales Q/Q	73.75%	Earnings	May 08 AMC	Avg Volume	1.63M	Price	14.75
SMA20	-2.60%	SMA50	-7.63%	SMA200	-33.29%	Trades		Volume	1,128,805	Change	-0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Aug-05-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Jun-21-22	Downgrade	Jefferies	Buy → Underperform	$25 → $10
Jun-16-22	Upgrade	Jefferies	Hold → Buy	$25
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy	$30 → $31
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$36

Show Previous Ratings

Jun-18-24 09:04AM	Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting (Business Wire)
Jun-07-24 11:30AM	Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue? (Zacks)
May-29-24 10:01AM	3 Sorry Pharma Stocks to Sell in May While You Still Can (InvestorPlace)
May-17-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-24 09:05AM	Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome (Business Wire)
01:15PM	Loading…
May-10-24 01:15PM	ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches (GuruFocus.com)
11:20AM	UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating (MT Newswires)
10:01AM	Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating (MT Newswires)
May-09-24 04:58PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire) -11.21%
03:29PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:07AM	Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating (MT Newswires)
05:59AM	Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss (Zacks)
03:37AM	ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-08-24 08:57PM	ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates (Zacks)
04:15PM	Loading…
04:15PM	Acadia: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview (Business Wire)
May-04-24 02:27AM	Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) (GuruFocus.com)
May-01-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-24 12:17PM	UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating (MT Newswires)
Apr-29-24 04:16PM	Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship (Business Wire)
Apr-24-24 04:05PM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 (Business Wire)
Apr-22-24 09:04AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada (Business Wire)
Apr-20-24 09:15AM	5 Best Healthcare Stocks to Buy Under $20 (Insider Monkey)
Apr-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-24 04:05PM	Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-11-24 02:10PM	3 Pharma Stocks to Sell in April Before They Crash & Burn (InvestorPlace)
Apr-10-24 01:28AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares (GuruFocus.com)
Apr-02-24 04:05PM	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development (Business Wire)
Apr-01-24 04:05PM	Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
11:30AM	Loading…
Mar-28-24 11:30AM	Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? (Zacks)
02:00AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares (GuruFocus.com)
Mar-20-24 01:31PM	Billionaire Steve Cohen and Insiders are Buying These 5 Stocks (Insider Monkey)
Mar-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace)
Mar-13-24 04:05PM	Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day (Business Wire)
Mar-12-24 04:08PM	Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study (Investor's Business Daily) -17.20%
03:05PM	Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short (Investopedia)
11:06AM	Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails (Zacks)
09:30AM	Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? (InvestorPlace)
07:43AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-11-24 04:46PM	UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study (Reuters)
04:13PM	Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study (Reuters)
04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia (Business Wire)
Feb-29-24 09:05AM	Acadia Pharmaceuticals to Participate in TD Cowens 44th Annual Health Care Conference on March 6, 2024 (Business Wire)
08:44AM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:05PM	Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch (Investor's Business Daily) -9.92%
09:12AM	Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down (Zacks)
Feb-27-24 05:20PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:56PM	ACADIA Pharmaceuticals Inc. Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:27PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview (Business Wire)
Feb-22-24 08:16PM	ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Feb-21-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-24 10:00AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-13-24 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-30-24 08:48PM	Acadia Announces Additions to Executive Team (Business Wire)
05:00PM	20 Countries With The Highest Number of Drug Trafficking in the World (Insider Monkey)
Jan-26-24 05:31PM	Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US (Insider Monkey)
Jan-25-24 08:42AM	10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Jan-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-18-24 04:05PM	Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic (Business Wire)
Jan-12-24 05:02PM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares (GuruFocus.com)
Dec-21-23 04:05PM	Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 (Business Wire) +6.37%
Dec-18-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-23 09:24PM	Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID (pimavanserin) (Business Wire) +34.48%
04:14PM	Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug (Investor's Business Daily)
01:41PM	Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID (pimavanserin) Patent Litigation (Business Wire)
Nov-30-23 09:05AM	Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome (Business Wire)
Nov-27-23 09:05AM	Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimers Disease Psychosis (Business Wire)
Nov-21-23 11:03PM	Insider Sell Alert: EVP Brendan Teehan Sells Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
05:00PM	Acadia Pharmaceuticals Announces Change in Research and Development Leadership (Business Wire)
Nov-17-23 09:40AM	Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year? (Zacks)
Nov-16-23 08:42AM	Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-14-23 04:12PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-08-23 05:24PM	3 Biotech Stocks With the Strongest Clinical Pipelines (InvestorPlace) -5.09%
Nov-04-23 01:10PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:51PM	ACADIA Pharmaceuticals Inc. Reports Record Revenues in Q3 2023 (GuruFocus.com)
04:37PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview (Business Wire)
Oct-31-23 04:05PM	Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference (Business Wire)
Oct-26-23 10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 09:05AM	Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program (Business Wire)
Oct-19-23 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023 (Business Wire)
Oct-18-23 05:00PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-10-23 10:49AM	Why Acadia Pharmaceuticals Stock Is Rising Today (Motley Fool) +7.73%
09:32AM	Rivian upgraded, Qorvo downgraded: Wall Street's top analyst calls (The Fly)
Oct-07-23 05:01AM	EVP, General Counsel, Secretary Austin Kim Sells 16,369 Shares of ACADIA Pharmaceuticals Inc (GuruFocus.com)
Sep-30-23 10:30AM	2 Growth Stocks I'd Buy on the Dip (Motley Fool)
Sep-22-23 06:23PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-23 04:05PM	Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications (Business Wire)
Aug-30-23 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-28-23 06:00PM	2 Supercharged Growth Stocks Billionaires Can't Stop Buying (Motley Fool)
Aug-22-23 08:30AM	Can This Red-Hot Biotech Stock Keep Beating the Broader Markets? (Motley Fool)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-14-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks)
Aug-02-23 04:26PM	Acadia: Q2 Earnings Snapshot (AP Finance) -6.85%
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	14.79	975	14,420	34,564	Jun 11 06:00 PM
DAVIS STEPHEN	CEO	May 02 '24	Sale	16.94	11,427	193,573	155,231	May 03 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '24	Sale	16.94	3,503	59,341	32,053	May 03 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	May 02 '24	Sale	16.94	3,477	58,900	42,133	May 03 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Sale	16.94	1,326	22,462	14,370	May 03 06:00 PM
DAVIS STEPHEN	CEO	Apr 08 '24	Sale	17.87	26,574	474,877	144,267	Apr 09 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	17.87	2,716	48,535	28,742	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Apr 08 '24	Sale	17.87	2,568	45,890	38,796	Apr 09 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '24	Sale	17.87	1,790	31,987	13,100	Apr 09 06:00 PM
DAVIS STEPHEN	CEO	Mar 27 '24	Sale	17.90	17,714	317,081	118,842	Mar 27 07:58 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	17.90	5,434	97,269	26,183	Mar 27 07:57 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Mar 27 '24	Sale	17.90	5,140	92,006	36,340	Mar 27 08:00 PM
DAVIS STEPHEN	CEO	Feb 26 '24	Sale	24.67	5,577	137,585	101,890	Feb 27 06:02 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 26 '24	Sale	24.67	772	19,045	21,067	Feb 27 06:13 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Feb 26 '24	Sale	24.67	624	15,394	31,432	Feb 27 06:10 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 26 '24	Sale	24.67	474	11,694	11,391	Feb 27 06:07 PM
DAVIS STEPHEN	CEO	Jan 08 '24	Sale	29.96	3,732	111,811	96,521	Jan 09 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 08 '24	Sale	29.96	731	21,901	30,949	Jan 09 06:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 08 '24	Sale	29.96	590	17,676	46,901	Jan 09 06:00 PM
Kihara James	Principal Accounting Officer	Dec 15 '23	Sale	28.30	2,000	56,600	11,025	Dec 15 07:37 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Nov 20 '23	Sale	22.64	5,108	115,645	20,486	Nov 21 06:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Nov 20 '23	Sale	22.64	4,960	112,294	30,393	Nov 21 06:00 PM
Kihara James	Principal Accounting Officer	Nov 20 '23	Sale	22.64	1,985	44,940	13,025	Nov 21 06:00 PM
DAVIS STEPHEN	CEO	Oct 06 '23	Sale	21.96	51,563	1,132,323	89,131	Oct 06 09:59 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Oct 06 '23	Sale	21.96	16,369	359,463	45,857	Oct 06 10:00 PM
Kihara James	Principal Accounting Officer	Sep 15 '23	Sale	25.88	2,000	51,760	10,778	Sep 19 06:31 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Aug 21 '23	Sale	29.00	10,000	289,970	15,682	Aug 23 07:31 PM
DAVIS STEPHEN	CEO	Jul 14 '23	Option Exercise	20.77	100,000	2,077,000	136,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 14 '23	Sale	30.04	100,000	3,004,350	36,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 12 '23	Sale	25.05	55,104	1,380,449	36,695	Jul 13 08:27 PM
DAVIS STEPHEN	CEO	Jul 11 '23	Sale	25.00	16,498	412,450	91,799	Jul 13 08:27 PM

Open in Screener

CPRX

Catalyst Pharmaceuticals Inc

Jun 20 • 04:00PM ET

15.18

Dollar change +0.21
Percentage change 1.40	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

CPRX Catalyst Pharmaceuticals Inc daily Stock Chart

Held by: IJR XBI VTI IWM FBT VXF IJT SPSM IWO SLYG

Index	RUT	P/E	28.19	EPS (ttm)	0.54	Insider Own	13.94%	Shs Outstand	107.12M	Perf Week	-1.75%
Market Cap	1.79B	Forward P/E	11.79	EPS next Y	1.29	Insider Trans	-0.96%	Shs Float	101.65M	Perf Month	-10.28%
Income	65.12M	PEG	-	EPS next Q	0.23	Inst Own	74.55%	Short Float	7.15%	Perf Quarter	-10.23%
Sales	411.35M	P/S	4.36	EPS this Y	49.52%	Inst Trans	9.06%	Short Ratio	6.53	Perf Half Y	7.66%
Book/sh	4.76	P/B	3.19	EPS next Y	36.73%	ROA	12.36%	Short Interest	7.27M	Perf Year	20.29%
Cash/sh	2.63	P/C	5.78	EPS next 5Y	-	ROE	14.55%	52W Range	11.55 - 17.50	Perf YTD	-9.70%
Dividend Est.	-	P/FCF	14.11	EPS past 5Y	-	ROI	11.54%	52W High	-13.23%	Beta	0.70
Dividend TTM	-	Quick Ratio	4.83	Sales past 5Y	4106.79%	Gross Margin	78.14%	52W Low	31.43%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	5.09	EPS Y/Y TTM	-37.90%	Oper. Margin	19.04%	RSI (14)	41.99	Volatility	2.49% 3.08%
Employees	167	Debt/Eq	0.01	Sales Y/Y TTM	60.38%	Profit Margin	15.83%	Recom	1.00	Target Price	27.29
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-27.29%	Payout	0.00%	Rel Volume	1.06	Prev Close	14.97
Sales Surprise	-0.34%	EPS Surprise	-4.19%	Sales Q/Q	15.40%	Earnings	May 08 AMC	Avg Volume	1.11M	Price	15.18
SMA20	-3.95%	SMA50	-2.89%	SMA200	4.50%	Trades		Volume	1,183,754	Change	1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-24	Initiated	Citigroup	Buy	$27
Mar-07-24	Initiated	BofA Securities	Buy	$23
Dec-21-23	Initiated	Oppenheimer	Outperform	$30
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral	$10 → $15.50
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral	$6 → $1
Sep-30-14	Reiterated	ROTH Capital	Buy	$5 → $6
Sep-16-14	Reiterated	ROTH Capital	Buy	$3.50 → $5
Sep-15-14	Reiterated	H.C. Wainwright	Buy	$5 → $13
Oct-21-13	Reiterated	Aegis Capital	Buy	$4 → $5.50
Sep-24-13	Initiated	Maxim Group	Buy	$4
Sep-06-13	Reiterated	Aegis Capital	Buy	$3.50 → $4
Apr-18-13	Initiated	Aegis Capital	Buy	$2.50
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform	$3.70
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
Dec-15-08	Initiated	Merriman Curhan Ford	Buy

Show Previous Ratings

Jun-07-24 11:30AM	Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report? (Zacks)
May-30-24 01:41PM	Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE (GlobeNewswire)
May-28-24 08:03AM	Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-15-24 08:00AM	2 Incredible Growth Stocks to Buy Hand Over Fist Right Now (Motley Fool)
May-10-24 05:20PM	Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:40AM	Loading…
May-09-24 11:40AM	Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues (Zacks) +6.32%
May-08-24 05:04PM	Catalyst: Q1 Earnings Snapshot (Associated Press Finance)
04:16PM	Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 10:01AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:00AM	Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 (GlobeNewswire)
Apr-25-24 01:00AM	Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May (GlobeNewswire)
Apr-24-24 01:45PM	Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026 (InvestorPlace)
Apr-22-24 08:00AM	Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
Mar-29-24 11:30AM	Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? (Zacks)
08:03AM	Loading…
Mar-28-24 08:03AM	Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day (GlobeNewswire)
Mar-27-24 08:03AM	Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
07:44AM	3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
Mar-14-24 02:00AM	Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE (Vamorolone) in the United States (GlobeNewswire)
Mar-13-24 07:55AM	Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-10-24 03:24PM	3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio (InvestorPlace)
Mar-05-24 08:03AM	Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Feb-29-24 12:10PM	Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up (Zacks) +10.10%
Feb-28-24 07:20PM	Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:35PM	Catalyst: Q4 Earnings Snapshot (Associated Press Finance)
06:03PM	Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-24 08:03AM	Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE (GlobeNewswire)
Feb-21-24 09:00AM	Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE ) Study Results in the Peer-Reviewed Journal Neurology (GlobeNewswire)
Feb-14-24 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
09:50AM	Loading…
Jan-18-24 09:50AM	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
04:54AM	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances (InvestorPlace)
Jan-15-24 08:45AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-14-24 08:40AM	Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024 (Motley Fool)
Jan-12-24 09:45AM	Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term (Zacks)
Jan-09-24 04:57PM	Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
04:05PM	Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering (GlobeNewswire)
Jan-08-24 08:55AM	3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January (InvestorPlace)
Jan-05-24 08:02AM	Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.85%
Jan-04-24 04:49PM	Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Dec-18-23 06:30AM	Catalyst Pharmaceuticals Announces FIRDAPSE New Drug Application Submitted in Japan by Partner DyDo Pharma (GlobeNewswire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-08-23 11:30AM	Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report? (Zacks)
Dec-05-23 08:03AM	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies (GlobeNewswire) -5.38%
Dec-04-23 08:03AM	Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions (GlobeNewswire)
Nov-16-23 08:05AM	Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-09-23 06:10AM	Catalyst: Q3 Earnings Snapshot (Associated Press Finance)
Nov-08-23 04:11PM	Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Nov-02-23 10:37AM	Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE (GlobeNewswire)
10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
Nov-01-23 10:01AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-30-23 08:03AM	Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo (GlobeNewswire)
Oct-26-23 03:19PM	Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals (GlobeNewswire)
Oct-23-23 08:03AM	Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-19-23 08:03AM	Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer (GlobeNewswire)
Oct-16-23 08:03AM	Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida (GlobeNewswire)
Oct-13-23 08:03AM	Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE (GlobeNewswire)
Oct-12-23 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:40AM	This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar (Zacks)
Sep-18-23 08:03AM	Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-08-23 11:30AM	Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report? (Zacks)
Sep-06-23 01:06PM	Unraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key Metrics (GuruFocus.com)
Aug-16-23 10:56AM	Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer (GlobeNewswire)
Aug-14-23 08:05AM	Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress (GlobeNewswire)
Aug-11-23 06:09AM	Catalyst Pharmaceuticals Second Quarter 2023 Earnings: EPS: US$0.35 (vs US$0.21 in 2Q 2022) (Simply Wall St.)
Aug-09-23 05:50PM	Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates (Zacks) +6.37%
04:41PM	Catalyst: Q2 Earnings Snapshot (AP Finance)
04:17PM	Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 02:44PM	7 Strong Buy Value Stocks You Should Be Loading Up On Now (InvestorPlace)
Jul-25-23 08:03AM	Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End (GlobeNewswire)
Jul-24-23 08:03AM	Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-23-23 10:21AM	Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.)
Jul-19-23 06:00AM	Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals (GlobeNewswire)
Jul-05-23 05:50PM	Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know (Zacks)
Jul-02-23 01:46PM	7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing (InvestorPlace)
Jun-29-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 05:50PM	Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know (Zacks)
Jun-21-23 08:00PM	CPRX: Raising target price to $14.00 (Argus Research)
Jun-20-23 06:00AM	Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals (GlobeNewswire)
Jun-19-23 09:30AM	Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Jun-14-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-09-23 11:30AM	Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 09:30AM	Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest? (Zacks)
08:03AM	Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023 (GlobeNewswire)
May-30-23 08:03AM	Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors (GlobeNewswire)
May-22-23 08:15AM	Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy? (Motley Fool)
May-12-23 09:30AM	Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views? (Zacks)
May-11-23 08:41AM	Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) high institutional ownership speaks for itself as stock continues to impress, up 5.5% over last week (Simply Wall St.) -19.19%
May-10-23 05:55PM	Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates (Zacks)
04:53PM	Catalyst: Q1 Earnings Snapshot (AP Finance)
04:27PM	Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year (GlobeNewswire)
May-09-23 08:03AM	Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day (GlobeNewswire)
May-03-23 05:45PM	Catalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know (Zacks)
May-01-23 08:03AM	Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report (GlobeNewswire) +6.41%
Apr-27-23 05:45PM	Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-26-23 08:00PM	CPRX: Lowering target price to $17.00 (Argus Research)
12:45PM	3 Reasons Growth Investors Will Love Catalyst (CPRX) (Zacks)
Apr-24-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
08:03AM	Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-20-23 12:26PM	We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease (Simply Wall St.)

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Del Carmen Jeffrey	Chief Commercial Officer	Jun 07 '24	Sale	16.07	7,541	121,184	18,427	Jun 11 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Jun 05 '24	Option Exercise	4.01	80,000	320,800	131,391	Jun 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Jun 05 '24	Sale	16.16	80,000	1,292,800	51,391	Jun 07 05:00 PM
Daly Richard J	President and CEO	Jun 04 '24	Option Exercise	4.01	40,000	160,400	252,147	Jun 05 05:00 PM
Daly Richard J	President and CEO	Jun 04 '24	Sale	15.97	17,323	276,735	234,824	Jun 05 05:00 PM
Harper Molly	Director	Jun 03 '24	Sale	16.30	5,333	86,949	0	Jun 05 05:00 PM
Tierney David S	Director	Apr 08 '24	Option Exercise	4.01	25,000	100,250	373,874	Apr 10 05:15 PM
Tierney David S	Director	Apr 08 '24	Sale	15.68	25,000	392,000	348,874	Apr 10 05:15 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 27 '24	Sale	16.44	25,000	411,000	124,433	Mar 28 04:45 PM
DENKHAUS DONALD A	Director	Feb 05 '24	Option Exercise	4.01	40,000	160,400	434,333	Feb 06 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Jan 02 '24	Option Exercise	1.13	250,000	282,500	4,385,256	Jan 03 05:19 PM
O'Keeffe Charles B	Director	Jan 02 '24	Option Exercise	1.13	60,000	67,800	681,724	Jan 03 05:18 PM
Tierney David S	Director	Jan 02 '24	Option Exercise	1.13	10,000	11,300	344,874	Jan 03 05:19 PM
Harper Molly	Director	Dec 15 '23	Option Exercise	5.78	10,000	57,800	10,000	Dec 19 05:00 PM
Harper Molly	Director	Dec 15 '23	Sale	14.39	14,000	201,420	0	Dec 19 05:00 PM
Tierney David S	Director	Dec 12 '23	Option Exercise	1.13	50,000	56,500	383,541	Dec 14 05:00 PM
Tierney David S	Director	Dec 12 '23	Sale	13.32	50,000	666,250	333,541	Dec 14 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 11 '23	Option Exercise	1.13	150,000	169,500	797,457	Dec 13 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 11 '23	Option Exercise	1.13	60,000	67,800	110,557	Dec 12 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 11 '23	Sale	13.76	60,000	825,780	50,557	Dec 12 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 08 '23	Option Exercise	1.13	40,000	45,200	90,557	Dec 12 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Dec 08 '23	Sale	14.28	40,000	571,000	50,557	Dec 12 05:00 PM
Daly Richard J	Director	Dec 07 '23	Option Exercise	1.13	60,000	67,800	208,000	Dec 11 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Dec 06 '23	Option Exercise	1.13	50,000	56,500	88,367	Dec 08 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Dec 06 '23	Sale	14.02	50,000	701,000	38,367	Dec 08 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 05 '23	Sale	14.24	40,000	569,600	647,457	Dec 07 05:00 PM
DENKHAUS DONALD A	Director	Aug 03 '23	Option Exercise	1.13	60,000	67,800	393,000	Aug 04 05:00 PM

Open in Screener

PHIO

Phio Pharmaceuticals Corp

Jun 20 • 04:00PM ET

0.7129

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

PHIO Phio Pharmaceuticals Corp daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-3.59	Insider Own	0.98%	Shs Outstand	4.59M	Perf Week	-0.71%
Market Cap	3.27M	Forward P/E	0.19	EPS next Y	3.78	Insider Trans	11.12%	Shs Float	4.55M	Perf Month	-9.06%
Income	-9.38M	PEG	-	EPS next Q	-0.51	Inst Own	3.28%	Short Float	3.89%	Perf Quarter	-33.37%
Sales	0.00M	P/S	-	EPS this Y	65.00%	Inst Trans	-15.11%	Short Ratio	0.75	Perf Half Y	-7.11%
Book/sh	1.22	P/B	0.58	EPS next Y	307.69%	ROA	-113.26%	Short Interest	0.18M	Perf Year	-76.63%
Cash/sh	1.41	P/C	0.51	EPS next 5Y	-	ROE	-145.23%	52W Range	0.50 - 3.23	Perf YTD	-6.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	62.38%	ROI	-167.34%	52W High	-77.93%	Beta	1.45
Dividend TTM	-	Quick Ratio	5.48	Sales past 5Y	-36.96%	Gross Margin	-	52W Low	42.58%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	5.48	EPS Y/Y TTM	67.11%	Oper. Margin	0.00%	RSI (14)	45.27	Volatility	8.16% 7.00%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	85.09%	Payout	-	Rel Volume	0.21	Prev Close	0.71
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	237.00K	Price	0.71
SMA20	-4.52%	SMA50	-3.01%	SMA200	-26.74%	Trades		Volume	50,395	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Jun-18-24 07:30AM	Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging (Newsfile)
May-28-24 07:30AM	Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 (Newsfile)
May-23-24 05:00PM	Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Newsfile)
May-17-24 09:00AM	Phio Pharmaceuticals Secures New Investor (GlobeNewswire) +7.44%
May-16-24 08:00AM	Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) (GlobeNewswire) -8.45%
01:00PM	Loading…
May-15-24 01:00PM	Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study (GlobeNewswire) +9.02%
May-09-24 11:53PM	PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024 (InvestorPlace) -8.51%
05:25PM	Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update (GlobeNewswire)
Apr-30-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) (GlobeNewswire)
Apr-22-24 01:10PM	Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells (GlobeNewswire) +29.69%
Apr-16-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) (GlobeNewswire)
Apr-11-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) (GlobeNewswire)
Apr-03-24 07:30AM	National Spotlight Features Phio's Innovative RNAi Technology Platform (GlobeNewswire)
Apr-02-24 07:30AM	Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-24 07:30AM	Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire) -21.50%
02:00PM	Loading…
Mar-13-24 02:00PM	Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research (GlobeNewswire)
Mar-06-24 10:30AM	Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders (GlobeNewswire) +6.63%
Jan-31-24 08:00AM	Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire)
Dec-07-23 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds (GlobeNewswire) -42.14%
Nov-09-23 04:30PM	Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -10.53% +5.88%
07:30AM	Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas (GlobeNewswire)
Nov-03-23 12:00PM	Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control (GlobeNewswire) +6.57%
Oct-12-23 11:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -32.31%
Oct-11-23 07:30AM	Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894 (GlobeNewswire) +87.05%
Sep-06-23 07:30AM	Phio CEO to Speak at Wainwright Conference in New York in September (GlobeNewswire)
Aug-21-23 07:30AM	Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute (GlobeNewswire)
Aug-10-23 04:30PM	Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-02-23 01:30PM	Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
May-31-23 08:00AM	Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) -13.15%
May-24-23 07:30AM	Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute (PR Newswire)
12:00PM	Loading…
May-18-23 12:00PM	Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells (PR Newswire) +34.31%
May-16-23 07:30AM	Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas (PR Newswire) +21.36%
May-11-23 05:00PM	Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -10.14%
Apr-20-23 02:20PM	Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Apr-18-23 12:10PM	Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -19.24%
07:30AM	Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL (PR Newswire)
Apr-17-23 07:30AM	Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity (PR Newswire) +18.48%
Mar-22-23 05:05PM	Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update (PR Newswire) +8.22%
Feb-22-23 07:30AM	Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer (PR Newswire)
Feb-13-23 07:30AM	Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Feb-10-23 07:30AM	Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification (PR Newswire) -11.68%
Jan-25-23 08:30AM	Phio Pharmaceuticals Announces Reverse Stock Split (PR Newswire) -6.45%
Jan-06-23 04:30PM	Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco (PR Newswire) +40.26%
01:30PM	Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors (PR Newswire)
Dec-21-22 04:15PM	Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma (PR Newswire)
Nov-10-22 06:25PM	Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.13% -11.07%
05:05PM	Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
09:00AM	Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th (PR Newswire)
Oct-25-22 12:00PM	What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock (Zacks)
Oct-12-22 09:38AM	Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS (Zacks) +9.19%
Oct-07-22 05:42PM	Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia (Zacks)
Oct-06-22 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PR Newswire)
Sep-29-22 08:30AM	Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman (PR Newswire) -5.20%
Sep-27-22 03:51PM	Encompass Health (EHC) Plans Hospital to Aid Florida Footprint (Zacks)
Sep-26-22 12:09PM	Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug (Zacks)
Sep-22-22 07:30AM	Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference (PR Newswire)
Sep-12-22 07:30AM	Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PR Newswire)
Aug-11-22 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Jul-11-22 06:53AM	Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Is About To Turn The Corner (Simply Wall St.)
Jun-06-22 02:15PM	Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting (PR Newswire)
May-16-22 12:22PM	Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells (Benzinga)
08:00AM	Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022 (PR Newswire)
May-12-22 04:50PM	Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-05-22 08:33AM	Phio Pharmaceuticals Announces Senior Leadership Personnel Change (PR Newswire)
May-03-22 07:30AM	Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022 (PR Newswire)
May-02-22 04:30PM	Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022 (PR Newswire)
07:30AM	Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors (PR Newswire)
Apr-26-22 10:15AM	Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma (PR Newswire) -8.77%
Apr-18-22 09:30AM	Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer (PR Newswire)
Apr-11-22 03:39PM	We're Keeping An Eye On Phio Pharmaceuticals' (NASDAQ:PHIO) Cash Burn Rate (Simply Wall St.) -25.53%
10:41AM	Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism (GlobeNewswire)
Apr-08-22 01:00PM	Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022 (PR Newswire) +159.18%
Mar-22-22 05:00PM	Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update (PR Newswire)
Mar-08-22 04:30PM	Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022 (PR Newswire) +5.71%
Feb-22-22 09:30AM	Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2 (PR Newswire)
Jan-11-22 12:30PM	3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today (InvestorPlace) +8.41%
07:30AM	Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma (PR Newswire)
Jan-03-22 07:30AM	Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference (PR Newswire) +9.00%
Dec-06-21 09:28AM	Analysts Expect Breakeven For Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Before Long (Simply Wall St.) +5.08%
Nov-12-21 07:00AM	Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting (PR Newswire)
Nov-10-21 04:40PM	Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Oct-18-21 07:05AM	Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting (PR Newswire)
Oct-07-21 09:00AM	Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-30-21 08:05AM	Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021 (PR Newswire)
Sep-16-21 12:12PM	38 Stocks Moving In Thursday's Mid-Day Session (Benzinga) +10.66%
08:08AM	Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation (Benzinga)
07:40AM	20 Stocks Moving in Thursday's Pre-Market Session (Benzinga)
07:05AM	Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 (PR Newswire)
Sep-03-21 07:05AM	Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th (PR Newswire)
Aug-31-21 08:05AM	Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 (PR Newswire) +8.33%
Aug-12-21 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Jul-07-21 04:30PM	Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th (PR Newswire)
Jun-22-21 11:04AM	Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th (PR Newswire)
Jun-14-21 04:09PM	Is Phio Pharmaceuticals Corp. (PHIO) A Good Stock To Buy? (Insider Monkey) +9.05% -6.22%
08:00AM	Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June (PR Newswire)
Jun-04-21 08:00AM	Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches (PR Newswire)
May-13-21 05:00PM	Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update (PR Newswire) -8.78%
May-11-21 01:10PM	Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies (Benzinga) -14.12%
08:00AM	Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells (PR Newswire)
Apr-29-21 07:30AM	Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings (PR Newswire)

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bitterman Robert J	President & CEO	Jun 07 '24	Buy	0.74	1,000	740	20,990	Jun 11 05:00 PM
Bitterman Robert J	President & CEO	Jun 06 '24	Buy	0.75	1,000	750	19,990	Jun 10 05:00 PM
Bitterman Robert J	President & CEO	Feb 26 '24	Buy	0.91	2,500	2,275	18,990	Feb 27 04:42 PM
Bitterman Robert J	President & CEO	Jul 01 '23	Buy	2.84	1,000	2,840	19,211	Jul 05 06:00 PM
Bitterman Robert J	President & CEO	Jun 30 '23	Buy	2.88	1,000	2,880	18,211	Jul 05 06:00 PM

Open in Screener

CRNX

Crinetics Pharmaceuticals Inc

Jun 20 • 04:00PM ET

44.21

Dollar change -0.08
Percentage change -0.18	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

CRNX Crinetics Pharmaceuticals Inc daily Stock Chart

Held by: VTI XBI IWM VXF IBB IWN SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-3.77	Insider Own	6.72%	Shs Outstand	78.86M	Perf Week	-7.47%
Market Cap	3.49B	Forward P/E	-	EPS next Y	-3.82	Insider Trans	-6.14%	Shs Float	73.56M	Perf Month	-12.66%
Income	-235.46M	PEG	-	EPS next Q	-0.86	Inst Own	98.60%	Short Float	6.83%	Perf Quarter	-2.81%
Sales	0.00M	P/S	-	EPS this Y	3.77%	Inst Trans	1.29%	Short Ratio	5.60	Perf Half Y	32.96%
Book/sh	11.14	P/B	3.97	EPS next Y	-7.45%	ROA	-36.44%	Short Interest	5.03M	Perf Year	121.27%
Cash/sh	11.42	P/C	3.87	EPS next 5Y	-	ROE	-40.76%	52W Range	15.76 - 53.70	Perf YTD	24.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.59%	ROI	-25.55%	52W High	-17.67%	Beta	0.68
Dividend TTM	-	Quick Ratio	17.72	Sales past 5Y	64.83%	Gross Margin	-105.50%	52W Low	180.52%	ATR (14)	1.87
Dividend Ex-Date	-	Current Ratio	17.72	EPS Y/Y TTM	-15.15%	Oper. Margin	0.00%	RSI (14)	42.17	Volatility	3.05% 4.26%
Employees	290	Debt/Eq	0.06	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.23	Target Price	67.92
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-8.52%	Payout	-	Rel Volume	0.53	Prev Close	44.29
Sales Surprise	220.00%	EPS Surprise	-14.87%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	897.34K	Price	44.21
SMA20	-4.80%	SMA50	-4.63%	SMA200	18.93%	Trades		Volume	478,094	Change	-0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43
Aug-13-18	Initiated	JP Morgan	Neutral	$29

Show Previous Ratings

Jun-18-24 04:30PM	EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year 2024 Pacific Southwest Award Winner (GlobeNewswire)
Jun-12-24 02:38AM	Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ... (GuruFocus.com) +6.60%
Jun-10-24 06:35PM	Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 12:16PM	Crinetics Unveils 'Stunning' Results In Highly Anticipated Study (Investor's Business Daily)
12:00PM	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly (GlobeNewswire)
12:00PM	Loading…
12:00PM	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) (GlobeNewswire)
May-31-24 02:46AM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
May-30-24 04:05PM	Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
May-22-24 08:00AM	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-13-24 10:53AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 05:38PM	Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:03PM	Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing (MT Newswires)
12:47PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results (GuruFocus.com)
May-09-24 08:55PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:35PM	Loading…
05:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:03PM	Crinetics Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 04:05PM	Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 (GlobeNewswire) +6.78%
May-07-24 08:55AM	Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating (MT Newswires)
May-02-24 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-28-24 08:10AM	Insiders Are Dumping These 5 Healthcare Stocks (Insider Monkey) +5.36%
Mar-26-24 07:01PM	Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-22-24 07:02PM	Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ... (GuruFocus.com)
07:02PM	Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-21-24 02:32AM	Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares (GuruFocus.com)
Mar-20-24 11:46AM	Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals (Zacks)
05:14AM	Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar? (Zacks)
Mar-19-24 04:48PM	Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why (Benzinga) +19.11%
04:03PM	Loading…
04:03PM	Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win (Investor's Business Daily)
08:08AM	Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win (Investor's Business Daily)
06:16AM	UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study (Reuters)
06:08AM	Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study (Reuters)
06:00AM	Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients (GlobeNewswire)
Mar-12-24 04:05PM	Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Mar-11-24 04:05PM	Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:57AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.43%
Feb-28-24 04:36PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ... (GuruFocus.com) +5.66%
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement (GlobeNewswire)
Feb-15-24 03:14AM	Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc (GuruFocus.com)
Feb-14-24 04:05PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 04:05PM	Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.42%
Jan-26-24 11:01PM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Company Shares (GuruFocus.com)
Jan-13-24 05:03AM	Crinetics Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-10-24 04:33PM	Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 03:03AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ... (GuruFocus.com)
Jan-03-24 08:00AM	Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 07:02AM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares (GuruFocus.com)
Dec-23-23 05:01AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ... (GuruFocus.com)
Dec-18-23 04:05PM	Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire) +11.49%
Dec-11-23 04:05PM	Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-23 05:25AM	12 Stocks Billionaire Steve Cohen Just Bought and Sold (Insider Monkey)
Nov-20-23 04:05PM	Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-17-23 08:39AM	Billionaire Steve Cohen Goes Big on These 2 Strong Buy Stocks Heres Why You Should Follow (TipRanks) +5.82%
Nov-10-23 05:00PM	Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.01%
Nov-09-23 05:45AM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth (GuruFocus.com) -6.19%
Nov-08-23 09:55AM	Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High? (Zacks)
08:50AM	Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength (Zacks)
Nov-07-23 04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-23 05:03AM	Insider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Oct-23-23 09:55AM	Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet (Zacks)
08:50AM	What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing' (Zacks)
Oct-20-23 01:02AM	Insider Sell: Chief Medical Officer Alan Krasner Sells 7,000 Shares of Crinetics Pharmaceuticals Inc (GuruFocus.com) +5.92%
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Oct-10-23 05:00PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-23 07:00AM	7 Speculative Stocks Set to Explode Higher (InvestorPlace)
Sep-28-23 11:18AM	Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why (Zacks)
Sep-20-23 08:00AM	Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023 (GlobeNewswire)
Sep-15-23 08:37AM	Why Crinetics Pharmaceuticals Stock Soared This Week (Motley Fool)
Sep-12-23 10:26PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +17.29% -6.70%
Sep-11-23 04:04PM	Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63% (Investor's Business Daily) +63.31%
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
12:57PM	Why Shares of Crinetics Pharmaceuticals Are Jumping Monday (Motley Fool)
06:00AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:43AM	Crinetics shares surge after "positive" hormonal disorder drug trial results (Investing.com)
Sep-10-23 10:00AM	Crinetics Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly (GlobeNewswire)
Sep-05-23 08:55PM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Aug-13-23 09:02AM	Will Crinetics Pharmaceuticals (NASDAQ:CRNX) Spend Its Cash Wisely? (Simply Wall St.)
Aug-10-23 05:34PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 07:00AM	Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-23 08:01AM	Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly (GlobeNewswire)
Jul-10-23 04:18PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
Jun-21-23 07:59AM	New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023 (GlobeNewswire)
Jun-12-23 07:30AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-09-23 07:30AM	Crinetics to Highlight Broad Pipeline at ENDO 2023 (GlobeNewswire)
May-10-23 04:21PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.27%
May-06-23 08:07AM	Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-04-23 07:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
Apr-16-23 09:34AM	The past year for Crinetics Pharmaceuticals (NASDAQ:CRNX) investors has not been profitable (Simply Wall St.)
Apr-10-23 04:31PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-28-23 03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-10-23 04:37PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.05%
Mar-06-23 07:05AM	We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-28-23 05:25PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-10-23 05:21PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Betz Stephen F.	Chief Scientific Officer	Jun 10 '24	Sale	43.86	3,000	131,580	83,643	Jun 11 04:35 PM
Betz Stephen F.	Chief Scientific Officer	May 28 '24	Sale	47.49	3,000	142,470	86,643	May 30 04:28 PM
Betz Stephen F.	Chief Scientific Officer	May 10 '24	Sale	49.43	3,000	148,290	89,643	May 14 06:29 PM
Struthers Richard Scott	President & CEO	May 08 '24	Option Exercise	9.28	107,448	997,117	364,933	May 10 04:57 PM
Struthers Richard Scott	President & CEO	May 08 '24	Sale	49.40	107,448	5,307,931	257,485	May 10 04:57 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Option Exercise	16.89	14,375	242,794	42,161	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 15 '24	Option Exercise	1.91	20,000	38,200	257,835	Apr 17 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Sale	44.47	14,375	639,256	27,786	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Option Exercise	9.28	40,951	380,025	278,786	Apr 08 05:09 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Sale	49.17	40,951	2,013,561	237,835	Apr 08 05:09 PM
Okey Stephanie	Director	Mar 28 '24	Option Exercise	18.29	17,500	320,075	23,500	Apr 02 04:35 PM
Okey Stephanie	Director	Mar 28 '24	Sale	46.38	17,500	811,650	6,000	Apr 02 04:35 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Option Exercise	23.98	30,000	719,400	84,939	Mar 26 04:30 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Sale	44.31	32,359	1,433,675	52,580	Mar 26 04:30 PM
Fust Matthew K	Director	Mar 20 '24	Option Exercise	20.92	60,000	1,254,975	36,036	Mar 22 04:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Option Exercise	16.89	14,375	242,794	38,500	Mar 22 04:52 PM
Fust Matthew K	Director	Mar 20 '24	Sale	44.14	60,000	2,648,150	18,536	Mar 22 04:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Sale	44.06	15,089	664,763	27,786	Mar 22 04:52 PM
Wilson Marc	CFO	Mar 19 '24	Sale	42.91	6,942	297,881	110,630	Mar 20 06:32 PM
Betz Stephen F.	Chief Scientific Officer	Jan 25 '24	Sale	37.26	3,000	111,780	73,298	Jan 26 05:50 PM
Betz Stephen F.	Chief Scientific Officer	Jan 10 '24	Sale	37.65	3,000	112,950	76,298	Jan 12 04:12 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Option Exercise	16.89	14,375	242,794	20,286	Jan 04 04:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Sale	35.00	14,375	503,125	5,911	Jan 04 04:45 PM
Wilson Marc	CFO	Jan 02 '24	Option Exercise	9.28	10,000	92,800	106,055	Jan 04 04:43 PM
Wilson Marc	CFO	Jan 02 '24	Sale	35.47	10,000	354,700	96,055	Jan 04 04:43 PM
Betz Stephen F.	Chief Scientific Officer	Dec 26 '23	Sale	35.89	3,000	107,670	79,298	Dec 27 05:20 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Option Exercise	16.89	9,583	161,857	15,494	Dec 22 06:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Sale	34.57	9,583	331,284	5,911	Dec 22 06:45 PM
Betz Stephen F.	Chief Scientific Officer	Dec 11 '23	Sale	32.87	3,000	98,610	82,298	Dec 13 04:44 PM
Betz Stephen F.	Chief Scientific Officer	Nov 27 '23	Sale	31.84	3,000	95,520	85,298	Nov 29 04:31 PM
Struthers Richard Scott	President & CEO	Nov 09 '23	Option Exercise	1.91	50,000	95,500	185,522	Nov 13 04:33 PM
Struthers Richard Scott	President & CEO	Nov 03 '23	Option Exercise	9.28	199,082	1,847,481	334,604	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 03 '23	Sale	30.56	199,082	6,083,946	135,522	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 02 '23	Option Exercise	9.28	918	8,519	136,440	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 02 '23	Sale	29.95	918	27,494	135,522	Nov 06 06:02 PM
Wilson Marc	CFO	Nov 01 '23	Option Exercise	9.28	10,000	92,800	105,601	Nov 03 07:38 PM
Wilson Marc	CFO	Nov 01 '23	Sale	28.75	10,000	287,500	95,601	Nov 03 07:38 PM
Krasner Alan Seth	Chief Medical Officer	Oct 17 '23	Option Exercise	12.01	7,000	84,070	50,210	Oct 19 05:01 PM
Krasner Alan Seth	Chief Medical Officer	Oct 17 '23	Sale	30.00	7,000	210,000	43,210	Oct 19 05:01 PM
Struthers Richard Scott	President & CEO	Aug 14 '23	Option Exercise	1.91	10,000	19,100	135,522	Aug 16 04:30 PM
Struthers Richard Scott	President & CEO	Jul 13 '23	Sale	20.35	14,157	288,095	630,805	Jul 13 04:56 PM
Struthers Richard Scott	President & CEO	Jul 12 '23	Sale	20.17	11,459	231,128	644,962	Jul 13 04:56 PM
Struthers Richard Scott	President & CEO	Jul 11 '23	Sale	20.14	24,384	491,094	656,421	Jul 13 04:56 PM

Open in Screener

PTGX

Protagonist Therapeutics Inc

Jun 20 • 04:00PM ET

31.43

Dollar change -1.16
Percentage change -3.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

PTGX Protagonist Therapeutics Inc daily Stock Chart

Held by: XBI VTI IWM VXF IBB IWO SCHA LABU IWN VTWO

Index	RUT	P/E	12.83	EPS (ttm)	2.45	Insider Own	5.55%	Shs Outstand	57.71M	Perf Week	-7.48%
Market Cap	1.84B	Forward P/E	-	EPS next Y	-1.41	Insider Trans	-4.22%	Shs Float	55.40M	Perf Month	0.54%
Income	162.11M	PEG	-	EPS next Q	-0.60	Inst Own	99.17%	Short Float	6.10%	Perf Quarter	8.83%
Sales	314.95M	P/S	5.85	EPS this Y	220.33%	Inst Trans	-9.30%	Short Ratio	6.07	Perf Half Y	51.62%
Book/sh	9.56	P/B	3.29	EPS next Y	-184.59%	ROA	37.30%	Short Interest	3.38M	Perf Year	16.45%
Cash/sh	5.50	P/C	5.71	EPS next 5Y	-	ROE	41.75%	52W Range	13.72 - 35.96	Perf YTD	37.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.38%	ROI	28.93%	52W High	-12.60%	Beta	2.11
Dividend TTM	-	Quick Ratio	15.72	Sales past 5Y	2462.45%	Gross Margin	98.95%	52W Low	129.08%	ATR (14)	1.64
Dividend Ex-Date	-	Current Ratio	15.72	EPS Y/Y TTM	191.97%	Oper. Margin	47.21%	RSI (14)	50.39	Volatility	4.50% 5.47%
Employees	112	Debt/Eq	0.00	Sales Y/Y TTM	36565.08%	Profit Margin	51.47%	Recom	1.17	Target Price	43.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	588.87%	Payout	-	Rel Volume	1.04	Prev Close	32.59
Sales Surprise	-2.88%	EPS Surprise	-3.17%	Sales Q/Q	-	Earnings	May 08 AMC	Avg Volume	557.36K	Price	31.43
SMA20	-0.84%	SMA50	8.28%	SMA200	32.54%	Trades		Volume	581,936	Change	-3.56%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23
May-09-19	Upgrade	Stifel	Hold → Buy	$11 → $17
Dec-06-18	Initiated	Nomura	Buy	$13
Jan-29-18	Initiated	Stifel	Buy	$32
Jul-21-17	Initiated	BTIG Research	Buy	$36

Show Previous Ratings

Jun-14-24 03:00AM	Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control (ACCESSWIRE)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace) +16.10%
May-31-24 07:30AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 (ACCESSWIRE)
May-14-24 04:05PM	Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress (ACCESSWIRE) +6.28%
May-07-24 11:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.12%
09:04PM	Loading…
09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)
04:23PM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event (ACCESSWIRE)
04:05PM	Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
07:00AM	Loading…
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
04:05PM	Loading…
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +8.05%
04:05PM	Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
09:05AM	Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting (ACCESSWIRE)
Nov-01-23 04:05PM	Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis (ACCESSWIRE)
07:30AM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Oct-30-23 04:05PM	Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors (ACCESSWIRE)
Oct-09-23 07:00AM	Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications (ACCESSWIRE)
Oct-03-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Sep-05-23 07:30AM	Protagonist Therapeutics to Present at Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Aug-09-23 07:00AM	Protagonist Receives $34 Million from Warrant Exercises (ACCESSWIRE)
Aug-03-23 04:48PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-18-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Jul-05-23 09:33AM	Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment (Benzinga)
Jul-04-23 03:30AM	Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis (ACCESSWIRE)
Jun-30-23 08:50AM	Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-15-23 09:55AM	Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know (Zacks)
Jun-13-23 08:50AM	Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going (Zacks)
Jun-09-23 08:05AM	Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV (ACCESSWIRE)
Jun-06-23 07:30AM	Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress (ACCESSWIRE)
Jun-01-23 04:01PM	Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (ACCESSWIRE) +5.45%
May-26-23 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01% (Zacks)
May-12-23 03:14PM	Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment (Benzinga)
07:00AM	Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 (PR Newswire)
May-11-23 04:05PM	Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference (PR Newswire)
10:17AM	Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association (PR Newswire)
May-05-23 04:03PM	Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm (Investor's Business Daily) +5.13%
May-04-23 05:02PM	Protagonist Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Apr-20-23 09:51PM	Why Shares of Protagonist Therapeutics Rose This Week (Motley Fool)
Apr-17-23 06:35AM	Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share Price (Simply Wall St.) +10.03%
Apr-04-23 10:45PM	Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock (ACCESSWIRE) -5.57% -16.38%
04:11PM	Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock (ACCESSWIRE)
Mar-21-23 03:49AM	Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength? (Zacks)
Mar-20-23 06:08AM	Analysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts (Simply Wall St.)
Mar-17-23 06:06AM	Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-15-23 04:01PM	Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
01:39PM	Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study (Benzinga)
07:30AM	Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera (ACCESSWIRE)
Mar-09-23 11:14AM	Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More (Zacks)
Mar-08-23 12:19PM	Protagonist (PTGX) Up on Positive Results From FRONTIER Study (Zacks)
10:02AM	Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-07-23 11:54AM	Why Protagonist Therapeutics Shares Are Trading Higher Today (Benzinga) +51.91%
08:00AM	Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis (PR Newswire)
Jan-25-23 03:24AM	Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last? (Zacks)
Jan-14-23 07:14AM	Are Investors Undervaluing Protagonist Therapeutics, Inc. (NASDAQ:PTGX) By 50%? (Simply Wall St.)
Dec-21-22 04:05PM	Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) +5.05%
Dec-05-22 09:55AM	Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-01-22 07:05AM	Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-16-22 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (PR Newswire)
Nov-11-22 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337% (Zacks)
05:11AM	Protagonist Therapeutics Third Quarter 2022 Earnings: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:05PM	Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 09:16AM	Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting (PR Newswire)
Oct-12-22 06:10AM	Investors in Protagonist Therapeutics (NASDAQ:PTGX) have unfortunately lost 74% over the last year (Simply Wall St.)
Oct-05-22 09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect? (Zacks)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waddill William D.	Director	Jun 07 '24	Option Exercise	12.88	8,000	103,040	20,000	Jun 11 04:30 PM
PATEL DINESH V PH D	President and CEO	Jun 07 '24	Sale	35.19	35,000	1,231,650	515,415	Jun 11 04:30 PM
Waddill William D.	Director	Jun 07 '24	Sale	35.00	8,000	280,000	12,000	Jun 11 04:30 PM
Ali Asif	Chief Financial Officer	Apr 18 '24	Sale	25.11	1,234	30,986	37,163	Apr 19 08:05 PM
PATEL DINESH V PH D	President and CEO	Apr 01 '24	Sale	28.31	25,000	707,750	549,590	Apr 02 08:29 PM
SELICK HAROLD E	Director	Mar 07 '24	Option Exercise	1.89	6,490	12,266	27,996	Mar 11 08:00 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Option Exercise	12.17	12,000	146,040	52,645	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Option Exercise	6.09	12,975	79,018	24,975	Mar 01 08:45 PM
PATEL DINESH V PH D	President and CEO	Mar 01 '24	Sale	31.62	30,000	948,600	574,590	Mar 01 08:46 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Sale	32.24	14,248	459,318	38,397	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Sale	31.34	12,975	406,636	12,000	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Feb 29 '24	Sale	30.69	9,939	305,048	40,645	Mar 01 08:45 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Option Exercise	7.38	5,000	36,900	192,567	Jan 11 08:00 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Sale	25.00	5,000	125,000	187,567	Jan 11 08:00 PM
PATEL DINESH V PH D	President and CEO	Dec 13 '23	Sale	20.08	75,000	1,506,000	534,347	Dec 15 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '23	Sale	16.24	1,848	30,012	22,527	Jan 04 08:09 PM
Gupta Suneel	Chief Development Officer	Oct 19 '23	Option Exercise	7.38	20,000	147,600	168,317	Oct 23 04:31 PM
PATEL DINESH V PH D	President and CEO	Oct 18 '23	Option Exercise	4.21	6,000	25,260	609,347	Oct 19 04:55 PM

Open in Screener

CYTK

Cytokinetics Inc

Jun 20 • 04:00PM ET

51.82

Dollar change -0.12
Percentage change -0.23	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IJH VTI VB IWM VBK VXF XBI MDY IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-5.40	Insider Own	3.30%	Shs Outstand	114.66M	Perf Week	-4.11%
Market Cap	5.94B	Forward P/E	-	EPS next Y	-4.36	Insider Trans	-7.10%	Shs Float	110.87M	Perf Month	-14.49%
Income	-530.60M	PEG	-	EPS next Q	-1.08	Inst Own	101.16%	Short Float	14.81%	Perf Quarter	-23.07%
Sales	3.75M	P/S	1584.45	EPS this Y	16.56%	Inst Trans	-1.36%	Short Ratio	8.69	Perf Half Y	43.59%
Book/sh	-3.78	P/B	-	EPS next Y	4.09%	ROA	-62.50%	Short Interest	16.42M	Perf Year	45.32%
Cash/sh	5.40	P/C	9.59	EPS next 5Y	15.00%	ROE	-	52W Range	25.98 - 110.25	Perf YTD	-37.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.79%	ROI	-161.27%	52W High	-53.00%	Beta	0.75
Dividend TTM	-	Quick Ratio	7.19	Sales past 5Y	12.30%	Gross Margin	-254.77%	52W Low	99.46%	ATR (14)	2.59
Dividend Ex-Date	-	Current Ratio	7.19	EPS Y/Y TTM	-17.98%	Oper. Margin	-13272.04%	RSI (14)	41.98	Volatility	3.52% 4.67%
Employees	423	Debt/Eq	-	Sales Y/Y TTM	-96.17%	Profit Margin	-14141.74%	Recom	1.44	Target Price	83.35
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	3.54%	Payout	-	Rel Volume	0.57	Prev Close	51.94
Sales Surprise	-8.52%	EPS Surprise	-16.29%	Sales Q/Q	-81.90%	Earnings	May 08 AMC	Avg Volume	1.89M	Price	51.82
SMA20	-0.45%	SMA50	-13.63%	SMA200	-6.58%	Trades		Volume	1,080,095	Change	-0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-24-24	Downgrade	UBS	Buy → Neutral	$61 → $92
Jan-05-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$60 → $90
Nov-09-23	Initiated	Goldman	Buy	$50
Nov-07-23	Initiated	B. Riley Securities	Buy	$66
Aug-15-23	Initiated	SVB Securities	Outperform	$58
Feb-17-23	Initiated	BofA Securities	Neutral	$49
Dec-23-22	Reiterated	Needham	Buy	$60 → $58
Dec-20-22	Initiated	Truist	Buy	$60
Oct-11-22	Initiated	UBS	Buy	$80
Jan-28-22	Initiated	Goldman	Buy	$74
Dec-22-21	Initiated	Oppenheimer	Outperform	$55
Dec-10-21	Initiated	JP Morgan	Overweight	$58
Oct-07-21	Initiated	Jefferies	Buy	$75
Mar-12-21	Initiated	Wolfe Research	Outperform	$50
Feb-18-21	Initiated	Barclays	Overweight	$28
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$22 → $41
Oct-29-20	Initiated	Goldman	Neutral	$16
Jul-10-20	Initiated	Raymond James	Strong Buy	$39
May-05-20	Initiated	Mizuho	Buy	$31
Apr-09-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$25

Show Previous Ratings

Jun-18-24 01:49AM	Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) (GuruFocus.com)
Jun-17-24 07:30AM	Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants (GlobeNewswire)
Jun-12-24 02:37AM	Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development (GuruFocus.com)
Jun-10-24 07:00PM	Insider Sale: Director Muna Bhanji Sells Shares of Cytokinetics Inc (CYTK) (GuruFocus.com)
Jun-05-24 07:55AM	Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks (BioPharma Dive) +12.75%
06:14AM	Loading…
06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
03:00AM	Insider Sale: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) (GuruFocus.com)
Jun-04-24 04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:38AM	Insider Sale: VP, Chief Accounting Officer Robert Wong Sells Shares of Cytokinetics Inc (CYTK) (GuruFocus.com)
May-29-24 04:00PM	Cytokinetics to Participate in June Investor Conferences (GlobeNewswire)
May-28-24 04:00PM	Cytokinetics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
May-27-24 06:28PM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-24-24 11:12AM	Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday (Zacks)
May-23-24 09:40AM	Investors say 'no bueno' as Cytokinetics stymies M&A prospects with complex Royalty deal (FierceBiotech.com) -17.31%
07:50AM	Loading…
07:50AM	Cytokinetics secures up to $575M in royalty deal, frustrating investors (BioPharma Dive)
May-22-24 11:30PM	Cytokinetics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:10PM	Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
04:02PM	Cytokinetics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:00PM	Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
May-17-24 07:30AM	Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology (GlobeNewswire)
May-15-24 07:30AM	Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024 (GlobeNewswire)
May-14-24 04:01PM	Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug (Investor's Business Daily)
May-13-24 05:24PM	Health Care Roundup: Market Talk (The Wall Street Journal) -6.78%
04:08PM	Cytokinetics Slumps Despite 'Pristine' Results For Bristol Myers-Rivaling Heart Drug (Investor's Business Daily)
09:43AM	Cytokinetics Reveals More From The Study That Boosted Shares 83% (Investor's Business Daily)
09:33AM	Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine (GlobeNewswire)
09:33AM	Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress (GlobeNewswire)
09:11AM	Cytokinetics shows hand in high stakes rivalry with BMS' Camzyos (FierceBiotech.com)
May-10-24 12:37PM	Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials (GuruFocus.com)
10:48AM	Loading…
May-09-24 10:48AM	Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating (MT Newswires)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:01AM	Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ... (GuruFocus.com)
May-08-24 09:00PM	CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:18PM	Cytokinetics Q1 Net Loss Narrows, Revenue Declines (MT Newswires)
05:10PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:06PM	Cytokinetics: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cytokinetics Reports First Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 (GlobeNewswire)
07:30AM	Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy (GlobeNewswire)
02:23AM	Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells Shares (GuruFocus.com)
May-07-24 05:02PM	Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing (MT Newswires)
04:00PM	Cytokinetics to Hold Annual Meeting of Stockholders (GlobeNewswire)
02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
May-02-24 04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 10:01AM	Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-29-24 04:00PM	Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress (GlobeNewswire)
Apr-26-24 04:44PM	Cytokinetics Appoints Sung Lee as CFO (MT Newswires)
06:00AM	3 Biotech Stocks to Buy on the Dip: April 2024 (InvestorPlace)
Apr-24-24 04:00PM	Cytokinetics to Announce First Quarter Results on May 8, 2024 (GlobeNewswire)
Apr-10-24 09:27AM	This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? (MarketWatch)
07:30AM	Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress (GlobeNewswire)
Apr-09-24 07:00PM	EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK) (GuruFocus.com)
Apr-05-24 07:30AM	Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73 Annual Scientific Session (GlobeNewswire) +5.10%
Apr-02-24 04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-24 04:00PM	Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-24 08:15AM	Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session (GlobeNewswire)
Mar-20-24 08:30AM	2 Incredible Growth Stocks to Buy Right Now (Motley Fool)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace) +6.02%
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
Mar-12-24 06:46AM	Q4 2023 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 04:00PM	Cytokinetics to Participate in March Investor Conferences (GlobeNewswire) -8.52%
Mar-01-24 06:47PM	Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 07:30AM	Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day (GlobeNewswire)
Feb-28-24 10:27AM	No ongoing sale process at Cytokinetics, CEO says following Novartis acquisition rumors (FierceBiotech.com) -9.75%
10:22AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:30AM	Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials (GlobeNewswire)
Feb-27-24 05:10PM	Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:42PM	Cytokinetics Inc (CYTK) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:17PM	Cytokinetics: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Cytokinetics Reports Fourth Quarter 2023 Financial Results (GlobeNewswire)
Feb-13-24 04:00PM	Cytokinetics to Announce Fourth Quarter Results on February 27, 2024 (GlobeNewswire)
Feb-12-24 12:38AM	Cytokinetics, Incorporated (CYTK) Rose on Successful Clinical Trial (Insider Monkey)
Feb-09-24 10:01AM	How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month (Investor's Business Daily)
Feb-08-24 09:10AM	3 Biotech Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Feb-06-24 04:00PM	Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-05-24 05:30PM	Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H (The Wall Street Journal)
Jan-29-24 07:30AM	Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program (GlobeNewswire)
Jan-25-24 07:30AM	Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten (GlobeNewswire)
Jan-18-24 01:00PM	Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024 (GlobeNewswire)
Jan-12-24 04:40PM	Todays Stock Market Movers: JPMorgan, Bank of America, Citigroup, Delta, United, UnitedHealth, Tesla, and More (Barrons.com) -5.15%
02:47PM	Cytokinetics (CYTK) Down on Report of Novartis Not Interested (Zacks)
01:07PM	These Stocks Are Moving the Most Today: JPMorgan, Bank of America, Citigroup, Delta, United, UnitedHealth, Tesla, and More (Barrons.com)
05:27AM	Novartis reportedly backs out of Cytokinetics deal, denting biotech's stock (FierceBiotech.com)
Jan-11-24 04:22PM	Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition (Benzinga) -16.41%
04:05PM	Cytokinetics, Albertsons, Kroger, Boeing: Trending tickers (Yahoo Finance Video)
12:58PM	Cytokinetics Stock Drops After Journal Report That Novartis Deal Might Be Off (The Wall Street Journal)
12:54PM	UPDATE 1-Novartis drops pursuit of Cytokinetics - WSJ (Reuters)
12:47PM	Novartis Pursuit of Cytokinetics Cools (The Wall Street Journal)
12:30PM	Novartis drops pursuit of Cytokinetics - WSJ (Reuters)
Jan-10-24 01:04PM	Cytokinetics Deal Rumors Take Traders on White-Knuckle Ride (Bloomberg)
Jan-09-24 01:17PM	Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis (Zacks) -5.64%
Jan-08-24 05:14PM	Novartis in Advanced Talks to Buy Cytokinetics (The Wall Street Journal) +15.29%
04:42PM	Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout. (Investor's Business Daily)
02:12PM	Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal (Investor's Business Daily)
01:11PM	Cytokinetics Stock Jumps After Report of Possible Novartis Deal (The Wall Street Journal)
01:05PM	Novartis in advanced talks to buy Cytokinetics- WSJ (Reuters)
Jan-03-24 04:00PM	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PARSHALL B LYNNE	Director	Jun 17 '24	Option Exercise	10.68	5,000	53,400	25,600	Jun 17 05:17 PM
Blum Robert I	President & CEO	Jun 17 '24	Sale	52.60	22,500	1,183,391	416,645	Jun 17 05:13 PM
PARSHALL B LYNNE	Director	Jun 17 '24	Sale	52.55	5,000	262,750	20,600	Jun 17 05:17 PM
Malik Fady Ibraham	EVP Research & Development	Jun 11 '24	Option Exercise	7.96	5,422	43,159	142,792	Jun 11 04:22 PM
Malik Fady Ibraham	EVP Research & Development	Jun 11 '24	Sale	53.04	7,788	413,106	135,004	Jun 11 04:22 PM
Bhanji Muna	Director	Jun 10 '24	Sale	52.07	2,000	104,140	17,631	Jun 10 04:15 PM
Blum Robert I	President & CEO	Jun 04 '24	Sale	48.85	22,500	1,099,125	439,145	Jun 07 04:03 PM
PARSHALL B LYNNE	Director	Jun 03 '24	Option Exercise	10.68	5,000	53,400	20,600	Jun 04 04:30 PM
Wong Robert	VP, Chief Accounting Officer	Jun 03 '24	Sale	48.88	13,011	635,978	16,653	Jun 03 04:33 PM
PARSHALL B LYNNE	Director	Jun 03 '24	Sale	48.64	5,000	243,200	15,600	Jun 04 04:30 PM
Harrington Robert Arthur	Director	Jun 03 '24	Sale	48.64	1,580	76,851	15,541	Jun 05 05:23 PM
Malik Fady Ibraham	EVP Research & Development	May 07 '24	Option Exercise	6.67	14,186	94,621	152,603	May 07 04:37 PM
Malik Fady Ibraham	EVP Research & Development	May 07 '24	Sale	65.11	15,547	1,012,265	137,056	May 07 04:37 PM
HENDERSON JOHN T	Director	Apr 25 '24	Sale	64.54	10,562	681,671	32,070	Apr 25 06:54 PM
Malik Fady Ibraham	EVP Research & Development	Apr 09 '24	Option Exercise	6.67	28,605	190,795	171,172	Apr 09 04:38 PM
Malik Fady Ibraham	EVP Research & Development	Apr 09 '24	Sale	74.31	32,605	2,422,918	138,567	Apr 09 04:38 PM
Malik Fady Ibraham	EVP Research & Development	Mar 05 '24	Option Exercise	6.67	28,604	190,789	167,577	Mar 05 04:05 PM
Malik Fady Ibraham	EVP Research & Development	Mar 05 '24	Sale	67.56	32,604	2,202,606	138,973	Mar 05 04:05 PM
HENDERSON JOHN T	Director	Feb 14 '24	Option Exercise	4.44	5,000	22,200	47,632	Feb 14 04:04 PM
HENDERSON JOHN T	Director	Feb 14 '24	Sale	76.48	5,000	382,400	42,632	Feb 14 04:04 PM
Blum Robert I	President & CEO	Feb 13 '24	Option Exercise	6.67	12,500	83,375	454,297	Feb 13 04:01 PM
Blum Robert I	President & CEO	Feb 13 '24	Sale	76.85	12,500	960,625	441,797	Feb 13 04:01 PM
Malik Fady Ibraham	EVP Research & Development	Feb 06 '24	Option Exercise	6.67	28,605	190,795	175,578	Feb 06 04:43 PM
Malik Fady Ibraham	EVP Research & Development	Feb 06 '24	Sale	79.30	32,605	2,585,496	142,973	Feb 06 04:43 PM
Blum Robert I	President & CEO	Jan 31 '24	Option Exercise	6.67	12,500	83,375	454,297	Feb 02 04:41 PM
Blum Robert I	President & CEO	Jan 31 '24	Sale	79.57	12,500	994,625	441,797	Feb 02 04:41 PM
Blum Robert I	President & CEO	Jan 19 '24	Option Exercise	6.67	12,500	83,375	454,297	Jan 22 05:19 PM
Blum Robert I	President & CEO	Jan 19 '24	Sale	81.42	12,500	1,017,750	441,797	Jan 22 05:19 PM
HENDERSON JOHN T	Director	Jan 12 '24	Option Exercise	4.44	5,000	22,200	47,632	Jan 12 05:20 PM
HENDERSON JOHN T	Director	Jan 12 '24	Sale	85.14	5,000	425,700	42,632	Jan 12 05:20 PM
Malik Fady Ibraham	EVP Research & Development	Jan 04 '24	Option Exercise	7.96	11,678	92,957	162,651	Jan 04 04:36 PM
Malik Fady Ibraham	EVP Research & Development	Jan 04 '24	Sale	86.98	15,678	1,363,712	146,973	Jan 04 04:36 PM
Blum Robert I	President & CEO	Jan 02 '24	Option Exercise	6.67	12,500	83,375	454,297	Jan 02 05:55 PM
Blum Robert I	President & CEO	Jan 02 '24	Sale	85.08	12,500	1,063,500	441,797	Jan 02 05:55 PM
WIERENGA WENDALL	Director	Dec 27 '23	Option Exercise	4.44	10,000	44,400	23,653	Dec 27 04:11 PM
WIERENGA WENDALL	Director	Dec 27 '23	Sale	73.60	10,000	736,000	18,653	Dec 27 04:11 PM
HENDERSON JOHN T	Director	Dec 18 '23	Option Exercise	6.72	13,020	87,494	44,838	Dec 19 04:12 PM
Blum Robert I	President & CEO	Dec 18 '23	Option Exercise	6.67	12,500	83,375	454,297	Dec 19 04:13 PM
Blum Robert I	President & CEO	Dec 18 '23	Sale	36.95	12,500	461,875	441,797	Dec 19 04:13 PM
HENDERSON JOHN T	Director	Dec 18 '23	Sale	36.34	2,458	89,324	42,380	Dec 19 04:12 PM
Blum Robert I	President & CEO	Nov 30 '23	Option Exercise	6.67	12,500	83,375	453,917	Dec 01 04:15 PM
Blum Robert I	President & CEO	Nov 30 '23	Sale	32.99	12,500	412,375	441,417	Dec 01 04:15 PM
Blum Robert I	President & CEO	Nov 15 '23	Option Exercise	6.67	12,500	83,375	453,917	Nov 15 05:22 PM
Blum Robert I	President & CEO	Nov 15 '23	Sale	34.57	12,500	432,125	441,417	Nov 15 05:22 PM
Malik Fady Ibraham	EVP Research & Development	Nov 09 '23	Sale	35.40	2,500	88,500	150,664	Nov 09 04:35 PM
Blum Robert I	President & CEO	Oct 30 '23	Option Exercise	6.67	12,500	83,375	453,917	Oct 30 04:02 PM
Blum Robert I	President & CEO	Oct 30 '23	Sale	32.17	12,500	402,125	441,417	Oct 30 04:02 PM
Blum Robert I	President & CEO	Oct 16 '23	Option Exercise	6.67	12,500	83,375	453,917	Oct 16 05:57 PM
Blum Robert I	President & CEO	Oct 16 '23	Sale	33.70	12,500	421,250	441,417	Oct 16 05:57 PM
Malik Fady Ibraham	EVP Research & Development	Oct 12 '23	Sale	35.89	2,500	89,725	153,164	Oct 12 06:39 PM
Blum Robert I	President & CEO	Oct 06 '23	Option Exercise	6.67	12,500	83,375	453,917	Oct 06 04:52 PM
Blum Robert I	President & CEO	Oct 06 '23	Sale	30.00	12,500	375,000	441,417	Oct 06 04:52 PM
Malik Fady Ibraham	EVP Research & Development	Sep 14 '23	Sale	34.86	2,500	87,150	155,664	Sep 14 04:09 PM
Blum Robert I	President & CEO	Sep 13 '23	Option Exercise	6.67	12,500	83,375	453,917	Sep 13 04:09 PM
Blum Robert I	President & CEO	Sep 13 '23	Sale	34.90	12,500	436,206	441,417	Sep 13 04:09 PM
Blum Robert I	President & CEO	Aug 25 '23	Option Exercise	7.70	12,500	96,275	453,917	Aug 28 06:45 PM
Blum Robert I	President & CEO	Aug 25 '23	Sale	33.99	12,500	424,875	441,417	Aug 28 06:45 PM
WIERENGA WENDALL	Director	Aug 21 '23	Option Exercise	6.72	6,020	40,454	24,225	Aug 21 04:01 PM
WIERENGA WENDALL	Director	Aug 21 '23	Sale	32.02	6,020	192,760	18,205	Aug 21 04:01 PM
Blum Robert I	President & CEO	Aug 11 '23	Option Exercise	9.54	12,500	119,287	453,125	Aug 11 04:18 PM
Blum Robert I	President & CEO	Aug 11 '23	Sale	32.37	12,500	404,589	441,417	Aug 11 04:18 PM
Malik Fady Ibraham	EVP Research & Development	Aug 10 '23	Sale	31.70	2,500	79,250	158,164	Aug 10 04:14 PM
Blum Robert I	President & CEO	Aug 01 '23	Option Exercise	9.65	12,500	120,625	452,108	Aug 01 04:57 PM
Blum Robert I	President & CEO	Aug 01 '23	Sale	32.63	12,500	407,856	441,417	Aug 01 04:57 PM
Blum Robert I	President & CEO	Jul 13 '23	Option Exercise	9.65	12,500	120,625	453,917	Jul 13 04:10 PM
Blum Robert I	President & CEO	Jul 13 '23	Sale	35.28	12,500	440,940	441,417	Jul 13 04:10 PM
Malik Fady Ibraham	EVP Research & Development	Jul 13 '23	Sale	35.37	2,500	88,425	160,664	Jul 13 04:09 PM
Bhanji Muna	Director	Jul 07 '23	Sale	34.12	2,000	68,235	14,031	Jul 07 04:17 PM
Blum Robert I	President & CEO	Jul 03 '23	Option Exercise	9.65	12,500	120,625	453,917	Jul 05 04:18 PM
Blum Robert I	President & CEO	Jul 03 '23	Sale	32.60	12,500	407,500	441,417	Jul 05 04:18 PM

Open in Screener

LLY

Lilly(Eli) & Co

Jun 20 • 04:00PM ET

885.99

Dollar change -5.47
Percentage change -0.61	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO SPY IVV VUG XLV IWF VHT QUAL IVW

Index	S&P 500	P/E	132.68	EPS (ttm)	6.68	Insider Own	10.50%	Shs Outstand	949.38M	Perf Week	2.15%
Market Cap	842.04B	Forward P/E	46.28	EPS next Y	19.14	Insider Trans	-2.15%	Shs Float	850.66M	Perf Month	13.13%
Income	6.14B	PEG	2.12	EPS next Q	2.79	Inst Own	73.22%	Short Float	0.72%	Perf Quarter	14.64%
Sales	35.93B	P/S	23.43	EPS this Y	116.35%	Inst Trans	0.66%	Short Ratio	2.38	Perf Half Y	52.82%
Book/sh	13.48	P/B	65.72	EPS next Y	40.00%	ROA	10.48%	Short Interest	6.16M	Perf Year	96.04%
Cash/sh	2.72	P/C	325.58	EPS next 5Y	62.63%	ROE	51.15%	52W Range	434.34 - 894.87	Perf YTD	51.99%
Dividend Est.	5.30 (0.60%)	P/FCF	-	EPS past 5Y	13.74%	ROI	16.42%	52W High	-0.99%	Beta	0.41
Dividend TTM	4.86 (0.55%)	Quick Ratio	1.03	Sales past 5Y	9.91%	Gross Margin	80.16%	52W Low	103.99%	ATR (14)	18.63
Dividend Ex-Date	May 15, 2024	Current Ratio	1.35	EPS Y/Y TTM	7.91%	Oper. Margin	31.58%	RSI (14)	76.30	Volatility	2.15% 2.13%
Employees	43000	Debt/Eq	2.05	Sales Y/Y TTM	29.76%	Profit Margin	17.08%	Recom	1.62	Target Price	881.28
Option/Short	Yes / Yes	LT Debt/Eq	1.92	EPS Q/Q	66.67%	Payout	77.91%	Rel Volume	1.29	Prev Close	891.46
Sales Surprise	-1.88%	EPS Surprise	4.64%	Sales Q/Q	25.98%	Earnings	Apr 30 BMO	Avg Volume	2.59M	Price	885.99
SMA20	5.50%	SMA50	12.19%	SMA200	30.63%	Trades		Volume	3,346,279	Change	-0.61%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-21-24	Downgrade	DZ Bank	Buy → Hold	$820
Feb-16-24	Reiterated	Morgan Stanley	Overweight	$805 → $950
Dec-21-23	Downgrade	Daiwa Securities	Buy → Outperform	$660 → $610
Nov-09-23	Initiated	Deutsche Bank	Hold	$535
Oct-20-23	Resumed	UBS	Buy	$612 → $710
Aug-09-23	Upgrade	Jefferies	Hold → Buy	$408 → $615
Jul-26-23	Reiterated	Citigroup	Buy	$360 → $525
Jul-14-23	Initiated	HSBC Securities	Buy	$560
May-24-23	Reiterated	UBS	Buy	$447 → $498
May-24-23	Reiterated	BofA Securities	Buy	$450 → $500
Mar-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$360 → $375
Mar-06-23	Initiated	Jefferies	Hold	$290
Feb-15-23	Downgrade	Societe Generale	Hold → Sell
Nov-18-22	Initiated	Credit Suisse	Outperform	$395
Sep-22-22	Upgrade	UBS	Neutral → Buy	$335 → $363
May-23-22	Initiated	SVB Leerink	Outperform	$341
Apr-06-22	Resumed	Morgan Stanley	Overweight	$265 → $364
Mar-10-22	Initiated	Daiwa Securities	Outperform	$286
Jan-21-22	Upgrade	DZ Bank	Hold → Buy	$291
Jan-03-22	Reiterated	Bernstein	Mkt Perform	$250 → $300

Show Previous Ratings

Jun-20-24 05:45PM	Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
04:16PM	Why Wall Street Is Chasing Ozempic Wannabes (The Wall Street Journal)
03:24PM	Obesity-Drug Developers Look at Whats Next for a $100 Billion Market (Barrons.com)
02:25PM	Eli Lilly Has a New Drug That Could Push the Stock Higher (Motley Fool)
02:07PM	WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs (Associated Press Finance)
01:38PM	Loading…
01:38PM	Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug? (Investor's Business Daily)
11:58AM	Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
11:23AM	Eli Lilly Files More Lawsuits at Sellers of Counterfeit Mounjaro, Zepbound (The Wall Street Journal)
10:42AM	Eli Lilly is cracking down on knock off versions of its popular weight loss and diabetes drug (Quartz)
09:01AM	Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now (Zacks)
08:30AM	Eli Lilly's Growth Prospects Just Got a Huge Upgrade (Motley Fool)
06:30AM	The Fed Needs to Cut Rates Eventually Amid This Economic Slowdown. Heres Why, and 4 Other Things to Know Today. (Barrons.com)
Jun-19-24 01:53PM	50 Largest Companies in Every State in the US (Insider Monkey)
Jun-18-24 03:51PM	Why the GLP-1 impact on other industries 'will take years' (Yahoo Finance)
03:51PM	New Weight-Loss Drugs and Devices Are Coming This Week (Barrons.com)
11:31AM	Loading…
11:31AM	Amazon Widens RxPass Eligibility To Include Prime Members With Medicare (Investopedia)
Jun-17-24 05:53PM	Stocks close higher, Trump tax cuts: Market Domination Overtime (Yahoo Finance Video)
05:00PM	Eli Lilly unveils new North Carolina plant for GLP-1 drugs (Yahoo Finance Video)
01:01PM	Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs (Investor's Business Daily)
12:32PM	Broadcom Is on Track to Edge Past Eli Lillys Market Value. AI Is Helping It Do So. (Barrons.com)
07:00AM	Two Is Better Than One in the Alzheimers Market (The Wall Street Journal)
01:32AM	Lillys Phase II results in Alzheimers disease have most experts saying donanemab is done (Clinical Trials Arena)
Jun-16-24 12:05PM	Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. (Motley Fool)
Jun-15-24 02:05PM	Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy? (Motley Fool)
07:15AM	Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster (Motley Fool)
06:50AM	3 Growth Stocks You Can Buy Right Now Without Any Hesitation (Motley Fool)
06:12AM	Exit Alert: 3 Stocks to Offload Before the Downturn (InvestorPlace)
Jun-14-24 04:19PM	Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar (Investor's Business Daily)
04:08PM	Eli Lilly unveils new manufacturing plant for GLP-1 pens (Yahoo Finance)
01:17PM	June consumer sentiment disappoints, Tesla short-selling: Catalysts (Yahoo Finance Video)
12:34PM	Loading…
12:34PM	Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research (Pharmaceutical Technology)
12:07PM	Food companies worried about weight loss drugs can just make healthier food, Eli Lilly CEO says (Quartz)
11:58AM	Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market (Yahoo Finance Video)
10:44AM	Eli Lilly wants to replace Zepbound with an even stronger weight loss drug (Quartz)
07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace)
06:37AM	3 Stocks to Sell as Ozempic Surges in Popularity (InvestorPlace)
05:50AM	Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug (Motley Fool)
Jun-13-24 09:51PM	Lillys Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP. (The Wall Street Journal)
09:50AM	Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term (Zacks)
07:46AM	Billionaire Israel Englander is Buying This Weight Loss Stock in 2024 (Insider Monkey)
05:55AM	Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever. (Motley Fool)
Jun-12-24 10:00AM	3 Stocks Quietly Preparing for a 10X Surge: June Edition (InvestorPlace)
08:00AM	Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To Triple (Investor's Business Daily)
07:30AM	A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge (Motley Fool)
05:25AM	Is Eli Lilly the Best Pharmaceutical Stock for You? (Motley Fool)
Jun-11-24 08:31PM	Jim Cramer looks at Eli Lilly's outlook as the company's Alzheimer drug goes through FDA (CNBC TV)
08:31PM	Eli Lilly may have developed the greatest drug of all time, says Jim Cramer (CNBC TV)
06:40PM	Oil prices, National Amusement ends Skydance talks: Market Domination (Yahoo Finance Video)
04:41PM	Eli Lilly's new Alzheimer's treatment could 'lift' drug market (Yahoo Finance Video)
04:32PM	These Stocks Moved the Most Today: Apple, GM, Boeing, GameStop, and More (Barrons.com)
04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
02:57PM	FOMC meeting, Ford vice chair on hybrid growth: Morning Brief (Yahoo Finance Video)
02:56PM	These Stocks Are Moving the Most Today: Apple, GM, Boeing, Shopify, and More (Barrons.com)
01:22PM	Apple stock hits a new record, Oracle releases Q4 results: Yahoo Finance (Yahoo Finance Video)
12:25PM	FDA Advisers Like Lillys Alzheimers Drug. Its Good News for Biogen. (Barrons.com)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
10:49AM	Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer's Drug (InvestorPlace)
10:20AM	Stocks to Watch Tuesday: Apple, Eli Lilly, Coinbase (The Wall Street Journal)
09:29AM	Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod (Zacks)
08:45AM	Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises (GlobeNewswire)
08:29AM	Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs (CNBC TV)
08:22AM	Donanemab approval would fuel growth of amyloid-blocking Alzheimers drugs, analysts say (BioPharma Dive)
08:20AM	Midday movers: Coinbase, Yext fall; Apple, GM rise (Investing.com)
07:35AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:52AM	Here's Why Viking Therapeutics (VKTX) Shares Rose in Q1 (Insider Monkey)
05:50AM	Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy? (Motley Fool)
04:57AM	Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? (Motley Fool)
04:30AM	Eli Lilly inches higher premarket after FDA advisory panel backs Alzheimer's drug (Investing.com)
Jun-10-24 10:12PM	Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab (Investopedia)
07:30PM	Analyst Report: Eli Lilly and Company (Morningstar Research)
06:40PM	FDA advisers say Eli Lilly Alzheimer's treatment is effective (CNBC TV)
05:17PM	FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
04:56PM	FDA panel votes to recommend Eli Lilly's Alzheimer's drug (Yahoo Finance Video)
04:25PM	FDA advisers say Eli Lilly's Alzheimer's treatment is effective (CNBC TV)
04:18PM	FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment (Yahoo Finance)
04:05PM	Alzheimer's drug that can slow disease gets backing from FDA advisers (Associated Press Finance)
03:01PM	7 Over-Hyped Stocks to Sell Before They Plunge: June Edition (InvestorPlace)
02:32PM	Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan' (Yahoo Finance)
12:18PM	Lilly Alzheimers drug gets unanimous backing of FDA panel (BioPharma Dive)
10:27AM	Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
10:24AM	Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz (CNBC TV)
09:00AM	Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:45AM	7 Blue-Chip Stocks to Add to Your June Buy List (InvestorPlace)
Jun-08-24 10:05AM	The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock? (Motley Fool)
09:03AM	Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks (PR Newswire)
07:40AM	Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm (InvestorPlace)
Jun-07-24 02:00PM	Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting Is It A Buy? (Investor's Business Daily)
01:33PM	Top Stock Movers Now: GameStop, Docusign, Vail Resorts, and More (Investopedia)
07:53AM	Magnificent Seven? Just Two Members Clear This Bar (Investor's Business Daily)
05:45AM	Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance? (Motley Fool)
12:06AM	Is Eli Lilly and Company (LLY) A Good 'Quality Stock' to Buy Now? (Insider Monkey)
Jun-06-24 05:27PM	How Alphabet Could Become the Next $3 Trillion Stock (Barrons.com)
05:23PM	The 3 Most Undervalued Pharma Stocks to Buy in June 2024 (InvestorPlace)
05:10PM	Can GLP-1 weight-loss drug manufacturers keep momentum up? (Yahoo Finance Video)
01:08PM	Mutual Funds Keep Buying Up Google, These 2 Other Big Caps (Investor's Business Daily)
12:07PM	Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile (Benzinga)
10:21AM	Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO (Zacks)
10:05AM	13 Best Quality Stocks To Buy (Insider Monkey)
08:15AM	In review of Lilly Alzheimers drug, FDA staff focus on safety, patient selection (BioPharma Dive)
06:58AM	Alphabets next CFO Anat Ashkenazi fills a void for the company at key time during AI Revolution, says top analyst (Fortune)

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LILLY ENDOWMENT INC	10% Owner	Jun 17 '24	Sale	885.91	194,978	172,733,708	97,583,810	Jun 18 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 14 '24	Sale	882.47	15,022	13,256,490	97,778,788	Jun 17 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 10 '24	Sale	860.78	75,510	64,997,274	97,793,810	Jun 11 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 07 '24	Sale	852.29	139,490	118,886,587	97,869,320	Jun 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 06 '24	Sale	837.82	179,617	150,485,878	98,008,810	Jun 07 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 05 '24	Sale	836.32	20,383	17,046,673	98,188,427	Jun 06 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 03 '24	Sale	829.77	192,794	159,974,050	98,208,810	Jun 04 04:00 PM
Norton Johna	EVP, Global Quality	Jun 03 '24	Sale	819.38	7,056	5,781,545	25,428	Jun 03 04:14 PM
Zakrowski Donald A	SVP, Finance, & CAO	Jun 03 '24	Sale	819.47	750	614,602	7,130	Jun 03 04:15 PM
Rau Diogo	EVP & CIDO	Jun 01 '24	Option Exercise	0.00	6,300	0	14,146	Jun 04 04:14 PM
LILLY ENDOWMENT INC	10% Owner	May 31 '24	Sale	822.11	22,206	18,255,871	98,401,604	Jun 03 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 29 '24	Sale	811.04	130,385	105,747,975	98,423,810	May 30 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 28 '24	Sale	809.00	2,052	1,660,068	98,554,195	May 29 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 24 '24	Sale	809.21	92,563	74,902,998	98,556,247	May 28 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 23 '24	Sale	809.99	50,767	41,120,963	98,648,810	May 24 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 22 '24	Sale	804.18	12,974	10,433,483	98,699,577	May 23 04:00 PM
LILLY ENDOWMENT INC	10% Owner	May 21 '24	Sale	805.45	186,259	150,021,694	98,712,551	May 22 04:00 PM
Zakrowski Donald A	SVP, Finance, & CAO	Mar 11 '24	Sale	753.60	750	565,200	7,880	Mar 11 04:27 PM
LILLY ENDOWMENT INC	10% Owner	Feb 16 '24	Sale	780.99	169,684	132,521,930	98,898,810	Feb 20 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 15 '24	Sale	760.46	50,316	38,263,417	99,068,494	Feb 16 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 09 '24	Sale	740.60	206,257	152,753,428	99,118,810	Feb 12 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 08 '24	Sale	740.06	8,743	6,470,336	99,325,067	Feb 09 04:05 PM
Van Naarden Jacob	EVP & Pres., Loxo@Lilly	Feb 01 '24	Option Exercise	0.00	3,618	0	15,463	Feb 02 04:22 PM
White Anne E.	EVP & Pres, Lilly Neuroscience	Feb 01 '24	Option Exercise	0.00	4,124	0	62,050	Feb 02 04:20 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 01 '24	Option Exercise	0.00	9,941	0	115,262	Feb 02 04:25 PM
Norton Johna	EVP, Global Quality	Feb 01 '24	Option Exercise	0.00	1,268	0	31,382	Feb 02 04:24 PM
Hakim Anat	EVP, GC & Secretary	Feb 01 '24	Option Exercise	0.00	4,442	0	26,631	Feb 02 04:32 PM
Ricks David A	President, Chair, and CEO	Feb 01 '24	Option Exercise	0.00	29,611	0	455,054	Feb 02 04:28 PM
Yuffa Ilya	EVP & President, LLY Int'l	Feb 01 '24	Option Exercise	0.00	3,702	0	16,676	Feb 02 04:29 PM
Jonsson Patrik	EVP&Pres, LLY Dia&Obe, LLY USA	Feb 01 '24	Option Exercise	0.00	4,124	0	41,065	Feb 02 04:26 PM
LILLY ENDOWMENT INC	10% Owner	Jan 31 '24	Sale	648.07	78,573	50,920,924	99,333,810	Feb 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 30 '24	Sale	645.22	76,215	49,175,200	99,412,383	Jan 31 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 29 '24	Sale	645.07	54,032	34,854,422	99,488,598	Jan 30 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 16 '24	Sale	645.60	1,180	761,806	99,542,630	Jan 17 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 11 '24	Sale	634.13	12,344	7,827,686	99,543,810	Jan 12 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 10 '24	Sale	630.59	163,730	103,246,373	99,556,154	Jan 11 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Jan 09 '24	Sale	631.81	34,538	21,821,413	99,719,884	Jan 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Jan 04 '24	Sale	630.28	14,388	9,068,445	99,754,422	Jan 05 02:15 PM
Zakrowski Donald A	SVP, Finance, & CAO	Dec 01 '23	Option Exercise	0.00	4,810	0	9,518	Dec 04 04:17 PM
Zakrowski Donald A	SVP, Finance, & CAO	Nov 06 '23	Sale	571.10	670	382,637	4,708	Nov 06 04:25 PM
LILLY ENDOWMENT INC	10% Owner	Oct 11 '23	Sale	605.44	215,000	130,169,879	99,768,810	Oct 12 04:00 PM
Weems Alonzo	EVP, ERM & CECO	Sep 12 '23	Sale	590.98	1,148	678,445	7,760	Sep 13 04:14 PM
LILLY ENDOWMENT INC	10% Owner	Sep 07 '23	Sale	571.41	210,000	119,995,275	99,983,810	Sep 08 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 31 '23	Sale	554.81	46,541	25,821,607	100,193,810	Sep 01 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 30 '23	Sale	555.32	6,181	3,432,417	100,240,351	Aug 31 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 29 '23	Sale	554.10	28,747	15,928,697	100,246,532	Aug 30 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 28 '23	Sale	554.12	37,660	20,868,163	100,275,279	Aug 29 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 25 '23	Sale	554.38	63,572	35,243,238	100,312,939	Aug 28 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 24 '23	Sale	554.74	20,992	11,645,029	100,376,511	Aug 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 23 '23	Sale	555.69	1,307	726,284	100,397,503	Aug 24 04:00 PM
Zakrowski Donald A	SVP, Finance, & CAO	Aug 21 '23	Sale	546.51	600	327,906	5,378	Aug 22 04:34 PM
LILLY ENDOWMENT INC	10% Owner	Aug 15 '23	Sale	543.72	50,222	27,306,747	100,398,810	Aug 16 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 14 '23	Sale	539.08	164,778	88,829,243	100,449,032	Aug 15 04:00 PM
ELI LILLY & Co	10% Owner	Aug 11 '23	Buy	14.92	1,718,493	25,639,916	100	Aug 14 04:30 PM
LILLY ENDOWMENT INC	10% Owner	Aug 11 '23	Sale	528.50	83,039	43,886,430	100,613,810	Aug 14 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 10 '23	Sale	528.13	3,000	1,584,405	100,696,849	Aug 11 03:50 PM
LILLY ENDOWMENT INC	10% Owner	Aug 09 '23	Sale	528.83	123,961	65,554,314	100,699,849	Aug 10 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Aug 08 '23	Sale	523.74	204,409	107,056,405	100,823,810	Aug 09 05:10 PM
LILLY ENDOWMENT INC	10% Owner	Jul 21 '23	Sale	466.62	591	275,773	101,028,219	Jul 24 03:55 PM
LILLY ENDOWMENT INC	10% Owner	Jun 30 '23	Sale	467.60	164,125	76,744,390	101,028,810	Jul 03 12:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 29 '23	Sale	465.08	44,115	20,517,137	101,192,935	Jun 30 03:00 PM
LILLY ENDOWMENT INC	10% Owner	Jun 28 '23	Sale	465.41	11,760	5,473,168	101,237,050	Jun 30 09:06 AM
LILLY ENDOWMENT INC	10% Owner	Jun 22 '23	Sale	459.28	107,022	49,153,574	101,248,810	Jun 23 11:27 AM

Open in Screener

URGN

UroGen Pharma Ltd

Jun 20 • 04:00PM ET

15.47

Dollar change -1.40
Percentage change -8.30	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

URGN UroGen Pharma Ltd daily Stock Chart

Held by: IWM IBB IWO IZRL SPDW VTWO IWC IWN ITEQ GSSC

Index	RUT	P/E	-	EPS (ttm)	-3.39	Insider Own	14.84%	Shs Outstand	32.49M	Perf Week	21.62%
Market Cap	558.93M	Forward P/E	-	EPS next Y	-2.94	Insider Trans	-0.48%	Shs Float	30.77M	Perf Month	19.83%
Income	-104.32M	PEG	-	EPS next Q	-0.86	Inst Own	83.31%	Short Float	17.08%	Perf Quarter	3.41%
Sales	84.30M	P/S	6.63	EPS this Y	-1.13%	Inst Trans	-0.53%	Short Ratio	9.43	Perf Half Y	3.06%
Book/sh	-1.11	P/B	-	EPS next Y	18.11%	ROA	-66.54%	Short Interest	5.26M	Perf Year	32.34%
Cash/sh	4.56	P/C	3.39	EPS next 5Y	-	ROE	-	52W Range	8.69 - 24.13	Perf YTD	3.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.89%	ROI	-179.57%	52W High	-35.89%	Beta	1.13
Dividend TTM	-	Quick Ratio	7.20	Sales past 5Y	13144.25%	Gross Margin	89.53%	52W Low	78.02%	ATR (14)	1.38
Dividend Ex-Date	-	Current Ratio	7.47	EPS Y/Y TTM	29.75%	Oper. Margin	-82.12%	RSI (14)	54.16	Volatility	18.75% 8.34%
Employees	201	Debt/Eq	-	Sales Y/Y TTM	24.00%	Profit Margin	-123.74%	Recom	1.40	Target Price	43.88
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	25.47%	Payout	-	Rel Volume	3.11	Prev Close	16.87
Sales Surprise	-12.20%	EPS Surprise	-11.93%	Sales Q/Q	9.24%	Earnings	May 13 BMO	Avg Volume	557.26K	Price	15.47
SMA20	9.32%	SMA50	11.00%	SMA200	6.09%	Trades		Volume	1,730,974	Change	-8.30%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Jun-17-24 10:51PM	UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants (Business Wire) -7.71%
04:46PM	UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
05:00AM	Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains? (Zacks)
Jun-13-24 04:05PM	UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug (Investor's Business Daily) +37.58% +9.71%
10:45AM	UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
08:00AM	Loading…
Jun-07-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-24 08:00AM	UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 (Business Wire)
Jun-05-24 08:00AM	UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
Jun-03-24 08:00AM	UroGen Pharma Appoints David Lin as New Chief Commercial Officer (Business Wire)
May-22-24 08:00AM	UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit (Business Wire)
May-14-24 08:20AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:32AM	UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations (GuruFocus.com)
08:00AM	UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights (Business Wire)
May-07-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
12:20PM	Loading…
May-05-24 12:20PM	New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy (Business Wire)
May-04-24 03:20PM	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 (Business Wire)
11:50AM	New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial (Business Wire)
May-03-24 08:00AM	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 (Business Wire)
Apr-17-24 12:02PM	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers (Business Wire)
Apr-15-24 08:00AM	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-03-24 08:00AM	UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals (Business Wire)
Mar-15-24 10:30AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -17.97%
09:32AM	UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges (GuruFocus.com)
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 (Business Wire)
Mar-08-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-04-24 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024 (Business Wire)
Feb-26-24 08:00AM	UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference (Business Wire) +5.09%
08:00AM	Loading…
Feb-01-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
Jan-24-24 08:00AM	UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102 (Business Wire)
Jan-17-24 08:00AM	UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers (Business Wire) +6.27%
Jan-11-24 08:00AM	UroGen Pharma to Participate in the B. Riley Healthcare Conference (Business Wire)
Dec-08-23 04:00PM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-15-23 01:50PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials (GuruFocus.com)
08:00AM	UroGen Pharma Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-13-23 08:00AM	UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology (Business Wire)
Nov-07-23 08:00AM	UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire)
Oct-03-23 08:00AM	Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 (Business Wire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-08-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-23 01:40PM	UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why (Zacks)
Aug-17-23 07:00AM	New Treatment for Bladder Cancer Offers This Biotech a Second Chance (The Wall Street Journal) -14.16%
Aug-12-23 09:18AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments (Business Wire)
Aug-08-23 08:00AM	The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-02-23 05:00PM	UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (Business Wire) -6.45%
Aug-01-23 10:05AM	Opportunities Outweigh Risks: Oppenheimer Sees at Least 60% Gains in These 2 Stocks (TipRanks) -6.28%
Jul-31-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-23 01:41PM	Why Shares of UroGen Pharma Jumped Friday (Motley Fool) +26.38%
Jul-27-23 09:55AM	UroGen Announces $120 Million Private Placement of Ordinary Shares (Business Wire) +98.56%
09:50AM	UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials (Business Wire)
Jul-25-23 04:10PM	UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors (Business Wire)
Jul-10-23 08:00AM	Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation (Business Wire) -5.28%
Jul-06-23 08:00AM	UroGen Pharma to Host UGN-102 Data Event on July 27, 2023 (Business Wire) +5.08%
Jun-20-23 08:00AM	Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration (Business Wire)
Jun-09-23 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.33%
Jun-02-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
May-22-23 01:18PM	With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
May-16-23 12:13PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.00%
08:00AM	UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
May-04-23 08:00AM	UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 (Business Wire)
May-02-23 10:02AM	Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline (Zacks) -8.61%
May-01-23 02:00PM	First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation (Business Wire) +23.30%
Apr-30-23 08:00AM	New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis (Business Wire)
Apr-25-23 08:00AM	UroGen Pharma to Present at H.C. Wainwright BioConnect Conference (Business Wire)
Apr-18-23 12:16PM	UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares (Simply Wall St.)
Mar-18-23 02:06AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 09:15AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments (Business Wire)
Mar-09-23 04:00PM	UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023 (Business Wire) -8.27%
Mar-06-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-23 04:00PM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Feb-27-23 08:15AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-15-23 09:06AM	Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer (Business Wire)
Feb-06-23 05:33AM	UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-11-23 08:00AM	Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Jan-09-23 12:19PM	The past five years for UroGen Pharma (NASDAQ:URGN) investors has not been profitable (Simply Wall St.)
Dec-19-22 08:00AM	UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
Dec-13-22 12:13PM	With 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
Dec-09-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-02-22 12:00PM	UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Dec-01-22 07:00PM	UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Nov-21-22 04:00PM	UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference (Business Wire) -7.51%
Nov-16-22 11:24AM	Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Estimates (Simply Wall St.)
Nov-14-22 08:00AM	UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma (Business Wire)
Nov-12-22 07:33AM	UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -16.32%
08:00AM	UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
Nov-09-22 08:00AM	UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors (Business Wire) -7.66%
Nov-03-22 08:00AM	UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (Business Wire)
Oct-12-22 04:29AM	Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.22%
Oct-11-22 11:54AM	10 Best Immunotherapy Stocks To Buy Now (Insider Monkey)
08:00AM	UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers (Business Wire)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenberg Mark	Chief Medical Officer	Jun 10 '24	Sale	13.08	5,153	67,401	144,284	Jun 11 01:15 PM
Schoenberg Mark	Chief Medical Officer	Mar 18 '24	Sale	14.05	12,000	168,600	139,437	Mar 20 04:38 PM
Smith Jason Drew	General Counsel	Jan 31 '24	Sale	15.74	4,993	78,590	18,824	Feb 02 07:12 PM
Schoenberg Mark	Chief Medical Officer	Jan 31 '24	Sale	15.74	3,789	59,639	149,423	Feb 02 07:07 PM
Smith Jason Drew	General Counsel	Aug 31 '23	Sale	18.01	3,800	68,438	18,407	Sep 05 04:28 PM

Open in Screener

RAPP

Rapport Therapeutics Inc.

Jun 20 • 04:00PM ET

22.18

Dollar change -3.10
Percentage change -12.26	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

RAPP Rapport Therapeutics Inc. daily Stock Chart

Held by: MNTL

Index	-	P/E	-	EPS (ttm)	-	Insider Own	22.62%	Shs Outstand	35.38M	Perf Week	-2.42%
Market Cap	784.73M	Forward P/E	-	EPS next Y	-	Insider Trans	7.51%	Shs Float	27.37M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	0.20%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-1.12	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	5.46	P/C	4.06	EPS next 5Y	-	ROE	-	52W Range	18.00 - 27.11	Perf YTD	6.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-18.19%	Beta	-
Dividend TTM	-	Quick Ratio	20.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	23.22%	ATR (14)	4.28
Dividend Ex-Date	-	Current Ratio	20.10	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	15.06% -
Employees	52	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.79	Prev Close	25.28
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	512.98K	Price	22.18
SMA20	-5.91%	SMA50	-5.91%	SMA200	-5.91%	Trades		Volume	404,703	Change	-12.26%

Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HEALY JAMES	Director	Jun 10 '24	Buy	17.00	558,824	9,500,008	1,863,327	Jun 10 07:38 PM

Open in Screener

TYRA

Tyra Biosciences Inc

Jun 20 • 04:00PM ET

16.99

Dollar change -0.21
Percentage change -1.22	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

TYRA Tyra Biosciences Inc daily Stock Chart

Held by: VTI IWM VXF AVUV SCHA IWN VTWO IWO IWC AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.68	Insider Own	49.18%	Shs Outstand	43.02M	Perf Week	-11.19%
Market Cap	891.47M	Forward P/E	-	EPS next Y	-2.09	Insider Trans	-0.87%	Shs Float	26.67M	Perf Month	-9.24%
Income	-75.45M	PEG	-	EPS next Q	-0.41	Inst Own	52.30%	Short Float	7.36%	Perf Quarter	-2.19%
Sales	0.00M	P/S	-	EPS this Y	-5.66%	Inst Trans	-0.09%	Short Ratio	13.84	Perf Half Y	30.79%
Book/sh	7.43	P/B	2.29	EPS next Y	-22.20%	ROA	-22.87%	Short Interest	1.96M	Perf Year	1.49%
Cash/sh	7.29	P/C	2.33	EPS next 5Y	-	ROE	-23.63%	52W Range	10.38 - 21.14	Perf YTD	22.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-102.86%	ROI	-19.05%	52W High	-19.63%	Beta	1.03
Dividend TTM	-	Quick Ratio	44.83	Sales past 5Y	0.00%	Gross Margin	-	52W Low	63.68%	ATR (14)	1.16
Dividend Ex-Date	-	Current Ratio	44.83	EPS Y/Y TTM	-35.33%	Oper. Margin	0.00%	RSI (14)	43.09	Volatility	5.20% 6.45%
Employees	49	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	25.20
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-24.30%	Payout	-	Rel Volume	0.93	Prev Close	17.20
Sales Surprise	-	EPS Surprise	23.08%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	141.77K	Price	16.99
SMA20	-5.84%	SMA50	-1.75%	SMA200	10.56%	Trades		Volume	131,850	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$25 → $15
Jun-30-23	Initiated	Wedbush	Outperform	$27
Feb-03-23	Initiated	Oppenheimer	Outperform	$17
Jun-23-22	Initiated	H.C. Wainwright	Buy	$12
Mar-08-22	Upgrade	Jefferies	Hold → Buy	$31 → $27
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	Jefferies	Buy	$19
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	BofA Securities	Buy	$22

Jun-07-24 12:00PM	Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks)
May-23-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
May-09-24 10:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights (PR Newswire)
04:05PM	Loading…
May-07-24 04:05PM	Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors (PR Newswire)
Mar-19-24 09:53PM	TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023 (InvestorPlace) +7.89%
09:01PM	Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress (GuruFocus.com)
04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights (PR Newswire)
Mar-05-24 11:27PM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares (GuruFocus.com)
Mar-01-24 12:40AM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares (GuruFocus.com)
Feb-27-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Feb-07-24 04:05PM	Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference (PR Newswire)
03:12AM	President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA) (GuruFocus.com)
Feb-02-24 08:00AM	Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing (PR Newswire) +29.29%
05:30PM	Loading…
Feb-01-24 05:30PM	Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-22-23 09:00AM	Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 (PR Newswire)
Nov-08-23 04:05PM	Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference (PR Newswire)
Nov-07-23 04:05PM	Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights (PR Newswire) -5.00%
Sep-21-23 08:00AM	Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings (PR Newswire)
Sep-12-23 04:05PM	Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-10-23 04:05PM	Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights (PR Newswire)
Aug-01-23 08:00AM	Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Jun-16-23 08:50AM	Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength (Zacks) +6.25%
Jun-07-23 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet (Zacks) -5.63%
May-25-23 08:00AM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
May-23-23 08:50AM	What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing' (Zacks)
May-22-23 09:55AM	Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade (Zacks)
Apr-09-23 09:30AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.)
04:05PM	Loading…
Mar-29-23 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-27-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA) (Zacks)
Mar-22-23 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights (PR Newswire) -5.01%
Mar-01-23 08:40AM	Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings? (Zacks)
07:00AM	Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia (PR Newswire)
Feb-22-23 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire) -7.99% -9.04%
Nov-29-22 07:00AM	Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 (PR Newswire)
Nov-24-22 09:55AM	How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184% (Zacks)
Nov-10-22 04:20PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet (Zacks)
Nov-03-22 04:05PM	Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights (PR Newswire) -7.00%
Nov-02-22 04:05PM	Tyra Biosciences Announces Planned Chief Financial Officer Transition (PR Newswire)
Oct-31-22 09:22AM	We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth (Simply Wall St.)
Oct-13-22 08:00AM	Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.46%
Sep-08-22 04:05PM	Tyra Biosciences to Participate at September 2022 Investor Conferences (PR Newswire) +8.24%
Sep-05-22 08:15AM	Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress (PR Newswire)
Aug-04-22 04:05PM	Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights (PR Newswire) +14.97%
May-24-22 08:55AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.) -5.68%
May-05-22 04:05PM	Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights (PR Newswire)
Mar-03-22 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights (PR Newswire) -10.21%
Feb-22-22 04:05PM	Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference (PR Newswire)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +14.48%
Dec-15-21 09:29AM	Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-10-21 04:05PM	Tyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference (PR Newswire)
Nov-03-21 04:05PM	Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights (PR Newswire) +19.92% +8.25%
Sep-22-21 08:22AM	3 Stocks Insiders Are Buying (Benzinga) -7.11%
Sep-20-21 07:52AM	3 Stocks Insiders Are Buying (Benzinga) -6.83%
Sep-17-21 05:28AM	56 Biggest Movers From Yesterday (Benzinga)
Sep-15-21 10:41AM	Tyra Biosciences stock soars more than 60% on public debut (MarketWatch)
Sep-14-21 09:00PM	Tyra Announces Pricing of Upsized Initial Public Offering (PR Newswire)
06:51AM	Tyra Biosciences upsizes IPO to 9 million shares vs. prior 6.7 million for valuation of up to $626 million (MarketWatch)

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KAPLAN GILLA	Director	Jun 13 '24	Option Exercise	0.61	61,392	37,449	89,623	Jun 18 05:01 PM
Bensen Daniel	Chief Operating Officer	Jun 10 '24	Sale	20.00	3,502	70,045	427,981	Jun 10 07:10 PM
Bensen Daniel	Chief Operating Officer	Jun 07 '24	Sale	20.00	200	4,000	431,483	Jun 10 07:10 PM
Bensen Daniel	Chief Operating Officer	Mar 11 '24	Sale	20.00	200	4,000	431,683	Mar 13 05:46 PM
Bensen Daniel	Chief Operating Officer	Mar 07 '24	Sale	20.00	68	1,360	431,883	Mar 08 05:38 PM
Bensen Daniel	Chief Operating Officer	Mar 06 '24	Sale	20.09	1,733	34,819	431,951	Mar 08 05:38 PM
Bensen Daniel	Chief Operating Officer	Mar 05 '24	Sale	20.02	1,189	23,802	433,684	Mar 05 05:40 PM
Bensen Daniel	Chief Operating Officer	Mar 04 '24	Sale	20.08	5,063	101,654	434,873	Mar 05 05:40 PM
Bensen Daniel	Chief Operating Officer	Mar 01 '24	Sale	20.04	2,900	58,112	439,936	Mar 05 05:40 PM
Bensen Daniel	Chief Operating Officer	Feb 29 '24	Sale	20.00	2,050	41,003	442,836	Feb 29 06:58 PM
Bensen Daniel	Chief Operating Officer	Feb 28 '24	Sale	20.13	5,849	117,729	444,886	Feb 29 06:58 PM
Bensen Daniel	Chief Operating Officer	Feb 27 '24	Sale	20.00	745	14,900	450,735	Feb 29 06:58 PM
Bensen Daniel	Chief Operating Officer	Feb 12 '24	Sale	20.00	1,501	30,020	451,480	Feb 14 09:00 PM
Bensen Daniel	Chief Operating Officer	Feb 07 '24	Sale	18.09	9,587	173,466	452,981	Feb 09 07:26 PM
Bensen Daniel	Chief Operating Officer	Feb 06 '24	Sale	18.09	15,413	278,827	462,568	Feb 06 08:23 PM
Harris Todd	President and CEO	Feb 05 '24	Sale	16.97	13,817	234,430	1,502,697	Feb 06 08:22 PM
Bensen Daniel	Chief Operating Officer	Feb 02 '24	Option Exercise	0.61	25,393	15,490	553,374	Feb 06 08:23 PM
Harris Todd	President and CEO	Feb 02 '24	Sale	16.50	86,183	1,421,655	1,516,514	Feb 06 08:22 PM
Bensen Daniel	Chief Operating Officer	Feb 02 '24	Sale	16.33	75,393	1,231,097	477,981	Feb 06 08:23 PM
Bensen Daniel	Chief Operating Officer	Jul 21 '23	Option Exercise	0.61	3,900	2,379	531,881	Jul 21 08:52 PM
Bensen Daniel	Chief Operating Officer	Jul 21 '23	Sale	16.01	3,900	62,428	527,981	Jul 21 08:52 PM
Bensen Daniel	Chief Operating Officer	Jul 19 '23	Option Exercise	0.61	207	126	528,188	Jul 21 08:52 PM
Bensen Daniel	Chief Operating Officer	Jul 19 '23	Sale	16.07	207	3,328	527,981	Jul 21 08:52 PM
Bensen Daniel	Chief Operating Officer	Jul 17 '23	Option Exercise	0.61	1,900	1,159	529,881	Jul 17 07:35 PM
Bensen Daniel	Chief Operating Officer	Jul 17 '23	Sale	16.03	1,900	30,464	527,981	Jul 17 07:35 PM
Bensen Daniel	Chief Operating Officer	Jul 13 '23	Option Exercise	0.61	500	305	528,481	Jul 17 07:35 PM
Bensen Daniel	Chief Operating Officer	Jul 13 '23	Sale	16.13	500	8,065	527,981	Jul 17 07:35 PM
Bensen Daniel	Chief Operating Officer	Jul 12 '23	Option Exercise	0.61	201	123	528,182	Jul 12 06:41 PM
Bensen Daniel	Chief Operating Officer	Jul 12 '23	Sale	16.23	201	3,262	527,981	Jul 12 06:41 PM
Bensen Daniel	Chief Operating Officer	Jul 11 '23	Option Exercise	0.61	500	305	528,481	Jul 12 06:41 PM
Bensen Daniel	Chief Operating Officer	Jul 11 '23	Sale	16.02	500	8,009	527,981	Jul 12 06:41 PM
Bensen Daniel	Chief Operating Officer	Jul 10 '23	Option Exercise	0.61	1,202	733	529,183	Jul 12 06:41 PM
Bensen Daniel	Chief Operating Officer	Jul 10 '23	Sale	16.01	1,202	19,240	527,981	Jul 12 06:41 PM
Bensen Daniel	Chief Operating Officer	Jul 03 '23	Option Exercise	0.61	4,265	2,602	532,246	Jul 03 05:31 PM
Bensen Daniel	Chief Operating Officer	Jul 03 '23	Sale	16.37	4,265	69,814	527,981	Jul 03 05:31 PM
Bensen Daniel	Chief Operating Officer	Jun 30 '23	Option Exercise	0.61	18,819	11,480	546,800	Jul 03 05:31 PM
Bensen Daniel	Chief Operating Officer	Jun 30 '23	Sale	16.97	18,819	319,419	527,981	Jul 03 05:31 PM
Bensen Daniel	Chief Operating Officer	Jun 29 '23	Option Exercise	0.61	17,281	10,541	545,262	Jul 03 05:31 PM
Bensen Daniel	Chief Operating Officer	Jun 29 '23	Sale	16.49	17,281	285,014	527,981	Jul 03 05:31 PM
Bensen Daniel	Chief Operating Officer	Jun 28 '23	Option Exercise	0.61	13,524	8,250	541,505	Jun 28 08:31 PM
Bensen Daniel	Chief Operating Officer	Jun 28 '23	Sale	16.91	13,524	228,637	527,981	Jun 28 08:31 PM
Bensen Daniel	Chief Operating Officer	Jun 27 '23	Option Exercise	0.61	16,028	9,777	544,009	Jun 28 08:31 PM
Bensen Daniel	Chief Operating Officer	Jun 27 '23	Sale	16.91	16,028	271,075	527,981	Jun 28 08:31 PM
Bensen Daniel	Chief Operating Officer	Jun 26 '23	Option Exercise	0.61	17,232	10,512	545,213	Jun 28 08:31 PM
Bensen Daniel	Chief Operating Officer	Jun 26 '23	Sale	16.77	17,232	288,925	527,981	Jun 28 08:31 PM
Harris Todd	Chief Executive Officer	Jun 23 '23	Sale	17.01	20,712	352,261	1,601,276	Jun 26 07:30 PM
Harris Todd	Chief Executive Officer	Jun 22 '23	Sale	17.04	3,478	59,251	1,621,988	Jun 26 07:30 PM

Open in Screener

ELVN

Enliven Therapeutics Inc

Jun 20 • 04:00PM ET

21.04

Dollar change +0.57
Percentage change 2.78	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

ELVN Enliven Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC ESML

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	42.74%	Shs Outstand	41.29M	Perf Week	-7.52%
Market Cap	989.72M	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-16.11%	Shs Float	26.93M	Perf Month	-12.33%
Income	-79.60M	PEG	-	EPS next Q	-0.55	Inst Own	57.30%	Short Float	20.19%	Perf Quarter	9.53%
Sales	0.00M	P/S	-	EPS this Y	-12.60%	Inst Trans	-9.18%	Short Ratio	15.46	Perf Half Y	79.83%
Book/sh	6.79	P/B	3.10	EPS next Y	-22.31%	ROA	-24.66%	Short Interest	5.44M	Perf Year	-3.44%
Cash/sh	6.81	P/C	3.09	EPS next 5Y	-	ROE	-26.14%	52W Range	9.80 - 26.00	Perf YTD	52.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.16%	ROI	-25.05%	52W High	-19.08%	Beta	1.08
Dividend TTM	-	Quick Ratio	13.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	114.69%	ATR (14)	1.52
Dividend Ex-Date	-	Current Ratio	13.47	EPS Y/Y TTM	-216.13%	Oper. Margin	0.00%	RSI (14)	46.80	Volatility	6.34% 7.35%
Employees	46	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	34.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	32.00%	Payout	-	Rel Volume	0.88	Prev Close	20.47
Sales Surprise	-	EPS Surprise	0.61%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	351.67K	Price	21.04
SMA20	-4.15%	SMA50	-0.74%	SMA200	32.32%	Trades		Volume	310,777	Change	2.78%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
03:03PM	Loading…
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
09:01AM	Loading…
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heyman Richard A.	Director	Jun 17 '24	Sale	21.48	1,270	27,278	134,615	Jun 20 07:20 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 06 '24	Option Exercise	2.48	1,133	2,810	1,133	Jun 10 06:46 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 06 '24	Sale	20.06	1,133	22,722	0	Jun 10 06:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 29 '24	Option Exercise	1.12	12,000	13,440	12,000	May 31 04:05 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 29 '24	Sale	21.73	12,000	260,800	0	May 31 04:05 PM
Kintz Samuel	PRESIDENT AND CEO	May 28 '24	Option Exercise	1.12	12,000	13,440	12,000	May 30 05:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 28 '24	Option Exercise	2.48	4,250	10,540	4,250	May 30 05:54 PM
Kintz Samuel	PRESIDENT AND CEO	May 28 '24	Sale	23.18	12,000	278,210	0	May 30 05:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 28 '24	Sale	23.18	4,250	98,530	0	May 30 05:54 PM
ORBIMED ADVISORS LLC	Director	May 16 '24	Sale	22.14	1,033,300	22,877,262	254,814	May 20 05:00 PM
Gupta Rishi	Director	May 16 '24	Sale	22.14	1,033,300	22,877,262	254,814	May 20 05:03 PM
Heyman Richard A.	Director	May 16 '24	Sale	23.74	1,270	30,150	135,885	May 20 07:46 PM
Patel Anish	CHIEF OPERATING OFFICER	May 14 '24	Option Exercise	2.48	1,107	2,745	1,107	May 16 07:29 PM
Patel Anish	CHIEF OPERATING OFFICER	May 14 '24	Sale	25.00	1,107	27,675	0	May 16 07:29 PM
Patel Anish	CHIEF OPERATING OFFICER	May 09 '24	Option Exercise	2.48	260	645	260	May 13 07:35 PM
Patel Anish	CHIEF OPERATING OFFICER	May 09 '24	Sale	25.06	260	6,515	0	May 13 07:35 PM
Patel Anish	CHIEF OPERATING OFFICER	May 06 '24	Option Exercise	2.48	4,875	12,090	4,875	May 08 08:40 PM
Patel Anish	CHIEF OPERATING OFFICER	May 06 '24	Sale	22.72	4,875	110,769	0	May 08 08:40 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 03 '24	Option Exercise	2.48	1,000	2,480	1,000	May 07 06:58 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 03 '24	Sale	22.50	1,000	22,500	0	May 07 06:58 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 29 '24	Option Exercise	1.12	12,000	13,440	12,000	May 01 07:04 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Option Exercise	2.48	3,250	8,060	3,250	May 01 07:02 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 29 '24	Sale	17.92	12,000	214,988	0	May 01 07:04 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 29 '24	Sale	16.97	3,250	55,165	0	May 01 07:02 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 25 '24	Option Exercise	1.12	12,000	13,440	12,000	Apr 29 06:50 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 25 '24	Sale	16.89	12,000	202,700	0	Apr 29 06:50 PM
Heyman Richard A.	Director	Apr 15 '24	Sale	19.99	1,270	25,383	137,155	Apr 15 07:03 PM
Ballal Rahul D.	Director	Apr 11 '24	Option Exercise	13.21	53,400	705,266	75,741	Apr 12 06:23 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 11 '24	Option Exercise	1.12	47,709	53,434	47,709	Apr 15 07:05 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 11 '24	Option Exercise	2.48	20,000	49,600	20,000	Apr 15 07:02 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 11 '24	Option Exercise	2.48	14,903	36,959	17,500	Apr 15 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 11 '24	Option Exercise	2.48	14,000	34,720	14,000	Apr 15 07:04 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 11 '24	Option Exercise	1.12	30,000	33,600	30,000	Apr 15 07:06 PM
Ballal Rahul D.	Director	Apr 11 '24	Sale	23.95	53,400	1,279,068	22,341	Apr 12 06:23 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 11 '24	Sale	25.04	47,709	1,194,700	0	Apr 15 07:05 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 11 '24	Sale	25.04	30,000	751,332	0	Apr 15 07:06 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 11 '24	Sale	25.07	20,000	501,478	0	Apr 15 07:02 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 11 '24	Sale	25.03	17,500	438,098	0	Apr 15 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 11 '24	Sale	24.72	14,000	346,149	0	Apr 15 07:04 PM
Heyman Richard A.	Director	Apr 11 '24	Sale	25.03	5,045	126,279	138	Apr 15 07:03 PM
Heyman Richard A.	Director	Apr 11 '24	Sale	25.00	649	16,225	28,567	Apr 15 07:03 PM
Ballal Rahul D.	Director	Apr 10 '24	Option Exercise	12.60	13,600	171,360	35,941	Apr 12 06:23 PM
Ballal Rahul D.	Director	Apr 10 '24	Sale	21.01	13,600	285,744	22,341	Apr 12 06:23 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 08 '24	Sale	18.60	4,875	90,687	2,597	Apr 10 08:35 PM
Ballal Rahul D.	Director	Apr 04 '24	Option Exercise	12.60	3,485	43,911	25,826	Apr 08 08:40 PM
Ballal Rahul D.	Director	Apr 04 '24	Sale	19.15	3,485	66,729	22,341	Apr 08 08:40 PM
Ballal Rahul D.	Director	Apr 01 '24	Option Exercise	5.73	3,237	18,534	25,578	Apr 03 09:32 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 01 '24	Option Exercise	1.12	12,000	13,440	12,000	Apr 03 09:30 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 01 '24	Sale	18.60	12,000	223,146	0	Apr 03 09:30 PM
Ballal Rahul D.	Director	Apr 01 '24	Sale	19.08	3,237	61,758	22,341	Apr 03 09:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '24	Option Exercise	2.48	3,250	8,060	3,250	Mar 29 05:59 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	18.25	3,250	59,302	0	Mar 29 05:59 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 25 '24	Option Exercise	1.12	12,000	13,440	12,000	Mar 27 05:03 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 25 '24	Sale	17.56	12,000	210,661	0	Mar 27 05:03 PM
Ballal Rahul D.	Director	Mar 20 '24	Option Exercise	5.52	13,278	73,295	35,619	Mar 22 07:46 PM
Ballal Rahul D.	Director	Mar 20 '24	Sale	19.16	13,278	254,462	22,341	Mar 22 07:46 PM
Heyman Richard A.	Director	Mar 19 '24	Sale	14.50	1,270	18,419	143,470	Mar 21 06:41 PM
Patel Anish	CHIEF OPERATING OFFICER	Mar 06 '24	Sale	15.64	4,875	76,239	7,472	Mar 08 07:52 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 29 '24	Option Exercise	1.12	12,000	13,440	12,000	Mar 04 05:55 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 29 '24	Sale	16.42	12,000	197,006	0	Mar 04 05:55 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '24	Option Exercise	2.48	3,250	8,060	3,250	Feb 29 05:27 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '24	Sale	16.97	3,250	55,163	0	Feb 29 05:27 PM
Heyman Richard A.	Director	Feb 15 '24	Sale	17.42	1,270	22,117	144,740	Feb 20 07:41 PM
5AM Partners VI, LLC	10% Owner	Feb 14 '24	Sale	14.90	825,000	12,292,500	635,341	Feb 16 04:15 PM
Patel Anish	CHIEF OPERATING OFFICER	Feb 06 '24	Sale	15.11	4,875	73,658	12,347	Feb 08 08:47 PM
5AM Partners VI, LLC	10% Owner	Jan 31 '24	Sale	15.00	500,000	7,500,000	771,983	Feb 02 04:29 PM
Heyman Richard A.	Director	Jan 30 '24	Sale	16.41	1,270	20,840	146,010	Feb 01 08:10 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 29 '24	Option Exercise	1.12	12,000	13,440	12,000	Jan 31 09:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 29 '24	Option Exercise	2.48	3,250	8,060	3,250	Jan 31 09:20 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 29 '24	Sale	15.85	12,000	190,256	0	Jan 31 09:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 29 '24	Sale	15.81	3,250	51,388	0	Jan 31 09:20 PM
Kintz Samuel	President and CEO	Jan 25 '24	Option Exercise	1.12	12,000	13,440	12,000	Jan 29 08:01 PM
Kintz Samuel	President and CEO	Jan 25 '24	Sale	15.69	12,000	188,229	0	Jan 29 08:01 PM
Patel Anish	Chief Operating Officer	Jan 22 '24	Sale	15.13	4,875	73,783	17,222	Jan 24 06:38 PM
Hohl Benjamin	Chief Financial Officer	Jan 02 '24	Option Exercise	2.48	9,383	23,270	9,383	Jan 02 07:59 PM
Patel Anish	Chief Operating Officer	Jan 02 '24	Sale	15.00	11,000	165,053	22,097	Jan 02 08:00 PM
Hohl Benjamin	Chief Financial Officer	Jan 02 '24	Sale	15.01	9,383	140,839	0	Jan 02 07:59 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 29 '23	Option Exercise	1.12	12,000	13,440	12,000	Jan 03 07:01 PM
Hohl Benjamin	Chief Financial Officer	Dec 29 '23	Option Exercise	2.48	20	50	20	Jan 02 07:59 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 29 '23	Sale	14.28	12,000	171,381	0	Jan 03 07:01 PM
Patel Anish	Chief Operating Officer	Dec 29 '23	Sale	15.00	20	300	33,097	Jan 02 08:00 PM
Hohl Benjamin	Chief Financial Officer	Dec 29 '23	Sale	15.00	20	300	0	Jan 02 07:59 PM
Hohl Benjamin	Chief Financial Officer	Dec 28 '23	Option Exercise	2.48	2,467	6,118	2,467	Jan 02 07:59 PM
Patel Anish	Chief Operating Officer	Dec 28 '23	Sale	15.08	2,520	37,996	33,117	Jan 02 08:00 PM
Hohl Benjamin	Chief Financial Officer	Dec 28 '23	Sale	15.07	2,467	37,188	0	Jan 02 07:59 PM
Kintz Samuel	President and CEO	Dec 26 '23	Option Exercise	1.12	12,000	13,440	12,000	Dec 28 04:29 PM
Hohl Benjamin	Chief Financial Officer	Dec 26 '23	Option Exercise	2.48	100	248	100	Dec 27 05:26 PM
Kintz Samuel	President and CEO	Dec 26 '23	Sale	14.64	12,000	175,709	0	Dec 28 04:29 PM
Patel Anish	Chief Operating Officer	Dec 26 '23	Sale	15.01	102	1,531	35,637	Dec 27 05:28 PM
Hohl Benjamin	Chief Financial Officer	Dec 26 '23	Sale	15.00	100	1,500	0	Dec 27 05:26 PM
Kintz Samuel	President and CEO	Dec 22 '23	Option Exercise	1.12	8,175	9,156	8,175	Dec 26 07:31 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 22 '23	Option Exercise	1.12	6,546	7,332	6,546	Dec 26 07:32 PM
Hohl Benjamin	Chief Financial Officer	Dec 22 '23	Option Exercise	2.48	1,030	2,554	1,030	Dec 27 05:26 PM
Kintz Samuel	President and CEO	Dec 22 '23	Sale	13.05	8,175	106,655	0	Dec 26 07:31 PM
Lyssikatos Joseph P	Chief Scientific Officer	Dec 22 '23	Sale	13.07	6,546	85,530	0	Dec 26 07:32 PM
Hohl Benjamin	Chief Financial Officer	Dec 22 '23	Sale	15.07	1,030	15,525	0	Dec 27 05:26 PM
Patel Anish	Chief Operating Officer	Dec 22 '23	Sale	15.03	983	14,776	35,739	Dec 27 05:28 PM
Heyman Richard A.	Director	Dec 22 '23	Sale	13.00	168	2,184	147,280	Dec 26 07:29 PM
Heyman Richard A.	Director	Dec 22 '23	Sale	13.00	35	455	29,216	Dec 26 07:29 PM
Kintz Samuel	President and CEO	Dec 21 '23	Option Exercise	1.12	20	22	20	Dec 26 07:31 PM

Open in Screener

KALV

KalVista Pharmaceuticals Inc

Jun 20 • 04:00PM ET

11.21

Dollar change -0.16
Percentage change -1.41	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

KALV KalVista Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IWN IBB VTWO IWC DFAS ITOT DFAC

Index	RUT	P/E	-	EPS (ttm)	-3.14	Insider Own	34.00%	Shs Outstand	34.17M	Perf Week	-9.23%
Market Cap	472.95M	Forward P/E	-	EPS next Y	-2.48	Insider Trans	6.21%	Shs Float	27.84M	Perf Month	-5.64%
Income	-108.30M	PEG	-	EPS next Q	-0.71	Inst Own	79.58%	Short Float	19.83%	Perf Quarter	-8.34%
Sales	0.00M	P/S	-	EPS this Y	8.98%	Inst Trans	2.24%	Short Ratio	15.29	Perf Half Y	5.26%
Book/sh	2.56	P/B	4.38	EPS next Y	18.11%	ROA	-68.23%	Short Interest	5.52M	Perf Year	16.41%
Cash/sh	1.79	P/C	6.26	EPS next 5Y	-	ROE	-79.33%	52W Range	7.21 - 16.88	Perf YTD	-8.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.84%	ROI	-114.19%	52W High	-33.59%	Beta	0.90
Dividend TTM	-	Quick Ratio	5.44	Sales past 5Y	-30.33%	Gross Margin	-	52W Low	55.48%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	5.44	EPS Y/Y TTM	12.33%	Oper. Margin	0.00%	RSI (14)	40.05	Volatility	3.44% 4.01%
Employees	118	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	29.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-10.98%	Payout	-	Rel Volume	0.45	Prev Close	11.37
Sales Surprise	-	EPS Surprise	-12.42%	Sales Q/Q	-	Earnings	Mar 11 BMO	Avg Volume	361.05K	Price	11.21
SMA20	-4.47%	SMA50	-4.48%	SMA200	0.05%	Trades		Volume	161,847	Change	-1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-20	Initiated	H.C. Wainwright	Buy	$30
Jul-29-19	Initiated	SVB Leerink	Outperform	$31
Mar-20-19	Initiated	Needham	Buy	$35
Oct-30-18	Initiated	Jefferies	Buy	$30
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy	$18

Jun-18-24 06:30AM	KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jun-06-24 06:30AM	KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 (Business Wire)
Jun-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 06:30AM	KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 (Business Wire)
May-31-24 04:09PM	KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema (Business Wire)
06:30AM	Loading…
May-24-24 06:30AM	KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 (Business Wire)
May-21-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
May-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-24 06:30AM	KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year (Business Wire) +7.31%
Apr-22-24 06:30AM	KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors (Business Wire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 06:30AM	KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-24 06:30AM	KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas (Business Wire)
Mar-12-24 06:30AM	KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat (Business Wire)
06:30AM	Loading…
Mar-11-24 06:30AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire) -8.77%
Mar-08-24 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas (Business Wire)
Mar-07-24 06:30AM	KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer (Business Wire)
Mar-06-24 06:30AM	KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference (Business Wire)
Mar-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-24 06:30AM	KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +6.79%
Feb-26-24 06:30AM	KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +8.82%
Feb-20-24 06:30AM	KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat (Business Wire) -7.13%
Feb-16-24 06:30AM	KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-15-24 06:30AM	KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-14-24 04:18PM	KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-13-24 07:10AM	UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease (Reuters) -7.42%
06:40AM	KalVista meets main goals in late-stage trial for skin condition treatment (Reuters)
06:30AM	KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema (Business Wire)
01:30AM	Kalvista pill succeeds in late-stage study for rare swelling disorder (BioPharma Dive)
06:30AM	Loading…
Feb-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-24 12:02PM	Hedge Fund and Insider Trading News: David Einhorn, Crispin Odey, Bill Ackman, Stanley Druckenmiller, Ken Griffin, Burke Herbert Financial Services (BHRB), KalVista Pharmaceuticals, Inc. (KALV), and More (Insider Monkey)
Jan-13-24 03:12AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ... (GuruFocus.com)
Jan-12-24 03:03AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ... (GuruFocus.com)
Dec-30-23 09:02AM	Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV) (GuruFocus.com)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-20-23 06:30AM	KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology (Business Wire)
Dec-07-23 04:49PM	KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter Results (GuruFocus.com) -9.03%
06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-23-23 05:14AM	Insider Sell Alert: CEO Thomas Crockett Offloads Shares of KalVista Pharmaceuticals Inc (GuruFocus.com)
Nov-22-23 05:04AM	Insider Sell Alert: KalVista Pharmaceuticals Inc's Benjamin Palleiko Sells 13,008 Shares (GuruFocus.com)
Nov-14-23 10:31PM	3 Micro-Cap Stocks That Could Be Moonshots (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (Business Wire)
Nov-13-23 06:30AM	KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved (Business Wire)
Nov-07-23 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-02-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (Business Wire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-25-23 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks) -6.71%
Oct-24-23 06:30AM	KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (Business Wire)
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks)
Oct-03-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-20-23 09:02AM	Is it a Good Idea to Invest in KalVista (KALV) Stock Now? (Zacks)
Sep-19-23 06:30AM	KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-14-23 01:04AM	Insider Sell: Director Albert Cha Sells 18,000 Shares of KalVista Pharmaceuticals Inc (GuruFocus.com)
Sep-07-23 06:30AM	KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update (Business Wire)
Sep-06-23 09:40AM	Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-28-23 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA (Business Wire)
Aug-02-23 04:15PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-23 06:30AM	KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer (Business Wire)
Jul-24-23 06:30AM	KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit (Business Wire)
Jul-14-23 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit (Business Wire)
Jul-10-23 09:54AM	KalVista (KALV) Surges 15% on Update From Angioedema Study (Zacks)
Jul-07-23 06:30AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results (Business Wire) +14.97%
Jul-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-12-23 06:30AM	KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology (Business Wire)
Jun-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-02-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) (Business Wire)
May-31-23 06:30AM	KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference (Business Wire)
May-23-23 06:30AM	KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference (Business Wire)
May-08-23 06:30AM	KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop (Business Wire)
May-02-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-27-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop (Business Wire)
Apr-20-23 09:55AM	Wall Street Analysts See a 145.38% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High? (Zacks)
Apr-19-23 12:53PM	Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation (Simply Wall St.)
Apr-12-23 11:06AM	Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio (Zacks) -5.79%
06:30AM	KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks)
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks)
Apr-04-23 09:55AM	Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet (Zacks)
Mar-22-23 09:55AM	KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) -11.02%
Mar-09-23 06:30AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results (Business Wire) -5.41%
Mar-03-23 09:55AM	Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High? (Zacks)
Feb-27-23 06:30AM	KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting (Business Wire)
Feb-16-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology (Business Wire)
Feb-14-23 06:30AM	KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development (Business Wire)
Feb-10-23 06:30AM	KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet (Business Wire)
Feb-07-23 12:00PM	What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet (Zacks)
06:30AM	KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session (Business Wire)
Feb-03-23 06:30AM	KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference (Business Wire)
Feb-02-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-05-23 06:30AM	KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President (Business Wire)
Jan-04-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-30-22 06:48AM	After losing 48% in the past year, KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-27-22 06:30AM	KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering (Business Wire) +15.07%
Dec-08-22 06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results (Business Wire)
Dec-05-22 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jun 07 '24	Sale	11.53	7,465	86,068	224,547	Jun 10 06:42 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 20 '24	Sale	11.76	21,959	258,337	216,387	May 21 05:57 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 20 '24	Sale	11.76	13,175	154,997	70,325	May 21 05:58 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 20 '24	Sale	11.76	11,610	136,586	80,074	May 21 05:55 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	May 20 '24	Sale	11.76	8,088	95,151	72,858	May 21 05:59 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	Feb 20 '24	Sale	14.07	28,288	397,929	62,157	Feb 21 09:51 PM
Crockett Thomas Andrew	CEO	Feb 20 '24	Sale	14.11	24,888	351,289	211,203	Feb 21 09:41 PM
Palleiko Benjamin L	CFO, CBO	Feb 20 '24	Sale	14.11	22,802	321,846	187,315	Feb 21 09:46 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 20 '24	Sale	14.12	14,295	201,774	52,886	Feb 21 09:44 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 20 '24	Sale	14.11	12,053	170,124	72,895	Feb 21 09:48 PM
Crockett Thomas Andrew	CEO	Feb 14 '24	Sale	15.01	58,356	875,883	181,676	Feb 16 04:20 PM
Palleiko Benjamin L	CFO, CBO	Feb 14 '24	Sale	15.01	40,855	613,205	159,088	Feb 16 04:21 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 14 '24	Sale	15.01	39,886	598,661	66,160	Feb 16 04:18 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	Feb 14 '24	Sale	15.01	28,171	422,827	71,657	Feb 16 04:19 PM
Venrock Healthcare Capital Par	10% Owner	Feb 08 '24	Buy	14.70	29,747	437,281	4,824,731	Feb 08 08:11 PM
Venrock Healthcare Capital Par	10% Owner	Feb 07 '24	Buy	14.56	51,827	754,601	4,794,984	Feb 08 08:11 PM
Venrock Healthcare Capital Par	10% Owner	Feb 06 '24	Buy	14.74	4,474	65,947	4,743,157	Feb 08 08:11 PM
Crockett Thomas Andrew	CEO	Feb 01 '24	Sale	16.22	10,000	162,198	117,532	Feb 05 05:55 PM
Venrock Healthcare Capital Par	10% Owner	Jan 30 '24	Buy	14.47	88,099	1,274,793	4,738,683	Feb 01 04:38 PM
Venrock Healthcare Capital Par	10% Owner	Jan 29 '24	Buy	14.22	80,600	1,146,132	4,650,584	Jan 29 07:07 PM
Venrock Healthcare Capital Par	10% Owner	Jan 26 '24	Buy	12.98	4,174	54,179	4,569,984	Jan 29 07:07 PM
Venrock Healthcare Capital Par	10% Owner	Jan 25 '24	Buy	12.73	7,030	89,492	4,565,810	Jan 29 07:07 PM
Venrock Healthcare Capital Par	10% Owner	Jan 24 '24	Buy	12.44	20,686	257,334	4,558,780	Jan 24 08:24 PM
Venrock Healthcare Capital Par	10% Owner	Jan 23 '24	Buy	12.54	10,897	136,648	4,538,094	Jan 24 08:24 PM
Venrock Healthcare Capital Par	10% Owner	Jan 22 '24	Buy	12.55	67,546	847,702	4,527,197	Jan 24 08:24 PM
Venrock Healthcare Capital Par	10% Owner	Jan 19 '24	Buy	12.43	25,000	310,750	4,459,651	Jan 19 06:02 PM
Venrock Healthcare Capital Par	10% Owner	Jan 18 '24	Buy	12.51	39,680	496,397	4,434,651	Jan 19 06:02 PM
Venrock Healthcare Capital Par	10% Owner	Jan 17 '24	Buy	12.60	78,925	994,455	4,394,971	Jan 19 06:02 PM
Venrock Healthcare Capital Par	10% Owner	Jan 16 '24	Buy	12.73	19,599	249,495	4,316,046	Jan 16 07:04 PM
Venrock Healthcare Capital Par	10% Owner	Jan 11 '24	Buy	12.68	6,647	84,284	4,296,447	Jan 16 07:04 PM
Feener Edward P.	Chief Scientific Officer	Jan 11 '24	Sale	13.03	22,679	295,514	39,828	Jan 12 04:26 PM
Venrock Healthcare Capital Par	10% Owner	Jan 10 '24	Buy	12.67	47,700	604,359	4,289,800	Jan 10 08:57 PM
Venrock Healthcare Capital Par	10% Owner	Jan 09 '24	Buy	12.56	20,816	261,449	4,242,100	Jan 10 08:57 PM
Feener Edward P.	Chief Scientific Officer	Jan 09 '24	Sale	13.00	100	1,300	62,507	Jan 10 06:05 PM
Venrock Healthcare Capital Par	10% Owner	Jan 08 '24	Buy	12.44	69,184	860,649	4,221,284	Jan 10 08:57 PM
Feener Edward P.	Chief Scientific Officer	Jan 08 '24	Sale	13.01	17,221	224,000	62,607	Jan 10 06:05 PM
Venrock Healthcare Capital Par	10% Owner	Jan 04 '24	Buy	12.11	41,764	505,762	4,152,100	Jan 05 04:13 PM
Venrock Healthcare Capital Par	10% Owner	Jan 03 '24	Buy	12.20	17,605	214,781	4,110,336	Jan 05 04:13 PM
Venrock Healthcare Capital Par	10% Owner	Dec 29 '23	Buy	12.49	6,013	75,102	4,092,731	Dec 29 06:44 PM
Venrock Healthcare Capital Par	10% Owner	Dec 28 '23	Buy	12.50	471,490	5,893,625	4,086,718	Dec 29 06:44 PM
Venrock Healthcare Capital Par	10% Owner	Dec 27 '23	Buy	11.97	41,514	496,923	3,615,228	Dec 29 06:44 PM
Crockett Thomas Andrew	CEO	Dec 27 '23	Sale	12.02	30,000	360,453	127,532	Dec 28 04:28 PM
Crockett Thomas Andrew	CEO	Nov 20 '23	Sale	8.23	14,807	121,851	157,532	Nov 21 04:30 PM
Palleiko Benjamin L	President, CFO, CBO & Sec'y	Nov 20 '23	Sale	8.23	13,008	107,047	112,443	Nov 21 04:31 PM
Audhya Paul K.	Chief Medical Officer	Nov 20 '23	Sale	8.23	7,985	65,711	36,568	Nov 21 04:34 PM
Yea Christopher	Chief Development Officer	Nov 20 '23	Sale	8.23	7,113	58,535	46,046	Nov 21 04:32 PM
Feener Edward P.	Chief Scientific Officer	Nov 20 '23	Sale	8.23	4,958	40,801	79,828	Nov 21 04:33 PM
Cha Albert	Director	Sep 11 '23	Option Exercise	7.49	18,000	134,820	18,000	Sep 13 04:29 PM
Cha Albert	Director	Sep 11 '23	Sale	10.50	18,000	189,050	0	Sep 13 04:29 PM
Crockett Thomas Andrew	CEO	Aug 18 '23	Sale	10.73	14,876	159,602	146,756	Aug 21 08:05 PM
Palleiko Benjamin L	President, CFO, CBO & Sec'y	Aug 18 '23	Sale	10.73	13,067	140,192	95,254	Aug 21 08:05 PM
Audhya Paul K.	Chief Medical Officer	Aug 18 '23	Sale	10.73	8,020	86,045	26,023	Aug 21 08:09 PM
Yea Christopher	Chief Development Officer	Aug 18 '23	Sale	10.73	7,142	76,624	41,662	Aug 21 08:06 PM
Feener Edward P.	Chief Scientific Officer	Aug 18 '23	Sale	10.73	4,976	53,386	73,289	Aug 21 08:07 PM

Open in Screener

APLT

Applied Therapeutics Inc

Jun 20 • 04:00PM ET

4.45

Dollar change -0.05
Percentage change -1.11	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

APLT Applied Therapeutics Inc daily Stock Chart

Held by: SURI VTI VXF DWAS IWC BBC AVUS HKND

Index	-	P/E	-	EPS (ttm)	-1.32	Insider Own	22.81%	Shs Outstand	114.27M	Perf Week	-15.56%
Market Cap	508.50M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-3.37%	Shs Float	88.20M	Perf Month	5.95%
Income	-96.51M	PEG	-	EPS next Q	-0.18	Inst Own	72.60%	Short Float	4.85%	Perf Quarter	-35.51%
Sales	10.66M	P/S	47.70	EPS this Y	12.40%	Inst Trans	-5.86%	Short Ratio	5.30	Perf Half Y	50.34%
Book/sh	0.59	P/B	7.55	EPS next Y	62.95%	ROA	-189.48%	Short Interest	4.28M	Perf Year	202.72%
Cash/sh	1.28	P/C	3.47	EPS next 5Y	-	ROE	-682.16%	52W Range	1.18 - 9.39	Perf YTD	32.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-8.72%	ROI	-143.35%	52W High	-52.61%	Beta	1.98
Dividend TTM	-	Quick Ratio	1.80	Sales past 5Y	0.00%	Gross Margin	95.68%	52W Low	277.12%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	1.80	EPS Y/Y TTM	59.67%	Oper. Margin	-586.31%	RSI (14)	44.53	Volatility	6.87% 7.50%
Employees	25	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-905.38%	Recom	1.20	Target Price	11.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-123.12%	Payout	-	Rel Volume	1.07	Prev Close	4.50
Sales Surprise	-94.30%	EPS Surprise	-320.33%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	806.41K	Price	4.45
SMA20	-1.89%	SMA50	-3.28%	SMA200	20.59%	Trades		Volume	862,766	Change	-1.11%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-24	Initiated	RBC Capital Mkts	Outperform	$12
Feb-22-24	Initiated	Leerink Partners	Outperform	$12
Jan-04-22	Downgrade	Barclays	Overweight → Equal Weight	$44 → $7
Aug-27-21	Downgrade	Goldman	Neutral → Sell	$16 → $10
Jun-25-21	Resumed	Goldman	Neutral	$18
Oct-08-20	Initiated	Truist	Buy	$85
Apr-22-20	Initiated	Goldman	Buy	$60
Feb-27-20	Initiated	Barclays	Overweight	$64
Jun-10-19	Initiated	Robert W. Baird	Outperform	$24
Jun-10-19	Initiated	Cowen	Outperform
Jun-10-19	Initiated	Citigroup	Buy	$29

Show Previous Ratings

May-10-24 02:47PM	Applied Therapeutics Inc (APLT) Reports Q1 2024 Earnings: A Deep Dive into Financials and ... (GuruFocus.com)
May-09-24 01:55PM	APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Applied Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 07:00AM	Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Apr-15-24 07:00AM	Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer (GlobeNewswire)
07:00AM	Loading…
Apr-04-24 07:00AM	Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024 (GlobeNewswire)
Mar-28-24 05:12PM	UPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drug (Reuters) -6.91%
04:42PM	US FDA extends review of Applied Therapeutics' genetic disease drug (Reuters)
04:30PM	Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia (GlobeNewswire)
Mar-13-24 09:23AM	Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why (Zacks)
Mar-08-24 04:32AM	Applied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical Progress (GuruFocus.com)
Mar-06-24 07:00AM	Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results (GlobeNewswire)
Feb-28-24 01:01PM	FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder (Benzinga) +32.62%
09:48AM	Why Is Applied Therapeutics (APLT) Stock Up 59% Today? (InvestorPlace)
08:05AM	Applied Therapeutics Announces $100 Million Private Placement (GlobeNewswire)
08:00AM	Loading…
08:00AM	Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-15-24 07:00AM	Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency (GlobeNewswire) +39.93%
Jan-05-24 09:23AM	Why Is Applied Therapeutics (APLT) Stock Down 30% Today? (InvestorPlace) -40.63%
03:31AM	Constellation Brands, Costco, Peloton rise premarket; Apple, Tesla fall (Investing.com)
02:32AM	Applied Therapeutics fails heart disease phase 3, seeks partner to bring molecule to market (FierceBiotech.com)
Jan-04-24 04:05PM	Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy (GlobeNewswire) +5.57%
Jan-03-24 07:00AM	Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia (GlobeNewswire)
Nov-09-23 08:34AM	Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ... (GuruFocus.com) -10.39%
07:30AM	Applied Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:00AM	Applied Therapeutics to Present at the UBS Biopharma Conference 2023 (GlobeNewswire)
Nov-01-23 07:00AM	Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7 (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Sep-28-23 07:00AM	Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting (GlobeNewswire)
Sep-06-23 07:00AM	Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023 (GlobeNewswire) +42.86%
07:42AM	Loading…
Aug-11-23 07:42AM	We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate (Simply Wall St.)
Aug-10-23 07:00AM	Applied Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-25-23 07:00AM	Applied Therapeutics Provides Regulatory Update on Galactosemia Program (GlobeNewswire) +6.38%
Jun-22-23 07:00AM	Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association (GlobeNewswire)
Jun-15-23 07:00AM	Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society (GlobeNewswire)
May-25-23 07:00AM	Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency (GlobeNewswire)
May-11-23 07:00AM	Applied Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace)
Apr-24-23 07:00AM	Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity (GlobeNewswire) +16.28%
07:00AM	Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission (GlobeNewswire)
Mar-23-23 06:30AM	Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results (GlobeNewswire) -5.61%
Mar-18-23 09:54AM	Quite a few insiders invested in Applied Therapeutics, Inc. (NASDAQ:APLT) last year which is positive news for shareholders (Simply Wall St.)
Mar-01-23 07:00AM	Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-16-23 10:46AM	Applied Therapeutics Reveals Pivotal Study Data In Hereditary Neuropathy (Benzinga) +17.00%
07:00AM	Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency (GlobeNewswire)
Feb-09-23 07:00AM	Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-04-23 06:00AM	Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe (GlobeNewswire) +15.28%
Nov-09-22 07:00AM	Applied Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -8.62%
Oct-31-22 07:00AM	Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022 (GlobeNewswire) +6.73%
Oct-25-22 07:00AM	Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy (GlobeNewswire) +6.91%
Oct-09-22 09:13AM	Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62 (Simply Wall St.)
Oct-06-22 11:18AM	Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical Significance (Benzinga) -33.47%
07:00AM	Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format (GlobeNewswire)
Sep-02-22 09:55AM	Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now (Zacks) -8.45%
Aug-12-22 07:00AM	Applied Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-28-22 07:00AM	Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference (GlobeNewswire)
Jun-22-22 10:12PM	Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants (GlobeNewswire) -28.97%
04:10PM	Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants (GlobeNewswire)
Jun-16-22 08:08AM	Companies Like Applied Therapeutics (NASDAQ:APLT) Could Be Quite Risky (Simply Wall St.) -9.49%
Jun-03-22 07:00AM	Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia (GlobeNewswire)
May-20-22 09:50AM	Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase (Zacks) -5.26%
May-19-22 07:00AM	Applied Therapeutics to Present at the UBS Global Healthcare Conference (GlobeNewswire)
May-18-22 11:47AM	Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate (Zacks) -7.65%
11:03AM	Horizon (HZNP) Begins Enrollment in Alopecia Areata Study (Zacks)
May-17-22 11:31AM	Seagen's (SGEN) Stock Up on CEO's Resignation Announcement (Zacks)
May-13-22 10:30AM	Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia (Zacks)
08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 06:59AM	Applied Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks)
May-05-22 07:30AM	Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society (GlobeNewswire) -6.34%
May-03-22 10:47AM	What Awaits Meridian Bioscience (VIVO) This Earnings Season? (Zacks)
May-02-22 07:12AM	Great news for Applied Therapeutics, Inc. (NASDAQ:APLT): Insiders acquired stock in large numbers last year (Simply Wall St.)
Apr-28-22 10:24AM	Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-12-22 11:47AM	Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study (Zacks) -7.76%
Apr-08-22 11:39AM	Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal (Zacks)
Apr-04-22 07:30AM	Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders (GlobeNewswire) +9.21%
Mar-31-22 11:05AM	Here's Why You Should Retain Universal Health (UHS) Stock Now (Zacks) -7.46%
Mar-22-22 11:36AM	Encompass Health's (EHC) Nationwide Hospital Count Rises to 147 (Zacks)
Mar-16-22 07:30AM	Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics (GlobeNewswire) +5.26%
Mar-15-22 12:19PM	Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left? (Zacks)
Mar-10-22 07:30AM	Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results (GlobeNewswire)
Mar-01-22 07:00AM	Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences (GlobeNewswire)
Feb-28-22 07:30AM	Applied Therapeutics Supports 15th Annual Rare Disease Day (GlobeNewswire) -5.53%
Feb-10-22 07:00AM	Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Jan-03-22 12:43PM	Why Applied Therapeutics Stock Is Sliding Today (Motley Fool) -30.50%
08:25AM	Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder (Benzinga)
07:00AM	Applied Therapeutics Provides Regulatory Update on Galactosemia Program (GlobeNewswire)
03:14AM	Applied Therapeutics Tanks as Drug Candidate for Rare Disease Faces Delays (Investing.com)
Dec-16-21 07:00AM	Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency (GlobeNewswire) -8.51%
Nov-18-21 07:00AM	Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism (GlobeNewswire) -11.18%
04:55AM	Great news for Applied Therapeutics, Inc. (NASDAQ:APLT): Insiders acquired stock in large numbers last year (Simply Wall St.)
Nov-12-21 07:00AM	Applied Therapeutics Reports Third Quarter 2021 Financial Results (GlobeNewswire) +5.59%
Oct-25-21 07:00AM	Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency (GlobeNewswire) +11.35%
Oct-18-21 07:00AM	Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids (GlobeNewswire)
Oct-06-21 12:00PM	Applied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why (Zacks)
Sep-17-21 06:19AM	Is Applied Therapeutics (NASDAQ:APLT) Using Debt Sensibly? (Simply Wall St.)
Sep-09-21 10:01AM	Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate (Benzinga)
07:00AM	Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids (GlobeNewswire)
Aug-12-21 07:00AM	Applied Therapeutics Reports Second Quarter 2021 Financial Results (GlobeNewswire)

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shendelman Shoshana	President and CEO	Jun 06 '24	Sale	4.32	61,795	266,954	3,756,019	Jun 10 04:29 PM
Perfetti Riccardo	Chief Medical Officer	Jun 06 '24	Sale	4.32	22,003	95,053	1,009,534	Jun 10 04:28 PM
Funtleyder Leslie D.	Chief Financial Officer	Jun 06 '24	Sale	4.32	16,980	73,354	291,441	Jun 10 04:25 PM
ALEXANDRIA REAL ESTATE EQUITIE	10% Owner	Jun 05 '24	Sale	4.24	150,000	636,000	5,855,077	Jun 06 06:45 PM
ALEXANDRIA REAL ESTATE EQUITIE	10% Owner	Jun 04 '24	Sale	4.21	150,000	631,500	6,005,077	Jun 06 06:45 PM
Shendelman Shoshana	President and CEO	Mar 14 '24	Sale	5.39	318,573	1,717,108	3,817,814	Mar 18 06:12 PM
Perfetti Riccardo	Chief Medical Officer	Mar 14 '24	Sale	5.39	110,804	597,234	1,031,537	Mar 18 06:02 PM
Hansard Adam	Chief Commercial Officer	Mar 14 '24	Sale	5.39	48,871	263,415	732,919	Mar 18 06:00 PM
Funtleyder Leslie D.	Chief Financial Officer	Mar 14 '24	Sale	5.39	28,727	154,839	308,421	Mar 18 05:57 PM
Kanter Stacy J.	Director	Dec 01 '23	Buy	2.18	30,000	65,367	63,000	Dec 05 07:03 PM
Shendelman Shoshana	President and CEO	Nov 30 '23	Sale	1.97	3,968	7,817	2,596,387	Dec 01 07:42 PM
Perfetti Riccardo	Chief Medical Officer	Nov 30 '23	Sale	1.97	1,583	3,119	692,341	Dec 01 07:42 PM
Hansard Adam	Chief Commercial Officer	Nov 30 '23	Sale	1.97	965	1,901	381,790	Dec 01 07:42 PM
ALEXANDRIA REAL ESTATE EQUITIE	10% Owner	Nov 03 '23	Sale	2.31	143,450	331,370	5,580,077	Nov 06 04:56 PM
ALEXANDRIA REAL ESTATE EQUITIE	10% Owner	Nov 02 '23	Sale	2.32	103,808	240,835	5,723,527	Nov 06 04:56 PM
ALEXANDRIA REAL ESTATE EQUITIE	10% Owner	Nov 01 '23	Sale	2.36	172,742	407,671	5,827,335	Nov 02 04:44 PM
ALEXANDRIA REAL ESTATE EQUITIE	10% Owner	Oct 31 '23	Sale	2.41	155,000	373,550	6,000,077	Nov 02 04:44 PM
Shendelman Shoshana	President and CEO	Sep 27 '23	Sale	2.70	115,632	312,206	2,600,355	Sep 29 08:03 PM
Perfetti Riccardo	Chief Medical Officer	Sep 27 '23	Sale	2.70	10,932	29,516	693,924	Sep 29 08:02 PM
Hansard Adam	Chief Commercial Officer	Sep 27 '23	Sale	2.70	9,720	26,244	382,755	Sep 29 08:02 PM
MARCUS JOEL S	Director	Sep 15 '23	Option Exercise	1.05	12,375	12,994	453,414	Sep 19 08:08 PM

Open in Screener

THRD

Third Harmonic Bio Inc

Jun 20 • 04:00PM ET

12.34

Dollar change +0.02
Percentage change 0.16	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

THRD Third Harmonic Bio Inc daily Stock Chart

Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC VTWV IWV

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	62.81%	Shs Outstand	40.10M	Perf Week	-11.48%
Market Cap	505.32M	Forward P/E	-	EPS next Y	-1.47	Insider Trans	-0.23%	Shs Float	15.23M	Perf Month	-14.31%
Income	-29.59M	PEG	-	EPS next Q	-0.29	Inst Own	39.80%	Short Float	7.62%	Perf Quarter	33.26%
Sales	0.00M	P/S	-	EPS this Y	-48.03%	Inst Trans	-	Short Ratio	8.55	Perf Half Y	24.65%
Book/sh	6.55	P/B	1.89	EPS next Y	-27.47%	ROA	-10.53%	Short Interest	1.16M	Perf Year	146.80%
Cash/sh	6.42	P/C	1.92	EPS next 5Y	-	ROE	-10.84%	52W Range	4.72 - 16.94	Perf YTD	12.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-11.10%	52W High	-27.15%	Beta	2.86
Dividend TTM	-	Quick Ratio	66.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	161.17%	ATR (14)	0.78
Dividend Ex-Date	-	Current Ratio	66.10	EPS Y/Y TTM	32.17%	Oper. Margin	0.00%	RSI (14)	39.74	Volatility	5.28% 6.55%
Employees	30	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.83	Target Price	17.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	50.98%	Payout	-	Rel Volume	0.37	Prev Close	12.32
Sales Surprise	-	EPS Surprise	35.50%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	135.80K	Price	12.34
SMA20	-10.41%	SMA50	-2.39%	SMA200	29.47%	Trades		Volume	49,797	Change	0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-24	Initiated	Stifel	Buy	$23
Jun-07-24	Initiated	Raymond James	Outperform	$18
Dec-16-22	Downgrade	Jefferies	Buy → Hold	$30 → $3.60
Dec-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$5
Oct-10-22	Initiated	Morgan Stanley	Overweight	$34
Oct-10-22	Initiated	Jefferies	Buy	$30
Oct-10-22	Initiated	Cowen	Outperform

May-28-24 04:05PM	Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-24 04:36PM	Third Harmonic Bio Insider Sold Shares Worth $331,066, According to a Recent SEC Filing (MT Newswires) +7.92%
May-15-24 12:52PM	THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q1 2024 (InvestorPlace)
08:05AM	Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-10-24 07:02PM	Insider Sale: CEO Natalie Holles Sells Shares of Third Harmonic Bio Inc (THRD) (GuruFocus.com)
07:00PM	Loading…
Apr-15-24 07:00PM	Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares (GuruFocus.com)
Mar-28-24 08:30AM	Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors (GlobeNewswire)
Mar-26-24 09:02PM	Third Harmonic Bio Inc (THRD) Reports Decreased Net Loss in Q4, Aligns with Analyst Projections (GuruFocus.com) +5.46%
01:53PM	THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q4 2023 (InvestorPlace)
08:05AM	Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 04:00PM	Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update (GlobeNewswire)
Dec-29-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice (Zacks)
Dec-08-23 01:05PM	Insider Sell Alert: Third Harmonic Bio Inc's Julie Person Divests 12,863 Shares (GuruFocus.com) +5.40%
Nov-09-23 09:30AM	Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ... (GuruFocus.com)
08:30AM	Loading…
08:30AM	Third Harmonic Bio Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 08:30AM	Third Harmonic Bio Announces Leadership Changes (GlobeNewswire) -9.22%
Aug-31-23 08:30AM	Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 08:10AM	Third Harmonic Bio Announces Second Quarter 2023 Financial Results (GlobeNewswire) -7.00%
Jul-26-23 09:40AM	Target downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly) +9.11%
Jul-25-23 08:30AM	Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 (GlobeNewswire) +5.26%
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-24-23 11:02AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
May-11-23 05:00PM	Third Harmonic Bio Announces First Quarter 2023 Financial Results (GlobeNewswire) -7.32%
Mar-29-23 08:05AM	Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire)
Dec-23-22 06:32AM	Daily Vickers Top Buyers & Sellers for 12/23/2022 (Argus Research)
Dec-22-22 05:41AM	The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug (American City Business Journals)
Dec-15-22 10:10AM	Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns (Benzinga) -78.28%
09:53AM	Third Harmonic Plunges Almost 80% After Ending Study for Skin-Inflammation Drug (Bloomberg)
08:49AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
08:22AM	Loading…
08:22AM	Third Harmonic's stock falls 75% after discontinuing clinical trial (MarketWatch)
07:00AM	Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria (GlobeNewswire)
Nov-21-22 04:05PM	Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-22 04:15PM	Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:01AM	These Bases, Breakouts And Buy Zones Offer Fresh Opportunities (Investor's Business Daily) -6.14%
Sep-19-22 04:10PM	Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.56%
Sep-15-22 11:41AM	Third Harmonic Bio stock opens more than 20% above IPO price (MarketWatch)
07:58AM	Third Harmonic Bio prices upsized IPO at $17 a share, midpoint of range (MarketWatch)

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dittman Jennifer	Chief Development Oper Officer	Jun 07 '24	Sale	14.17	494	7,000	0	Jun 10 04:26 PM
Dittman Jennifer	Chief Development Oper Officer	May 20 '24	Sale	14.00	1,042	14,588	0	May 22 04:36 PM
Dittman Jennifer	Chief Development Oper Officer	May 16 '24	Sale	14.04	23,578	331,066	0	May 20 04:33 PM
Holles Natalie C.	CEO	May 09 '24	Option Exercise	4.20	20,222	84,932	1,239,058	May 10 04:04 PM
Holles Natalie C.	CEO	May 09 '24	Sale	12.18	20,222	246,300	1,218,836	May 10 04:04 PM
Holles Natalie C.	CEO	Apr 11 '24	Option Exercise	4.20	13,558	56,944	1,232,394	Apr 15 04:14 PM
Holles Natalie C.	CEO	Apr 11 '24	Sale	12.19	13,558	165,214	1,218,836	Apr 15 04:14 PM
Person Julie	CHIEF ADMINISTRATIVE OFFICER	Apr 04 '24	Option Exercise	4.20	1,107	4,649	1,107	Apr 08 05:21 PM
Person Julie	CHIEF ADMINISTRATIVE OFFICER	Apr 04 '24	Sale	10.00	1,107	11,070	0	Apr 08 05:21 PM
Person Julie	Chief Administrative Officer	Dec 05 '23	Option Exercise	4.20	12,863	54,025	12,863	Dec 07 04:04 PM
Conner Edward R.	Chief Medical Officer	Dec 05 '23	Option Exercise	4.20	4,790	20,118	4,790	Dec 07 04:03 PM
Person Julie	Chief Administrative Officer	Dec 05 '23	Sale	10.30	12,863	132,484	0	Dec 07 04:04 PM
Conner Edward R.	Chief Medical Officer	Dec 05 '23	Sale	10.03	4,790	48,062	0	Dec 07 04:03 PM

Open in Screener

QNRX

Quoin Pharmaceuticals Ltd ADR

Jun 20 • 04:00PM ET

0.6239

Dollar change +0.0128
Percentage change 2.09	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

QNRX Quoin Pharmaceuticals Ltd ADR daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-7.54	Insider Own	-	Shs Outstand	3.80M	Perf Week	-12.14%
Market Cap	2.37M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-	Shs Float	1.12M	Perf Month	-18.46%
Income	-8.43M	PEG	-	EPS next Q	-0.63	Inst Own	5.11%	Short Float	1.06%	Perf Quarter	-30.68%
Sales	0.00M	P/S	-	EPS this Y	69.16%	Inst Trans	-	Short Ratio	0.18	Perf Half Y	-84.64%
Book/sh	2.40	P/B	0.26	EPS next Y	53.24%	ROA	-48.76%	Short Interest	0.01M	Perf Year	-90.37%
Cash/sh	3.87	P/C	0.16	EPS next 5Y	-	ROE	-84.12%	52W Range	0.60 - 12.00	Perf YTD	-87.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	67.35%	ROI	-92.36%	52W High	-94.80%	Beta	1.97
Dividend TTM	-	Quick Ratio	3.61	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.97%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	3.61	EPS Y/Y TTM	83.73%	Oper. Margin	0.00%	RSI (14)	32.69	Volatility	8.03% 7.15%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	5.48
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	52.79%	Payout	-	Rel Volume	0.48	Prev Close	0.61
Sales Surprise	-	EPS Surprise	-46.05%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	65.35K	Price	0.62
SMA20	-13.00%	SMA50	-14.19%	SMA200	-79.00%	Trades		Volume	31,236	Change	2.09%

Jun-12-24 08:00AM	Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland (GlobeNewswire)
May-09-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 04:10PM	Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +6.34%
Mar-15-24 10:52AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 04:05PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results (GlobeNewswire) -13.79%
04:05PM	Loading…
Mar-07-24 04:05PM	Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET (GlobeNewswire) -8.47%
Mar-05-24 08:34AM	Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today? (InvestorPlace) -48.28%
08:00AM	Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering (GlobeNewswire)
Mar-04-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire)
Feb-14-24 09:00AM	Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome (ACCESSWIRE)
Feb-08-24 08:00AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product (GlobeNewswire)
Dec-13-23 08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome (GlobeNewswire)
Nov-10-23 12:19PM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:46PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -8.26%
Nov-03-23 08:41AM	Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET (GlobeNewswire)
09:32AM	Loading…
Oct-24-23 09:32AM	REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire) +8.04%
08:28AM	Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire)
Oct-02-23 12:25PM	QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials (Zacks)
Aug-09-23 08:30AM	Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders (NewMediaWire)
Aug-02-23 04:45PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -10.67% +6.26%
Jul-27-23 08:00AM	Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET (GlobeNewswire)
May-24-23 08:15AM	Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial (GlobeNewswire)
May-08-23 05:00PM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results (GlobeNewswire) +14.90% -14.23%
May-02-23 08:30AM	Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET (GlobeNewswire)
Mar-22-23 09:13AM	QNRX: Patients Dosed in Both Concurrent Studies; Potentially Adding New Assets to Product Portfolio (Zacks Small Cap Research) +5.92%
Mar-21-23 08:30AM	Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial (GlobeNewswire)
Mar-11-23 02:59AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 05:08PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.83%
Mar-02-23 04:05PM	Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET (GlobeNewswire)
Mar-01-23 08:30AM	A Pivotal Year Ahead for Quoin Pharmaceuticals (NewMediaWire)
08:39AM	Loading…
Feb-22-23 08:39AM	Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -47.90%
Dec-13-22 08:30AM	Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome (GlobeNewswire)
Dec-05-22 11:15AM	QNRX: Moving QRX003 Forward in Concurrent Studies (Zacks Small Cap Research)
Nov-10-22 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire) +17.07%
Nov-03-22 07:00AM	Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th (GlobeNewswire)
Nov-01-22 08:30AM	Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th (GlobeNewswire)
Oct-18-22 08:30AM	Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients (GlobeNewswire) +44.44%
Sep-13-22 08:30AM	Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study (GlobeNewswire) -7.75%
Aug-23-22 01:43PM	QNRX: Enhanced Financial Flexibility to Move QRX003 & Other Assets Forward (Zacks Small Cap Research) -9.13%
Aug-18-22 07:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire) -10.40%
Aug-11-22 04:30PM	Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th (GlobeNewswire)
Aug-09-22 04:23PM	Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering (GlobeNewswire) -8.77%
Aug-05-22 09:28AM	Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering (GlobeNewswire) -62.38%
Jul-28-22 08:30AM	Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe (GlobeNewswire)
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada (Zacks)
Jul-15-22 08:30AM	Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements (GlobeNewswire) -12.75%
07:30AM	Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada (PR Newswire)
Jul-06-22 08:30AM	Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study (GlobeNewswire) +13.18%
Jun-15-22 04:01PM	Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) -14.60% -10.11%
08:30AM	Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China (GlobeNewswire)
Jun-14-22 08:30AM	Quoin Pharmaceuticals: Strategically Building For Future Success (Newsfile) +6.02%
Jun-10-22 10:23AM	15 Best Penny Stocks To Invest In (Insider Monkey)
Jun-06-22 11:22AM	Why Are Quoin Pharma Shares Trading Higher Today? (Benzinga) -7.50%
08:00AM	Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug (ACCESSWIRE)
May-23-22 08:30AM	Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University (GlobeNewswire)
May-17-22 08:30AM	Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome (Newsfile) +12.64%
May-11-22 11:24AM	When Will Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Breakeven? (Simply Wall St.) -8.48%
Apr-25-22 01:05PM	QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications (Zacks Small Cap Research) +10.00%
08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Mar-24-22 08:30AM	Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024 (Newsfile)
Mar-15-22 08:41AM	Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Mar-10-22 08:00AM	Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) +14.34%
Mar-01-22 08:00AM	Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) +5.41%
Feb-17-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Feb-10-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Feb-08-22 08:30AM	Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy (Newsfile)
Jan-26-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) -6.52%
Jan-24-22 07:15AM	QNRX: Laying the Groundwork to Launch Multiple Treatments for Rare & Orphan Diseases (Zacks Small Cap Research)
Dec-15-21 09:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) -12.58%
Dec-14-21 08:30AM	The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease Therapeutics (Newsfile)
Nov-16-21 08:30AM	Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising Pipeline (Newsfile)
Nov-11-21 08:30AM	Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoins Lead Asset, QRX003 (GlobeNewswire) -21.74%
Nov-08-21 08:00AM	Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003 (GlobeNewswire) -8.94%
Nov-04-21 09:25AM	Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer (GlobeNewswire)
Nov-02-21 08:30AM	Quoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, Australia (GlobeNewswire)

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LANGER DENNIS	Director	Jun 07 '24	Sale	0.73	297	217	53	Jun 10 04:10 PM

Open in Screener

RCKT

Rocket Pharmaceuticals Inc

Jun 20 • 04:00PM ET

20.85

Dollar change +0.17
Percentage change 0.82	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

RCKT Rocket Pharmaceuticals Inc daily Stock Chart

Held by: XBI VTI IWM VXF VB IBB VBK IWO SCHA LABU

Index	RUT	P/E	-	EPS (ttm)	-2.87	Insider Own	7.81%	Shs Outstand	90.28M	Perf Week	-8.27%
Market Cap	1.89B	Forward P/E	-	EPS next Y	-2.04	Insider Trans	-5.78%	Shs Float	83.69M	Perf Month	-8.67%
Income	-249.31M	PEG	-	EPS next Q	-0.71	Inst Own	99.56%	Short Float	11.25%	Perf Quarter	-25.16%
Sales	0.00M	P/S	-	EPS this Y	10.56%	Inst Trans	5.52%	Short Ratio	14.89	Perf Half Y	-25.16%
Book/sh	4.87	P/B	4.28	EPS next Y	21.95%	ROA	-49.16%	Short Interest	9.41M	Perf Year	-7.70%
Cash/sh	3.64	P/C	5.73	EPS next 5Y	41.70%	ROE	-55.38%	52W Range	14.89 - 32.53	Perf YTD	-30.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.09%	ROI	-53.66%	52W High	-35.90%	Beta	1.12
Dividend TTM	-	Quick Ratio	10.47	Sales past 5Y	0.00%	Gross Margin	-	52W Low	40.03%	ATR (14)	0.94
Dividend Ex-Date	-	Current Ratio	10.47	EPS Y/Y TTM	14.46%	Oper. Margin	0.00%	RSI (14)	37.72	Volatility	3.38% 4.23%
Employees	268	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	49.08
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	9.66%	Payout	-	Rel Volume	1.57	Prev Close	20.68
Sales Surprise	-	EPS Surprise	1.87%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	632.24K	Price	20.85
SMA20	-5.18%	SMA50	-8.49%	SMA200	-13.25%	Trades		Volume	991,815	Change	0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy	$64
Feb-18-21	Initiated	Needham	Buy	$75
Dec-16-20	Initiated	UBS	Buy	$75
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy	$34
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy	$30
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy	$27
Feb-05-19	Initiated	Oppenheimer	Outperform	$39
Sep-13-18	Initiated	Ladenburg Thalmann	Buy	$30

Show Previous Ratings

Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Loading…
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
07:00AM	Loading…
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily) +9.21%
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
07:00AM	Loading…
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)
Sep-18-23 07:30AM	Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully (Motley Fool)
Sep-15-23 11:00AM	Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week (Zacks)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks) +13.28%
Sep-13-23 04:34PM	These Stocks Moved the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com) +38.85%
01:50PM	Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce (Investor's Business Daily)
01:36PM	These Stocks Are Moving the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com)
12:30PM	Stock Market Weighs In On Inflation Data; Vaccine Maker Leads The S&P 500 (Investor's Business Daily)
12:23PM	What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today? (Benzinga)
12:15PM	Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023 (AP Finance)
11:56AM	Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday (Motley Fool)
10:54AM	Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential Value Driver. (Barrons.com)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
12:01AM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
Sep-12-23 04:02PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease (Business Wire)
Sep-06-23 04:05PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-10-23 07:14AM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +6.25%
Jun-12-23 04:34PM	3 Small-Cap Stocks You Cant Ignore Now (InvestorPlace)
Jun-09-23 09:24AM	Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag (Zacks)
Jun-08-23 07:00AM	Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-31-23 07:00AM	Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
May-23-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) (Business Wire)
May-19-23 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-18-23 06:12AM	Heres Why Rocket Pharmaceuticals (RCKT) Stock Suffered in Q1 (Insider Monkey)
May-17-23 04:26PM	Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist (Yahoo Finance Video)
May-09-23 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-04-23 04:21PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +5.24% +12.36%
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
May-03-23 04:01PM	Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference (Business Wire)
Apr-11-23 04:01PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Apr-04-23 04:01PM	Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage (Business Wire)
Mar-01-23 04:01PM	Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference (Business Wire) +5.41%
Feb-27-23 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (Business Wire)
Feb-09-23 04:01PM	Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
Feb-05-23 09:07AM	Even with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70k (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-23-23 10:15AM	Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:55AM	Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet (Zacks)
Jan-09-23 04:01PM	Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease (Business Wire)
Jan-06-23 09:55AM	Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade (Zacks)
Jan-03-23 04:01PM	Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-22 06:00AM	Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting (Business Wire) -13.90%
Dec-12-22 10:00AM	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire) +6.58%
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Dec-01-22 04:01PM	Rocket Pharmaceuticals Completes Acquisition of Renovacor (Business Wire) +8.10%
Nov-21-22 08:00AM	Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-16-22 07:59AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (Simply Wall St.) -5.99%
Nov-03-22 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)
09:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses (Business Wire)
Oct-27-22 09:55AM	Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks)
Oct-14-22 06:35PM	Alkermes, Allakos, and Other Stocks See Action From Activist Investors (Barrons.com) +7.10%
Oct-12-22 06:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-11-22 09:55AM	Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect? (Zacks)
Oct-10-22 08:00AM	Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa (Business Wire)
Oct-03-22 11:21PM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) +11.10%
04:42PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-30-22 06:00AM	Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 (Business Wire) +13.68%
Sep-27-22 08:00AM	Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference (Business Wire) +7.41%
Sep-20-22 05:07PM	Cambridge biotech acquired for $53M following move from Philadelphia (American City Business Journals) -8.40%
11:14AM	Why Is Renovacor (RCOR) Stock Up 18% Today? (InvestorPlace)
10:06AM	Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases (Benzinga)
06:00AM	Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy (Business Wire)
Sep-16-22 08:00AM	Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 (Business Wire) -10.21%

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shah Gaurav	CEO	May 16 '24	Sale	23.35	9,790	228,596	728,069	May 20 04:33 PM
Patel Kinnari	See Remarks	May 16 '24	Sale	23.35	4,046	94,474	400,972	May 20 04:26 PM
Militello John	See Remarks	May 16 '24	Sale	23.35	1,079	25,195	53,327	May 20 04:36 PM
Wilson Martin	General Counsel	May 16 '24	Sale	23.35	1,048	24,471	65,762	May 20 04:29 PM
Shah Gaurav	CEO	May 14 '24	Option Exercise	0.00	17,662	0	646,134	May 20 04:33 PM
Wilson Martin	General Counsel	May 14 '24	Option Exercise	0.00	2,420	0	21,100	May 20 04:29 PM
Patel Kinnari	See Remarks	May 14 '24	Option Exercise	0.00	9,543	0	301,824	May 20 04:26 PM
Militello John	See Remarks	Apr 22 '24	Sale	22.87	833	19,051	54,406	Apr 24 04:06 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Option Exercise	4.34	29,624	128,627	124,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Sale	24.05	10,000	240,520	114,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Option Exercise	4.34	70,000	303,940	165,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Sale	24.36	70,000	1,705,265	95,160	Apr 16 05:45 PM
White Mark Andrew	See Remarks	Apr 08 '24	Sale	24.64	12,532	308,763	75,226	Apr 10 08:39 PM
Makker Gotham	Director	Mar 21 '24	Sale	28.43	274,000	7,790,943	365,912	Mar 25 08:58 PM
Militello John	See Remarks	Mar 21 '24	Sale	28.10	2,490	69,979	55,239	Mar 25 08:54 PM
Militello John	See Remarks	Feb 29 '24	Option Exercise	12.55	10,000	125,500	31,517	Mar 04 06:54 PM
Militello John	See Remarks	Feb 29 '24	Sale	29.84	10,000	298,450	21,517	Mar 04 06:54 PM
Wilson Martin	General Counsel	Feb 29 '24	Sale	29.33	4,100	120,257	18,680	Mar 04 06:48 PM
Shah Gaurav	CEO	Feb 16 '24	Sale	29.84	20,272	604,876	554,762	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 16 '24	Sale	29.84	7,132	212,805	238,346	Feb 21 08:54 PM
Wilson Martin	General Counsel	Feb 16 '24	Sale	29.84	3,576	106,701	6,136	Feb 21 08:54 PM
Militello John	See Remarks	Feb 16 '24	Sale	29.84	3,238	96,615	13,195	Feb 21 08:54 PM
Militello John	See Remarks	Feb 14 '24	Option Exercise	0.00	6,274	0	16,433	Feb 16 04:05 PM
Patel Kinnari	See Remarks	Feb 14 '24	Option Exercise	0.00	26,189	0	245,478	Feb 16 04:05 PM
Militello John	See Remarks	Jan 22 '24	Sale	27.20	638	17,356	10,159	Jan 23 04:22 PM
Militello John	See Remarks	Jan 18 '24	Option Exercise	0.00	1,586	0	10,797	Jan 22 04:05 PM
Makker Gotham	Director	Nov 15 '23	Sale	22.53	20,000	450,646	1,296,497	Nov 16 07:24 PM
Militello John	See Remarks	Nov 14 '23	Option Exercise	0.00	725	0	9,485	Nov 16 06:58 PM
Patel Kinnari	See Remarks	Nov 14 '23	Option Exercise	0.00	3,989	0	220,437	Nov 16 07:17 PM
Militello John	See Remarks	Oct 20 '23	Sale	17.06	564	9,623	8,760	Oct 25 09:38 AM
Patel Kinnari	See Remarks	Oct 05 '23	Option Exercise	0.00	3,333	0	101,594	Oct 10 04:11 PM
Makker Gotham	Director	Sep 29 '23	Sale	21.14	4,677	98,864	1,316,497	Oct 02 09:02 PM
Makker Gotham	Director	Sep 28 '23	Sale	21.03	10,312	216,880	1,321,174	Oct 02 09:02 PM
Shah Gaurav	CEO	Aug 17 '23	Sale	15.47	4,767	73,750	524,854	Aug 21 04:05 PM
Patel Kinnari	See Remarks	Aug 17 '23	Sale	15.47	1,534	23,733	216,448	Aug 21 04:05 PM
Militello John	See Remarks	Aug 17 '23	Sale	15.47	284	4,394	5,570	Aug 21 04:05 PM
Patel Kinnari	See Remarks	Aug 14 '23	Option Exercise	0.00	3,989	0	217,982	Aug 15 04:16 PM
Militello John	See Remarks	Aug 14 '23	Option Exercise	0.00	725	0	7,854	Aug 15 04:17 PM
Shah Gaurav	CEO	Aug 14 '23	Option Exercise	0.00	7,979	0	529,621	Aug 15 04:06 PM
Militello John	See Remarks	Jul 20 '23	Sale	19.03	573	10,906	7,129	Jul 24 04:05 PM
Militello John	See Remarks	Jul 18 '23	Option Exercise	0.00	1,586	0	7,702	Jul 20 04:05 PM

Open in Screener

IMMX

Immix Biopharma Inc

Jun 20 • 04:00PM ET

1.92

Dollar change -0.09
Percentage change -4.48	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

IMMX Immix Biopharma Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	41.78%	Shs Outstand	19.92M	Perf Week	-10.28%
Market Cap	50.71M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.19%	Shs Float	15.38M	Perf Month	-23.81%
Income	-18.21M	PEG	-	EPS next Q	-	Inst Own	19.50%	Short Float	2.20%	Perf Quarter	-29.93%
Sales	0.00M	P/S	-	EPS this Y	-24.00%	Inst Trans	19.79%	Short Ratio	2.63	Perf Half Y	-71.00%
Book/sh	1.06	P/B	1.82	EPS next Y	-8.60%	ROA	-76.56%	Short Interest	0.34M	Perf Year	-20.00%
Cash/sh	1.11	P/C	1.73	EPS next 5Y	-	ROE	-91.75%	52W Range	1.55 - 7.75	Perf YTD	-72.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.30%	ROI	-62.83%	52W High	-75.23%	Beta	0.17
Dividend TTM	-	Quick Ratio	5.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	23.87%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	5.82	EPS Y/Y TTM	-37.71%	Oper. Margin	0.00%	RSI (14)	39.49	Volatility	9.57% 9.82%
Employees	17	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-25.78%	Payout	-	Rel Volume	0.66	Prev Close	2.01
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	-	Avg Volume	128.74K	Price	1.92
SMA20	-8.33%	SMA50	-14.58%	SMA200	-45.92%	Trades		Volume	84,636	Change	-4.48%

Jun-17-24 09:35AM	Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum (GlobeNewswire)
Jun-10-24 08:30AM	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships (GlobeNewswire)
May-13-24 09:53AM	IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 (InvestorPlace)
May-10-24 09:35AM	Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation (GlobeNewswire)
Apr-29-24 02:50PM	Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment (MT Newswires)
09:39AM	Loading…
09:39AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma (GlobeNewswire)
Apr-18-24 09:37AM	Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States (GlobeNewswire) -11.60%
09:32AM	Immix Biopharma on Track to Dose NXC-201 Patients in United States (GlobeNewswire)
Apr-15-24 09:36AM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-02-24 07:53AM	IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 (InvestorPlace)
Mar-20-24 09:46AM	Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial (GlobeNewswire)
Mar-05-24 09:35AM	Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative (GlobeNewswire) -8.06%
Feb-21-24 09:31AM	Immix Biopharma 12 Month Review Progress Update (GlobeNewswire)
Feb-08-24 04:45PM	Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock (GlobeNewswire) +6.60%
Feb-07-24 09:37AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis (GlobeNewswire) +7.07%
10:30PM	Loading…
Feb-05-24 10:30PM	Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock (GlobeNewswire) -19.89% -6.29%
03:20PM	Immix Biopharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-24-24 08:35AM	Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products (GlobeNewswire)
Jan-04-24 09:34AM	Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board (GlobeNewswire)
Dec-18-23 09:39AM	Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board (GlobeNewswire) -8.94%
Dec-11-23 09:36AM	Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 (GlobeNewswire)
Nov-30-23 09:46AM	Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:50AM	What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' (Zacks) +5.39%
Nov-22-23 11:10AM	Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down (Zacks) +5.01%
09:19AM	Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
Nov-21-23 09:46AM	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing (GlobeNewswire)
Nov-06-23 09:18AM	Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire) +20.73%
09:12AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire)
08:40AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients (GlobeNewswire)
Oct-31-23 09:55AM	Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.37%
08:58AM	Loading…
Oct-26-23 08:58AM	Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board (GlobeNewswire)
Oct-16-23 09:05AM	Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Oct-03-23 09:14AM	Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting (GlobeNewswire) +5.31%
Oct-02-23 08:06AM	Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma (GlobeNewswire) +26.61%
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-21-23 08:55AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis (GlobeNewswire) +15.38%
Sep-19-23 09:10AM	Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +24.15%
Sep-15-23 01:18PM	Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX) (GuruFocus.com) +5.12%
Sep-07-23 10:38AM	The 3 Best Speculative Stocks to Buy Now: September 2023 (InvestorPlace)
08:41AM	Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference (GlobeNewswire)
Sep-01-23 08:39AM	Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board (GlobeNewswire) +12.81%
Aug-23-23 08:37AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma (GlobeNewswire) +11.11%
Aug-18-23 09:20AM	Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board (GlobeNewswire) +6.13%
Aug-16-23 09:05AM	Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) (GlobeNewswire)
Jul-25-23 08:42AM	Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting (GlobeNewswire)
Jul-17-23 09:37AM	Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial (GlobeNewswire) -6.11%
Jul-10-23 09:47AM	Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Jun-26-23 09:49AM	Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial (GlobeNewswire) -6.90%
Jun-22-23 09:53AM	Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors (GlobeNewswire)
Jun-20-23 09:45AM	Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors (GlobeNewswire) +8.11%
Jun-16-23 09:43AM	Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors (GlobeNewswire) -5.93%
Jun-14-23 07:30AM	Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program (GlobeNewswire)
Jun-12-23 09:49AM	Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors (GlobeNewswire)
May-26-23 09:53AM	Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +9.38%
May-22-23 01:48PM	Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis (Benzinga) +6.71%
08:31AM	We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-21-23 04:05PM	Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
04:00PM	Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
May-04-23 12:30PM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
May-03-23 04:42PM	What's Going On With Immix Biopharma Stock Today (Benzinga)
08:00AM	Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab (GlobeNewswire)
Apr-26-23 05:30PM	Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris (GlobeNewswire) +24.32%
Apr-04-23 08:00AM	Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting (GlobeNewswire) -7.45%
Mar-31-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells (GlobeNewswire) +5.81%
Mar-23-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential (GlobeNewswire) -7.94%
Mar-10-23 07:45PM	Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank (GlobeNewswire) -7.69% +14.45%
Mar-06-23 08:00AM	ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14 (GlobeNewswire)
Feb-27-23 08:45AM	Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission (GlobeNewswire)
Feb-15-23 08:30AM	Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S. (GlobeNewswire)
Feb-09-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting (GlobeNewswire) -16.59%
Feb-07-23 08:00AM	Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer (GlobeNewswire) -8.01%
Jan-13-23 08:00AM	Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
Jan-06-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached (GlobeNewswire) -8.24%
Dec-28-22 08:00AM	Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting (GlobeNewswire) +8.50%
Dec-20-22 08:00AM	Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire) -5.08%
Dec-19-22 08:00AM	ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors (GlobeNewswire)
Dec-14-22 12:43PM	Why Immix Biopharma Shares Are Surging Today? (Benzinga) +23.29%
08:00AM	Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) (GlobeNewswire)
Dec-13-22 08:00AM	Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
05:06AM	We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely (Simply Wall St.)
Dec-12-22 08:00AM	ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing (GlobeNewswire) +7.91%
Nov-11-22 08:00AM	Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher (GlobeNewswire) +16.67%
Oct-25-22 08:00AM	Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26 (GlobeNewswire)
Oct-18-22 08:00AM	ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site (GlobeNewswire)
Sep-07-22 12:05PM	ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials (GlobeNewswire)
Aug-23-22 06:36AM	Insiders who bought in the last 12 months lose an additional US$175k as Immix Biopharma, Inc. (NASDAQ:IMMX) drops to US$28m (Simply Wall St.)
Aug-01-22 10:10AM	10 Best Penny Stocks to Buy and Hold According to Reddit (Insider Monkey)
May-21-22 08:26AM	We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth (Simply Wall St.)
May-20-22 10:19AM	ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug (Benzinga) +30.06%
08:47AM	ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study (GlobeNewswire)
May-09-22 08:00AM	Immix Biopharma Announces Share Repurchase Program (GlobeNewswire)
Apr-05-22 09:30AM	ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022 (GlobeNewswire) -22.01%
Mar-16-22 10:13AM	Multiple insiders bought Immix Biopharma, Inc. (NASDAQ:IMMX) stock earlier this year, a positive sign for shareholders (Simply Wall St.) +19.12%
Mar-07-22 08:00AM	Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022 (GlobeNewswire) -10.90%
Feb-22-22 08:00AM	ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease (GlobeNewswire) -9.50%
Feb-01-22 11:36AM	5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI (InvestorPlace) +13.55%
09:30AM	ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022 (GlobeNewswire)
Jan-31-22 08:00AM	ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data (GlobeNewswire)
Jan-25-22 12:17PM	Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies (Benzinga)
10:15AM	IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale (GlobeNewswire)

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rachman Ilya M	CEO and Chairman	Jun 07 '24	Buy	2.13	2,600	5,538	1,136,259	Jun 10 09:00 AM
Morris Gabriel S	CFO	Jun 07 '24	Buy	2.12	2,500	5,298	285,834	Jun 10 09:00 AM
Morris Gabriel S	CFO	Jun 04 '24	Buy	1.81	3,300	5,973	283,334	Jun 05 09:00 AM
Rachman Ilya M	CEO and Chairman	Jun 04 '24	Buy	1.81	3,300	5,970	1,133,659	Jun 05 09:00 AM
Morris Gabriel S	CFO	May 14 '24	Buy	2.23	4,500	10,042	85,816	May 14 09:29 PM
Rachman Ilya M	CEO and Chairman	May 14 '24	Buy	2.25	4,300	9,660	912,000	May 14 09:28 PM
Hsu Jason	Director	Dec 11 '23	Buy	4.67	31,000	144,894	813,000	Dec 12 06:25 PM
Hsu Jason	Director	Dec 08 '23	Buy	4.88	25,000	122,025	782,000	Dec 12 06:25 PM
Hsu Jason	Director	Sep 15 '23	Buy	2.49	7,000	17,396	757,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 14 '23	Buy	2.58	10,000	25,772	750,000	Sep 18 07:03 PM
Ng Carey	Director	Sep 14 '23	Buy	2.58	10,000	25,760	10,000	Sep 15 06:27 PM
Hsu Jason	Director	Sep 12 '23	Buy	2.83	30,000	84,864	740,000	Sep 18 07:03 PM
Adams Helen C.	Director	Sep 12 '23	Buy	2.96	13,000	38,492	13,000	Sep 14 05:20 PM
Hsu Jason	Director	Sep 11 '23	Buy	2.89	25,000	72,280	710,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 08 '23	Buy	2.53	10,000	25,317	685,000	Sep 12 04:58 PM
BUCHAN MELISSA JANE	Director	Sep 07 '23	Buy	2.46	20,000	49,226	20,000	Sep 11 05:18 PM
Marquet Magda	Director	Sep 06 '23	Buy	2.47	9,000	22,213	20,000	Sep 08 05:46 PM
Marquet Magda	Director	Sep 05 '23	Buy	2.47	10,000	24,722	11,000	Sep 06 04:33 PM
Marquet Magda	Director	Aug 31 '23	Buy	2.01	1,000	2,010	1,000	Sep 05 06:43 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MDGL

RNA

MLYS

NKTR

AVTE

ANIP

TLPH

KPRX

TRDA

UTHR

ARCT

RZLT

ANIX

DYN

NEXI

NRIX

ZOM

PCRX

AKRO

ACRS

PEPG

NUVB

SPRY

FGEN

VRTX

REGN

RARE

KRON

ALRN

ASRT

MRUS

BMEA

DAWN

INSM

GERN

IRWD

JAZZ

YMAB

AMPH

ACAD

CPRX

PHIO

CRNX

PTGX

CYTK

LLY

URGN

RAPP

TYRA

ELVN

KALV

APLT

THRD

QNRX

RCKT

IMMX

Upgrade your FINVIZ experience